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Abstract 
Pancreatic cancer (pancreatic ductal adenocarcinoma, PDAC) is one of the most 
lethal tumour types world-wide. The majority of patients present late with locally 
advanced or metastatic disease. Therefore, despite advances in operative 
techniques, perioperative management and oncological treatments, the overall 5-
year survival remains <5%. Determining tumoural factors that contribute towards its 
aggressive nature may help in identifying novel molecular biomarkers and/or 
therapeutic targets. MicroRNAs (miRNAs) are small non-coding RNAs that 
negatively regulate target gene expression and are able to act as tumour 
suppressors or oncogenes. MiRNAs have been extensively profiled and implicated in 
the initiation and progression of PDAC. Furthermore, there is a possibility of 
translating miRNAs into clinically useful biomarkers. Here, I developed upon these 
initial observations and demonstrate that miRNAs can be used to differentiate low 
risk pancreatic benign cystic tumours (BCTs) from PDAC. We confirmed that these 
miRNAs regulate the expression of known PDAC oncogenes, and that miR-16, miR-
126 and let-7d target BCL2, CRK and KRAS respectively. Next, in order to 
investigate the main contributors to tumourigenesis, an integrated molecular analysis 
(miRNA-mRNA) was performed in PDAC. By using a combination of network-based 
bioinformatics, miR-21, miR-23a and miR-27a were prioritised as important in PDAC 
progression. We demonstrated that the use of a combination of miRNA inhibitors 
(against miR-21, miR-23a and miR-27a) in a murine subcutaneous PDAC xenograft 
model was able to reduce tumour growth, better than oncomiR-21 inhibition alone. 
BTG2 and NEDD4L were found to be direct targets of the miRNA combination and 
were established as new candidate tumour suppressors in PDAC. The clinical 
relevance of this 3 miRNA signature was demonstrated, as high expressors of the 
combination have poor overall survival after surgical resection, independent of other 
clinicopathologic factors. Together, these studies identify specific miRNAs as 
important regulators of PDAC tumourigenesis and their possible use as biomarkers.  
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CHAPTER 1: INTRODUCTION 
 
1.1 Pancreatic Cancer 
1.1.1 Ductal Adenocarcinoma of the Pancreas 
Around the world, more than 200,000 people die each year from pancreatic 
cancer [1] and the annual incidence rate is approximately 8/100,000 persons [2]. 
Adenocarcinoma is the most frequent type of pancreatic cancer (pancreatic ductal 
adenocarcinoma, PDAC) and the slower-growing neuroendocrine tumours account 
for only a small fraction of the disease [3]. The studies in this thesis have 
investigated the molecular aspects of ductal adenocarcinoma of the pancreas.  
PDAC remains the 4th leading cause of cancer-related deaths in the USA [4]. 
Indeed, 43,920 people were diagnosed with PDAC, with 37,390 succumbing to the 
disease in the USA in 2012 [4]. Similarly, in the UK, 8,463 people were diagnosed 
with PDAC, with 7,901 succumbing to the disease in 2010 [5]. It therefore accounts 
for 2.6% of all newly diagnosed cancers in the UK, and is the 5th most common 
cause of cancer death. Thus, the incidence rates can be said to be almost equal to 
mortality rates [1]. The majority of patients present late with locally advanced 
unresectable or metastatic disease. Even if surgical resection can be performed 
(<20% are eligible), most already have clinically undetectable micro-metastases and 
therefore rapid disease recurrence occurs, resulting in an extremely poor prognosis 
[6, 7]. Overall there has been very little progress in improving outcomes over the 
past 30 years. Despite advances in operative techniques, perioperative management 
and oncological treatments, the overall 5-year survival has still not improved to any 
meaningful extent and is only 6% (compared to 2% in 1975-1977)[4]. This can, 
however, rise to up to 12-19% in some specialised high-volume centres and even 
higher if resection margins are clear (R0) and lymph-nodes (LNs) are not involved 
(N0) [8-10]. Thus, the 5-year overall survival (OS) for these surgically resected 
patients ranges from 10 to 25% [11].  
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Improvements in survival rates can only be achieved by earlier detection and 
this is reliant on the future development of better screening methodologies (e.g. 
highly sensitive / specific diagnostic biomarkers and imaging modalities). As a 
consequence, screening for sporadic PDAC, as opposed to those at high-risk, has 
not yet been proven to be beneficial and needs further investigation [12]. New 
approaches for PDAC diagnosis and treatment are urgently needed. 
 
1.1.2 Aetiology of Pancreatic Cancer 
 As treatments have not succeeded in controlling PDAC, prevention may play 
an even more important role in reducing mortality rates. International variations in the 
incidence and time trends for this disease suggest that environmental factors are 
significant in the aetiology of PDAC (e.g. rates continue to increase in Japan, where 
the incidence was low 40 years ago; in USA the highest rates of incidence and 
mortality are among African Americans) [1]. Indeed, as well as country-specific 
differences, there are also subtle geographic and regional differences [3]. 
1.1.1.1 Age and sex 
 PDAC is more prevalent in males than in females in all race and ethnicity 
groups [3]. Increasing age is a major risk factor for PDAC as the incidence rate rises 
steeply after 50 years, and <10% of cases occur among individuals younger than 55 
years, with the median age of diagnosis being 71 years [3].  
1.1.1.2 Alcohol, smoking, chronic pancreatitis and diabetes 
 Alcohol is known to increase the risk of pancreatitis, in a dose-dependent 
manner [3], and the risk of subsequent chronic pancreatitis (CP) increases at a 
threshold of approximately 4 to 5 drinks/day [13, 14]. However, the relationship 
between alcohol and PDAC is blurred, even though alcohol abuse can lead to CP, 
which is a risk factor for PDAC. Indeed, it is difficult to establish alcohol as an 
independent risk-factor for PDAC because of the close association between heavy 
alcohol use and smoking, the latter of which has been proven in several studies [15]. 
However, investigating 7000 PDAC deaths during a 24 year period of follow-up, 
Gapstur et al. [16] found that consumption of spirits of 3 or more drinks per day, 
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increases PDAC mortality independent of smoking (1.4-fold higher risk). This 
suggests that alcohol is a life-style modifiable risk-factor for PDAC.  
Cigarette smoking, as well as exposure to environmental tobacco smoke, 
increases risk of PDAC by up to 75% (dependent on number smoked and duration) 
[17]. This modifiable risk-factor is reduced to levels of never smokers within 5 years 
of quitting. Since tobacco smoking is a known risk factor for PDAC, this is likely to 
explain some of the international and gender differences [1]. It is estimated that  
25% of all cases of PDAC can be attributed to smoking [3].  
Probably the most important risk factor for the development of PDAC is CP. 
Approximately 5% of patients with CP will develop PDAC over a period of 20 years 
[18]. While the causal relationship between CP and PDAC is not well understood, 
evidence is pointing towards the repeated inflammatory insults to the pancreas as 
the main factor which contributes to malignant transformative events in the 
pancreatic (duct and acinar) cells [19]. There is now confirmation that this process, 
known as “acinar to ductal metaplasia”, is an important precursor to pancreatic 
tumourigenesis, and subsequent co-operation with oncogenic RAS (Rat sarcoma) 
protein signalling and loss of tumour suppressor barriers, results in progression to 
pancreatic intraepithelial neoplasias (PanINs) and ultimately to PDAC [20]. Whilst 
this is proven in vitro and in animal models, the potential role of anti-inflammatory 
drugs (e.g. Cox2 specific inhibitors) and antioxidants as preventative and/or 
therapeutic agents for PDAC is unknown and results from clinical studies are 
awaited [20]. Another type of CP is hereditary pancreatitis, which has been 
associated with several gene mutations including PRSS1, PRSS2, SPINK1 and 
CTRC, and these patients have a cumulative risk of developing PDAC of 40–55% 
[2]. 
1.1.1.3 Other risk factors 
With the exception of tobacco smoking, other risk factors for PDAC are not 
very well-established. Jiao et al. [21] have shown that obesity, low vegetable and 
fruit intake, and physical inactivity are possible modifiable risk-factors. Other known 
risk factors include intake of red or processed meat and high-temperature cooking 
[22]; non-O blood group (15-20%) [23]; occupational exposures, for example to 
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chlorinated hydrocarbon solvents and nickel [24]; possible Helicobacter pylori 
infection [2, 25] and periodontal disease [26]. A recent study quashed previous 
theories and showed that total coffee, decaffeinated coffee, and tea consumption are 
not related to the risk of developing PDAC [27]. 
Studies have also suggested that diabetes mellitus, in particular type 2, is 
associated with an increased risk for PDAC [28]. Conversely, the use of metformin 
has been associated with reduced risk of developing PDAC [29] and also better 
outcomes for those with established tumours [30]. These effects may be due to 
metabolic reprogramming by metformin [31]. 
1.1.1.4 Familial History 
A family history of PDAC (defined as families in which a pair of 1st-degree 
relatives have been diagnosed with pancreatic tumours) is an extremely important 
risk factor for the disease, and this accounts for approximately 7-10% of affected 
individuals [32]. These patients also tend to have more precancerous lesions than 
those with sporadic PDAC and also have an increased risk of developing extra-
pancreatic tumours. Whilst familial PDAC is well-documented, there are several 
possible genetic abnormalities responsible and many (85-90%) have still not been 
identified. Furthermore, germline genetic testing of patients with PDAC is probably 
not used enough and this is largely due to the clinicians’ failure to recognise the 
possibility of a familial cancer syndrome from the family history [32]. Germline 
mutations associated with an inherited susceptibility for PDAC include: BRCA2 
(possibly also BRCA1), PALB2 (partner and localiser of BRCA2), CDKN2A, STK11, 
PRSS1 and ATM [33] genes, and Lynch syndrome (hereditary non-polyposis colon 
cancer).  
The early detection of PDAC is unreliable, and furthermore current treatment 
strategies are unsatisfactory with surprisingly little benefit in survival. Thus, modifying 
lifestyle factors and the absolute avoidance of smoking may be the best prevention 
against this disastrous disease. 
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1.1.2 Clinical Characteristics and Diagnosis of Pancreatic Cancer 
The lack of signs and symptoms of PDAC results in delayed detection. Early-
stage disease is usually clinically silent and only becomes apparent after the tumour 
invades surrounding tissues or spreads to distant organs [32]. Most people who 
present therefore have advanced disease. Approximately 65% of PDACs occur in 
the head of pancreas (HOP), whereas 15% occur in the body and tail of the gland 
[34]. Typical presenting symptoms are subtle and can include abdominal pain (80%) 
which may radiate to the back [35], weight loss and obstructive jaundice if the mass 
obstructs the bile duct in the HOP. It is important to note that tumours not in the HOP 
(i.e. uncinate process, body and tail) may present with abdominal pain and weight 
loss, rather than jaundice and pruritis. Interestingly, at the time of surgery, uncinate 
process tumours are associated with higher incidence of superior mesenteric artery 
(SMA) encasement and perineural invasion [36]. This extrapancreatic extension at 
the time of clinical presentation results in reduced eligibility for pancreatic resection 
[36]. Weight loss is a sign of advanced disease and can be due to anorexia, 
malabsorption from pancreatic ductal obstruction, and cachexia [32]. Pancreatic 
ductal obstruction can also result in attacks of pancreatitis. Trousseau’s syndrome is 
a classical sign of PDAC (as well as lung cancer and gliomas) and is characterised 
by deep or superficial venous thrombosis, hypercoagulability and/or migratory 
thrombophlebitis. Diabetes or glucose intolerance may occur if there is considerable 
damage to the pancreas, and clinicians should be wary of patients with new-onset 
diabetes and weight-loss [32]. Gastric-outlet / duodenal obstruction with nausea and 
vomiting can also occur with more advanced disease [32]. Rarely patients can 
present with gastrointestinal bleeding. In a recent study of primary care records [35], 
nine features of PDAC were identified including jaundice, abdominal pain, 
nausea/vomiting, back pain, constipation, diarrhoea, weight loss, malaise, and new-
onset diabetes. Although many of these symptoms are vague, it may be that patients 
with multiple symptoms should be selected for further investigations by their General 
Practitioner [35]. 
Routine blood tests are often non-specific and can include mild abnormalities 
in liver-function (if not overtly jaundiced), hyperglycaemia and anaemia. 
Carbohydrate Antigen (CA) 19-9 is the only blood-borne tumour marker routinely 
used in clinical practice. CA19-9 is an isolated Lewis antigen of the MUC1 protein, 
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which is commonly expressed in the cells of tumours of the upper gastrointestinal 
(GI) tract, particularly PDAC [37, 38]. However, CA19-9 may also be positive in 
patients with non-malignant diseases, such as cirrhosis, CP, cholangitis and other GI 
cancers (colorectal, oesophageal and hepatocellular) [37]. Importantly, serum CA19-
9 may be elevated in the presence of hyperbilirubinaemia. Furthermore, some 
patients (approximately 10% of the Caucasian population) are negative for Lewis 
antigen (Le-a / Le-b) and are therefore unable to synthesize CA 19-9 and have 
undetectable levels, even with very advanced disease [38, 39]. These limitations of 
CA19-9 have been further defined in a recent meta-analysis of 11 studies that 
included 2,316 patients [37]. This revealed the pooled sensitivity for CA19-9 was 
0.803 (95% CI 0.777–0.826), with a pooled specificity of 0.802 (95% CI 0.780–0.823) 
for diagnosing PDAC [37]. Due to the issues surrounding the diagnostic role and 
reliability of CA19-9, there has been concerted effort in the discovery of novel blood-
based biomarkers for PDAC, including circulating tumour cells (CTCs), circulating 
cell-free DNA (cfDNA) and circulating microRNAs (miRNAs) [40]. Interestingly, two 
recent studies demonstrated that an elevated post-operative CA 19-9 levels are an 
independent predictor for poor survival [41, 42], renewing interest in the prognostic 
value of this serum marker. 
When there is clinical suspicion of pancreatic disease, patients often undergo 
ultrasonography (US), however the imaging of choice for the initial diagnosis and 
staging of PDAC is tri-phasic pancreatic-protocol computed tomography (CT). A 
summary of the current TNM (tumour, nodes, and metastasis) staging can be seen 
in Table 1. Abdominal CT scanning is performed after intravenous (iv) contrast 
infusion, with scanning sequences initiated 20-25 seconds (arterial phase), 40 
seconds (pancreatic or late arterial phase), and 60–80 seconds (portal venous 
phase) from the injection of contrast [43]. Maximum arterial conspicuity against 
background occurs during the early arterial phase, and CT allows preoperative 
planning and the creation of vascular maps (i.e. relationship of tumour to the SMA 
and coeliac axis, as well as superior mesenteric and portal veins) [43]. Non-contrast 
images are also obtained routinely. The most widely used acquisition is the venous 
phase, and this is the timing for routine abdominal imaging and staging of 
hypovascular cancers. McNulty et al. [44] found that although pancreatic 
enhancement is maximal during the pancreatic phase, PDAC conspicuity is 
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equivalent in the pancreatic and portal venous phases. Indeed, the reported 
sensitivity of CT for detecting PDAC ranges from 89% to 97% [45]. However, routine 
imaging techniques such as CT or MRI cannot detect PDAC at an early stage nor 
differentiate between some benign and pre-malignant lesions [46]., Bipat et al. [47] 
have performed a meta-analysis of 1,823 patients and demonstrated that helical CT 
determines PDAC surgical resectability with 81% sensitivity and 82% specificity, and 
that it is superior to both magnetic resonance imaging (MRI) and trans-abdominal 
US.  
Recently, endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) 
has been found to be a very specific and minimally invasive technique for the 
effective pre-operative diagnosis and staging of pancreatic tumours [46, 48, 49]. 
EUS-FNA is an accurate method for the cytopathologic confirmation of solid 
pancreatic lesions that has become an essential tool for pre-operative planning. 
Recent meta-analysis has shown that pooled sensitivity for malignant cytology was 
85% and specificity was 98%, and if suspicious cytological results were included to 
determine true neoplasms, the sensitivity increased to 91%, but specificity dropped 
to 94% [50]. However, the sensitivity of EUS-FNA for predicting malignancy in 
pancreatic cystic lesions is much lower at 24% with a specificity of 97% [51].  
 
Table 1 - Staging of PDAC. 
T, tumour; N, nodes; M, metastasis; SMA, superior mesenteric artery. 
 
Stage 
Pre-operative 
Status 
TNM Levels Description 
I Resectable T1 or T2, N0, M0 
No extrapancreatic disease, no 
encasement of the coeliac axis or 
SMA 
II 
Potentially 
Resectable 
T1 or T2, N1, M0; 
T3, N0 or N1, M0 
Regional lymph nodes may be 
involved, no encasement of 
coeliac axis or SMA, possible 
extrapancreatic involvement 
III Unresectable T4, N0 or N1, M0 
Regional lymph nodes may be 
involved, encasement of coeliac 
axis or SMA 
IV Unresectable T (any), N (any), M1 Liver, peritoneal, lung metastases 
 
Focussing on solid PDAC, Nawaz et al. [52] performed a pooled analysis and 
examined the use of EUS for pre-operative staging of PDAC versus (vs.) CT and 
assessed 3 factors: nodal staging, vascular invasion, and resectability. They found 
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that EUS was more sensitive and accurate in detecting malignant LNs than CT, with 
a pooled sensitivity of 69% and specificity of 81%. Furthermore, the addition of EUS-
FNA to diagnostic EUS has the potential to increase the sensitivity of nodal staging 
to 82% [53]. EUS also has the ability to carefully assess the involvement of coeliac 
axis lymphadenopathy, which indicates an unresectable state. CT scanning can be 
falsely negative for vascular invasion in approximately 20% of PDAC patients [54]. 
However, the meta-analysis revealed EUS accuracy for the detection of vascular 
invasion ranged between 62-100% with a pooled sensitivity of 85% and specificity of 
91% [52]. CT and EUS had comparable specificities. Finally, Nawaz et al. [52] found 
that EUS and CT scan perform similarly in predicting surgical resectability. In their 
analysis, the accuracy of EUS for detecting resectability ranged between 62-94% 
with a pooled sensitivity of 90% and specificity of 86%. It is important to note that the 
definition of resectability varies amongst pancreatic surgeons, as many are now 
performing arterial and venous resections.  
Notably, positron-emission tomography (PET) can be useful if CT findings are 
equivocal [39]. In addition, endoscopic retrograde cholangiopancreatography 
(ERCP) can help to define the pancreatic and bile-duct anatomy and can be used to 
obtain ductal brushings and lavage, thereby providing tissue for diagnosis [39]. More 
importantly, ERCP is used for patients with jaundice in whom an endoscopic stent 
can be placed to relieve obstruction. 
 
1.1.3 Molecular Characteristics of Pancreatic Cancer  
Advances in the study of the molecular biology of PDAC have encouraged 
translational research, allowed a greater understanding of the origins of the disease, 
revealed new treatment targets and given hope for personalised therapy and 
superior disease management [55]. Indeed, tumours with similar clinicopathologic 
characteristics can have dramatic molecular differences, which may explain 
variations in clinical behavior. Data suggest that PDAC results from a sequential 
accumulation of gene mutations [39]. It is thought that infiltrating carcinomas of the 
pancreas arise from well-defined PanIN precursor lesions in the small ducts of the 
pancreas. Pancreatic adenocarcinoma can also evolve from pancreatic benign cystic 
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tumours (BCT) such as intraductal papillary mucinous neoplasms (IPMNs) and 
mucinous cystic neoplasms (MCNs).  
However, PanINs are the best characterised precursors of PDAC, and are 
microscopic, non-invasive epithelial neoplasms arising in the ducts [56]. Notably, all 
PanIN lesions display an enlargement of the ductal lumen, and usually involve ducts 
<5 mm in diameter [56]. The features in cellular and ductal architecture atypia have 
been seen to occur in three discrete grades [57]. Furthermore, PanIN-1 lesions can 
be subdivided into flat (PanIN-1A) and papillary (PanIN-1B) types [58]. PanIN-2 
lesions have columnar ductal cells with nuclear abnormalities such as loss of 
polarity, nuclear crowding, enlarged nuclei and hyperchromatism, and are mostly 
papillary structures with thin fibrovascular cores, although some can be flat and 
epithelial-like [56]. PanIN-3 lesions are usually papillary and are rarely flat. They 
contain cells with severe nuclear atypia, and have the appearance of epithelial cells 
budding into the lumen, forming into true papillary and bridging ductal structures with 
less connection to the basement membrane and no invasion [56, 58]. During this 
progression, there are various genetic and epigenetic alterations accompanying the 
cellular and ductal changes at each stage (Figure 1A and B) [46, 59].  
As can be seen in Figure 1A, PDAC tumourigenesis is primarily characterised 
by accumulation of mutations including activation of KRAS oncogene, inactivation of 
tumour-suppressor gene (p16INK4A/CDKN2A [inhibitor of cyclin dependent kinase 4 
/ cyclin-dependent kinase inhibitor 2], followed by inactivation of tumour-suppressor 
genes TP53 and SMAD4 [aka deleted in pancreatic cancer 4; DPC4]). In addition, 
there is considerable chromosomal instability  in PDAC, characterised by abnormal 
numbers or structures of chromosomes [60]. Furthermore, critically shortened 
telomeres can cause chromosomal instability, and this is an indispensable event in 
most human epithelial cancers, and is also seen universally amongst PanINs [61]. 
Telomere shortening and activating point mutations in the KRAS oncogene mainly 
occur early in PanIN-1 lesions, CDKN2A is inactivated in intermediate and late 
lesions (PanIN-2/3), and the TP53, SMAD4, and BRCA2 genes are inactivated later 
in PanIN-3 lesions [62].  
In their landmark study in 2008, Jones et al. [63] performed whole-exome 
sequencing of 24 PDACs. This investigation of protein-coding exons of 20,661 genes 
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revealed that PDACs contain an average of 63 genomic alterations, most of which 
are point mutations [63]. Thus, there were 12 core signalling pathways and 
processes determined to be driving PDAC tumourigenesis, each encompassing 
alterations in several cancer-related genes (Figure 2) [63]. Since then 2 further core 
pathways have been identified (Figure 2). Biankin et al. [64] have reported the most 
comprehensive up-to-date evaluation of the PDAC genome using whole exome 
sequencing and copy number analysis of 99 tumours [64]. This study revealed a 
multitude of novel mutated genes including those involved in chromatin modification 
(EPC1 and ARID2), DNA damage repair (ATM) and others (ZIM2, MAP2K4, NALCN, 
SLC16A4 and MAGEA6), and supports the involvement of axon guidance genes in 
PDAC carcinogenesis [64]. Whilst Shain et al. [65] have found that the central 
tumour suppressive SWItch/Sucrose NonFermentable (SWI/SNF) chromatin 
remodelling complex (including ARID1A, ARID1B, PBRM1, SMARCA2 and 
SMARCA4) is targeted in PDAC. 
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Figure 1 - Molecular changes during progression of pancreatic cancer. 
(A) Normal duct epithelium progresses to infiltrating carcinoma through a series of 
histologically defined precursors, pancreatic intraepithelial neoplasia (PanINs). PanINs are 
classified into early and late lesions, starting with PanIN-1A, 1B (hyperplasia) and 
progressing to PanIN-2 and then to PanIN-3 or carcinoma in situ. The progressive 
accumulation of somatic alterations in critical genes is shown below. (B) Histological images 
of benign pancreatic ductal epithelial cells, progressive PanIN lesions and invasive 
carcinoma, with associated genetic alterations. Reproduced from [59] and [46] respectively. 
 
  
A 
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Figure 2 - Core signalling pathways whose component genes are altered in PDAC. 
The 12 pathways and processes whose genes are altered in most PDACs based on whole 
exome sequencing are shown in various colours and the 2 pathways more recently identified 
in RED [64, 65]. Therapeutic targeting of one or more of these pathways, rather than specific 
gene alterations that occur within a pathway, provides a new strategy for treating PDAC. 
Modified from [63] and [66]. 
 
KRAS is one of the members of the RAS oncogene family that encode small 
membrane-bound GTPases involved in regulating cellular signal transduction [67]. 
Activating mutations of KRAS (mostly codon 12, but also affecting codons 13 or 61) 
cause the induction of cell proliferation, survival and motility through several 
downstream effector pathways (e.g. phosphatidylinositol 3-kinase (PI3K)/AKT 
pathway, the RAF/MEK/ERK pathway and nuclear factor κB (NF-κB)) [68, 69]. 
Oncogenic mutated KRAS is expressed in up to 95% of PDAC cases and is involved 
in the initiation or early phase of pancreatic tumourigenesis [70, 71]. Recent laser 
capture microdissection (LCM) of PDAC and adjacent PanIN-2/3 lesions and 
subsequent exome sequencing confirmed that KRAS(G12) mutations were present 
in 87% and 90% respectively [58].  
This is supported by transgenic mice models based on conditional 
endogenous expression of the mutant KRAS. These mice have been generated with 
a KRAS mutation in codon 12 that substitutes an aspartic acid residue for a glycine, 
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resulting in a constitutively active RAS protein. These KRASG12D mice develop the 
full-spectrum of PanINs and also PDAC [72]. Thus activated KRAS appears to be an 
essential and early somatic genetic alteration in PDAC progression [73]. As 
mentioned previously, acinar cells can also undergo reprogramming and form 
metaplastic ducts and PanIN lesions, which is termed “acinar to ductal metaplasia” 
(ADM) [74, 75]. Genetically engineered mouse models (GEMM) indicated that the 
acinar/centroacinar compartment can give rise to ductal neoplasia, and the 
subsequent ADMs were thought to be the originating lesions for their PDAC [74]. 
Oncogenic KRAS was again thought to be responsible, but Shi et al. [74] 
demonstrated that whilst 61% of ADM lesions had associated PanINs, only 63% had 
identical KRAS mutations. This suggests that KRAS mutations may not be essential 
for human PDAC progression and that other low frequency gene mutations can 
trigger other pathways [73]. Indeed, Greer et al. [75] showed that KRAS activation 
alone is insufficient for ADM and PanIN development and additional stresses are 
required. They went on to demonstrate that loss of Numb accelerates acinar cell 
dedifferentiation during pancreatitis and deregulated KRAS signalling [75]. 
Importantly, genome sequencing [63] has identified many other low frequency gene 
mutations (and core signalling pathways) in PDAC. Yachida et al. [76] reported that 
all 4 driver mutations, in the KRAS, CDKN2A, TP53 and SMAD4 genes, are seen 
concomitantly in a mere 37% of PDACs. Individually, the COSMIC database 
(http://www.sanger.ac.uk/genetics/CGP/cosmic/) estimates the frequency of these 
mutations, as KRAS in 71%, TP53 in 52%, CDKN2A in 23% and SMAD4 in 22% of 
PDACs. 
Silencing KRAS in mouse PDAC xenografts, using a small interfering RNA 
(siRNA), has been shown to reduce tumour growth and also improve sensitivity to 
gemcitabine (GEM) chemotherapy [77]. However, targeting the RAF/MEK/ERK 
signalling pathway downstream of RAS with the oral multikinase inhibitor Sorafenib, 
in combination with GEM, has not provided any benefit to PDAC patients in Phase II 
and III studies [78, 79]. Interestingly, Rachakonda et al. revealed that those Stage 
III/IV PDAC patients with KRAS mutations (78%; 134/171 patients), particularly 
G12D, have reduced OS and this could be a potential independent prognostic 
marker (hazard ratio, HR=1.87; 95%CI 0.99–3.51; P = 0.05) [73]. Thus, identifying a 
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KRAS mutation could be used as a tool for guiding treatment, just as it is currently as 
a predictor of resistance to cetuximab in metastatic colorectal cancer (CRC) [80].  
Tumour suppressor genes are also frequently inactivated in PDAC due to 
chromosomal alterations or mutations. The tumour suppressor CDKN2A, which 
encodes p16 protein (a regulator of the G1-S transition), is intimately linked to 
negative regulation of the cell cycle through interactions with cyclin dependent 
kinase 4 (CDK4) and p53 in cell cycle G1 progression [39]. Loss of 
p16/INK4A/CDKN2A is found in >90% of PDACs [71]. Indeed, a mouse model with a 
conditional knock-in and knock-out of KRASG12D; Ink4a/Arfflox/flox shows rapid 
progression of PanIN lesions to metastatic PDAC [81, 82]. Clinically, Rachakonda et 
al. [73] found that there was no significant difference in OS associated with loss of 
CDKN2A in their patients; although the small subgroup with concomitant KRAS 
mutations and CDKN2A aberrations (18%; 31/171 patients) had the poorest OS 
compared to those without any mutations (median 13 vs. 30 months; P = 0.03). This 
combination was also an independent prognostic factor, with the HR for aberrations 
in both genes being 2.77 (95%CI 1.23–6.23; P = 0.01) [73]. 
Mutations in the TP53 gene encoding p53 result in a loss of normal function 
allowing the cells to escape DNA damage control checkpoints and programmed cell 
death, thus contributing to genomic instability [39]. TP53 is abnormal in 50-75% of 
PDACs [39, 82]. Alterations in the transforming growth factor (TGF)-β pathway 
components are also common in PDAC, with loss of SMAD4 in 55-60%, and loss of 
TGFβRI and TGFβRII in <5% [82, 83]. Deletion of SMAD4 results in increased TGF-
β signalling, loss of SMAD4-dependent cell growth inhibition and increased SMAD4 
independent epithelial-to-mesenchymal transition (EMT) [84]. Loss of SMAD4 at 
immuno-labelling post-operatively has been found to be an independent prognostic 
factor for poor OS (HR=2.045; P=0.014) and reduced disease-free survival (DFS) 
duration [83]. Combined with a KRASG12D background in a GEMM, loss of SMAD4 
induces the development of pancreatic IPMNs and MCNs [82]. However, compound 
mutant GEMMs, incorporating the 4 mutant alleles for KRAS, CDKN2A, TP53 and 
SMAD4, strongly support the genetic basis of PDAC progression. These pancreas-
specific promoters (PSP)-Cre (PSP-Cre) GEMMs develop PanINs, which can 
progress to frank malignancy after induction of pancreatitis by cerulein [82].  
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In the genomic landscape of PDAC, it is clear that these 4 “mountain” genes 
(KRAS, CDKN2A, TP53, and SMAD4) contribute to carcinogenesis [83]. Numerous 
candidate cancer genes that are altered at low frequency (“hills”) have also been 
identified. These genes, which are mutated in <20% of PDACs, include oncogenes 
like BRAF, MYB, AKT2 and EGFR; and tumour suppressors like MAP2K4, STK11, 
ACVR1B, ACVR2A, FBXW7 and EP300 [32, 85-87]. In addition, epigenetic changes 
(alterations in DNA methylation, histone modifications and effects of non-coding 
RNAs [ncRNAs]) can alter gene expression in PDACs [32]. For example, CDKN2A is 
inactivated in 40% of PDACs by homozygous deletion, in another 40% by an 
intragenic mutation coupled with loss of the second allele, and in 15% by 
hypermethylation of the CDKN2A gene promoter [62]. Several other important PDAC 
related genes undergo aberrant methylation-mediated functional loss, including 
MLH1 (a genome-maintenance gene), CDH1 (gene encoding E-cadherin), SPARC, 
DUSP6, RELN, RASSF1A, CCND2, TFPI2, RUNX3, SOCS1, and TSLC1 [88]. There 
are also several overexpressed genes due to promoter hypomethylation such as 
S100A4, S100P, SFN, MSLN, CLDN4, and MUC genes [89] [90].  
To examine changes during progression, Yachida et al. [91] performed 
comparative lesion sequencing, in which genetic alterations present in one PDAC 
sample were analysed in additional samples that were geographically or temporally 
distinct from the same patient. Interestingly, this revealed that the original parental 
clones harboured the majority of the 4 driver mutations and that geographically 
distinct subclones within the tumour had an accumulation of progressor mutations 
superimposed on their landscape leading to clonal evolution and metastasis [91]. 
Importantly, there was no consistent genetic signature identified within these 
metastatic subclones, highlighting the difficulties in discovering targeted therapies for 
and treating metastatic disease [91]. Amazingly, this genomic sequencing also 
suggested that PDAC is a slowly developing disease with at least 12 years between 
the initiating mutations and the formation of parental clones, and a further 7 years 
until the formation of subclones with the potential for metastatic spread [91]. They 
estimated that patients die an average of 3 years after that point. Unfortunately, it is 
probably during this late period that most patients become symptomatic and 
diagnosed. 
 40 
 
Whilst significant improvements in the understanding of the molecular biology 
of PDAC have been made, many of the exact mechanisms underlying this disease 
remain unknown. MiRNAs have emerged as a potential source of clinically useful 
molecular biomarkers for the early diagnosis, assessment of prognosis, and potential 
discovery of more effective therapeutic targets in human cancers. Thus, research 
has now been directed at exploring the PDAC miRNome, which is the basis of this 
thesis. 
 
1.1.4 Treatment of Pancreatic Cancer 
 PDAC has a dismal outlook without surgery, and outcomes remain poor even 
after radical resection aiming for a curative result. Given the paucity of successful 
chemotherapeutic options currently available, the onus now remains on 
investigations into tumour biology to reveal new targets, pathways and approaches 
that can lead to improvements in survival outcomes.  
Further explanation for the lethality of this tumour is its incredible resistance to 
virtually all chemotherapies, including the current standard of care chemotherapy, 
GEM. Recent meta-analysis of Phase III trials looking at the efficacy of molecular 
targeted agents in combination with GEM in unresectable PDAC found no significant 
survival benefit compared to GEM alone and were associated with increased 
toxicities [92]. However, after PDAC resection there is good evidence to support 
adjuvant GEM chemotherapy [CONKO-001 [93]] or 5-fluorouracil (5-FU) [ESPAC-1 
[94]]. In addition, the use of adjuvant chemoradiation (CRT) appears to be of benefit 
after PDAC resection [95, 96]. The advantages of adjuvant CRT are greatly debated, 
with many in the USA favoring its use, whilst it is currently not recommended in 
Europe due to a lack of any randomised trial data demonstrating a survival benefit 
[97]. Nevertheless, in order to achieve better survival results, more effective systemic 
therapies need to be developed and combined with optimal local–regional treatment 
(e.g. surgery plus adjuvant CRT), along with biomarkers to guide the sequencing of 
treatment modalities and identify which individuals would benefit from aggressive 
adjuvant, or even neoadjuvant therapies (i.e. personalised medicine). Thus 
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determining tumour biological factors that contribute towards the aggressive nature 
of PDAC may help in identifying novel biomarkers and/or therapeutic targets.  
1.1.4.1 Oncological Treatments for Pancreatic Cancer 
The development of new targeted therapies has become a major goal in the 
modern era of cancer research and treatment and has provided a significant stimulus 
for the evolving field of pharmacogenomics (genetic variation on drug response) [98]. 
However, in breast cancer (BC), tamoxifen, the first targeted anti-cancer agent, was 
initially developed and used in the early 1970s, but some 30 years passed before the 
emergence of the next major targeted therapy, trastuzumab. In contrast to the 
initially slow progress in targeted therapy design during this period, there was 
significant success in the development or reinvention of ”non-targeted” 
chemotherapeutic agents and chemotherapy regimens through large Phase II and 
Phase III studies. However, the design of such drugs and combination regimens has 
not always resulted in significant improvements in cancer patient care and survival. 
Much of this must be attributed to a lack of understanding of the role of 
pharmacogenomics in both response and toxicity associated with these agents, and 
there are few better examples of this than GEM in PDAC. Furthermore, despite the 
significant advances over the last decade in the development of molecularly targeted 
therapies in many human cancers, the impact of novel agents on clinical outcomes in 
PDAC patients has been lacking [98]. 
5-FU was the recognised treatment for advanced PDAC until 1997, but 
following an observed improvement in clinical benefit (determined by pain scores 
and analgesic requirements), and OS in a randomised comparison with 5-FU, GEM 
was established as the standard of care for treating this disease [99]. Subsequently 
trialled chemotherapy regimens, that often included GEM, have had variable success 
but often failed to demonstrate an OS benefit over GEM alone. A large phase III 
study comparing GEM with GEM plus capecitabine (GEM-CAP), did demonstrate a 
significant benefit in objective response rate and progression free survival with the 
combination regimen, but only showed a trend for improvement in OS, although a 
subsequent meta-analysis of two additional studies involving 935 patients showed a 
significant survival benefit in favour of GEM-CAP (HR=0.86; 95% CI, 0.75 to 0.98; 
P=0.02) [100]. Others have shown increased response rates, but often at the 
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expense of increased toxicity. FOLFIRINOX (infusional 5-FU, irinotecan and 
oxaliplatin) represents the most recent significant therapeutic advance in PDAC, as it 
improved survival in good performance status patients with metastatic disease by 4.3 
months compared with GEM alone [101], but again that came at the cost of 
significantly increased haematological and GI toxicities.  
Clinical trials involving multiple targeted agents acting on various cellular 
signaling pathways have also had variable success in terms of improving outcome 
measures. Erlotinib, which targets the epidermal growth factor receptor (EGFR), is 
potentially an exception to this as its use in combination with GEM in advanced 
patients was associated with a significant survival benefit (median 6.24 months vs. 
5.91 months) compared to GEM alone [102], although some would question the 
clinical significance of these findings. In a phase II study, GEM plus nab-paclitaxel 
was shown to be well tolerated and associated with a response rate of 48%, with a 
median OS of 12.2 months and a 48% 1-year survival [103]. Results from the phase 
III evaluation in metastatic pancreatic adenocarcinoma revealed that those treated 
with the synergistic drug combination had improved OS, benefitting a median of 1.8 
months, and 3.4 months when 25% of the patients were still alive [104]. 
Overall, there have not been many successes in improving treatments for 
PDAC in the GEM era. Arguably the greatest advance in chemotherapeutic strategy 
for treating this disease involves a combination regimen, FOLFIRINOX, that was 
associated with a median OS in good performance patients of only 11.1 months 
[101]. Whilst this is nearly double the median OS seen in patients treated with GEM 
alone, FOLFIRINOX therapy was also associated with significantly reduced levels in 
quality of life at 6 months [101]. Thus, throwing more and more chemotherapies into 
the equation is not necessarily the approach to adopt and one strategy in improving 
outcomes in PDAC should be to better understand which patients benefit most from 
current therapies and to potentially use synergistic agents to maximise response. A 
better understanding of the pharmacogenomics associated with the efficacy and 
toxicity of GEM and other anti-cancer drugs may be one tactic for achieving this.  
GEM is a deoxycytidine analogue and is administered as a prodrug that 
requires cellular uptake and intracellular phosphorylation to exert its action. Cellular 
uptake involves two families of nucleoside transporters, the sodium-dependent 
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hENT1 and 2 equilibrative transporters, and the sodium-independent hCNT 1–3 
concentrative transporters [105]. Following transport into cells GEM is 
phosphorylated by deoxycytidine kinase (DCK) to form GEM monophosphate 
(dFdCMP), which is subsequently phosphorylated to GEM diphosphate (dFdCDP) 
and GEM triphosphate (dFdCTP) by nucleoside monophosphate (UMP/CMP) and 
diphosphate kinase. GEM exerts its cytotoxic effect mainly through inhibition of DNA 
synthesis via the incorporation of active dFdCTP into the DNA strand [105]. It also 
has a unique mechanism of action known as ”self-potentiation” [106]. However, over 
90% of administered GEM is inactivated by cytidine deaminase (CDA) which 
converts active dFdCTP into inactive 2’-deoxy-2’ ,2’-difluorouridine (dFdU). 
Additionally, phosphorylated GEM metabolites are reduced by cellular 5’-
nucleotidase (50 -NT), and dFdCMP is also inactivated by deoxycytidine 
monophosphate deaminase (DCTD) [105]. Therefore, pharmacogenomics must play 
a key role in the inter-patient variability of GEM’s anti-tumour activity and toxicity, as 
the complex pathways involved in its metabolism and mechanism of action provide 
several key stages that may be affected by an increase or decrease in the activity of 
one or more of these components. 
A number of studies have correlated tumour hENT levels with clinical 
outcomes in PDAC patients and results suggest a lack of clinical benefit to the use of 
GEM in those with absent or low hENT1 levels [107, 108]. This hypothesis has 
recently been assessed in the "Low hENT1 and Adenocarcinoma of the Pancreas" 
(LEAP) trial, which is the first trial to use an integral biomarker in PDAC [109]. In this 
study, patients with low hENT1-expressing metastatic PDAC, determined by 
immunohistochemistry, were randomised to receive GEM vs. C0-101, a lipid-
conjugated form of GEM that enters the cell independent of hENT1 [110]. 
Unfortunately, within the GEM arm, there was no significant difference in survival 
between the high and low hENT1 subgroups (HR=1.147; 95% CI 0.809-1.626) [110]. 
There is significant variability in DCK expression levels between patients 
carrying different DCK genotypes [111] and in a study of 44 patients with advanced 
PDAC, reduced expression of DCK was shown to correlate with reduced OS and 
progression-free survival following GEM based chemotherapy (14.6 vs. 21.7 months, 
P<0.04) [112]. Others have shown that pharmacogenomic variation in the 
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deamination of GEM and its monophosphate might contribute to variation in 
therapeutic response to this drug [113]. Furthermore, genetic polymorphisms of 
various DNA damage and repair genes can have significant effects on outcome 
following GEM based chemotherapy [114]. 
PDAC has historically been very difficult to treat with standard chemotherapy 
and the outcome for most patients is usually very poor. Although a number of 
common mutations have been identified as playing a significant role in the 
development and progression of PDAC, the reasons behind this poor outcome and 
response to therapy is unclear. Clinically not all PDACs behave in the same way. 
Relapse rates for patients diagnosed with early stage disease are high, but some 
patients do not and the reasons for this are unknown. Furthermore, we see 
significant variability in terms of response and toxicity to GEM therapy in PDAC 
patients, with objective response rates in the region of 10-15% in advanced disease. 
Many patients who do respond can do so for a prolonged period of time and to these 
patients, GEM is often very beneficial. However, the majority of patients do not 
obtain any significant benefit from GEM monotherapy. Although these differences 
may relate to variability in the expression of oncogenes and tumour suppressor 
genes that drive tumour growth, it appears likely that pharmacogenomic factors must 
also play an important role. Therefore, it is imperative that new prognostic and 
predictive biomarkers are found that can identify which PDAC patients are most 
likely to benefit from GEM or other anti-cancer drugs and which patients may benefit 
more from an alternative regimen. 
The challenge remains to develop more effective, less toxic systemic 
therapies against PDAC, and this may well lie in the design of novel targeted 
therapies. There has been recent progress toward understanding the genetic events 
in the development of PDAC, in combination with advances in the field of 
pharmacogenomics, offering hope that we may build on recent achievements to 
better utilise standard treatments, such as GEM, as well as to develop more effective 
therapeutic strategies for PDAC in the future. 
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1.1.4.2 Surgical Treatments for Pancreatic Cancer 
It is clear that PDAC is a molecularly complex and aggressive disease and 
surgical interventions are often too late in the disease course and are therefore 
effectively only a macroscopic “debulking” and certainly inadequate to clear 
microscopic and undetectable metastatic disease. Complete surgical resection is 
currently the only option for potential cure, but only 15-20% of patients present with 
potentially resectable disease at time of diagnosis [11, 70]. The main features which 
preclude resection include distant metastatic disease and tumour invasion into local 
arteries, namely the coeliac axis or SMA. However, with advances in radiological 
technology, PDAC is being identified at an earlier stage than before and more 
patients are being deemed suitable for surgical resection.  
There are two surgical procedures that have the potential for a cure: the 
classic Kausch-Whipple operation (pancreaticoduodenectomy, PD), where part of 
the pancreas, the gallbladder, the duodenum, the pylorus (outlet of the stomach) and 
the distal (lower) part of the stomach are removed, and the pylorus-preserving 
pancreaticoduodenectomy (PPPD), where the stomach and the pylorus are not 
resected. Both operations are well described and these open procedures have 
become the gold-standard techniques in specialist pancreatic centres. Recent meta-
analysis has shown that no relevant differences exist in mortality, morbidity or 
survival between these two operations [115]. Furthermore, as surgical technologies 
and peri-operative care continue to improve, the hazard associated with these 
procedures has significantly reduced.  
Currently, prognostic factors for predicting survival in PDAC are poorly 
defined. The traditional clinicopathologic factors, including tumour characteristics, 
remain the only significant and clinically used features able to predict survival after 
PDAC resection. However, there is often discordance between histological 
characteristics, tumour stage and survival [10, 116]. In general, for surgically 
resected patients, higher survival rates are associated with smaller tumour size 
(<2cm) [117], resection margin negative (R0) [118] and LN negative disease [119]. 
These findings suggest that identifying patients at risk of developing PDAC at an 
earlier stage may reduce mortality. Furthermore, apart from determining tumour size, 
LN involvement and vascular compromise on imaging, and cytological grade from 
 46 
 
biopsy sampling, many of these criteria can only be made histopathologically and 
cannot be assessed effectively pre-operatively. Serum carbohydrate antigen 19-9 
(CA 19-9) is the only marker used in clinical practice to identify disease progression 
during PDAC treatment [6] and elevated levels post-operatively correlate with 
resection margin positivity (R1) and the development of distant metastases [42]. 
Thus, as with the issues of determining the optimal oncological treatments, there is 
an urgent need for pre and post-operative tumour biomarkers that are prognostic and 
predictive of surgical treatment outcomes in PDAC. Indeed, there may be overlap 
between these biomarkers as PDAC treatment is multimodal. 
  
 47 
 
1.2 microRNAs (miRNAs)  
MicroRNAs (miRNAs or miRs) are small endogenous ncRNAs ~17–25 
nucleotides (nt) in length, differing substantially from messenger RNAs (mRNAs) 
which tend to between 2000-5000 base pairs (bp) in length. MiRNAs play important 
post-transcriptional roles in gene regulation in animals and plants by targeting 
mRNAs, occasionally for direct cleavage, but usually for either translational 
repression or transcript destabilisation [120]. The final abundance of mature, 
processed miRNAs is instrumental to the degree to which mRNA targets are 
repressed. As a result, numerous mechanisms of altering miRNA transcription and 
processing (biogenesis), localisation, and binding behaviours have come under 
scrutiny. Disruption of these carefully tuned processes can disrupt the homeostasis 
and operation of miRNAs, causing them to operate pathologically. Their disrupted 
operation may still co-ordinately regulate mRNA targets, contributing to the aberrant, 
but still robust phenotypes observed in many human cancers. 
1.2.1 Caenorhabditis elegans and the discovery of miRNAs 
In 1993, Wightman et al. and Lee et al. discovered the first miRNA gene, lin-4, 
whilst working on the nematode Caenorhabditis elegans, as a gene necessary for 
the timing of postembryonic development (passage from larva to adult) [121, 122]. 
They found lin-4 RNA was intriguing in that it had two forms: a large 61-nt RNA, 
which was able fold into a stem-loop structure (a hairpin), and a small 22-nt RNA, 
which was part of the stem of the larger form (Figure 3A) [121-123]. They 
discovered that the small lin-4 RNA binds (by imperfect pairing and antisense) to 
complementary sequences that are repeated 7 times in the lin-14 mRNA 3’ 
untranslated region (3’UTR), forming a RNA-RNA interaction that downregulated lin-
14 gene expression (Figure 3B). LIN-14 protein is involved in developmental 
transition between the first (L1) and second (L2) larval stages. After the synthesis of 
LIN-14 protein is repressed by lin-4 during the early larval stages of C. elegans 
development, the expression of L2 and third stage (L3) specific molecules in larval 
development can occur (Figure 3C) [124]. 
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In 2000, the second miRNA gene, let-7, was also discovered in C. Elegans 
and regulates late larval development by inhibiting LIN-41 expression (Figure 3C) 
[125, 126]. The let-7 miRNA is a heterochronic switch gene expressed during the L2 
and L3 stages of development, which if lost causes reiteration of larval cell fates 
during the adult stage and vice versa [123, 125]. Let-7 encodes a temporally 
regulated 21-nt RNA that represses LIN-41 via two closely spaced let-7 
complementary sites (LCSs) in the 3'UTR (Figure 3C) [126]. Shortly after its 
discovery, let-7 was found to be broadly conserved across many animal species and 
multiple copies of the let-7 gene were identified in the human genome [123, 126]. It 
was then realised that miRNAs were not oddities particular to the worm and this lead 
to miRNA research beginning in earnest with many miRNAs subsequently being 
found in plants, animals and even viruses [123].  
 
 
 
A 
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Figure 3 - The lin-4 gene: pre-miRNA, mature miRNA structure and temporal 
expression. 
(A) The lin-4 miRNA has been mapped to a 693 bp region within the ninth intron of F59G1.4. 
Processing of the primary lin-4 transcript (pri-miRNA) by Drosha-DGCR8 liberates the pre-
miRNA. Dicer processes the pre-miRNA further into a 21-nt RNA duplex. The two miRNA 
strands are separated and one strand is loaded into Argonaute (Ago) to form an active RNA-
induced silencing complex (RISC). (B) Sense–antisense binding of lin-4 miRNA to 3'UTR of 
lin-14. The 7 putative lin-4 binding sites in the 3'UTR of lin-14; 3 out of the 7 sites are 
complementary to the seed sequence of lin-4, and the predicted base pairings are shown. 
The sense (top) strand represents the 3'UTR sequence, and the antisense (bottom) strand 
represents the mature lin-4 sequence. The seed region is underlined by a bar in each. (C) 
The temporal expression patterns of lin-4 and let-7. The vertical axis indicates the level of 
expression and the horizontal axis time, L1 to L4 larval stages. Reproduced from [123] and 
[127]. 
 
Since then, the miRBase database (http://www.mirbase.org/), hosted by the 
University of Manchester, was created in 2002 and now has 24,521 precursor 
miRNAs registered, which has increased dramatically from 4449 in 2007 [128]. 
There are 2,578 mature human miRNAs in miRBase version 20 [129], although 
many of these need to be experimentally validated. Currently there is an intensive 
effort to match miRNAs with definitive targets. However, as miRNA targets contain 
imperfect complementary sites, hundreds of target mRNAs have been matched to a 
single given miRNA, and these predicted targets still require validation [126]. Also, 
whilst a single miRNA can regulate many different mRNA targets, several different 
miRNAs can also bind to and synergistically control a single mRNA target [130].  
 
It is estimated that miRNAs potentially target 30–60% of the protein-coding 
genes in the human genome [123, 131]. MiRNAs are now widely recognised as 
important negative regulators of gene expression and are able to control a wide 
variety of fundamental cellular processes including development, metabolism, signal-
transduction, cell-cycle, apoptosis, pluripotency, differentiation, transformation and 
C 
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stress-responses [123, 128, 132]. Disruption of physiological miRNA-mediated gene 
regulation can lead to human disease and many miRNAs have been causally 
implicated in various human cancers [131, 132].  
1.2.2 Identification of a miRNA 
MiRNAs are defined as single-stranded ncRNAs that have the following 
combination of expression and biogenesis criteria [130, 133]. Firstly, the mature 
miRNA expression should be detectable by hybridisation to a size-fractionated RNA 
sample by northern blot analysis. Northern blotting allows confirmation of miRNAs 
because the blot can show both the mature miRNA ( 22 nt band) and hairpin 
precursor ( 70 nt band). Other detection methods that can be used include reverse 
transcription polymerase chain reaction (RT-PCR), primer extension analysis, 
microarray and RNase protection assay [130].  
Secondly, the mature miRNA should come from a precursor ( 60-80 nt) with 
a characteristic hairpin or fold-back structure that lacks large internal loops or bulges 
[130, 133]. The mature miRNA should occupy the stem part of the hairpin [133]. 
Thirdly, the small mature miRNA and to a lesser extent the hairpin structure should 
be conserved in different species. An additional criterion is that the hairpin precursor 
should be processed by Dicer and this can be demonstrated by an accumulation of 
the precursor in Dicer-deficient mutants, although it can be difficult to deplete Dicer 
in certain cell types [130, 133]. In order to annotate a small RNA as a miRNA, the 
first criterion (expression) plus the second (structure), or the first (expression) plus 
the third criterion (conservation) are required, otherwise it is simply a siRNA [130].  
1.2.3 miRNA genes and genomic organisation 
MiRNAs are generally named as miR- plus numbers (e.g. miR-21). miRNAs 
with a similar sequence, differing at only one or two nt positions (not including the 
seed sequence), are given a letter suffix (e.g. miR-196a and 196b) [134]. If two 
different mature miRNA sequences appear to be excised from opposite arms of the 
same hairpin precursor, these mature sequences are named 5p for 5′ arm and 3p for 
the 3′ arm (e.g. miR-196a-3p) [135]. It was previously thought that most miRNAs are 
transcribed from the intergenic (between protein-coding genes) regions of the 
genome from their own transcription units (TU), however it now appears that the 
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majority are located within intronic regions of protein-coding or non-coding TU [130, 
134, 136-139]. The expression of these intronic miRNAs occurs with the transcription 
of the hosting TU and therefore their host genes may be co-regulated [137, 138]. 
Some miRNAs are organised into clusters and approximately half of miRNA loci are 
in close proximity (<50 kilobases; kb) to the next miRNA and are transcribed from a 
single polycistronic TU [138, 140]. Clusters often contain two or more miRNAs with 
similar sequences and this combination allows synergistic biological effects (e.g. 
miR-23a/24-2/27a cluster) [138, 141].   
1.2.4 The biogenesis of miRNAs 
1.2.4.1 Transcription and nuclear processing by Drosha 
MiRNA genes are transcribed by RNA polymerase II (Pol II) to generate the 
primary transcripts (pri-miRNAs) in the nucleus [130, 142-144]. A small group of 
miRNAs that are associated with Alu repeats (a major middle repetitive nt sequence 
in the eukaryote genome) can be transcribed by Pol III [140]. Pol III also produces 
some of the shorter ncRNAs like transfer RNAs (tRNAs), 5S ribosomal RNA, and the 
U6 small nuclear RNA (snRNA) [120]. Pri-miRNAs are usually several kb long, 
contain a local hairpin “stem-loop” structure, and are capped and polyadenylated (i.e. 
are modified by addition of a 5′ 7-methyl guanylate (m7G) cap and a 3′-poly(A) tail) 
[137, 140, 142]. Transcription from the miRNA genes is generally directed by 
transcription factors (TF) that respond to multiple signals and are also controlled 
epigenetically [144].  
 
 The next step is the precise excision of the upper part of the hairpin / stem–
loop from the pri-miRNA in a process called “cropping” by an RNaseIII enzyme called 
Drosha, forming the precursor-miRNA (pre-miRNA) (Figure 4) [137, 145]. Drosha is 
a large 160kDa protein that is conserved in animals [140] and contains two RNase 
III domains (RIIIDs) and a double-stranded RNA-binding domain (dsRBD) that are 
crucial for pri-miRNA processing [130, 146]. Drosha forms a large nuclear 
"microprocessor" complex of 650 kDa in humans with its cofactor DiGeorge 
syndrome critical region gene 8 (DGCR8) protein (also known as Pasha in D. 
melanogaster and C. elegans), which assists in substrate recognition [130, 140]. The 
two RIIIDs of Drosha cleave the 5' and 3' arms of the pri-miRNA hairpin, whilst 
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DGCR8 functions as a molecular ruler to determine the precise cleavage site. This 
allows Drosha to cleave 11 bp away from the ssRNA/dsRNA junction at the base of 
the hairpin stem [147]. Interestingly, intron-derived miRNAs bypass Drosha-
mediated processing of pri-miRNAs into pre-miRNAs. If these so called "mirtrons" 
have the appropriate length and form a hairpin structure resembling a pre-miRNA 
after splicing and debranching, then they go on to be further processed by Dicer in 
the cytoplasm (Figure 4) [140, 147, 148]. There are also intragenic miRNAs found 
in regions that overlap an exon and an intron of non-protein-coding genes, although 
this is very rare. These are “exonic miRNAs” and their expression is co-ordinated by 
their host gene promoters [136]. 
1.2.4.2 Nuclear export by exportin-5 
The microprocessor complex endonucleolytically cleaves pri-miRNA into a 
60-70-nt pre-miRNA, that comprises a short double-stranded RNA (dsRNA) stem 
(>14 nt) with a base-paired 5′ end and a 1–8 nt protruding 3′ end (structure known as 
the "minihelix motif") [130, 140, 149, 150]. Nucleo-cytoplasmic transport of RNAs 
and proteins is dependent on soluble receptors called karyopherins that can dock at 
and translocate through the nuclear pore complex (large proteinaceous channels 
embedded in the nuclear membrane) [130, 149]. Export of pre-miRNA is mediated 
by one of these nuclear transport receptors, exportin-5, encoded by the XPO5 gene 
in humans (Figure 4) [151]. The specific structural features of a pre-miRNA are 
required for recognition by exportin-5 for transfer into the cytoplasm [152]. When 
cells are depleted of exportin-5, the levels of pre-miRNA and mature miRNA in the 
cytoplasm are significantly reduced [151, 152]. Exportin-5 binds cooperatively to its 
cargo and the guanosine triphosphate (GTP) bound form of the cofactor Ran 
GTPase in the nucleus, and releases the cargo following the hydrolysis of Ran-GTP 
to Ran-GDP in the cytoplasm [130, 151]. 
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Figure 4 - microRNA genomic organization, biogenesis and function. 
Figure legend continues on the next page. 
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Figure 4 – microRNA genomic organization, biogenesis and function. 
Genomic distribution of miRNA genes is seen at the top. The sequence encoding the miRNA 
is shown in RED. TF: transcription factor. (A) Clusters throughout the genome transcribed as 
polycistronic primary transcripts and subsequently cleaved into multiple miRNAs; (B) 
intergenic regions transcribed as independent transcriptional units; (C) intronic sequences (in 
GREY) of protein-coding or non-coding transcription units or exonic sequences (BLACK 
cylinders) of non-coding genes. The primary miRNA transcript (pri-miRNA) is produced by 
RNA polymerase II or III. Primary miRNAs (pri-miRNAs) are transcribed and receive a 7-
methylguanosine (7mGpppG) cap and a poly(A) tail. The pri-miRNA is processed into a 
precursor miRNA (pre-miRNA) stem-loop of ∼60 nucleotides (nt) in length by the 
microprocessor complex Drosha and its partner DiGeorge syndrome critical region gene 8 
(DGCR8). Exportin-5–Ran-GTP actively transports pre-miRNA into the cytosol, where it is 
processed by the Dicer RNaseIII enzyme, together with its partner TAR RNA binding protein 
(TRBP), into mature, 22 nt-long double strand miRNAs. The functional strand of the mature 
miRNA/miRNA* duplex (in RED) is recruited as a single-stranded molecule into the RNA-
induced silencing (RISC) effector complex and assembled through processes that are 
dependent on Dicer and other double strand RNA binding domain proteins, as well as on 
members of the Argonaute family. The passenger strand (miRNA*) is degraded. Mature 
miRNAs then guide the RISC complex to the 3′ untranslated regions (3′-UTR) of the 
complementary messenger RNA (mRNA) targets and repress their expression by several 
mechanisms: repression of mRNA translation, destabilisation of mRNA transcripts through 
cleavage, de-adenylation, and localisation in the processing body (P-body), where the 
miRNA-targeted mRNA can be sequestered from the translational machinery and degraded 
or stored for subsequent use. Scissors indicate the cleavage on pri-miRNA or mRNA. 
Modified from [153]. 
 
1.2.4.3 Cytoplasmic processing by Dicer 
After export from the nucleus, pre-miRNAs are next processed by the 
cytoplasmic RNase III Dicer by cleaving off the loop into 22 nt miRNA duplexes 
(miRNA-miRNA*) that have 2 nt protruding as overhangs at each 3' end (Figure 4) 
[130]. Dicer was originally found to have a role in generating siRNAs for RNA 
interference (RNAi) [154]. It was later shown that deletion of Dicer abolishes the 
production of mature miRNAs and it is therefore crucial for miRNA processing[154]. 
Dicer is a multi-domain protein of 200 kDa that has two RIIIDs, a dsRBD and a long 
N-terminal segment that contains a Dead-Box RNA Helicase domain, a DUF283 
domain and a PAZ domain. The Dead-Box RNA Helicase domain is an evolutionarily 
conserved domain for a family of enzymes that use ATP hydrolysis to unwind RNA 
duplexes. The domain is named after the DEAD (Asp-Glu-Ala-Asp) motif [130]. The 
PAZ domain is also found in the Argonaute (Ago) group of proteins [130].  
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Human Dicer next interacts with 2 proteins, TRBP (TAR RNA-binding protein; 
also known as TARBP2) and PACT (protein activator of PKR; also known as 
PRKRA), neither of which are required for the cleavage reaction itself, but contribute 
to the formation of the RNA-induced silencing complex (RISC) by recruiting the final 
core component, which is the protein Argonaute-2 (Ago2) [155-157]. Ago2 has two 
important functions: firstly, its PAZ domain binds to the 3' protruding end of small 
RNAs [158] and secondly, it has been shown to function as the “slicer” enzyme that 
cleaves target mRNA [159]. RISC is the cytoplasmic effector machinery of the 
miRNA pathway and contains a single-stranded miRNA guiding it to its target 
mRNAs. Cytoplasmic miRNA processing and RISC assembly are mediated by the 
RISC loading complex (RLC) [147]. The RLC complex is initiated independently of 
ATP hydrolysis by the assembly of Dicer, TRBP and Ago2, and the exported pre-
miRNA only joins the RLC after the formation of this complex [160]. 
1.2.4.4 Guide strand selection and mRNA targeting 
Mature miRNAs that are incorporated into the effector complex are known as 
”miRNP” (miRNA-containing ribonucleoprotein complex), “mirgonaute” or “miRISC” 
(miRNA-containing RNA-induced silencing complex) [130]. To form the active 
miRISC that performs gene silencing, the miRNA/miRNA* duplex needs to be 
separated into the functional guide strand, which is complementary to the mRNA 
target, and the passenger strand (miRNA*), which is subsequently degraded [130, 
147] (Figure 4). Various helicases are associated with the miRNA pathway, however 
a universal helicase responsible for miRNA/miRNA* unwinding has not yet been 
identified and may not actually be required. What is known is that the strand selected 
for incorporation into the miRISC and guiding depends on the thermodynamic 
stability of the base pairs at the two ends of the duplex: the miRNA strand with the 
relatively unstable base pair at its 5' end (e.g. GU pair compared with a GC pair) is 
loaded into miRISC [130, 140, 147, 148, 161]. The miRISC then binds by imperfect 
base pairing to the 3'UTR of the target mRNA in a sequence-specific manner, and 
induces mRNA cleavage, translational repression or cleavage-independent mRNA 
degradation (Figure 4 and 5) [162]. 
  
MiRNA-binding occurs by Watson–Crick consecutive base pairing between 
the 3′UTR of the target mRNA and the "seed" region (6-8 nt sequence) of the miRNA 
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at positions 2–8 counted from its 5′ end [163]. As the miRNA interaction with mRNA 
is imperfect, it has been predicted that single miRNA can target tens to hundreds of 
mRNAs [164]. In fact many mRNA sites that match the miRNA 5' seed sequence are 
preferentially conserved and probably >60% of human protein-coding genes are 
under selective pressure to maintain pairing to miRNAs [164]. Another major feature 
of animal miRNA–mRNA interactions is the lack of complementarity in the central 
part of the miRNA (usually positions 10 and 11) that precludes the RNAi-like 
endonucleolytic cleavage of the target mRNA in the middle of the duplex, but instead 
favours translational repression and exonucleolytic degradation of target mRNAs 
(Figure 5) [165]. Other important principles of the miRNA-mRNA interaction are that 
the 3' portion of the miRNA can also contribute to effective translational repression 
[166], the choice between translational suppression or mRNA degradation is largely 
affected by the degree of complementarity with the mRNA target [161] and that the 
interaction between miRNA and Ago proteins with mRNA may be influenced by other 
sequence-specific RNA-binding proteins such as GW182 [167]. 
 
Figure 5 - Modes of base pairing for small RNAs to target mRNAs. 
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Figure 5 – Modes of base pairing for small RNAs to target mRNAs.  
Perfect complementarity leads to endonucleolytic cleavage, catalysed by the human Ago2 
‘Slicer’ in the RISC complex. This mechanism applies to siRNAs and many plant miRNAs. In 
general, animal miRNAs show only partial complementarity (i.e. mismatches and bulges) to 
their target mRNAs. This precludes endonucleolytic cleavage and instead promotes 
translational repression and exonucleolytic degradation of target mRNAs. Modified from 
[165]. 
 
1.2.5 Regulation of miRNA biosynthesis and function 
1.2.5.1 Transcriptional control 
The regulation of miRNA transcription is an important control point for their 
expression and is very similar to that of protein-coding genes (e.g. the promoters of 
miRNA genes are controlled by TFs, enhancers, silencing elements, chromatin 
modifications and autoregulatory feedback loops) (Figure 6) [148]. Epigenetics are 
the mitotically heritable changes in gene expression without any change in the DNA 
sequence itself (Figure 6) [168-170]. Indeed, DNA methylation in promoter CpG 
islands plays a crucial role in tumourigenesis and occurs even earlier than other 
genetic events such as LOH and microsatellite instability. Saito et al. [171] were the 
first to show that epigenetic mechanisms, like DNA methylation and histone 
modifications, can affect miRNA expression. They found that miR-127 is embedded 
in a CpG island and can be significantly upregulated in cancer cells after treatment 
with 5-aza-2'-deoxycytidine (5-Aza-CdR; a potent DNA methylation inhibitor) and 4-
phenylbutyric acid (PBA; a histone deacetylase inhibitor), suggesting that there had 
been a re-expression of the miRNA genes which had previously been silenced 
epigenetically. In PDAC, several miRNAs have been shown to be regulated by 
aberrant DNA methylation including miR-132, 148a, 107, 34, and 124 [172]. 
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Figure 6 - Regulation of miRNA biosynthesis and function. 
The deregulated microRNA expression observed in cancer can be caused by chromosomal 
abnormalities, mutations, polymorphisms (SNPs), transcription factors, defects in Drosha 
and Dicer biogenesis machinery, and epigenetic changes. Although not involved with miRNA 
biogenesis, several other mechanisms exist that can alter mature miRNA levels and 
function. RBPs: RNA binding proteins; ceRNA: competing endogenous RNA; circRNA: 
circular RNA. Modified from [173]. 
 
Various Pol II-associated TFs can also up-regulate or down-regulate the 
expression of selected miRNAs (Figure 6). For example, myogenic TFs, such as 
myogenin and myoblast determination 1 (MYOD1), bind upstream of miR-1 and miR-
133 loci and induce the transcription of these miRNAs during myogenesis [140]. 
Another example is the c-MYC proto-oncogene (hereafter referred to as MYC) which 
is involved in 20% of all human cancers [174] and has been shown to activate 
transcription of the miR-17-92 polycistron (encoding miR-17, 18a, 19a, 20a, 19b-1, 
and 92a-1; aka Oncomir 1; more detail in section 1.4.4 and Figure 8 later) in 
lymphoma cells, which plays a role in angiogenesis and tumour growth [175]. 
Interestingly, two miRNAs in the cluster (miR-17 and 20a) negatively regulate 
expression of the E2F1 TF, which is an additional target of MYC that promotes cell 
cycle progression and apoptosis [175, 176]. Thus MYC can activate transcription of a 
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target gene, whilst simultaneously inhibiting its translation, allowing tight control 
between proliferation and apoptosis [174]. Ectopically expressed MYC can also 
increase the expression of miR-9 in neuroblastoma cells and HMLE (non-
transformed, immortalized human mammary epithelial) cells and is implicated in 
tumour cell invasiveness and metastasis [177, 178]. MYC is also able to cause broad 
repression of several tumour suppressor miRNAs (e.g. let-7 family, miR-34a, miR-
15a/16-1) [179]. Another MYC-repressed miRNA, miR-26a, has been used via a viral 
vector as a therapeutic strategy in a MYC-driven mouse hepatocellular carcinoma 
(HCC) model and was found to be able to reverse disease progression [180]. 
Tumour suppressor protein p53 can also exert some transcriptional control by 
increasing the expression of the miR-34a-c family (enhancing cell cycle arrest and 
apoptosis)[181, 182] and miR-107 (suppressing tumour growth and 
angiogenesis)[183]. 
1.2.5.2 Regulation of Drosha and Dicer miRNA processing 
miRNA processing by Drosha confers another important point of regulation 
and some nuclear RNA-binding proteins influence processing by interacting with a 
subset of pri-miRNAs (Figure 6) [140]. Drosha forms two types of complex, a small 
microprocessor complex that contains only Drosha and DGCR8 and processes the 
majority of pri-miRNAs, and a larger complex that contains Dead-Box RNA helicases 
(p72 an p68; aka DDX17 and DDX5), heterogeneous nuclear ribonucleoproteins and 
Ewing's sarcoma proteins [184]. p72 and p68 may act as a “scaffold” to recruit other 
factors (e.g. SMADs, p53 and oestrogen receptor ɑ; ER-ɑ) for the processing of a 
subset of pri-miRNAs, whose pre-miRNA and mature miRNA levels are reduced in 
homozygous p72 or p68 knockout mice [148, 162, 185].                                            
The processing of specific miRNAs can be regulated during Drosha-mediated 
cleavage. For example, the heterogeneous nuclear riboprotein A1 (hnRNP A1) binds 
to the conserved loop of pri-miR-18 and changes the hairpin configuration so that it 
is more favourable for Drosha processing [186]. TGF-β and bone morphogenetic 
factors (BMPs) recruit signal transducing SMADs which regulate gene expression at 
the transcription level and Drosha-mediated processing [148]. SMADs are recruited 
to pre-miRNA-21 by TGF-β and BMP and form a complex with p68, consequently 
Drosha-mediated processing is increased and the amount of mature miR-21 
 60 
 
increases resulting in contractile vascular smooth muscle cells [187]. Pri-miRNA 
processing is also dependent on the 5′-terminal capping of transcripts. Arsenite-
resistance protein 2 (ARS2) is a component of the nuclear cap-binding complex and 
interacts with Drosha to create pri-miRNA stability before processing [148, 188].  
LIN-28 is a stem-cell-specific negative regulator of let-7 family biogenesis and 
is able to interfere with Drosha and Dicer processing [147, 148]. Mature let-7 does 
not accumulate in undifferentiated embryonic stem cells despite constant expression 
of pri-let-7. LIN-28 interferes with Drosha cleavage of pri-let-7 by competitively 
binding to its terminal loop [189]. LIN-28 is also able to bind to pre-let-7 and cause 
uridylation (addition of ~14 nt U tail) thereby preventing Dicer processing and 
redirecting it towards degradation [190]. Interestingly, LIN-28 is down-regulated by 
miR-125 and let-7, allowing processing of pre-let-7 to proceed, whilst suppression of 
let-7 or miR-125 activity leads to up-regulation of LIN-28 and loss of pre-let-7 
processing activity [190]. Dicer is also regulated by let-7, which targets the coding 
region of Dicer mRNA, creating another feedback loop [191].  
Drosha is also able to self-regulate its own miRNA processing activity by 
decreasing the DCGR8 levels. Whilst DCGR8 stabilises Drosha at its middle domain, 
Drosha is able to cleave 2 hairpin structures in the 5'UTR and coding sequence of 
the Dgcr8 mRNA [192, 193]. This reduces Dgcr8 expression when sufficient 
microprocessor activity is available.  
Multiple mechanisms of Dicer regulation have also been described. The 
amino-terminal Dead-Box RNA Helicase domain of human Dicer inhibits its cleavage 
activity, when TRBP binds to Dicer in this region it causes stability and activation 
through a conformational rearrangement [147]. In fact mutations of TRBP are found 
in some carcinomas and are associated with decreased miRNA levels and Dicer 
instability [194]. Pre-miR-138 is expressed ubiquitously in all tissues and HeLa cells, 
but its mature form is restricted to certain cell types, despite normal pre-miR-138 
levels, suggesting tissue-specific Dicer processing of this miRNA [195]. Interestingly, 
the elimination of Dicer can elicit two opposite cell fates, either senescence or 
enhanced proliferation, in normal or cancer cells, respectively [196]. Therefore, an 
altered expression of Dicer has been associated with tumourigenesis and several 
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studies have associated aberrant Dicer expression with prognosis in various tumour 
types [197]. 
1.2.5.3 miRNA editing 
RNA sequences can be changed at the post-transcriptional level by 
deamination of adenosine (A) to inosine (I) thus altering the base-pairing and 
structural properties of the transcript [147]. This editing process is catalysed by 
adenosine deaminases that act on RNA (ADARs). Several pri-miRNAs and pre-
miRNAs (e.g. miR-22 [198], miR-151 [199], miR-142 [200]) have been described as 
targets of ADARs and the subsequent modifications can affect both Drosha and 
Dicer-mediated cleavage (enhancing or inhibiting), as well as preventing pre-miRNA 
export [148]. In addition, editing can change the miRNA complementarity to target 
sequences, especially if the edit is within the miRNA seed region [147].  
1.2.5.4 Regulation of miRNA targeting 
MiRNA targeting efficiency: Various factors in vivo can influence the ability 
of miRNAs to bind and regulate their specific target genes. Since the majority of 
miRNAs act on very specific sequences within the mRNA, the actual position of this 
binding site is crucial its subsequent recognition and regulation by the miRISC [201]. 
Optimal accessibility for the miRISC in the 3’UTR (i.e. AU richness and unstructured 
areas) correlates with targeting efficiency [202]. Transcriptome-wide evaluation of 
Ago2 binding by cross-linking immunoprecipitation (CLIP) has helped to identify 
many miRNAs binding outside of the 3’UTR [203]. Regulation through targeting sites 
within the 5’UTR [204], open reading frames (ORF) [205], and coding DNA 
sequences (CDS) [191, 206] has been validated. Of note, studies have shown that 
sites located in 3′ UTR are much more effective at inducing mRNA degradation, 
whilst sites in the CDS appear more disposed to inhibit translation [206]; and target 
sites in ORFs and 5′ UTRs are not very frequent and also less effective than those in 
3′ UTR [204]. Another factor is how the number of miRNA binding sites within an 
mRNA can influence regulation [201]. In general, increasing the number of target 
binding sites for the same or different miRNA species increases the efficiency of the 
target regulation [166, 201]. Overlapping miRNA binding sites can also influence 
regulation and this could explain why one mRNA target is affected over another 
[201]. It is also known that modifications in the Ago proteins [207] and miRISC co-
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factors [208] can both influence miRNA targeting efficiency. Finally RNA-binding 
proteins (RBPs) that interact with mRNAs can alter miRISC binding and function. For 
example, HuR (an RBP) can interact with >75% of the 3’ UTRs targeted by miRISC, 
and many of these HuR recognition sequences are either adjacent to or overlap 
miRNA binding sites, thereby increasing or decreasing mRNA regulation [209].  
miRNA target interactions: It has recently been shown that regulation in the 
miRNA pathway is a two-way affair (i.e. base pairing between a miRNA and its target 
mRNA results in reduced target expression, but also these interactions can impact 
the levels of the mature miRNA) [201]. Indeed, it may be exactly the miRNAs’ ability 
to target multiple transcripts that causes the strength of mRNA repression to be 
diluted across the available targets. At a basic level, the extent of regulation 
achieved is dependent on the ratio of mRNA and miRNA complexes available, 
through a titration mechanism [166]. If the abundance of miRNAs is depleted by 
other interactions, then their regulation of target mRNAs will be reduced. There have 
now been various “competing endogenous RNA” (ceRNA) or natural miRNA 
“sponges” identified, transcripts that may be, for example, transcribed pseudogenes 
or long noncoding RNAs (lncRNA), and are able to participate in mRNA regulation by 
competing for miRNA binding [210]. For example, the PTEN1 pseudogene competes 
with PTEN for mutually targeting miRNAs, as both contain shared miRNA binding 
sites [211]. As PTEN ceRNAs can sequester repressive miRNAs away from this 
tumour suppressor, their action may decrease tumourigenesis through increasing 
final levels of PTEN [201]. Thus, there is a complex network of “cross talking” 
between ceRNAs to indirectly modulate each other's abundance via miRNA binding 
[209]. Cross talk is maximised when both RNA species are at approximately 
equimolar concentrations [209]. Interestingly, binding of a miRNA to a ceRNA not 
only prevents that miRNA from binding to other target sites, but it can also suppress 
translation from the coding portion of the ceRNA itself [212]. Certain circular RNAs 
(circRNA; e.g. ciRS-7 for miR-7) have also emerged as potent ceRNAs with some 
shown to be able to bind multiple copies of a single miRNA to strongly relieve 
repression of its mRNA targets. CircRNAs can be expressed in a tissue-specific 
manner, are quite stable to degradation (being circular there are no free ends for 
RNA exonuclease enzymes to act on), and are often evolutionary conserved [210]. 
In cases where circular “sponges” are also highly expressed, the subsequent 
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“supersponge” activity may quickly and substantially alleviate the effects of specific 
miRNAs, and roles for this mechanism in marshalling developmental transitions and 
tumourigenesis are being explored [209].  
 
1.2.6 Mechanisms of protein synthesis repression by miRNAs 
1.2.6.1 Translational repression at the initiation stage 
Messenger RNA translation can be divided into the stages of initiation, 
elongation and termination, with the initiation stage thought to be the rate limiting 
step and undergoing the most regulation. We know that miRNAs function as 
ribonucleoprotein particles (miRISCs or miRNPs) and the Ago 1-4 proteins are the 
key components of these. Ago2 (“slicer”) can function in RNAi by endonucleolytically 
cleaving mRNA in the middle of the mRNA–siRNA duplex, whereas all the 4 Ago 
proteins appear to have a role in miRNA-mediated translational repression in 
mammals [159, 165], as well as directing miRNAs to the general degradation 
machinery [213]. If the miRNA processing pathway is inhibited (e.g. depletion of 
Dicer or Ago proteins; Figure 6) then there is a subsequent increase in the levels of 
many mRNA targets in the cells [214]. Conversely overexpression of miRNAs in cells 
results in down-regulation of mRNA transcripts containing complementary binding 
sites [215]. However, the increased mRNA degradation caused by miRNAs does not 
fully explain the observed reduction in subsequent protein synthesis, lending support 
to the existence of additional mechanisms of initiation and post-initiation translational 
repression (Figure 7) [165].  
 
The translation of most mRNAs requires a 5' terminal m7G cap, and the 
starting event is the assembly of the initiation complex with interaction between the 
cap and cap-binding factor eIF4E [165]. The 3′-poly(A) tail remains bound to the poly 
(A)-binding protein (PABP) and then eIF4E and PABP both bind to eIF4G, which 
together with the 40S ribosomal subunit are recruited to the mRNA in order to start 
elongation. Experiments using luciferase reporters, with 3 partially mismatched 
target sites in the 3'UTR targeted by endogenous let-7, have shown that miRNAs 
may affect m7G cap recognition with eIF4E as the potential molecular target [216] 
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and Ago proteins may compete with eIF4E for binding to the cap (Figure 7) [217]. 
A different study found that miRNAs may actually target the cap, as well as the 
3′-poly(A) tail (i.e. eIF4G which normally decorates the 3’ end of the message, 
encouraging circularisation, and enhanced translational efficiency) (Figure 7) [218].  
 
 
 
Figure 7 - Possible mechanisms of miRNA-mediated regulation of target mRNAs. 
A complex of eukaryotic initiation factors (eIFs) binds the 5’ cap and the cytoplasmic poly(A)-
binding protein (PABP), connecting the 5’ and 3’ ends of mRNAs and stimulating their 
translation by the ribosome (purple and lilac). (A) MiRISC can block translation at the 
initiation step by inhibition of 5’ cap recognition and/or (B) ribosomal recruitment 
(60S)/assembly. The repressed ribosome-free mRNA is relocated into P-bodies for either 
storage or degradation. (C) Next, the miRISC can induce deadenylation and thereby inhibit 
circularisation of the mRNA. (D) Translational repression can also be induced by the miRISC 
by inhibiting a step after initiation, such as promoting ribosome “drop off” or stimulating 
proteolysis of the nascent peptide. (E) Messenger RNA degradation can occur by the 
induction of deadenylation followed by decapping. MiRNA-mediated deadenylation and 
decay of target mRNAs by the Ccr4:Not1 deadenylase complex. (F) Perfect pairing between 
a miRNA and its mRNA target induces endonucleolytic cleavage of the mRNA by Argonaute-
2 (Ago2) followed by exonucleolytic degradation at the P-bodies. (G) MiRNAs have also 
been shown to upregulate target expression under specific conditions (e.g. miR-16 targets 
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the mRNA for myt1 kinase, in conjunction with Ago and fragile X mental retardation protein 1 
(FMR1), and increases its expression). The P-bodies are aggregates of translationally 
repressed mRNPs (messenger ribonucleoprotein particles) associated with the translation 
repression and mRNA decay machinery. The dotted arrows indicate mRNAs being located 
into P-bodies, where they can be degraded (by decapping or 5′ to 3′ exonuclease digestion) 
or stored for return to translation [219]. Modified from [220] and [201]. 
 
1.2.6.2 Repressed mRNAs are relocated to P-bodies 
Also important in this stage is the function of the P-bodies in which Ago 
proteins, miRNAs and mRNAs repressed by miRNAs all accumulate [216, 221, 222]. 
P-bodies are cytoplasmic foci that are enriched with factors involved in mRNA decay 
and translational repression, and lack ribosomes and translation initiation factors 
(except eIF4E) [165]. The mRNA decay factors contained within include: Ccr4:Not1 
complex (deadenylase catalysing partial deadenylation of mRNA [deadenylation is 
the shortening of the 3′-poly(A) tail leading to degradation of the mRNA), DcP1 and 2 
(decapping enzymes) and Xrn1 (enzyme for 5' to 3' exonucleolytic degradation of 
mRNA) [223]. In addition to this, the P-body components Dcp1 and 2, GW 182 and 
Rck/p54 have been implicated in miRNA-mediated translational repression and it is 
thought that these proteins interact with Ago proteins to form a "repressive complex" 
on the target mRNA that leads to relocation into the P-bodies (Figure 7) [165]. 
Interestingly, not all of the mRNAs relocated into the P-bodies are degraded and 
some are able to re-enter translation [224].  
1.2.6.3 Translational repression post-initiation 
The silencing of lin-14 and lin-28 mRNAs by the lin-4 miRNA was originally 
interpreted as translation repression after initiation [225]. Olsen and Ambros found 
that lin-4 target mRNAs remained largely unchanged during repression, suggesting 
that the mRNAs are successfully loaded with ribosomes and that translation 
repression occurs post-initiation [165]. Petersen et al. have gone on to propose a 
“ribosome drop-off” model where ribosomes translating mRNAs, repressed by 
miRNAs, terminate translation prematurely resulting in a reduced synthesis of full-
length polypeptides (Figure 7) [225]. Another post-initiation mechanism is that the 
association of repressed mRNAs with ribosomes encourages miRISCs to recruit 
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proteolytic enzymes that rapidly degrade nascent polypeptides as they emerge from 
the actively translating ribosomes (Figure 7) [165].  
 
 
1.3 Bioinformatic prediction and validation of miRNA targets 
and binding 
1.3.1 In silico techniques for miRNA target prediction 
In animals, miRNAs have partial complementarity to their mRNA targets and 
therefore have the potential to recognise many sequences in the 3'UTR, whilst 
causing actual translational repression in many fewer. Thus the bioinformatic 
prediction of miRNA targets in animals is a difficult task, as miRNA heteroduplexes 
can be more variable in structure, containing only short complementary sequences, 
that are interrupted by gaps, and mismatched base-pairs [226]. There are no specific 
rules that capture all known targets for functional miRNA–target pairing and different 
computational "in silico" approaches have been developed using various 
combinations of rules that approximate miRNA-mRNA interactions in vitro and in 
vivo. The various internet databases utilising these different computational methods 
can be seen in Table 2. These websites allow the user to enter a gene symbol and 
the algorithm will compute all predicted miRNA target sites within that gene, 
alternatively these algorithms will determine all of the potential mRNA targets of a 
given miRNA [227]. 
Some of the factors to take into account when predicting miRNA targets 
include: miRNA sequence complementarity in the form of the ‘‘seed’’ of bases 2-7 at 
5′ end that binds to the 3′ UTR sequence of potential target mRNAs (i.e. “canonical” 
sites); weaker 5′ complementarity should be compensated by pairing at the 3′ end of 
the miRNA in order to confer translational repression; and finally the sequence 
should ideally be stable with few G:U wobbles (i.e. when guanine and uracil base-
pair and form a hydrogen bond with each other), as these could cause local RNA 
distortion, reduce binding and therefore the silencing mechanism, especially if 
occurring inside the 5' seed region on a miRNA [226]. We now know that seed region 
base pairing is not always required and "non-canonical” binding can occur [228]. 
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Grimson et al. [229] have defined a 4-class hierarchy of canonical seed types and 
have also identified other “context” features of the target sites that may on average 
lead to reduced mRNA expression levels (e.g. the AU rich regions flanking the target 
site). This “context score” has been incorporated into the TargetScan prediction 
program. Importantly, proteomics studies of protein expression changes after miRNA 
modulation have confirmed many of these findings [163, 215]. In addition, these 
studies have shown that most targets with significantly reduced protein levels, also 
experience detectable reductions in the mRNA levels, demonstrating that changes in 
mRNA expression are a reasonable indicator for miRNA regulation [230]. 
 
 
 
Methods Strategy Website 
TargetScan 
Searching for the presence of 
conserved 8mer and 7mer sites 
that match the seed region of 
each miRNA. 
http://www.targetscan.org/ 
TargetScanS 
Seed variations only  http://genes.mit.edu/tscan/targetscanS2005.
html 
miRanda 
Weighted alignment emphasising 
seed  
http://www.microrna.org/ 
mirSVR 
Ranks miRNA target sites with a 
down-regulation score. Uses 
sequence and contextual 
features extracted from miRanda 
predicted target sites 
http://www.microrna.org/ 
PicTar Seed match or compensatory  http://pictar.mdc-berlin.de/ 
RNAhybrid 
Integrated match and energy  http://bibiserv.techfak.uni-
bielefeld.de/rnahybrid/ 
Target Boost 
Boosted genetic algorithm to 
create weighted sequence motifs 
that characterize the probable 
binding characteristics.  
https://demo1.interagon.com/targetboost/ 
RNA22 Best alignment  http://cbcsrv.watson.ibm.com/rna22.html 
Diana-microT 
Dynamic programming - 
dinucleotides  
http://diana.cslab.ece.ntua.gr/ 
MicroInspector 
Perfect seed, followed by 
alignment  
http://bioinfo.uni-plovdiv.bg/microinspector/ 
miTarget Short seed  http://cbit.snu.ac.kr/~miTarget/ 
Table 2 modified from [226]. 
 
The kinetics and thermodynamics of the association between miRNA and its 
target (the free energy, ∆G, of the 70 nt flanking the 5' and 3' sides of the predicted 
binding sites) can be determined by RNA folding programs (e.g. RNAfold, mfold and 
RNA Analyzer), although this has been found to be a generally poor predictor for 
Table 2 - Databases of miRNA target prediction algorithms available on the internet. 
Results can vary between databases and show a 10-20% overlap. 
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miRNA target sites [231]. In addition, many methods rely on the phylogenetic 
conservation of both sequence and structure (evolutionarily conserved sites on the 
3’UTRs of mRNA are considered more likely to be functional [232, 233]); 
thermodynamic stability of hairpins and sequence; structural similarity to known 
miRNAs, and genomic location relative to known miRNAs [226].  
There are two target prediction algorithms that deserve further mention. 
MirSVR is an algorithm that scores and ranks the efficiency of miRanda-predicted 
miRNA target sites by using supervised learning on mRNA expression changes 
following miRNA transfections [230]. It incorporates target site information and 
contextual features into a single integrated model. Furthermore, it uses support 
vector regression (SVR) to train on a wide range of features, including secondary 
structure accessibility of the site and conservation across species [230]. Using data 
from Ago immunoprecipitation (Ago-IP) experiments [234], allowing analysis targets 
bound to human Ago proteins, Betal et al. [230] found that mirSVR can appropriately 
identify genes that are regulated by multiple endogenous miRNAs, as compared to 
transfected miRNAs, which are often used at above normal physiological 
concentrations. They also found that different seed types had varying ranges of 
efficiencies [230]. They assessed the 4 main seed classes:  
 6-(oligo) mer  
 7-mer-m8 (i.e. an exact match to positions 2-8 of the mature miRNA 
[the seed + position 8]) 
 7-mer-A1 (i.e. an exact match to positions 2-7 of the mature miRNA 
(the seed) followed by an “A”)  
 8-mer (heptamer) 
As expected they found that the mirSVR scores were more negative distribution with 
ascending seed type hierarchy (i.e. 8-mers have generally lower scores than 7m8 
sites). In addition, using data from Photo Activatable Ribonucleoside enhanced CLIP 
(PAR-CLIP) experiments; they found that miRanda-mirSVR correctly identified the 
“non-canonical” sites, which accounted for approximately 7% of the detected sites 
[230]. Thus, mirSVR appears to be an effective method for predicting the extent of 
gene down-regulation at the mRNA or protein level, and is able to correctly identified 
functional, but poorly conserved target sites [230]. Of note, a recent substantial 
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analysis of recurrent pan-cancer associated miRNA-target relationships, using The 
Cancer Genome Atlas (TCGA) datasets, used miRanda-mirSVR as one of the target 
prediction tools [235], as well as another smaller integrated molecular analysis of 
ovarian cancer [236]. 
RNA22 is a popular miRNA target prediction algorithm, and this is probably 
because this tool differs from other prediction algorithms in the following ways [237, 
238]:  
 Does not rely on, nor require a target’s conservation across genomes  
 Trained with known miRNAs, not with experimentally validated 
heteroduplexes 
 Permits combinations of G:U wobbles and bulges in the seed region of 
a heteroduplex 
 Can successfully predict “non-canonical” targets, as well as targets 
sites beyond the 3′-UTR (e.g. 5’UTR, ORF or CDS).  
 Exhibits a high signal-to-noise ratio 
 Reduced bias as it finds putative miRNA binding sites in the sequence 
of interest first and then finds the targeting miRNA  
Miranda et al. [237] validated their RNA22 method by performing in vitro 
experiments, with luciferase assays, which demonstrated an average repression of 
>30% for 74% of the tested targets. Their analyses also suggested that some 
miRNAs may have up to a few thousand target genes [237]. 
1.3.2 High throughput miRNA and RNA profiling methods 
 For genome-wide studies, microarrays and small RNA / RNA-sequencing can 
be used to determine the abundance of endogenous miRNAs / mRNAs on a large 
scale, and even detect changes in the transcriptome after miRNA modulation in vitro. 
In brief there are various techniques available. 
Gene and miRNA microarrays: In general, for DNA and RNA analysis, 
microarrays remain an informative and inexpensive choice for a standardised 
genome-wide assay, which is amenable to high-throughput applications. A 
microarray is a multiplex “lab on a chip” on which a series of DNA or RNA target 
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sequences are spotted on to a solid substrate (e.g. a glass slide, silica “chip” or 
membrane) in an organised fashion, upon which tens of thousands of nucleic acid 
probes derived from the sample (e.g. normal or tumourous tissue) are hybridised. 
The main types of microarrays are: (1) arrays of human genomic DNA, (2) arrays of 
human complementary DNA (cDNA; from genes) or (3) arrays of human 
oligonucleotides (e.g. miRNA microarrays). The solid surface is can be an Affymetrix 
array or “Affy” chip or even a microscopic bead platform (e.g. Illumina array). The 
signal intensities for each spot can be determined, thereby providing a measure of 
the expression of thousands of genes or miRNAs in a single experiment [239]. 
The small size of miRNAs initially posed a challenge for conventional 
microarray techniques, as it has been difficult to create a single hybridisation 
condition suitable for all miRNAs on the chip [240]. Other concerns are that 
systematic bias could be introduced during reverse transcription, PCR amplification, 
enzymatic labelling or fluorescence tag ligation [240]. Thus, it is important, when 
possible, to validate microarray data using quantitative reverse-transcription real-
time polymerase chain reaction (RT-qPCR) techniques or comparison to the 
published literature.  
However, newer technologies have helped to abolish many of these 
problems. For example, the evolution of digital counting techniques has provided an 
alternative way to profile miRNA expression [241]. NanoString technology employs 
unique fluorescent–tagging of individual miRNA species (or mRNAs) followed by 
two-dimensional display and optical scanning and counting of miRNA molecules 
[241]. In brief, the method involves mixing total RNA with pairs of nCounter capture 
and reporter probes tailored to each miRNA, hybridising, washing away excess 
probes, immobilising probe-bound miRNAs on an imaging surface and scanning 
color-coded bar tags on the reporter probes [242]. The solution-phase hybridisation 
scheme is expected to minimize background signal and improve detection of low-
abundance miRNAs. Other advantages include that it provides a direct digital 
readout of each miRNA and its relative abundance; uses a small amount of total 
RNA (100 ng); and does not require cDNA synthesis or enzymatic reactions [242]. In 
addition, the NanoString nCounter System has a sensitivity that is higher than that of 
conventional microarrays (i.e. Affymetrix) and is similar to that of TaqMan RT-qPCR 
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[243]. A recent study by Kolbert et al. [241] compared miRNA expression profiling 
from RNA from formalin-fixed paraffin embedded (FFPE) and fresh frozen (FF) 
tissue samples using 5 platforms (Affymetrix, Agilent, and Illumina microarrays with 
each other and with NanoString miRNA counting and Next Generation Sequencing 
(NGS) miRNA-Seq). Firstly, they found that miRNA profiling of RNA from matched 
FF and FFPE samples is highly reproducible and strongly correlated [241]. Secondly, 
miRNA detection by Affymetrix, Agilent, and NanoString platforms was very similar, 
whilst the number of detected transcripts for Illumina and miRNA-Seq was 
substantially higher than these. Thirdly, Illumina and miRNA-Seq gave the highest 
average level of agreement amongst the commonly detected transcripts, and this is 
probably because these two platforms detect the most miRNAs. Finally, miRNA-Seq 
exhibited the highest correlation with the RT-qPCR results [241]. Thus, it appears 
that substantial inter-platform differences exist, although the authors conclude that 
the most commonly interrogated transcripts demonstrated general similarities in the 
level of expression across the platforms [241]. Furthermore, if the goal is the 
discovery of novel miRNA transcripts, then miRNA-Seq should be the preferred 
method, especially if cost and bioinformatic support are not an issue.  
Massive parallel sequencing: are high-throughput approaches to DNA 
sequencing (aka NGS). These methods are known as “massive parallel sequencing” 
because the sequencing reactions happen in a stepwise fashion, interwoven with 
detection steps, so that millions of reactions can be monitored simultaneously [244]. 
The concept behind NGS is that the bases of a small fragment of DNA are 
sequentially identified from signals emitted as each fragment is re-synthesised from 
a DNA template strand. All NGS technologies monitor the sequential addition of 
nucleotides to immobilised and spatially arrayed DNA templates, but they differ in 
how these templates (sequencing libraries) are generated and how these data are 
then analysed to reveal their sequences, whilst the actual sequencing stage remains 
fundamentally unchanged [245]. The starting material for all NGS experiments is 
double-stranded DNA, but the source of this material may vary (e.g. genomic DNA, 
reverse-transcribed RNA or cDNA, immunoprecipitated DNA) [245]. NGS 
experiments can therefore sequence the whole-genome or targeted 
genomic/epigenetic elements (e.g. exome, targeted sequencing [the “Mendelianome” 
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(coding regions of 2,993 known disease genes), or targeted disease gene panels to 
screen for relevant mutations], RNA-Seq or miRNA-Seq).  
For example, in whole-genome sequencing (WGS), genomic DNA is 
fragmented into a library of smaller segments that can be uniformly and accurately 
sequenced in many parallel reactions. Next, the newly identified strings of bases 
(“reads”) are then reassembled by aligning sequence reads back to a reference 
genome as a scaffold (resequencing). The full set of aligned reads then reveals the 
entire sequence of each chromosome in the genome [245]. WGS can identify single 
nucleotide polymorphisms (SNPs), structural variants (e.g. insertions, deletions, and 
translocations), and copy number variations (CNVs) [246]. There is valuable 
information to be gained from having a cancer patient's complete genome sequence, 
especially if it can be compared to the normal genome, as this will provide a 
description of somatic changes that have occurred during malignant transformation. 
Using WGS, some cancer driver mutations at low allele frequencies or low-frequency 
single-nucleotide variants (SNVs) may be found, in addition to other more prominent 
inherited cancer susceptibility mutations [245]. WGS also provides the opportunity to 
discover “progressor” mutations causing metastasis and actionable (“druggable”) 
mutations for targeted therapy. Furthermore, results from recent association studies 
have highlighted the use of studying a complete genome sequence, and have found 
that the vast majority (>80%) of disease-associated sequence variants fall outside of 
coding regions [245]. That said exome sequencing (i.e. 1.8% of the genome 
represented by protein-coding or RNA-coding regions) can be faster and more cost-
effective, though tending to exclude numerous classes of noncoding RNAs, many of 
which are being ascribed important gene regulatory functions. However, whilst 
exome sequencing can provide data on CNV, it can miss structural alterations [244]. 
Finally, NGS can also be used to sequence RNA populations in order to identify all 
of the genes that are transcribed from DNA (termed the “transcriptome”). 
Transcribed sequences also include untranslated (non–protein-coding) RNA species 
such as miRNAs and lncRNAs (long non-coding RNAs). However, these RNA 
sequences must first be converted to cDNA by reverse transcription, as NGS 
reactions require DNA substrates [245]. 
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1.3.3 CLIP (cross-linking immunoprecipitation) techniques for defining miRNA 
binding and target interactions 
Accurate identification of miRNA targets or target networks (targetome) is 
crucial to our understating of miRNA function in specific cellular pathways and 
processes. However, until recently web-tool based approaches and experimental 
techniques were limited in their ability to provide this information. Indeed, numerous 
predictions derived in silico can be false-negatives or false-positives, which are then 
difficult to assess. The false positive rate of in silico prediction programs has been 
estimated to be between 24–70% [228]. One of the other major issues, is that the 
predictions of functional miRNA target sites made in silico are in a genome wide 
fashion and do not take into account regulatory context at either the level of the 
target mRNA sequence or the cellular level (i.e. cell / tissue / tumour specific 
differences). Therefore, the dynamic nature of miRNA-mRNA interactions has been 
difficult to model [228]. This is even true when examining high throughput data. The 
advent of new methods, such as crosslinking and immunoprecipitation (CLIP) and 
high throughput sequencing, coupled with proteomics or seed-enrichment analyses 
has now allowed a much better understanding of disease-specific miRNA-
targetomes. 
Biochemical methods can now be coupled to bioinformatics analyses in order 
to efficiently identify miRNA binding and targets [201]. These can provide increased 
sensitivity and the ability to identify endogenous target mRNA transcripts or even the 
target sequence in the mRNA. As miRNAs play a key role in gene regulation by 
guiding Ago-containing miRNP effector complexes to target polynucleotides, earlier 
approaches were by Ago RIP-Chip (Argonaute RBP-Immunoprecipitation Biochip 
[microarray]). This involved immunopurification of the miRNP complexes (i.e. 
mRNAs specifically associated with Ago), isolation of the associated mRNAs, 
followed by identification of the targeted transcripts by microarray. This technique 
can provide data about specific miRNA-mRNA interactions, if these miRNAs are 
modulated, as well as global patterns of regulation by miRNAs [247]. 
New technologies now offer more powerful methods to study interactions 
between miRNAs and genes, including the possibility of characterizing multiplicity, 
redundancy and the additive effect of miRNAs in these complex networks [248]. 
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These include next-generation sequencing (NGS), combined with other methods, 
such as high-throughput sequencing of RNA isolated by ultraviolet (UV) crosslinking 
immunoprecipitation (HITS-CLIP aka CLIP-seq) [249], which can be used to decode 
miRNA-mRNA and protein-RNA interaction maps from in vitro or in vivo samples. 
These techniques can significantly reduce the false-positive rate of predictions of 
miRNA binding sites (by excluding many inaccurate putative miRNA-mRNA 
interactions) and provide identification of binding sites with single nucleotide 
resolution [249]. In brief, CLIP-seq involves tissue or cell lysates being irradiated with 
UV light, which cross links and stabilises protein–RNA interactions. Next, 
immunopurification of miRNPs is followed by an RNase-treatment step to degrade 
RNA fragments that are not protected by miRNP complexes; the protected 
fragments, including the associated miRNAs, are then isolated, converted to cDNA 
and subjected to deep-sequencing and computational analyses [201].  
Another in vitro CLIP technique is PAR-CLIP, which uses the addition of a 
photoactivatable ribonucleoside analogue (such as 4-thiouridine) in the culturing 
conditions [203, 250]. This can identify, on a transcriptome-wide scale, individual 
binding sites of the selected RBPs on their targets, their binding motifs and 
preferences [203]. However, whilst CLIP does provide more accurate miRNA target 
identification than target prediction programs, detecting an mRNA bound by the 
miRNP complex does not provide any information about its regulation (i.e. strength 
of binding does not necessarily correlate with the extent of down-regulation of the 
target mRNA caused by the miRNA) and it cannot reveal the potential mechanism of 
control. Thus, CLIP methods need to be combined with RNA-sequencing or 
quantitative proteomic platforms (e.g. stable isotope labelling with amino acids in 
culture; SILAC), in order to quantify changes in target expression levels. 
1.3.4 Techniques for miRNA target validation 
After bioinformatic analyses have predicted or identified a miRNA-mRNA 
interaction, a reporter assay can be used to validate the functional importance of the 
interaction [227]. During this assay, the binding of a given miRNA to its specific 
mRNA target site will repress reporter protein production and expression which can 
then be measured compared to a control. A clone of the 3'UTR of the target gene of  
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interest is created downstream of the luciferase (oxidative enzyme that produces 
bioluminescence; Firefly luciferase produces a greenish yellow light in the 550–
570nm range, whilst Renilla luciferase produces a blue light of 480nm) open reading 
frame sequence contained in the reporter plasmid [227]. The recombinant plasmid 
and a miRNA of interest are then transfected into a host cell, that does not 
endogenously express this miRNA, and luciferase fluorescence is measured 24-48 
hours after transfection. There are some important control experiments that need to 
be performed including: use of plasmids which do not contain the 3′-UTR fragment, 
the 3′-UTR inserted in the reverse orientation, and/or the 3′-UTR insert which does 
not contain the miRNA binding site of interest (which could be achieved by site 
directed mutagenesis). A control Renilla luciferase reporter plasmid should also be 
co-transfected so that the data can be normalised for experimental variation in 
plasmid transfection efficiencies [227].  
In order to show that the miRNA and its target mRNA are co-expressed, this 
can be demonstrated by Northern blotting or RT-qPCR using total RNA and specific 
primers and probes (e.g. TaqMan) for a given miRNA and mRNA target. Next, if the 
miRNA truely targets a transcript, then this should correspond to an alteration in the 
amount of protein produced. Thus, an overexpression ("gain of function") experiment 
can be performed by transfecting cells, known to produce the putative target protein, 
with precursor miRNAs and then measuring the amount of protein using Western 
blotting and antibodies against that protein [227]. Alternatively, a "loss of function" 
study can be performed where specific endogenous mature miRNA function can be 
inhibited using purchased antisense oligonucleotides (ASO). Alternatively, miRNA 
“sponges” can be engineered with multiple sites of partial complementarity in order 
to sequester specific miRNAs or titrate an entire family that share the same 5’ end 
sequence [201]. Therefore, if the miRNA-mRNA interaction is authentic, then the 
effects of the inhibitor or “sponge” to increase protein levels or activities can be 
clearly detected. It is important to choose the correct cell type for these experiments, 
for example if a miRNA mimic is thought to decrease target gene expression, they 
are best used in cells that express low levels of endogenous miRNAs and high target 
mRNA expression. In this case, when the miRNA mimic is over-expressed, a 
decrease in the target protein will be easily detectable [227]. The final step in 
confirming a miRNA-mRNA interaction is by demonstrating that its regulation effects 
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biological function of interest (i.e. signalling pathways, cell proliferation, cell 
differentiation, apoptosis, cell migration, etc).  
Clinically, archival tissues can be used and miRNA expression can be shown 
by in situ hybridisation (ISH) using "locked nucleic acid" (LNA) modified 
oligonucleotide probes to detect mature miRNAs, thus allowing a spatial resolution of 
miRNA expression, thereby combining molecular biology with traditional histology 
and cytology. If compared to haematoxylin & eosin (H&E) stained slides, this can 
allow some idea about cellular localisation of the miRNA. Furthermore, 
immunohistochemistry can be performed on the same tissues and target protein 
levels can be quantified and correlated to the level of miRNA expression. 
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1.4 The role of miRNAs in cancer 
MiRNAs are involved in most developmental and physiological processes and 
their deregulation is linked to many human diseases including cancer [251]. Many 
studies have shown that miRNAs can act both as oncogenes and tumour 
suppressors and expression profiling has associated specific miRNAs with a variety 
of cancers in the hope of developing tumour subtype-specific “signatures” (Table 3) 
[252-254]. Thus, miRNAs have the potential to become biomarkers (diagnostic 
and/or prognostic) for human cancers, as well as targets for molecular therapy [255]. 
A few important miRNAs involved in oncogenesis will be introduced. 
 
Table 3 – Early studies identified miRNAs associated with human cancers. 
TS, tumour suppressor; OG, oncogene. Modified from [253]. 
miRNA Gene loci Association with Cancer Function Ref. 
miR-15a 
miR-16 
Chromosome 
13q14 
Frequently deleted or down-regulated in B-cell 
chronic lymphocytic leukaemia; negatively regulates 
the anti-apoptotic gene BCL2  
TS 
[256, 
257] 
miR-143 
miR-145 
Chromosome 
5q32–33 
Decreased abundance in colorectal cancer (CRC); 
down-regulated in breast, prostate, cervical and 
lymphoid cancer cell lines; miR-145 is decreased in 
breast cancer 
TS 
[258, 
259] 
miR-21 
Chromosome 
17q23.2 
Anti-apoptotic factor; upregulated in glioblastomas , 
breast, colorectal, gastric, pancreatic ductal 
adenocarcinoma (PDAC) and lung cancer 
OG 
[258, 
260-
263][26
4-268]  
let-7 
family 
members 
Multiple loci 
Negatively regulate the RAS oncogenes; direct cell 
proliferation and differentiation; decreased 
abundance in lung cancer 
TS 
[269, 
270] 
miR-155 
Chromosome 
21q21 
Up-regulated in paediatric Burkitt (100-fold), Hodgkin, 
primary mediastinal and diffuse large-B-cell 
lymphomas (DLBCL); upregulated in human breast 
cancer, thyroid carcinoma, CRC, cervical cancer, 
PDAC and lung cancer (marker of poor prognosis) 
OG 
[258, 
266, 
271-
279] 
miR-17–
19b 
cluster 
Chromosome 
13q31–32 
Up-regulated by MYC; negatively regulates the E2F1 
oncogene; loss of heterozygosity of this cluster is 
found in hepatocellular carcinoma; overexpressed in 
B-cell lymphomas 
TS/OG 
[175, 
280][28
1, 282] 
 
1.4.1 miR-15/16-1 in chronic lymphocytic leukaemia (CLL) 
In 2002, Calin et al. provided the first evidence of altered miRNA expression 
in human cancer [256]. They found two miRNAs (mir-15a and miR-16-1) in a very 
small ~30 kb deleted chromosomal region at 13q14.3 which is lost in 65% of chronic 
lymphocytic leukaemia (CLL) cases. This suggested that these miRNAs were acting 
as tumour suppressors and their loss was the consequence of 13q14.3 deletion in 
 78 
 
CLL pathogenesis [132]. Later they found that miR-15a and miR-16-1 are down-
regulated in about 68% of CLL patients [256]. They went on to show that B-cell 
lymphoma 2 (BCL2), an anti-apoptotic gene, is overexpressed in CLL and miR15a 
and miR-16-1 negatively regulate it at a post-transcriptional level [257]. Thus, down-
regulation of miR-15a and miR-16-1 leads to increased expression of BCL2 and 
enhanced leukaemogenesis and lymphomagenesis in haematopoietic cells [253]. 
Following on from this, Calin et al. mapped the chromosomal location of the known 
miRNA genes [283]. Interestingly, they found that more than 50% of miRNA genes 
are located in cancer-associated genomic regions or in fragile sites (deletions or 
amplifications), which suggested that miRNAs may be playing important roles in the 
pathogenesis of human cancers [132, 253]. 
1.4.2 let-7 family  
In the same study, Calin et al. found that the let-7 family (12 human 
homologues) map to fragile regions, albeit on several chromosomes, that are 
involved in different types of tumours, including lung, ovarian, urothelial, cervical and 
BC (e.g. let-7g–let-7a1 cluster maps to 3p2, the let-7f-1–let-7d cluster maps to 
9q22.3, let-7a-2 maps to 11q23-q24 and let-7c maps to 21q21) [132, 283]. 
Expression of let-7 is reduced in many cancers, including lung cancer (with low 
expression associated with poor survival independent of disease stage) [269], 
primary squamous cell carcinoma of the head and neck (HNSCC; low let-7d) [284], 
ovarian cancer (low let-7d) [285], PDAC (low let-7a) [286], prostate cancer [287, 
288], and advanced BC [258]. The let-7 family function mainly as tumour 
suppressors and target oncogenes such as RAS [270, 289] and high mobility group 
A2 (HMGA2) [290, 291]. However, there are examples of purely oncogenic let-7 
behaviour, such as up-regulation of let-7b and let-7i is associated with high grade 
transformation in lymphoma [292] and let-7a can target caspase-3 mRNA, an 
essential protease activated during apoptosis, in squamous and HCC cell lines [293]. 
1.4.3 miR-155 
miR-155 is involved in many biological processes including haematopoiesis, 
inflammation and immunity, and also acts as an oncogenic miRNA in carcinogenesis 
[294]. The expression of miR-155 is increased in many different types of lymphoma 
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(paediatric Burkitt's, CLL, Hodgkin's, DLBCL) [271, 272] and also in various solid 
tumours (Table 3).  
The B cell integration cluster (BIC) is a non-protein coding genomic region 
that is also up-regulated in many lymphomas (Hodgkin's and paediatric Burkitt's) 
accelerating their pathogenesis, but is low in normal lymphoid organs [252]. Tam et 
al. found that miR-155 is actually encoded by a phylogenetically conserved region of 
the BIC gene by nucleotides 241–262 on chromosome 21q23 [295]. Eis et al. went 
on to find that miR-155 is overexpressed in a wide range of lymphomas derived from 
B cells, especially in DLBCL [296]. miR-155 promotes lymphomas in cells that also 
overexpress MYC, suggesting that it functions in co-operation with MYC [253].  
Another mechanism for the role of miR-155 in carcinogenesis has been found. 
Ovcharenko et al. showed that miR-155 (along with mir-145, mir-216, mir-182, and 
mir-96) is a potent suppressor of apoptosis in human T cell leukaemia Jurkat cells 
and in MDA-MB-453 BC cells [297]. The effect of miR-155 may be due to inhibition 
of caspase-3 activity, through which there is a substantial decrease of tumour protein 
53-induced nuclear protein 1 (TP53INP1), a pro-apoptotic stress-induced p53 target 
gene that has been shown to be reduced in early PDAC [298].  
1.4.4 miR-17-92 polycistron (OncomiR 1) 
The miR-17–92 cluster comprises 6 miRNA genes (miR-17, miR-18a, miR-
19a, miR-20a, miR-19b-1, and miR-92a-1; aka Oncomir 1) and is located in a region 
of 800 bp in the non-protein-coding gene C13orf25 at 13q31.3 [175, 299]. This 
chromosomal region has been found to be amplified in different types of lymphoma 
and in solid tumours [299]. In 2005, it was shown that miR-17-92 cluster has true 
oncogenic activity [280]. Firstly, Hannon and Hammond showed that enforced 
expression of the mir-17–92 cluster acted with MYC expression to promote 
proliferation, inhibit apoptosis, induce tumour angiogenesis and accelerate tumour 
development in a B-cell lymphoma mouse model [281] and then O'Donnell et al. 
showed that transcription of the miR-17-92 cluster is directly transactivated by MYC 
oncogene [175]. MiRNA expression profiling has revealed overexpression of this 
cluster in a wide variety of tumours, including lymphoma, breast, colon, lung, 
pancreas, prostate, and stomach cancer [266, 300]. The miRNAs within the cluster 
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can also down-regulate important tumour suppressor targets, such as PTEN, cell 
cycle inhibitor CDKN1A (p21; an inhibitor of the G1 to S phase checkpoint) and 
BCL2-interacting mediator of cell death (BIM) (Figure 8) [132]. BIM is a pro-
apoptotic protein that regulates cell death through its ability to antagonise anti-
apoptotic proteins like BCL2 [280]. Down-regulation of BIM by the miR-17-92 cluster 
can accelerate lymphomagenesis in transgenic mice bearing a MYC oncogene (Eµ-
myc mouse model) [301].  
The miR-17-92 cluster is also intimately involved in the function of E2F family 
of TFs, critical regulators of the cell cycle that normally drive cellular proliferation 
[280]. MYC can induce the transcription of both the mir-17–92 cluster and E2F1, and 
subsequently the mir-17–92 cluster can negatively regulate the translation of E2F1 
[253, 302]. In addition, the E2F1 and E2F3 proteins can activate miRNA genes in the 
miR-17–92 cluster creating another feedback loop [280]. In the presence of MYC, 
the miR-17–92 cluster limits E2F1 and dampens the cell-proliferative effects of MYC 
[253]. However, high levels of E2F1 can induce apoptosis, therefore this negative 
feedback promotes cell proliferation rather than cell death (Figure 8) [280]. 
Unsurprisingly, MYC regulates several other miRNAs during carcinogenesis and its 
expression results in complex interactions and feed-forward loops (i.e. the master TF 
regulates a miRNA and together with it a set of protein coding genes that are 
targeted by the same miRNA) [178, 303, 304].  
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Figure 8 - The role of MYC-regulated miRNAs in cancer. 
MYC induces the oncogenic miR-17-92 cluster (bottom right corner): miR-17/20a targets 
E2F1, a regulator of the cell cycle and apoptosis; miR-92 targets BIM, a pro-apoptotic gene 
that counteracts the anti-apoptotic activity of BCL2; and miR-19 targets PTEN, a negative 
regulator of the oncogenic prosurvival PI3K/AKT signalling pathway. MYC is also able to 
induce other oncogenic miRNAs and repress tumour suppressor miRNAs during 
carcinogenesis. Modified from [176]. 
 
1.4.5 OncomiR-21 
OncomiR-21 is the most studied miRNA in cancer and is repeatedly found to 
be over-expressed in a number of malignancies (Table 3) [173]. It was first identified 
in malignant human glioblastoma (GBM) and found to be highly over-expressed in all 
high-grade tissue samples from patients and cell cultures compared to non-
neoplastic samples [260, 261]. Chan et al. went on to show that knockdown of miR-
21 by anti-sense oligonucleotides (ASO) in cultured GBM cells activates caspases 
and leads to increased apoptosis [261]. miR-21 inhibition in MCF-7 BC cells also 
showed a dose-dependent reduction in cellular proliferation and lead to the discovery 
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of programmed cell death 4 (PDCD4) as the tumour suppressor targeted [305]. 
PDCD4 has been validated by many other groups and has a highly conserved miR-
21 target site in its 3'UTR [306]. In addition, reduced PDCD4 expression has been 
reported in many cancers (lung, brain, renal, breast, colon and pancreas) in which 
miR-21 is also overexpressed, suggesting that the interaction is clinically significant 
in carcinogenesis [306]. Thus, miR-21 functions as an oncogene by targeting pro-
apoptotic genes (Figure 9) [307]. Meng et al. showed that knockdown of miR-21 
made cholangiocarcinoma (CCA) cells more chemo-sensitive to GEM therapy 
compared to transfection with pre-miR-21 [308]. They found that miR-21 targets the 
tumour suppressor phosphatase and tensin homologue (PTEN) and its activation of 
the phophatidylinositol 3-kinase-AKT (PI3K/AKT) signalling (increasing cell growth, 
migration, and invasion) and showed this also in HCC cell lines where knockdown of 
miR-21 caused increased PTEN expression [308, 309]. In BC, miR-21 has also been 
found to target tropomyosin 1 (TPM1) by a proteomic analysis of tumour samples 
treated with anti-miR-21 [310]. MiR-21 overexpression in BC is associated with 
advanced clinical stage, LN positivity and poor prognosis [274, 311]. In CRC, 
overexpression is again associated clinically with poor survival and poor therapeutic 
outcome [267], as well as LN and distal spread [268]. In CRC cell lines, knockdown 
of miR-21 increase PDCD4 levels and reduces invasiveness, whilst the contrary is 
seen with overexpression [312]. Another target down-regulated upon miR-21 
overexpression is Sprouty2 (SPRY2), which causes enhanced formation of cellular 
protrusions and increased cell proliferation and migration in CRC SW480 cells [313, 
314]. Importantly, it is already known that SPRY2 can induce up-regulation of PTEN 
and inhibit cell proliferation and it seems that miR-21 negatively regulates PTEN 
through its repression of SPRY2 [314, 315]. Several in vitro studies have shown that 
knockdown of miR-21 results in reduced tumour cell growth [316], cell cycle arrest 
[317] and enhanced apoptosis [318]. Finally, it is interesting to note that miR-21 up-
regulation is also seen in other pathologies, such as cardiac hypertrophy [319], 
neointimal hyperplasia [320], and end-stage cardiac failure [321], suggesting that it 
may characterise abnormal cell growth or stress and not just oncogenesis [306]. 
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Figure 9 - The role of miR-21 in oncogenesis and its validated targets. 
MiR-21 is induced by AP-1 in response to RAS; PTEN and PDCD4 are downregulated by 
RAS in an AP-1 and miR-21-dependent fashion. MiR-21-mediated down-regulation of 
PDCD4 is essential for the maximal induction of AP-1 activity in response to RAS [322]. 
AC1MMYR2 is a specific small-molecule inhibitor which blocks the ability of Dicer to process 
pre-miR-21 to mature miR-21, resulting in up-regulation of PTEN, PDCD4 and RECK, and 
also reversal of EMT in epithelial cancer cells and also reduced tumour burden and 
improved survival in animal studies [323]. NFIB, nuclear factor I/B; EMT, epithelial-to-
mesenchymal transition; TGF-β, transforming growth factor beta; SPRY2, Sprouty 2; 
PDCD4, programmed cell death protein 4; PTEN, phosphatase and tensin homolog; RECK, 
reversion-inducing cysteine-rich protein with Kazal motifs; TPM1, tropomyosin-α1. Modified 
from [313]. 
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1.5 miRNAs involved in Pancreatic Cancer  
1.5.1 miRNA Expression Profiling in Pancreatic Cancer 
miRNAs are remarkably stable and are protected from degradation due to 
their small size (~22 nt) and presence within exosomes in bodily fluids [324]. Thus, 
the PDAC miRNome has been extensively profiled and distinctive miRNA signatures 
have been shown to be useful in detecting this malignancy in FF [276] and FFPE 
tissues [325], blood [326], biopsy [327], and stool [328] samples. Wan et al. have 
performed the first meta-analysis of diagnostic miRNAs in PDAC [329]. Interestingly, 
whilst they didn’t focus on an individual miRNA, they did show that blood-based 
miRNAs showed a higher overall accuracy (91% sensitivity, 96% specificity) at 
detecting PDAC than tissue-based miRNAs (85% sensitivity, 89% specificity). This is 
encouraging as blood-based biomarker assays will probably be the more desirable 
non-invasive method of choice for diagnosing and classifying PDAC in the future 
[329].  
Many miRNA expression profiling studies have identified numerous tissue 
specific miRNAs that are deregulated in PDAC compared to normal pancreas (NP), 
chronic pancreatitis (CP) and other tumours, and this can provide insights into the 
dysregulation in the “source cells” prior to investigations in biofluids or biopsy 
samples (Table 4).  
1.5.1.1 Early miRNA microarray profiling of PDAC 
In 2005, Lu et al. used bead-based flow cytometric miRNA expression 
profiling to look at 217 human miRNAs in 334 samples from multiple cancers [330]. 
Whilst this was one of the first large profiling studies, the authors were able to 
correctly diagnose 70% of poorly differentiated tumours from the expression profiles 
generated. In this study, they concluded that miRNA expression seemed globally up-
regulated in normal tissues compared with cancer, whilst global miRNA down-
regulation is now generally accepted to be more frequent in non-neoplastic tissues 
[331]. Jiang et al. [332] then performed a large profiling study on 32 human cancer 
cell-lines (including lung, breast, colorectal, haematological, prostate, pancreas and 
head & neck cancers) looking at 222 miRNAs including the different let-7 family 
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isoforms (using TaqMan minor groove binder probes). Hierarchical clustering 
revealed that most of the cell-lines clustered amongst the tissues from which each 
cell line had been derived from. 
In 2006, Volinia et al. published the most quoted large-scale miRNA profiling 
study of solid tumours [266]. This study included 540 samples from 6 solid tumours 
(lung, breast, stomach, prostate, colon, and pancreatic neuroendocrine tumours; 
PNET) using 228 mature miRNA probes. They were able to successfully identify a 
miRNA signature for each solid tumour and found that the expression profiles for 
prostate, colon, stomach and PNET were very similar, whilst lung and breast were 
markedly different. However, 61 differentially regulated miRNAs were still present in 
90% of the tumours and 21 were commonly up-regulated in 3 or more cancers 
including PNET. The most commonly up-regulated was miR-21 (in all 6 tumour 
types), whilst miR-191 and 17-5p were present in 5 of the 6 cancers [266]. Roldo et 
al. did further profiling in pancreatic neuroendocrine tumours and compared miRNA 
expressions from PNET and aggressive pancreatic acinar cell carcinomas (PACC) 
[333]. They found increased expression of miR-103 and 107, with lack of miR-155 
was able to distinguish normal from neoplastic pancreas. In addition, a 10 miRNA 
signature could discriminate these tumours with clinically very different behavior, 
whilst miR-204 overexpression was found to be highly specific for insulinomas and 
correlated with insulin expression more than insulin mRNA expression [333]. They 
went one step further and showed an inverse correlation between overexpression of 
miR-21 in metastatic and highly proliferative PNETs (high Ki67 index), with down-
regulation of its putative target gene PDCD4  [333]. Interestingly, miR-155 was 
down-regulated in PNET in both arrays [266, 333], despite its up-regulation in 
lymphomas and other tumours and its known oncogenic potential [271]. In a more 
recent study, Olson et al. profiled normal human islet samples, 19 PNETs, and 3 
liver metastases. They found miR-155, 142-3p, 142-5p and miR-146a up-regulated 
in human PNETs as compared with normal human islets [334].  
The expression profiling studies have also revealed the signature of NP, 
compared to other organs [277]. Szafranska et al. performed miRNA profiling with a 
377 probe array on NP and a reference set of 33 human tissues. This showed that 
lack of miR-133a and overexpression of miR-216 and 217 was NP specific 
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(confirmed later in an independent study [335]), although there was some expression 
seen in the duodenal samples (15-25 fold lower) [277]. MiR-216 and 217 were also 
significantly down-regulated in PDAC compared to NP and this may reflect a loss of 
normal acinar cell mass [277]. Indeed, miR-216a, 216b and 217 have been shown to 
be expressed at high levels in microdissected acinar cells, with significantly lower 
levels in normal ductal cells and virtually no expression in PDAC cells [336]. MiR-375 
has found to be down-regulated in PDAC in 6 different studies, including this one by 
Szafranska et al. [276, 277, 325, 337, 338], and up-regulated in NP [335], as well as 
reduced in CP and absent in PDAC cell-lines [277]. Interestingly, miR-375 is 
expressed at high levels in islet β- and non-β-cells during human pancreatic islet 
development along with miR-376 [339] and has been shown to regulate insulin 
secretion in isolated pancreatic β cells [340]. The low expression of miR-375 in CP 
and PDAC is therefore probably due to a reduced number of islet cells in these 
diseased tissues [277].  
Szafranska et al. then went on to compare the expression profiles of NP with 
PDAC, CP and PDAC cell-lines. The hierarchical clustering analysis revealed that 
profiles of CP are distinct from normal and cancer samples, but in general more 
similar to normal. A pair-wise comparison of Pearson correlation values then showed 
that global miRNA expression levels in CP were in between normal and PDAC, 
whilst the cell-lines were closer to PDAC than CP or normal [277]. In fact, out of the 
top 20 miRNAs they identified as deregulated in PDAC, 12 had similar expression 
levels in the PDAC cell-lines. They also found an additional 6 miRNAs (miR-18a, 31, 
93, 205, 221 and 224) that were over-expressed in both PDAC and PDAC cell-lines 
that were initially missed because of high P-values or low fold-change. There was a 
total of 94 significantly differentially expressed miRNAs between any two of the three 
groups (PDAC, CP and normal) [277]. Out of these, 90% were differentially 
expressed not only in PDAC vs. NP, but also in CP vs. NP, suggesting that the 
desmoplastic reaction in both diseases may be responsible. Nevertheless, principle 
component analysis showed a clear segregation of PDAC from CP and NP, 
indicating the miRNA expression network in PDAC could be distinguished [277]. 
Finally, miR-196a and 196b were proposed as highly discriminatory biomarkers as 
they are over-expressed 14-fold in PDAC and PDAC cell-lines, but absent from CP 
and NP samples. They then used a RT-qPCR index of miR-196a and 217 to 
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successfully identify PDAC, CP and NP tissues. This 2-miRNA classifier was later 
validated in 2008 on FF tissues and EUS-FNA samples and diagnosed PDAC with 
90% sensitivity (95% CI, 62-98%) and 100% specificity (95% CI, 56-100%) [337]. 
The authors suggest that the acinar-cell marker (miR-217) and PDAC marker (miR-
196a) may measure a decline in acinar cells with increasing ductal adenocarcinoma 
cell proliferation [337]. RT-qPCR confirmed that miR-196a was specific for PDAC 
cells and expression also increased with disease progression from PanIN-1b to 
PanIN-3 lesions [337]. This group have recently identified a 11-miRNA classifier that 
has 2-3 fold improved detection of PDAC in specimens with limited tumour material 
available for testing (ranging 10-88%) [338].  
Next, Bloomston et al. performed a microarray on 65 microdissected PDAC 
and adjacent tissue samples [325]. In their landmark paper, they identified 30 
miRNAs up-regulated in PDAC compared to NP tissue, although only 18 miRNAs 
were significant by prediction of microarray analysis (PAM). Three miRNAs were 
found to be down-regulated (miR-148a, 148b and 375). When PDAC was compared 
to CP there were 15 miRNAs up-regulated and 8 down-regulated, and this allowed 
correct classification of 93% of the samples. Between CP and NP there were a 
further 15 miRNAs up-regulated and 2 down-regulated. Thus 95% of PDAC samples 
could be differentiated from the other tissues.  
Lee et al. [276] performed the first precursor miRNA microarray for PDAC in 
2007. They looked at the levels of 201 precursor miRNAs (representing 222 mature 
miRNAs) in FF samples from surgical specimens (28 PDAC, 15 adjacent benign 
tissues, 4 CP, 6 NP and 9 PDAC cell-lines). They found 100 miRNA precursors (pre-
miRs) were aberrantly expressed in PDAC. Some of the mature miRNAs had been 
previously reported in human cancers (miR-155, 21, 100, 125, 221 and 222), whilst 
others had not (miR-376a and 301). Interestingly, 6 pre-miRs were >20 fold 
increased in PDAC (pre-miR-100, 125-b1, 212, 221, 301 and 424), whilst pre-miR-21 
was only elevated 15.7 fold compared to NP. Using PAM testing, the top 20 
differentially expressed pre-miRs were easily able to distinguish PDAC from NP. 
They then used ISH techniques and showed that 3 of the top differentially expressed 
miRNAs (miR-221, 376a and 301) were localised to tumour cells and not to the 
stromal compartment, or normal acini or ducts. Whilst miR-375 was not amongst 
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these, both its mature and precursor expression were confirmed as significantly 
decreased in PDAC by RT-qPCR.  
Kent et al. have gone on to provide a detailed evaluation of deregulated 
miRNA expression in 21 PDAC cell-lines and found some important functional 
consequences [341]. They established that 39 miRNAs had at least 2-fold or greater 
differential expression in PDAC cell-lines compared to control cells (2 non-
transformed human pancreatic ductal epithelial cell lines HPNE and HPDE). Key 
miRNAs were validated by northern blot analysis on total RNA isolated from cell lines 
and also from first-passage xenografts established directly from PDAC patients. 
They saw that miRNAs from the miR-200b cluster (miR-200b/200a/429) were up-
regulated in PDAC, 10.8, 3.1 and 2.5 fold respectively. They also noticed up-
regulation of miR-17-3p (3.2 fold), which is a member of miR-17-92 cluster (aka 
oncomiR-1), which is known to be highly oncogenic in other cancers [342], and also 
the miR-191 (3.6 fold). In contrast, miR-34a, an important component of the p53 
network [343], was frequently down-regulated (-3.7 fold) in PDAC cell lines. With 
these findings, they demonstrated that retroviral vector stable expression of the miR-
200 family and the miR-17-92 cluster significantly accelerates proliferation in HPNE 
cells with constitutively active mutant KRAS (HPNE-KRASG12D). However, enforced 
expression of miR-191 did not affect proliferation. In contrast, inhibition of the miR-
200 family, the miR-17-92 cluster or miR-191 cluster (miR-191 and 425) diminished 
anchorage independent growth. The constituent miRNAs for each cluster were used 
for these experiments (i.e. a pool of miRNA inhibitors for all 5 miRNAs of the miR-
200 family (miR-200a, 200b, 200c, 141 and 429) were transfected into 3 PDAC cell-
lines. The expression of the miR-200 family has been demonstrated to inhibit EMT, 
by negatively regulating the zinc finger E-box-binding homeobox 1 and 2 (ZEB1 and 
ZEB2) TFs that are direct repressors of E-cadherin [344]. Furthermore, the miR-200 
family indirectly suppresses EMT by inhibiting the translation of ZEB1 and ZEB2 
mRNAs. Using a linear regression analysis, they confirmed that miR-200 family and 
miR-200b cluster expression is positively associated with E-cadherin expression in 
13 random PDAC cell lines, whilst miR-200 family expression negatively correlated 
with that of ZEB1, but not ZEB2. Inhibition of miR-200 family expression in Panc-
2.03 cells resulted in enhanced ZEB1 and ZEB2 expression with repression of E-
cadherin, consistent with a loss of epithelial identity. Finally, they showed 
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replacement of miR-34a in Panc-1 and MiaPaCa2 dramatically inhibits cellular 
proliferation, demonstrating the anti-tumourigenic properties of miR-34a that are lost 
in PDAC cells [341]. 
1.5.1.2 Focussed attempts at miRNA biomarker discovery in PDAC 
 The problem of the cellular source of pancreatic miRNA expression is 
important and should be considered carefully. Normal pancreatic tissues consist 
mainly of acinar cells, and to a lesser extent, islets and ductal cells. In CP, the acinar 
cell component is replaced by extensive fibrosis, ductal proliferation, and acinar cell 
conversion into tubular complexes. PDAC tumours are a mix of neoplastic and 
stromal cells within a dense desmoplastic reaction acting as a scaffold for cancer cell 
growth [345, 346]. LCM of tissues or ISH allows more accurate analysis of miRNAs 
in neoplastic epithelial cells [276, 277, 347] and the choice of normal tissue may also 
have some consequence. For example, Szafranska et al. [277] analysed seven 
macrodissected NP samples, but these had all been taken from patients with some 
form of liver or pancreatic neoplasm in proximity to the sampling, thus there may 
have been some tumour cells present in the benign tissue. On the other hand, Lee et 
al. [276] used NP from patients with no neoplastic disease (e.g. sudden death, 
COPD, etc), which likely represents a better source material. However, many studies 
now compare tumour and normal adjacent tissues from the same patient during 
profiling experiments. 
In 2011, Schultz et al. [348] performed global expression profiling on FFPE 
tissue sections from surgical specimens in order to define miRNA patterns in PDAC 
and ampullary adenocarcinoma (AAC) compared to CP and NP. Interestingly, they 
deliberately chose not to use LCM on their samples, hoping to approximate an 
approach more likely to be used in routine clinical testing. The results were quite 
striking and revealed 83 miRNAs differentially expressed between PDAC and NP, 
whereas 32 miRNAs were differentially expressed between PDAC and CP, whilst the 
signatures for PDAC and AAC were highly correlated. Five miRNAs (miR-614, 492, 
622, 135b, and 196) were able to discriminate PDAC and AAC from benign tissue. In 
addition, they were able to validate the 2-miRNA classifier of PDAC (high miR-196b 
and low miR-217) that was first proposed by Szafranska et al. in 2008 [337] and 
identify 3 further significant profiles (Table 4). Using a complex mathematical least 
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absolute shrinkage and selection operator (LASSO) classifier, 19 miRNAs were 
found to separate PDAC from NP and CP with 98% accuracy. This study is 
encouraging as it shows that miRNAs have the potential to be measured in bulk 
pancreatic tissue and used to diagnose malignancy and therefore may be even 
easier to implement into clinical settings than previously expected. Of course one 
has to remember that whilst many of the results from these expression profiling 
studies overlap, the pancreatic miRNome of an individual patient is dependent on 
comparison with many other patients, so in order to diagnose an individual with 
PDAC the profiling results have to be compared to those from the local population 
with histologically proved diagnoses. 
In order to help resolve this issue, Munding et al. (Szafranska in lab group) 
[336] have attempted to identify single normalised miRNA biomarkers for PDAC. Like 
Schultz et al. [349], they used non-LCM tissue sections to reflect the natural 
heterogeneous cellular composition of PDAC and chronic pancreatitis. They first 
used LCM normal (n=4) and acinar (n=4), and PDAC cells (n=5; from xenograft 
tumours) and macrodissected FF tissues from CP (n=5) to assess miRNA 
expression in pancreatic tissues. They identified 15 biomarker miRNAs that were 
consistently up-regulated in PDAC with a fold change ≥2 compared to normal, acinar 
and CP tissues. From these 15 miRNAs, the highest ranking 10 were then validated 
using RT-qPCR. An additional 5 miRNAs, that are known to be important in PDAC 
tumourigenesis (i.e. miR-21, 200a, 27a, 15a and 217), were then included in the 
search for a biomarker. From these, miR-210 and 135b were the 2 top-ranking 
biomarker candidates and were further evaluated along with miR-196a, which had 
been found to be up-regulated in PDAC in several studies [277, 325, 337, 338, 348, 
350]. Interestingly, oncomiR-21 was not significantly differentially expressed in 
PDAC when compared to NP and CP, and was therefore not a candidate. Instead of 
using miR-217 for normalization, as in their previous study [337], miR-24 was found 
to be equally expressed in diseased and NP tissues, and so was used instead. 
Munding et al. demonstrated that this new 2-miRNA classifier (i.e. Ct(miR-135b) − 
Ct(miR-24)) was able to discriminate CP (n=33) from PDAC (n=42) with a sensitivity 
and specificity of 92.9% and 93.4% respectively [336].  
 91 
 
Since these studies, there has been a real drive towards using miRNAs as 
analytes in blood and biopsy samples in order to help diagnose and/or stratify PDAC. 
These aspects will be discussed later in this chapter. 
 
1.5.2 miRNAs acting as oncogenes or tumour suppressors in PDAC 
MiRNAs can act as oncogenes (oncomiRs) or tumour suppressor genes (TS-
miRs) depending on the function of those mRNA targets that they degrade or 
translationally inhibit. For example, the reduction of a TS-miR (due to gene deletion, 
reduced transcription or impaired processing), may lead to increased expression of 
the miRNA target oncogene resulting in tumourigenesis. Conversely, the up-
regulation of an oncomiR (due to gene amplification or increased transcription), may 
lead to tumour formation by reduced expression of a tumour suppressor gene target 
[351]. Some of the important genes that are modulated by up-regulated oncomiRs 
and down-regulated TS-miRs in PDAC will now be discussed.  
1.5.2.1 miRNAs regulating KRAS 
Several studies have investigated the regulation of KRAS by miRNAs and 
expression of the RAS oncogene is targeted by the tumour suppressor let-7 family in 
lung cancer [270], CRC [352] and BC [353]. It has also been suggested that KRAS 
up-regulation can lead to induction of LIN-28 (a negative regulator of let-7) via NF-
κB, thereby lowering let-7 expression [353]. This may be the mechanism for let-7 
down-regulation in pre-malignant lesions and KRAS-driven cancers. Torrisani et al. 
[286] demonstrated that let-7 is upregulated in normal ductal HPNE cells compared 
to PDAC cell-lines and similarly, in patient samples it is expressed in NP and 
pancreatic acini adjacent to PDAC, but not in stromal or cancerous cells. Using a 
plasmid-based system, let-7a levels were restored in Capan-1 PDAC cells (KRAS 
mutated) resulting in strong inhibition of cell proliferation, along with down-regulation 
of KRAS expression and mitogen activated protein kinase (MAPK) phosphorylation 
(a downstream effector of KRAS). However, subcutaneous xenografts in nude mice 
of Capan-1 cells stably overexpressing let-7 failed to exhibit stunted tumour growth 
in vivo compared to controls. Importantly, Oh et al. were able to show that ectopic 
expression of let-7a results in down-regulation of KRAS and improved sensitivity to 
radiation therapy in PDAC cells [354].   
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Table 4 - Summary of previous miRNA expression profiling studies in pancreatic cancer and pancreatic cancer cell-lines. 
Key: AUC: area under curve; FFPE: formalin-fixed paraffin embedded; PDAC: pancreatic ductal adenocarcinoma; CP: chronic pancreatitis; ND: normal ducts; 
NP: normal pancreas; AAC: ampullary adenocarcinoma; RT-PCR: reverse-transcription polymerase chain reaction; PACC: pancreatic acinar-cell carcinoma; 
PAM: prediction analysis of microarrays; LMD: laser microdissected; AZ: acinar cells. Red = up-regulated miRNAs; green = down-regulated miRNAs; blue = 
studies measuring 2-miR classifier of PDAC. *Note that the studies by Volinia et al. [266] and Roldo et al. [333] looked at pancreatic neuroendocrine tumours 
(PNET) and not PDAC (exocrine tumours). 
 
 
Year 
 
 
Author 
 
Ref. 
Number of miRNAs 
examined 
Study Design & Sample Size Important miRNA patterns in PDAC 
Putative Target Genes 
Identified 
General 
Expression 
2011 
Munding et al. 
(Szafranska 
in group) 
[336] 719 miRNAs 
From xenograft tumours, LMD: 
4 ND  
4 AZ  
5 PDAC  
From fresh frozen tissues, non-
LMD: 
5 CP 
Non-LMD FFPE samples used : 
52 PDAC 
43 CP 
miR-210, 135b, 425, 194, 429 (up-regulated) 
miR-199b-5p, 451, 145, 100, 148a (down-regulated) 
2-miR signatures: 
mirR196a/217 (validating Szafranska et al. 2008; AUC 
0.78) 
miR-196a/24 (AUC 0.81)  
miR-210/24 (AUC 0.76) 
miR-135b/24 (AUC 0.1) 
 
 
5 Up-regulated 
5 Down-
regulated 
2011 Schultz et al. [348] 754 miRNAs 
170 PDAC  
107 AAC 
23 CP 
28 NP 
(Non-LMD FFPE samples used) 
MiR-614, miR-492, miR-622, miR-135b, and miR-196 
were identified that were able to discriminate PDAC 
and AAC from NP and CP. 
4 profiles for PDAC + A-AC vs. CP + NP: 
mirR196a/217 (validating Szafranska et al. 2008) 
mirR411/198 
mirR614/122 
mirR614/93* 
 
42 Up-regulated 
41 Down-
regulated 
2010 Hao et al.  [349] Not disclosed 3 PDAC, 3 normal (matched) 
miR-483-3p, 34a*, 621, 1226, E1210, 1227 (up-
regulated)  
miR-493*, 517*, K12-2, 875-3p, 145*, 616 (down-
regulated) 
 
 
6 Up-regulated 
6 Down-
regulated 
2010 Yihui et al. [355] 576 miRNAs 
3 PDAC, 3 normal (matched), 2 
pancreatic cancer cell-lines 
Let-7b, miR-19b, 21, 23a, 24, 25, 27a, 125b, 200c, 214 
(up-regulated) 
miR-27a over-expressed in PANC-1 and Mia PACA-2 
cells 
miR-129, 198, 491, 518f, 596 (down-regulated)  
 
11 Up-regulated 
5 Down-
regulated 
2010 
Lee et al. 
(Szafranska is 
senior author) 
[338] 
 
Abstract 
only 
11 miRNAs 
216 PDAC (frozen, FFPE and 
FNAs) 
11 miRNA signature improved detection of PDAC 2-3 
fold in specimens with low amounts of tumour (10-
88%)  
compared to the 2-miRNA classifier miR-196a/217 
(Szafranska 2008)  
 
Not disclosed in 
abstract 
2010 Bhatti et al. 
[338] 
 
Abstract 
only 
5 miRNAs 
24 PDAC, 24 normal (matched), 
3 pancreatic cancer cell-lines 
miR-21 (up-regulated) ; correlated with disease stage 
and resectability  
miR-148a and 375 (down-regulated in cell-lines and 
tumours) 
 
1 Up-regulated 
2 Down-
regulated 
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2009 Kent et al. [341] 321 miRNAs 
21 pancreatic cancer cell-lines, 
2 normal (HPDE and HPNE 
non-transformed human 
pancreatic ductal epithelial cell-
lines) 
miR-7, 15a, 16, 17-3p, 26a, 26b, 29b, 30a-5p, 30b, 30c, 
30d, 31, 96, 182, 134, 141, 151, 155, 191, 193b, 200a, 
200b, 222, 361, 345, 429 (up-regulated) 
Let-7b, let-7c, let-7e, miR-34a, 99b, 125a, 143, 145, 
pre-199a, 199a, 204, 424 (down-regulated) 
 
26 Up-regulated 
12 Down-
regulated 
2009 Greither et al. [356] 6 miRNAs 56 PDAC 
miR-155, 203, 210, 222 (up-regulated) 
miR-216 and miR-217 (down-regulated) 
 
4 Up-regulated 
2 Down-
regulated 
2009 Zhang et al. [350] 
95 miRNAs (using 
QuantiMir real time 
RT-PCR system) 
17 PDAC, 17 normal (matched), 
10 pancreatic cancer cell-lines 
miR-15b, 95, 186, 190, 196a, 200b, 221, 222 (up-
regulated >3.3 fold in PDAC and cell-lines) 
 8 Up-regulated 
2008 Dillhoff et al. [357] 
1 miRNA 
(miR-21 only in TMA) 
80 PDAC, 45 CP,  
12 normal 
 
miR-21 overexpression in malignant cells only, not in 
surrounding stroma 
miR-21 expression did not correlate with tumour size, 
differentiation, nodal status or T stage 
miR-21 low expression levels in normal and CP 
 
 1 Up-regulated 
2008 
Szafranska et 
al. 
[337] 
13 miRNAs 
(miR-24 used for 
normalization) 
EUS-FNAs: 11 PDAC,  
1 PET, 1 atypical, 3 normal 
(from same patient) 
 
Frozen set: 8 PDAC, 6 CP, 6 
normal 
miR-31, 143, 145, 155, 196a, 205, 210 (up-regulated) 
miR-96, 130b, 148a, 217, 375 (down-regulated) 
miR-130b, 148a, 196a, 210, 217 (5-miRNA classifier of 
PDAC) 
High miR-196a and low miR-217 (2-miRNA classifier 
of PDAC; 90% sensitivity, 100% specificity) 
End-point RT-PCR confirmed miR-196a located in 
PDAC and PanIN lesions (PanIN-2 25%, PanIN-3 60%) 
and not normal ductal or acinar cells 
 
8 Up-regulated 
5 Down-
regulated 
2007 
Szafranska et 
al. 
[277] 377 miRNAs 
10 PDAC, 7 CP,  
7 normal (5 used in the array), 6 
pancreatic cancer cell-lines 
 
33 other normal human tissues 
(including stomach, duodenum 
and colon) 
Top 20 deregulated in PDAC: miR-143, 145, 146a, 150, 
155, 196a/b, 203, 210, 222, 223; miR-29c, 96, 130b, 
141, 148a/b, 216, 217, 375 
let-7i, miR-10a, 18, 21, 23a, 24, 31, 93, 99b, 100, 103, 
107, 125b, 140, 143, 145, 146a, 150, 155, 196a, 196b, 
199a, 203, 210, 214, 221, 222, 223, 224, 331, 452, 497 
(up-regulated) 
miR-196a and 196b (up-regulated in PDAC and cell-
lines, but absent in normal and CP) 
miR-29c, 30a-3p, 96, 130b, 141, 148a, 148b, 216, 217, 
375, 494 (down-regulated >5-fold) 
miR-200c, 200a, 200b (appeared down-regulated in 
PDAC, although not mentioned in the manuscript 
text)  
miR-18a, 31, 93, 205, 221, 224 (up-regulated in PDAC 
cell-lines and PDAC)  
Lack of miR-133a and overexpression of miR216 and 
217 (Normal pancreas classifier) 
- miR-217 and beta-catenin 
(cadherin-associated 
protein) or SDFR1 
- miR-146a and NUMB, SP8 
or KLF7 
- miR-221 / 222 and cyclin-
dependent kinase inhibitor 
1B (p27, Kip1) and 1C (p57, 
Kip2) 
- miR-196a and HOXB8 
-miR-93 and TP53INP1 
32 Up-regulated 
41 Down-
regulated 
(for PDAC vs. 
Normal) 
2007 
Bloomston et 
al. 
[325] 326 miRNAs 
65 PDAC, 65 normal (matched), 
42 CP 
miR-10a, 10b, 21, 23a, 23b, 99, 100, 100-1/2, 103-2, 
107, 125a, 125b-1, 143, 146, 155, 181a, 181b, 181b-2, 
181b-1, 181c, 181d, 196a, 199a-1, 199a-2, 205, 210, 
213, 220, 221, 222, 223 (up-regulated) 
miR-148a, 148b and 375 (down-regulated) 
miR-30a-3p, 105, 127, 187, 452, 518a-2 (able to 
distinguish long-term survivors with LN positive 
disease from those dying <24months) 
miR-196a-2 (up-regulated predicts poor survival) 
miR-99, 100, 100-1/2, 125a, 125b-1, 199a-1, 199a-2 
(overexpressed in PDAC and chronic pancreatitis vs. 
Normal) 
- miR-196a and HOXB8 
  
30 Up-regulated 
(18 by PAM 
score) 
3 Down-
regulated 
(for PDAC vs. 
Normal) 
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2007 Lee et al. [276] 
201 miRNA precursors 
(representing 222 
miRNAs) 
28 PDAC, 15 normal (matched), 
4 CP, 6 NP and 9 pancreatic 
cancer cell-lines 
Precursors to Let-7d, let-7f, miR-15b, 16-1, 21, 24-1, 
92-1, 100, 107, 125b-1, 155, 181a, 212, 424 (up-
regulated) 
miR-221, 301, 376a (up-regulated and localized to 
tumour cells by RT in situ PCR) 
Precursors to miR-139, 142-P, 345, 375 (down-
regulated) 
 
17 Up-regulated 
4 Down-
regulated 
2006 *Roldo et al. [333] 235 miRNAs 
40 PNET (also 4 PACC), 12 
normal 
 
miR-17, 20, 92-1, 99a, 99b, 100, 103, 107, 125a, 125b-
1, 129-b2, 129-2, 130a, 132, 342 (up-regulated) 
miR-21 (overexpressed in PNET, enhanced Ki67 
proliferation and liver mets) 
miR-155 (down-regulated) 
Overexpression of miR-103 and 107 with lack of miR-
155 discriminates tumours from normal pancreas 
miR-204 overexpressed in insulinomas and 
correlates with immunohistochemical staining of 
insulin better than insulin mRNA 
- miR-21 and PDCD4 
- miR-17-92 cluster and 
MYC 
 
87 Up-regulated 
8 Down-
regulated 
(for PNET only) 
 
2006 *Volinia et al. [266] 
 
228 miRNAs 
363 tumour samples (from 6 
types of solid tumour; 39 
PNET), 177 normal  
 
miR-17-5p, 20a, 21, 25, 29b-2, 24-1, 24-2, 30c, 32, 92-2, 
106a, 107, 128b, 146, 181b-1, 191, 199a-1, 214, 221, 
223 
(20 commonly up-regulated miRNAs in 3 or more 
solid tumours including PNET) 
pre-miR-152 and miR-155 (down-regulated) 
- miR-106a overexpression 
in colon cancer and Rb1 
- miR-20a down-regulation 
in breast cancer and 
TGFBR2 
55 Up-regulated 
2 Down-
regulated 
(for PNET only) 
 
2005 Jiang et al. [332] 
222 miRNAs 
+ let7 family 
32 human cancer cell-lines 
(including 2 pancreatic cancer 
cell-lines) 
miR-376 overexpressed in PANC-1 pancreatic cancer 
cells  
(also U6 snoRNA found to be consistently expressed 
in all cancer cell lines, therefore ideal as an 
endogenous control) 
 1 Up-regulated 
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Yu et al. [358] went on to recognise KRAS as a direct target of miR-96. They 
found that miR-96 targets the 3′UTR of KRAS and whilst overexpression in MIA 
PaCa-2 and PANC-1 cells did not reduce KRAS mRNA expression, there was 
however a significant reduction in KRAS translation, as indicated by reduced KRAS 
protein product. Furthermore, ectopic expression of miR-96 inhibited cell 
proliferation, migration and invasion, and promoted early apoptosis, identifying miR-
96 as a TS-miR in PDAC. These effects were attributed to the ability of miR-96 to 
negatively regulate the phosphorylated AKT (P-AKT) signaling pathway downstream 
of KRAS. Finally, xenografts of MIAPaCa-2 cells stably overexpressing miR-96 had 
significantly slower growth in vivo after 7 weeks compared to untreated controls.  
Next, Zhao et al. [359] found lower expression of miR-217 in PDAC tissues 
compared to paired adjacent NP (mainly expressed in acinar cells). MiR-217 was 
also confirmed to directly target the 3′-UTR of KRAS and overexpression 
dramatically reduced KRAS protein levels. Functionally, they found that miR-217 
inhibited growth and anchorage-independent growth in PDAC cell-lines. 
Furthermore, subcutaneous xenografts were injected twice intratumourally (IT) with a 
miR-217-vector, and over 5 weeks this miR-217 replacement caused a significant 
reduction in tumour growth in vivo. Interestingly, they found that miR-217 is also able 
to inhibit the constitutive phosphorylation of AKT. MiR-217 has already been 
validated by 6 groups as down-regulated in PDAC and these findings fit with our 
understanding of PDAC tumourigenesis as the vast majority of PDACs are KRAS-
driven [277, 337, 348, 356, 360]. 
Interestingly, Kent et al. [361] showed that activated KRAS signalling leads to 
repression of the miR-143/145 cluster and consequently a reduced tumourigenic 
potential of PDAC. They performed a custom microarray on normal ductal cells 
stably overexpressing constitutively active KRASG12D and found 6 miRNAs 
differentially expressed ≥2-fold: miR-34a, 199b and 31 were up-regulated and miR-
143, 145 and 27b were down-regulated. They showed that PDAC cells frequently 
have low expression of miR-143/145 and that these miRNAs are down-regulated in 
PDX-1-Cre; LSL-KRASG12D mice [361]. Retrovirally infected PDAC cells expressing 
miR-143/145 had normal rates of proliferation, but significantly reduced anchorage-
independent growth and were unable to form subcutaneous xenografts in nude mice 
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(either independently or in combination) [361]. They then demonstrated that KRAS 
signalling represses the transcription of these miRNAs by direct action of RREB1 at 
the miR-143/145 promoter [361]. Furthermore, miR-143 was found to target KRAS 
and miR-145 to target RREB1 (and also vice versa indirectly). This indicates that a 
“feed-forward” circuit exists, whereby KRAS-mediated repression of these miRNAs 
further accentuates RAS signalling [361].  
These studies provide further valuable information about the possibility of 
using miRNAs as therapeutic agents for the treatment of PDAC. It may be that 
clinical restoration of a “cocktail” of TS-miRs (let-7a, miR-96, 143/145 and 217) is 
able to contribute to PDAC control and other KRAS-driven cancers. 
1.5.2.2 miR-200 family and ZEB1 and ZEB2  
Whereas the primary tumour in most cases is susceptible to eradication by 
combined surgical and radiochemical treatments, its metastases are more difficult to 
eliminate and usually cause the death of the patient. The metastatic phenotype 
consists of a cascade of events that start with the primary tumour. Transition 
between the epithelial and mesenchymal states (EMT) has a key role in embryonic 
development, and is crucial in the development of metastasis from epithelial cancers. 
It refers to a complex molecular and cellular program in which epithelial cells lose 
their differentiated characteristics including their apicobasal polarity, cell-cell 
adhesion and lack of motility, acquiring instead a mesenchymal phenotype [362]. 
EMT is thus characterised by up-regulation of mesenchymal markers (i.e. S100A4, 
N-cadherin, vimentin, α-smooth muscle actin), down-regulation of epithelial cell 
surface markers and cytoskeleton components (i.e. E-cadherin, claudins, occludins, 
cytokeratins) and up-regulation and/or nuclear translocation of TFs (i.e. Snai1, Slug, 
Twist, ZEB1/2) [363].  
 
The ZEB family of TFs has 2 members (ZEB1 and ZEB2 aka SIP1) [364]. 
ZEB factors interact with DNA through the simultaneous binding of the 2 zinc-finger 
domains to high-affinity binding sites composed of bipartite E-boxes (CACCT and 
CACCTG), as found in the CDH1 promoter [365]. ZEB1/2 expression therefore 
results in the loss of functional E-cadherin (through silencing of CDH1), which is the 
hallmark of both EMT and increased carcinoma cell invasiveness [366]. EMT-related 
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molecular pathways have been implicated in the aggressiveness and lethality of 
PDAC [363]. ZEB1 is expressed in epithelial PDAC cells, as well as the tumour-
associated stroma, and their activation correlates with high tumour grade and poor 
prognosis, including early recurrence after surgery [367]. 
Recently, miRNAs have been discovered to have a role in metastasis 
principally by inducing or repressing components of the EMT process [344, 368] by 
either: direct repression of the cell-cell adhesion marker E-cadherin or by repression 
of TFs. Thus far, a pivotal role here is exerted by miRNAs belonging to the miR-200 
family (miR-200a, 200b, 200c, miR-141 and 429) and miR-205 [363]. These are 
expressed specifically in epithelial tissues and are down-regulated in Madin Darby 
canine kidney (MDCK) epithelial cells during EMT in response to TGF-β [344]. Loss 
of these miRNAs can be mainly ascribed to repressor activity of the ZEB family of 
TFs (especially miR-141 and 200c in PANC1 cells) [369]. It has been shown that 
TGF-β and ZEB1 are target genes of miR-200 family. In addition, ZEB1 and miR-200 
family members repress expression of each other in a reciprocal feedback loop 
[370]. Of these, miR-200c is has the strongest anti-ZEB1 and anti-EMT effect [364]. 
ZEB1 can in turn repress transcription of the miR-200c-141 and the miR-200b-200a-
429 polycistronic pri-miR transcripts by direct binding to their promoter regions [364]. 
Thus, there is a positive correlation between miR-200c levels and E-cadherin mRNA 
levels in PDAC cell lines (i.e. higher miR-200c levels are associated with a more 
epithelial phenotype) [371]. Those cell lines with higher miR-200c levels have lower 
invasion ability and overexpression of pre-miR-200c results in decreased cell 
proliferation in PANC-1, KP-3 and SUIT-2 cells [371]. The miR-200 family is also 
seen to be differentially expressed in the GEM-sensitive and resistant PDAC cell 
lines [372]. Li et al. found that miR-200 family was up-regulated in GEM-sensitive 
cells (i.e. L3.6pl, Colo357, BXPC3) and down-regulated in GEM-resistant cells (i.e. 
MIAPaCa-2, PANC-1, Aspc-1). Again, overexpression of miR-200a, 200b and 200c 
for 14 days in MIAPaCa-2 cells leads to reversal of an EMT phenotype with up-
regulation of E-cadherin and down-regulation of ZEB1 and vimentin at the mRNA 
and protein levels [372]. All in all, it is clear that miRNAs could be crucial in 
regulating EMT and causing a reversal in the form of the mesenchymal-to-epithelial 
(MET) transition in PDAC. 
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1.5.2.3 miR-34a and Tumour protein 53 (p53) 
 The tumour suppressor p53 can regulate miRNA transcription and processing, 
and miRNAs can also regulate p53 activity and expression, thus various 
feedback/feed forward loops have been identified [373]. p53 has been identified as a 
transcriptional regulator of miR-34a and several studies have implicated the miR-34 
family in the p53 tumour suppressor network [374]. miR-34a is often down-regulated 
in PDAC [375]. Replacement of miR-34a causes dramatic reprogramming of gene 
expression and promotes apoptosis [375]. Unsurprisingly, the miR-34a-responsive 
genes in PDAC include those that regulate cell-cycle progression, apoptosis, DNA 
repair, and angiogenesis [375]. Thus, re-expression of miR-34a in pancreatic cancer 
stem cells (CSCs) and PDAC cell lines has been shown to strongly inhibit cell 
proliferation, cell-cycle progression, self-renewal, EMT and invasion [374]. Although 
the p53–miRNA target networks are extremely complex, these findings suggest that 
perhaps modulating miR-34a could improve patient response to existing 
chemotherapies or even act as a standalone anti-cancer drug. Indeed, exogenous 
replacement of miR-34a in mice bearing therapeutically resistant mutant KRAS and 
p53 lung tumours reduced tumour formation and progression, supporting the use of 
miR-34a as a lung tumour-preventative and tumour-static agent [376].  
1.5.2.4 miRNAs regulating SMAD4 
TGF-β signalling is believed to be a major inducer of EMT in PDAC [363]. 
TGF-β acts via binding to specific receptors and transducing a canonical 
downstream signal through phosphorylation of SMAD2 and SMAD3, which complex 
with SMAD4 and translocate to the nucleus to induce the transcription of target 
genes [377]. SMAD4 is the final effector of TGF-β signal transduction. TGF-β directly 
enhances the invasion of PDAC cells and also stimulates cell-proliferation [378]. Two 
miRNAs have recently been identified as potent negative regulators of SMAD4 in 
PDAC by a Chinese group: miR-412 [379] and miR-483-3p [349]. Hao et al. [349, 
379] found that SMAD4 3’UTR is directly regulated by miR-421 and miR-483-3p and 
their individual overexpression in vitro promotes cell-proliferation and colony 
formation. Notably, SMAD4 is lost in 22% of PDACs. Interestingly, co-expression of 
miR-483-3p and TGF-β inhibits a reduction of E-cadherin levels, the hallmark of EMT 
normally seen with TGF-β treatment in PDAC cells. Thus, both may be potential 
 99 
 
targets for PDAC therapy, in particular for the prevention of metastatic spread. 
Surprisingly, these two miRNAs are not commonly up-regulated in previous profiling 
studies and in vivo experiments are warranted to further investigate their 
significance. 
 
1.5.3 miRNAs associated with prognostic significance in PDAC  
 
From these expression profiling studies, various miRNAs have been 
highlighted in PDAC progression and metastasis, and identified as potential clinical 
prognostic biomarkers (Table 5). Recently, studies have also indicated that aberrant 
miRNA expression can be responsible for resistance to chemotherapeutic agents.  
Surprisingly, the ideal prognostic miRNA signature for PDAC has not been 
decided upon, although high miR-21 levels appear to be consistently associated with 
poor prognosis (blood [380, 381] or tissue [380, 382-390]) and/or GEM resistance 
(Table 5 and Table 6).  
Interestingly, miR-10b has also been identified as over-expressed in PDAC 
[325, 391-394], and until recently its functional relevance has remained uncertain. 
MiR-10b has already been defined as a "metastamiR" in various tumour types (e.g. 
breast, oesophagus, lung, colorectal and liver), and it enhances metastasis by 
targeting genes such as HOXD10 [395], syndecan-1 (SDC-1) [396], and KLF4 [397]. 
Furthermore, miR-10b is a direct transcriptional target of Twist, an inducer of EMT 
and metastatic progression. However, compared to other tumour types (e.g. breast, 
prostate), Twist is not or only weakly expressed in PDAC, but can be activated 
during hypoxia in vitro and may play a crucial role in tumour invasion under such 
conditions [398]. Ectopic expression of miR-10b in non-metastatic BC cells promotes 
invasive and metastatic properties in vitro and in vivo, at least partly via direct 
repression of the homeobox TF HOXD10, leading to expression of RHOC, a positive 
regulator of metastasis [395]. However, miR-10b expression does not correlate 
clinically with risk of distant metastasis or prognosis in BC [399]. Ouyang et al. [391] 
have found that miR-10b is involved in the interaction between epidermal growth 
factor (EGF) and TGF-β signalling and therefore facilitating deleterious cross-talk 
and the metastatic phenotype of PDAC. Ouyang et al. [391] demonstrated that its 
 100 
 
overexpression results in increased EGF-induced invasion, EGFR phosphorylation 
and extracellular signal–regulated kinase 1 (ERK1)/2 activation in PDAC cells, by 
targeting Tat-interacting protein 30 (TIP30). Furthermore, they found that 
overexpression of miR-10b enhanced EGF and TGF-β-mediated cell invasion and 
the induction of EMT in vitro. These effects were markedly attenuated by both EGFR 
kinase inhibition, using erlotinib, and TGFβR1 kinase inhibition, using SB505124, 
and were completely abrogated by combined treatment. Conversely, PDAC cells 
stably over-expressing miR-10b were found to form faster and larger intra-pancreatic 
tumours in vivo compared to controls. In addition, miR-10b was also found to be up-
regulated in the plasma samples of PDAC patients compared to CP and normal 
individuals [391]. These data suggest that miR-10b could act as a blood-based 
biomarker for PDAC, as well as a therapeutic target for suppressing disease spread.  
MiR-10b is undoubtedly involved in metastatic progression of several cancers 
[400], but has only been found as upregulated in metastases of bladder cancer (not 
breast, colon or lung) [401]. Further investigating the relevance of miR-10b, we 
performed a small study that measured miR-10b in NP, PDAC and matched 
metastatic LNs [393]. Interestingly, whilst we confirmed miR-10b is upregulated in 
PDAC compared to NP, its expression is quite variable and increased expression 
could not be demonstrated in normal-matched LN metastases. This suggests that 
high miR-10b levels are helping to drive primary PDAC progression and distant 
spread, but that levels normalise once a macrometastasis has been formed (similar 
to the reversal of EMT), which could provide further rationale for inhibiting this 
metastamiR early in PDAC treatment. 
Preis et al. [394] presented data indicating that miR-10b is over-expressed in 
PDAC and can be used as a diagnostic marker in endoscopic-ultrasound guided 
fine-needle aspiration (EUS-FNA) biopsies of suspicious pancreatic lesions. In 
addition, miR-10b may be able to guide neoadjuvant GEM-based chemo-
radiotherapy and predict DFS and OS. Crucially, this study provides further evidence 
that miRNAs have the ability to “personalise” PDAC treatment and guide clinical 
decisions. MiR-10b may be a prognostic (i.e. high miR-10b patients have an 
unfavourable prognosis and may benefit from additional or more aggressive 
treatments) and also a predictive biomarker (i.e. low miR-10b patients will benefit 
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most from multimodality neoadjuvant treatment) for PDAC. Several miRNAs, notably 
oncomiR-21, miR-34a, miR-196a and the miR-200 family, have already been 
identified as being predictors of clinical outcome and/or deregulated in PDAC 
chemoresistance (Table 5 and 6). 
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Table 5 - miRNAs with prognostic significance in PDAC. 
MiR-21 appears to be a good candidate prognostic biomarker for PDAC. 
 
Author & 
Ref. 
miRNA Survival Findings 
Preis et al.  
[394] 
miR-10b High expression correlates with poor survival  
Ohuchida et 
al.  
[402] 
miR-142-5p 
& 204 
miR-34a 
High expression correlates with improved survival with adjuvant Gemcitabine after surgical resection 
High expression correlates with better survival in patients who did not receive adjuvant Gemcitabine treatment 
Jamieson et 
al.  
[387] 
miR-21 
miR-34a 
and 30d 
High tissue miR-21, and low miR-34a and miR-30d expression were associated with increased hazard of death after PDAC 
resection 
Greither et 
al.  
[356] 
miR-155, 
203, 210, 
222 
 
miR-216 & 
217 
Multivariate Cox's regression hazard analyses correlated elevated expression with reduced survival (RR = relative risk of 
cancer-related death): miR-155 = 2.50; miR-203 = 2.21; miR-210 = 2.48 and miR-222 = 2.05 
Combined overexpression of all 4 miRNAs correlates with poor prognosis independent of the progression of the disease (6.2-
fold increased risk of tumour-related death) 
Reduced expression correlates with poor survival 
Bloomston 
et al.  
[325] 
miR-219 & 
196a-2p 
 
High expression correlates with poor survival; patients with high miR-219 expression had median survival of 13.6 months vs. 
low expression 23.8 months (P=0.07); 2-year survival 25% vs. 49%. Whilst, patients with high miR-196a expression had 
median survival of 14.3 months vs. low expression 26.5 months (P=0.009); 2-year survival 17% vs. 64%. 
Kong et al.  
[403] 
miR-196a 
High plasma expression correlates with disease progression (higher expression in plasma of stage 3 and 4 PDAC, i.e. 
unresectable) and could be used to help select surgical candidates. Patients with high expression had median survival 6.1 
months vs. low expression 12.0 months (P=0.007); 1-year survival 0% vs. 40.6%. 
Ali et al.  
[404] 
miR-21 
let-7d 
High plasma miR-21 expression correlates with worse survival (1-year survival 15% vs. 37%; P=0.0032). 
Low let-7d expression was an independent prognostic marker 
Dillhoff et al. 
[357] 
miR-21 
High expression and lymph-node negative disease correlates with poorer survival; expression did not correlate with stage or 
size of tumour 
Yu et al.  
[371] 
miR-200c 
Patients with high expression had improved overall survival (42 months vs. low expression 19 months; P=0.03; 5-year survival 
33.5% vs. 11.2%). Low miR-200c = HR 2.2 times increased risk of death 
Hwang et al. 
[382] 
miR-21 Lower miR-21 expression with adjuvant Gemcitabine correlates with longer overall and disease-free survival 
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1.5.4 miRNAs involved in chemoresistance in pancreatic cancer  
1.5.4.1 Factors influencing chemoresistance 
The search for tumour specific miRNA expression signatures can provide 
powerful mechanistic information for the investigation and resolution of resistance to 
anti-cancer therapies. MiRNAs have the potential both to predict response and to 
help overcome resistance to anti-cancer treatment, so improving patient-tailored 
therapies; however they require substantial further validation before being introduced 
to the clinic.  
Chemotherapy is widely used in the treatment of various types of cancer and 
an adequate response is crucial for prolonging patient survival and improving quality 
of life. Despite the development of novel anti-cancer agents, drug resistance 
frequently hampers successful treatment and many tumours are still refractory to 
chemotherapy. Chemoresistance can be classified as either intrinsic or acquired. 
The intrinsic type of resistance refers to factors already present (including a 
combination of genetic and biochemical factors such as the genetic variability of the 
cancer cell population and the poor ability to transport the drug into the cells) that 
can make the intended anti-cancer therapy futile. Acquired resistance however 
develops over time, after exposure to chemotherapy, when tumours that were initially 
sensitive to a particular drug quickly develop resistance, often due to overgrowth of 
drug-resistant tumour cells [405]. The acquisition of chemoresistance correlates with 
increased aggressiveness and poor prognosis. Recognised causes of resistance to 
anti-cancer therapy include genetic (random drug-induced mutational events), 
epigenetic (drug-induced nonmutational alterations affecting the expression and 
function of critical genes) and karyotypic changes (drug-induced chromosomal 
abnormalities) [405]. Resistance is considered to be a multifactorial phenomenon 
and mechanisms include problems with drug delivery, drug metabolism and 
molecular changes in tumours affecting drug sensitivity [406]. Understanding the 
mechanisms involved is crucial to developing more effective treatments and better 
utilising currently available agents.  
The identification of biomarkers that can accurately classify tumours and help 
to improve the initial choice of anti-cancer treatment, by avoiding intrinsic resistance 
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and forecasting the development of acquired resistance, is paramount. Experimental 
evidence demonstrates that miRNAs are involved in the chemoresistant phenotype 
of tumour cells and specific profiles of miRNA expression can be correlated with the 
evolution of anti-cancer drug resistance. This miRNA-mediated form of drug 
resistance represents yet another cause of anti-cancer treatment failure [406] and 
suggests a role for tumour miRNAs, not only as diagnostic and predictive 
biomarkers, but also as targets which must be exploited to either optimise treatment 
response and/or produce direct anti-tumour effects. Several studies have shown the 
correction of specific deregulated miRNAs, using miRNA mimics or inhibitors, can 
normalize the gene regulatory network and signaling pathways, and potentially 
reverse unwanted phenotypes in cancerous cells [407]. MiRNA-based therapeutics 
therefore provide a very attractive anti-tumour approach as part of integrated cancer 
therapies. These strategies may allow us to overcome chemoresistance via 
exploiting a synergistic interaction with anti-cancer drugs, though the modulation of 
key proteins that affect drug activity, thereby improving the clinical outcome of 
cancer patients [408].  
Tumours presenting clinically as the same type or subtype can be very 
different at the molecular and miRNA level and therefore behave differently in 
response to anti-cancer therapy. Interestingly, the expression of various miRNAs is 
also affected by some anti-cancer agents, therefore providing an intertwined 
scenario whereby drugs modulate specific miRNAs, which in turn influence the 
chemosensitivity of cancer cells [409]. Early tumour profiling studies have led to an 
understanding of differential miRNA expression between clinical cases and 
molecular subtypes, however understanding their correlation with response to anti-
cancer cytotoxic therapies, radiotherapy and radical surgery and will allow for more 
robust prognostic signatures and further individualisation of care.  
The NCI-60, a panel of 60 diverse human cancer cell lines, has been used by 
the National Cancer Institute to screen >100,000 chemical compounds for anti-
cancer activity. These well studied cancer cell lines have been subjected to every 
"omic" analysis and have recently been extensively profiled for their changing 
miRNome and transcriptome in response to several anti-cancer cytotoxics [410, 
411]. Significant correlations have been demonstrated between miRNA expression 
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profiles and drug potency patterns, suggesting that miRNAs may provide a critical 
link for understanding mechanisms involved in chemosensitivity and 
chemoresistance [410].  
1.5.4.2 miRNAs associated with chemoresistance in PDAC 
As discussed, PDAC is one of the deadliest cancers and there has been little 
tangible progress in terms of treatments to date. A few miRNAs have been linked to 
PDAC chemoresistance (Table 6), and modulating these may result in better long-
term outcomes for patients when combined with standard chemotherapeutics.  
The one molecule that is repeatedly highlighted in this respect is oncomiR-21. 
MiR-21 targets the downstream portion of several oncogenic pathways (e.g. 
activated KRAS and EGFR signalling) and targets several tumour suppressors 
(Figure 9). The result is that miR-21 participates in many cancer-related processes 
such as cell proliferation, invasion, migration/motility, and resistance to cytotoxic 
chemotherapeutic agents [412]. Indeed, in vitro studies have clearly shown that 
inhibition of miR-21 increases sensitivity of PDAC cells to GEM [382, 413] and 5-FU 
[382] treatment. Furthermore, Sicard et al. [412] have also indicated that miR-21 
depletion (by IT injection of lentiviral vectors [LV] for stable expression of RNAi 
hairpins antisense to miR-21), combined with GEM treatment, strongly inhibits 
tumour progression and induces regression, in part due to stimulation of 
angiogenesis, presumably allowing enhanced drug delivery, but also by provoking 
PDAC cell death.  
Clinical studies have also provided further evidence that miR-21 determines 
chemoresistance in PDAC. The first study by Hwang et al. examined 81 PDAC 
samples from patients treated with GEM and found high miR-21 expression was 
associated with worse OS in both the adjuvant and metastatic settings [383]. Their 
subsequent study demonstrated a correlation between low miR-21 expression and 
improved outcome in patients with localised PDAC treated with adjuvant GEM or 5-
FU [382]. Jamieson et al. [387] also found that high expression of miR-21 (HR=3.22; 
1.21–8.58) was associated with poor OS after PDAC surgical resection. 
Furthermore, they showed that patients treated with adjuvant chemotherapy and 
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displaying low tumoural miR-21 levels did better than those with high miR-21 levels 
(median OS 27.5 vs. 16.4 months). 
Other miRNAs that could be targeted to improve PDAC chemosensitivity to 
GEM include those modulated by the histone acetyltransferase inhibitor garcinol (i.e. 
miR-21, 196a, 495, 605, 638, and 453) [414]. Furthermore, trichostatin A (histone 
deacetylase inhibitor) induces down-regulation of miR-21 and up-regulation of miR-
200c leading to increased apoptosis [415]. Restoring miR-200 family expression has 
also been shown to improve chemosensitivity by reversing EMT [372, 416] (Table 6).  
Interestingly, miRNAs have also been shown to affect the response to 
radiation therapy in PDAC, although very little data has emerged on this 
phenomenon. Wang et al. [417] found that miR-23b is an inhibitor of irradiation (IR)-
induced autophagy (the process reported to protect cells from IR-induced cellular 
damage, therefore enhancing radioresistance) and identified ATG12 as a direct 
target. MiR-23b was inversely correlated with ATG12 expression in patient samples. 
Oh et al. showed that ectopic overexpression of let-7a down-regulates KRAS (in 
those PDAC and lung cancer cells with a KRAS-activating mutation) and 
subsequently increases radiosensitivity [354].  
1.5.4.3 Determining pharmaco-miRNomics in PDAC 
The study of pharmacogenomics has become an essential component of 
successful drug-discovery and as such offers widespread public health benefits 
[418]. Helping to direct anti-cancer drug discovery, it provides an opportunity to 
develop superior, more targeted therapies with reduced toxicities. Thus, perhaps 
"pharmaco-miRNomics", a combination of pharmacology and miRNomics [226], 
referring to the future analysis of tumour miRNomes relevant to drug target 
discovery, metabolism, efficacy and toxicity, will play an increasingly important role in 
the multidisciplinary effort to treat cancer. This approach should lead to better tumour 
classification, prognostic stratification and ultimately individualised treatment 
strategies. 
However, from previous studies on the role of miRNAs in resistance to 
conventional chemotherapies, it is evident that similar to gene profiling studies, most 
emerging miRNA signatures are not fully overlapping. These results might be 
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explained by different tumour specimens (e.g. FF vs. FFPE, micro vs. macro-
dissected); experimental platforms (e.g. RT-qPCR vs. microarrays / NGS vs. ISH); 
tumour histology (type, stage, location, intra-tumour heterogeneity) and treatment 
regimens, as well as by small sample size and lack of multivariate analysis or 
correction for multiple testing. In this regard, the achievement of a general 
consensus on the techniques and controls to be used and the conduction of studies 
on a larger scale with associated pathobiological and clinical information, are 
warranted for the proper validation of specific miRNAs as new biomarkers of drug 
activity. 
Currently, substantial pre-clinical and clinical evidence exists in several 
tumour types illustrating how miRNAs are able to predict and/or abrogate the 
chemoresistance of individual malignancies to different anti-cancer therapies and 
can therefore potentially help to guide oncologists. Although these data are 
promising, larger prospective trials are required to validate the role of miRNAs in this 
capacity, but such studies should lead to significant changes in clinical treatment 
algorithms. Additionally, much data are derived from work using cancer cell lines, 
which have been removed from their in vivo environment, and therefore cannot be 
considered accurate surrogates for clinical tumours. Therefore further animal studies 
assessing many of the mechanisms of these miRNAs in vivo are urgently required. 
Overall the development of effective miRNA-modulating therapies remains a 
substantial challenge and approaches for in vivo delivery of miRNA-modulating 
molecules need to be improved (see section 1.6). 
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Table 6 - miRNAs associated with chemoresistance in PDAC. 
ING4, Inhibitor of Growth 4; PI3K, Phosphatidylinositol-3-kinase; PTEN, phosphatase and tensin homolog; MMP, matrix metalloproteinase; 
VEGF, Vascular endothelial growth factor; RECK, reversion-inducing cysteine-rich protein with kazal; NFκB, nuclear factor kappa-light-chain-
enhancer of activated B cells; B-DIM, BioResponse-formulated 3,3'-diindolymethane; G2535, is a mixture of genistein and other isoflavones. 
Modified from [419]. 
 
Author  Treatment investigated miRNA Chemoresistance / 
Chemosensitivity 
Mechanism 
Preis et al.  
[394]  
Neoadjuvant 
Gemcitabine-based 
chemoradiotherapy 
↓ miR-10b Chemosensitivity 
 
Some targets investigated by Ouyang et al. [391] 
Zhang et 
al.  
[420] 
Gemcitabine ↑ miR-214 Chemoresistance ING4 ↓ 
Giovannetti 
et al.  
[383] 
Gemcitabine ↑ miR-21 Chemoresistance 
Apoptosis ↓: PI3K/Akt ↑, PTEN ↓ 
Invasion ↑: MMP-2/MMP-9 ↑, VEGF↑ 
Hwang et 
al.  
[382] 
5-fluorouracil (5-FU) ↑ miR-21 Chemoresistance 
Predictor of chemoresistance and reduced 
proliferation 
Sicard et 
al. [412] 
Gemcitabine ↑ miR-21 Chemoresistance Depletion leads to Apoptosis ↑ and angiogenesis 
Park et al.  
[413] 
Gemcitabine 
 
↑ miR-21 
↑ miR-221 
Chemoresistance 
Chemoresistance 
Apoptosis ↓: PTEN ↓, RECK ↓ 
p27
kip1 
↓ 
Ali et al.  
[416] 
Gemcitabine  
CDF (analogue of 
curcumin) 
↓ miR-21 
↑ miR-200b & 200c 
Chemosensitivity 
 
Apoptosis ↑: PTEN ↑, pAkt ↓, NFκB ↓ 
 
Li et al.  
[372] 
Gemcitabine 
B-DIM and G2535 
↑ miR-200b 
 
Chemosensitivity 
 
EMT reversal: E-cadherin ↑, Vimentin ↓, ZEB1 ↓  
Transfection of precursor miR-200a, 200b and 200c is 
required for partial change in morphology in MiaPaCa-
2 cells 
Ji et al.  
[343] 
Gemcitabine  
Docetaxel 
Cisplatin 
 
↑ miR-34a 
Chemosensitivity 
and ↓ radioresistance 
Apoptosis ↑: Bcl-2 ↓, Notch-1 ↓, Notch-2 ↓,  
caspase-3 ↑ 
p53 up-regulation 
CD44
+
/CD133
+
 CSC ↓ 
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1.5.5 miRNAs in pancreatic precursor lesions  
Recently, there have been a number of influential studies assessing miRNA 
expression profiles in early pancreatic neoplasia, a critical stage at which to assess a 
tumour’s likely trajectory and prognosis. Table 7 summarises the up-to-date 
literature, but a few reports deserve additional comment.  
1.5.5.1 miRNA expression profiles in PanIN lesions 
Yu et al. have performed a key study in which they profiled the miRNA 
expression of the different grades of PanIN (microscopic precursors) compared to 
NP [421]. They used LCM of FF tissues to ensure cellular source and quality, and a 
TaqMan microarray of 735 human miRNAs. They had some important findings: 
firstly, miRNAs could differentiate PanIN lesions from NP, although between grades 
there was considerable overlap in signatures. Many miRNAs that were differentially 
expressed in PanINs, have also been found to be dysregulated in PDAC (e.g. up-
regulation: miR-21, 107, 146a, 155, 200a/b/c, and 203; down-regulation: miR-216b 
and 217), and many of these have oncogenic or tumour suppressive roles [421]. 
Other miRNAs not previously recognised (e.g. high miR-182, low miR-296-5p), were 
validated as dysregulated in PanINs and also PDAC. MiR-196b was the most 
overexpressed miRNA in PanIN-3 lesions (carcinoma in situ); miR-126, 125b, 127-
3p, 139-3p/5p, 216b, 218 and 452 were silenced, and these may represent useful 
diagnostic markers [421]. The findings from their study and others in the literature 
are summarised in Figure 10. These results [421] validate those from Du Rieu et al. 
[422] and LaConti et al. [423] who both found up-regulation of miR-21 with increasing 
PanIN grade (Table 7). Interestingly, Xue et al. [424] found that miR-148a and miR-
217 are down-regulated in PanIN 2-3, whilst miR-10b and miR-196a are significantly 
up-regulated, albeit in a smaller cohort of patients. Thus, a miRNA signature 
characterising high grade PanIN lesions seems to be emerging from these profiling 
studies. 
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Figure 10 - Progression of miRNA expression during pancreatic carcinogenesis. 
Modified from [421]. 
 
1.5.5.2 miRNA expression profiles in pancreatic cystic tumours 
 Using similar approaches the macroscopic precursor lesions of PDAC have 
been investigated (Table 7). Pancreatic cysts are now being detected more 
frequently due to increased recognition and the liberal use of cross-sectional 
imaging. There is a spectrum of pancreatic cystic lesions ranging from the 
completely benign and inflammatory, to the highly malignant. Pancreatic benign 
cystic tumours (BCT), especially those with a mucinous epithelial lining like the 
intraductal papillary mucinous neoplasms (IPMN), have the potential to become 
malignant. Differentiating benign pancreatic cystic lesions from neoplastic disease is 
critical to patient management and follow-up, as there is a possibility to prevent the 
development of pancreatic cancer by surgically resecting these pre-cancerous 
tumours prior to malignant transformation.  
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 IPMNs are intraductal mucin-producing neoplasms with tall, columnar, mucin-
containing epithelium with or without papillary projections. IPMNs are also 
characterised by dilatation of the main pancreatic duct and/or ectasia of side-branch 
ducts and mucin overproduction. IPMNs can progress into invasive carcinoma either 
tubular (conventional PDAC) or colloid adenocarcinoma [425]. Main duct and mixed-
type IPMNs have a significant risk of malignant transformation, whilst malignancy in 
branch-duct IPMNs is less common but not negligible [426, 427]. Several groups 
(Table 7) have attempted to determine miRNAs that differ between NP, IPMN and 
CEI. The goal of this is to develop a molecular-based test that can predict the 
malignant potential of an IPMN without having to subject the patient to major 
pancreatic surgery with its associated complications [426].  
 The most recent study by Lubezky et al. [428] examined IPMNs of varying 
degrees of dysplasia, as well as CEI (IPMN with invasive carcinoma), PDAC and NP 
samples by microarray (Table 7). They found that up-regulation of miR-21, miR-155 
and miR-708 and a decrease in miR-217 levels occurred during IPMN malignant 
transformation [428]. Interestingly, their observed fold-change increases as grade of 
IPMN worsens, suggesting this escalating signature corresponds to (and perhaps 
drives) a progressive malignant phenotype. In addition, miRNA expression was also 
compared between CEI and primary PDAC. This revealed that several crucial 
miRNAs were differentially expressed in PDAC compared to CEI (e.g. up-regulation 
of the miR-200 family, 21, 27a, 99a, 141, 143, 145, and 199a-3p/5p) [428]. These 
differences may partly explain the stark differences in outcome for these two types of 
pancreatic adenocarcinoma. 
 Of the miRNAs that Lubezky et al. [428] identified as dysregulated during 
IPMN malignant transformation, miR-21 and miR-155 have previously been shown 
to be up-regulated in benign IPMN [429] compared to NP and also in the progression 
of IPMN to CEI [430]. These are the most common PDAC-specific miRNAs. 
Additionally, high miR-21 expression is associated with high grade CEI tumours 
(P=0.03) and is a predictor of poor overall and DFS independent of LN and resection 
margin status (death risk: HR=3.3; progression risk: HR=2.3) [430]. MiR-216 and 
217 have been previously shown to be significantly down-regulated in PDAC 
compared to NP and this may identify loss of normal acinar cell mass [277]. Indeed, 
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miR-216a, 216b and 217 are expressed at high levels in microdissected acinar cells, 
with significantly lower levels in normal ductal cells and virtually no expression in 
PDAC cells [336]. MiR-708 was elevated 3.3 fold in malignant compared to benign 
IPMNs, and also in PDAC compared to CEI [428]. Interestingly, miR-708 has not 
been identified as dysregulated in pancreatic neoplasia previously. In lung cancer it 
acts as an oncogene by potentiating the WNT signalling pathway [431], however it 
operates as a TS-miR in renal cell carcinoma (RCC) by targeting E-cadherin 
regulators ZEB2 and BMI1 [432]; a metastasis-suppressor in patients with BC, by 
regulating cell migration and metastasis through a miR-708-Neuronatin-Ca2+-
ERK/FAK axis (miR-708 suppressed in BC metastases compared to the primary 
tumours) [433]; and a key negative regulator of CD44-expressing tumour-initiating 
cells, cells that are centrally involved in prostate cancer initiation, progression and 
development [434]. Clearly its expression is tissue and tumour-specific, and further 
studies in IPMN and PDAC are required to clarify its possible functions in pancreatic 
neoplasia.  
Unsupervised hierarchical clustering has given an excellent overview of the 
miRNA expression changes across the different IPMN grades, accurately 
discriminating the groups and allowing a focussed examination of miRNAs of 
possible importance in malignant transformation in IPMN [428]. In particular, miR-
203 and miR-222, were found to be up-regulated in PDAC vs. CEI (>2 fold; P<0.001) 
by this clustering approach [428] and are both independent predictors of poor OS 
after PDAC surgical resection [356]. The up-regulation of miR-203 is contrary to its 
behaviour as part of the ZEB/miR-200 loop, in which ZEB1 inhibits miR-200 
expression, but also that of miR-183 and miR-203, which together target the 
stemness-associated factor BMI1 to increase stem-cell properties and the 
tumourigenic capacity of PDAC cells [367]. High miR-203 and miR-200 expression in 
the PDAC samples used for the microarray [428] suggest quite an epithelial and well 
differentiated phenotype (high miR-200 compared to CEI), as opposed to 
mesenchymal and undifferentiated phenotypes expected with low miR-200 
expression. MiR-424* was found to be up-regulated 3.16 fold in malignant vs. benign 
IPMNs (slightly higher than oncomiR-21; 3.12 fold) [428]. Interestingly, some studies 
have shown a number of miRNA* species (passenger strands) to be physiologically 
relevant and to play roles in tumourigenesis [435]. Thus, miR-424* may be another 
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potential marker of IPMN malignant transformation. MiR-148a expression was 
reduced 5 fold in LG IPMNs vs. LG IPMNs containing CEI / CEI itself, and also in 
malignant vs. benign IPMNs [428]. Measurement of miR-148a from microdissected 
PanINs from KRASG12D mice showed miR-148a down-regulation as an early event in 
PDAC development occuring in PanIN-1b, PanIN-2 and PanIN-3 lesions [436]. 
Furthermore, miR-148a was found to be down-regulated by DNA hypermethylation in 
PDAC [436], however restoring its expression does not impact PDAC proliferation 
either in vitro or in vivo, suggesting it may be more useful as a biomarker than as a 
therapeutic tool [437]. MiR-199a was up-regulated in benign and malignant IPMNs 
vs. NP and also in PDAC vs. CEI [428]. As previously discussed, the TGF-β 
signalling pathway is important in PDAC tumourigenesis, and miR-199a has been 
shown to target SMAD4 in gastric cancer and its overexpression is able to impair 
TGF-β-induced cell-cycle arrest and apoptosis [438]. Multiple previous microarray 
studies have identified increased miR-199a in PDAC, so this could be a reliable 
biomarker for invasive carcinoma [387]. Finally, miR-31 was massively up-regulated 
in all types of IPMN compared to NP [428]. Although, it did not change with IPMN 
progression, it certainly appears to be a miRNA involved in IPMN development. 
Interestingly, in colorectal disease, miR-31 is elevated in adenomas and carcinoma 
compared to normal colonic mucosa [439]. However, recently controversial data has 
emerged on the dysregulation of miR-31 expression in PDAC vs. NP, as well as on 
its role in the regulation of PDAC cell migration and invasion which should prompt 
further studies on its use as a biomarker [385, 440].  
 In order to translate these findings into clinical use, there have been several 
studies that have looked at miRNAs enriched in CT-guided, EUS or endoscopic 
retrograde cholangiopancreatography (ERCP) biopsies of pancreatic lesions [286, 
336, 337, 394, 436, 441-443] and studies in which miRNAs were measured in fluid 
aspirated from pancreatic cystic tumours ex-vivo [429, 444, 445] (Table 8; note 
some overlap with Table 7). These data point to an exciting future where it may be 
possible to accurately diagnose dysplastic pancreatic cysts and/or PDAC from FNAs 
of lesions with a greater sensitivity and specificity than cytology alone. 
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Table 7 - miRNA signatures in precursor and malignant transformed pancreatic lesions. 
Year Author / 
Ref. 
Tissue type Sample Type, Sample Size & Study 
Design 
miRNA signatures  Significance 
2013 
Lubezky et 
al. [428] IPMN, CEI, PDAC 
Macrodissection of FFPE tissues: 10 
LG IPMN, 5 MG IPMN, 5 HG IPMN, 
10 CEI, and 5 PDAC. MiRNA 
microarray of 846 miRNAs.  
High miR-21, 155, 708; Low 
miR-217 
 Hierarchical clustering can separate benign and malignant 
lesions 
 A signature of malignant change in IPMNs may also contain: 
high miR-199a, miR-424*, miR-10a and miR-100; and low miR-
101 and miR-148a 
2012 
Alvino et al.  
 
[446] 
CEI, PDAC 
LCM FFPE surgical tissues: 10 CEI 
and 16 PDAC. Assessed for PTEN 
expression by ISH and miR-21 by RT-
qPCR. 
High miR-21 
 PDAC has higher miR-21 levels than CEI and consequently 
lower levels of its target PTEN 
2012 
Caponi et al.  
 
[430] 
CEI, IPMN 
Multicentric study. LCM FFPE 
surgical tissues: 65 CEI, 16 IPMN. 
MiRNA expression correlated with 
survival outcomes.  
High miR-21 and miR-155;  
Low miR-101 
 miR-21 and miR-155 up-regulated in IPMN progression from 
benign to malignant 
 miR-101 down-regulated in malignant compared to benign 
IPMN and normal pancreas  
 High miR-21 independently prognostic of poor OS and DFS in 
CEI 
2012 
Nakahara  
et al. 
 
[447] 
IPMN 
LCM of 5 benign and 5 malignant 
IPMNs FFPE tissues; 70 IPMN (51 
benign IPMN and 19 malignant IPMN 
lesions) used to examine EZH2 
expression by ISH 
Low miR-101 
 
 Reduced miR-101 allows increased expression of its target 
Enhancer of Zeste Homolog-2 (EZH2) in IPMN carcinogenesis 
2012  
Matthaei et 
al. 
 
[444] 
IPMN,  
other pancreatic 
cystic lesions 
High-throughput using 22 FFPE 
samples (10 LG IPMN and 12 HG 
IPMN) and 11 CF specimens (4 HG 
IPMN, 3 LG IPMN, 4 SMCA).  
Selected miRNA candidates validated 
in 33 FFPE and 49 cyst fluid 
specimens using RT-qPCR. 
Total of 9 miRNAs  
(miR-24, 30a-3p, 18a, 92a, 
342-3p, 99b, 106b, 142-3p 
and 523-3p) 
 
7 differentially expressed 
pairs (DiffPairs) of miRNAs 
 Novel biomarker approach to identify differentially expressed 
pairs of miRNA (DiffPairs) and logistic regression model  
 9 miRNA signature in pancreatic cyst fluid that distinguishes 
pancreatic cyst: high risk vs. low risk lesions 
 Sensitivity of 89%, a specificity of 100% and area under the 
curve (AUC) of 1 
 This signature may be useful for stratifying patients for surgery 
 
2012 
Panarelli et 
al. 
 
[442] 
IPMN, PDAC,  
other pancreatic 
cystic lesions 
Macrodissected FFPE surgical 
specimens: 17 PDAC, 11 IPMNs, 15 
non-neoplastic pancreata. 
FNA biopsies (EUS): 46 of 49 FFPE 
blocks yielded enough RNA for 
analysis (35 PDAC, 11 benign: 2 CP, 
2 SMCA, 7 pseudocysts). 
RT-qPCR used to measure miRNAs. 
Also, miRNA array performed on 8 
PDAC vs. 8 IPMNs. 
Surgical specimens: High 
miR-21, miR-221, 
miR-155, miR-100 in PDAC 
 
FNAs: High miR-21, miR-221 
and miR-196a in PDAC 
 
New 2-miR PDAC FNA 
classifier: miR-221+2*miR-
196a 
 Logistic regression model (miR-221+2*miR-196a) correctly 
predicted malignancy in 89% of FNA biopsy specimens (using 
cytology as standard) 
 Model misclassified 3 benign cytology specimens as positive 
for malignancy and 1 of 9 cancers as negative for malignancy 
 Sensitivity and specificity may be improved by using fresh 
aspirates and/or including additional miRNAs 
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2012 
Yu et al. 
 
[421] 
PanIN, PDAC 
MiRNA array performed on LCM 
FFPE surgical tissues: 34 PanINs 
(PanIN-1, n=12; PanIN-2, n=11; 
PanIN-3, n=11) and normal pancreas, 
n=15. Validation on further PanINs 
(n=11) and normal pancreatic ductal 
epithelium, n=9 and PDAC, n=14. 
For PanIN-3 vs. Normal: 
High miR-196b, miR-486-3p, 
miR-21, miR-18a/b, miR-101, 
miR-146a, miR-135b, miR-
222 and miR-106b 
Low miR-126 and miR-216b 
 MiR-196b was the most selectively differentially expressed 
miRNA in PanIN-3 lesions (up-regulated 65 fold). 
 Elevated miR-200a/b/c in PanIN-1 and 2. 
2011 
Ryu et al. 
 
[445] 
CEI, IPMN, MCNs 
Aspirate from surgical resection of 24 
cystic precursor lesions (3 CEI, 11 
IPMN, and 10 MCN) & 16 non-
mucinous cysts. 
 
400µl pancreatic cyst fluid was 
obtained; qRT-PCR used to measure 
miR-21, 155, 17-3p, 191, 221. 
High miR-21, miR-221 and 
miR-17-3p in mucinous vs. 
non-mucinous cysts 
 miR-221 or miR-17-3p: sensitivity 80%, specificity of 50% 
 miR-21 shows more robust performance; highest median AUC 
of 0.89, median specificity 76% at a sensitivity of 80% 
2011 
Park et al. 
 
[448] 
IPMN 
20 IPMN and HPNE (normal ductal 
epithelial) cells. 
miR-552, miR-25, miR-183, 
miR-1300, miR-196a,  
miR-182, miR-30c-1 
 MiR-196a and miR-183 up-regulated in IPMN tissues and 
PDAC cell lines compared with HPNE cells.  
 Inhibition of these miRNAs repressed cancer cell proliferation. 
2011 
LaConti  
et al.  
 
[423] 
PanIN, PDAC 
Tissue and blood harvested form p48-
Cre/LSL-KRAS
G12D
 mouse model. 
Mouse PanINs: PanIN-1 to 2, n=3; 
PanIN-3, n=3; PDAC, n=3. 
High miR-10, miR-21, miR-
100 and miR-155;  
Low miR-148a 
 Gemcitabine treatment caused a reduction in circulating miR-
155, suggesting this as a possible miRNA for monitoring 
disease. 
2010 
Du Rieu  
et al.  
 
[422] 
PanIN 
LCM of PanIN tissues from a 
conditional KRAS
G12D
 mouse model 
(n=29) and from patients (n=38: 
PanIN-1a, n=8; PanIN-1b, n=13; 
PanIN-2, n=6; PanIN-3, n=7). 
miR-21, miR-205, miR-221, 
miR-222 and let-7a increases 
with human PanIN grade 
 
 Increasing expression of these miRNAs with PanIN grade and 
peak levels in PanIN2/3 lesions. 
 Anti-proliferative let-7a also had high expression levels in 
PanIN 2/3 lesions. 
 LNA-ISH showed increasing frequency of miR-21 detection in 
pathological PanIN ductal cells with increasing grade (PanIN-1, 
40%; PanIN-2, 67%; PanIN-3, 100%). 
 MiR-21 production was regulated by KRAS (G12D) and 
epidermal growth factor receptor in PDAC cell lines. 
2009 
Habbe et al. 
 
[429] 
IPMN 
Aspirate from surgical resection 
from15 non-invasive IPMNs & 
matched normal pancreas. 
MiR-155 and miR-21 (most 
overexpressed) evaluated by LNA-
ISH in 64 archival IPMNs. 
MiR-155 and miR-21also measured in 
pancreatic juice from 10 resected 
IPMNs and 5 non-neoplastic controls. 
miR-21 (up 12.1 fold), miR-
100, miR-107, miR-155, miR-
181a, miR-181c, miR-210, 
miR-221, miR-223 
 
miR-155 (up 11.6 fold) as a 
biomarker for IPMN 
 
 10 up-regulated miRNAs >3-fold in IPMNs compared to normal 
pancreas (all 10 miRNAs are also overexpressed in PDAC) 
 miR-21 and 155 could not discriminate between IPMN 
adenoma, borderline or carcinoma-in-situ lesions 
 miR-155 increased expression in IPMN with intestinal or 
pancreatobiliary type epithelium vs. gastric foveolar lining 
 Up-regulation of miR-155 in 60% of IPMN pancreatic juice 
samples vs. 0% in normal controls 
 
 
 116 
 
2009 
Hanoun et 
al.  
 
[436] 
PanIN, PDAC, CP 
39 PDAC, 20 CP, PanINs (PanIN-1a, 
n=8; PanIN-1b, n=11; PanIN-2, n=10; 
PanIN-3, n=10). LCM of PanINs from 
mouse model:  
DNA was extracted from EUS-FNA 
biopsy samples to determine the 
methylation level of the region 
encoding miR-148a. 
Hyper-methylation of DNA 
region encoding 
miR-148a; resulting in 
low mature miR-148a 
 Low mature miR-148a in PanIN lesions. 
 Hyper-methylation of the miR-148a–coding region and 
repression of miR-148a production starts at the PanIN-1B 
stage 
 Hyper-methylation of miR-148a was able to differentiate PDAC 
from CP with 90% specificity and 46.2% sensitivity (90.4% 
positive predictive value and 47.4% negative predictive value) 
2008 
Szafranska 
et al.  
 
[337] 
PanINs 
Microdissection of PanIN-1b, n=4; 
PanIN-2, n=4; PanIN-3, n=5 
miR-196a 
 PanIN-1b lack miR-196a and have a chance of progressing to 
PDAC 
 PanIN-2, 25% positive for miR-196a; PanIN-3, 60% positive for 
miR-196a (high risk early lesions) 
CF: cyst fluid; SMCA: serous cyst-adenoma; IPMN: intraductal papillary mucinous neoplasm; CEI: carcinoma-ex-IPMN; MCN, mucinous cystic neoplasm; EUS-FNA: endoscopic 
ultrasound fine-needle aspiration; PET: pancreatic endocrine tumour; CP: chronic pancreatitis; RT-qPCR: quantitative real-time reverse transcriptase polymerase chain reaction; 
PNET: pancreatic neuroendocrine tumour; SPN: solid pseudopapillary neoplasm; AUC: area under the curve; LCM: laser capture microdissection; ISH: in situ hybridisation; PanIN, 
pancreatic intraepithelial neoplasia; LG: low grade; HG: high grade. 
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Table 8 - miRNAs in PDAC biopsies and pancreatic cyst fluid. 
Year Author / Ref. Sampling 
technique 
Sample Size, Tissue Type 
& Study Design 
miRNA signatures 
in malignancy 
Significance 
2013 
Henry et al.  
 
[441] 
Aspirate 
from PDs 
during 
ERCP 
42 pancreatic cystic tumours; 
Microarray of 379 most 
common miRNAs. 
UP: let-7b, miR-
27b, 99a, 100, 
125b, 145 and 483. 
DOWN: miR-92a 
and 212.  
 Usable amounts of RNA attainable from 500ul of cystic fluid, although only 58% of 
samples had enough for profiling 
 Some of these miRNAs (miR-100, 125b, 145, 27b) have been identified in other 
profiling studies 
 Correlation was found between RNA quantity and malignant potential 
2013 
Farrell et al.  
 
[449] 
EUS-FNA 
38 patients had CF 
aspiration and surgical 
resection.  
16 benign (5 SMCA, 11 
other); 18 pre-malignant (4 
MCN, 12 LG IPMN, 2 HG 
IPMN) and 4 CEI. 
MiR-21, 155, 181c, 196a, 
217 and 221 were 
measured.  
MiR-21 levels (RT-
qPCR) 
progressively 
increase from low 
in benign cysts, to 
high in malignant 
cysts. 
 No change in miR-155, 181c, 196a or 217 between benign, pre-malignant and 
malignant cysts. 
 MiR-221 in up-regulated in malignant but not pre-malignant cyst aspirates, 
suggesting its elevation is a late step in malignant transformation. 
 MiR-21 ISH staining confirmed RT-qPCR findings and miR-21 is highest in the 
invasive component of the malignant lesion compared to cyst wall. 
2012 
Ali et al.  
 
[450] 
FNAs 
either CT-
guided or 
EUS 
29 PDAC (69% had stage 
III/IV) and 15 NP; average of 
3 needle passes (range 2-5); 
cellular pellets were put into 
FFPE blocks and then 
examined for tumour cells 
prior to miRNA microarray. 
This was followed by qRT-
PCR validation. 
UP: miR-486-5p, 
451, 92a, 423-5p, 
124, 3687, 1246, 
1275, 17 and miR-
320.  
DOWN: miR-4286, 
720, 1280, 200c, 
26a, 146a, let-7f, 
let-7d, let-7c, and 
let-7b. 
 It is possible to accurately measure miRNAs in diagnostic PDAC FNAs from cells 
stored in FFPE blocks 
2012  
Matthaei et al. 
 
[444] 
Aspirate 
from 
surgical 
resection 
High-throughput using 22 
FFPE samples (10 low grade 
IPMNs and 12 high grade 
IPMNs) and 11 CF 
specimens (4 high grade 
IPMNs, 3 low grade IPMNs, 
4 SMCA).  
Selected miRNA candidates 
validated in 33 FFPE and 49 
CF specimens (20 SMCAs, 2 
low grade IPMNs, 11 
intermediate IPMNs, 6 high 
grade IPMNs, 5 PNETs, and 
5 SPNs) using RT-qPCR. 
 Total of 9 miRNAs 
(miR-24, 30a-3p, 
18a, 92a, 342-3p, 
99b, 106b, 142-3p 
and 523-3p) 
 
7 differentially 
expressed pairs 
(DiffPairs) of 
miRNAs 
 Novel biomarker approach to identify differentially expressed pairs of miRNA 
(DiffPairs) and logistic regression model  
 9 miRNA signature in pancreatic cyst fluid that distinguishes pancreatic cyst 
pathology implying resection (i.e. high risk of malignancy; high grade IPMNs, PNETs 
and SPNs) versus low risk lesions that can be conservatively managed (i.e. low 
grade IPMNs and SMCAs) 
 Sensitivity of 89%, a specificity of 100% and area under the curve (AUC) of 1 
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2012 
Panarelli et al. 
 
[442] 
FNA 
biopsies 
(?EUS) 
Macrodissected FFPE 
surgical specimens: 17 
PDAC, 11 IPMNs, 15 non-
neoplastic. 
FNAs: 46 of 49 FFPE blocks 
yielded enough RNA for 
analysis (35 PDAC, 11 
benign: 2 CP, 2 SMCA, 7 
pseudocysts). 
RT-qPCR used to measure 
miRNAs. 
Also, miRNA microarray 
performed on 8 PDAC vs. 8 
IPMNs. 
Surgical 
specimens -  
UP: miR-21, 221, 
155, 100. 
 
FNAs -  
UP: miR-21, 221 
and 196a 
 
New 2-miR PDAC 
FNA classifier: 
miR-221+2*miR-
196a 
 Logistic regression model (miR-221+2*miR-196a) correctly predicted malignancy in 
89% of FNA biopsy specimens (using cytology as standard) 
 Model misclassified 3 benign cytology specimens as positive for malignancy and 1 
of 9 cancers as negative for malignancy 
 Sensitivity and specificity may be improved by using fresh aspirates and/or including 
additional miRNAs 
2011 
Ryu et al. 
 
[445] 
Aspirate 
from 
surgical 
resection 
24 pancreatic cystic tumours 
(3 CEI, 11 IPMN, 10 MCN) 
16 non-mucinous cysts. 
 
400µl pancreatic CF was 
obtained; RT-qPCR used to 
measure miR-21, 155, 17-
3p, 191, 221. 
UP: miR-21, 221 
and 17-3p in 
mucinous vs. non-
mucinous cysts 
 miR-221 or miR-17-3p: sensitivity 80%, specificity of 50% 
 miR-21 shows more robust performance; highest median AUC of 0.89, median 
specificity 76% at a sensitivity of 80% 
2011 
Munding et al. 
(Szafranska is 
a senior author) 
[336] 
EUS-FNA 
52 PDAC, 43 CP 
(FFPE samples; 20 in 
training set and 75 in 
validation set) 
 
New 2-miR PDAC 
classifier: miR-
135b normalized 
to miR-24 
 Proposed single normalized molecular biomarker for EUS-FNA samples 
 Sensitivity and specificity for PDAC of 93%; area under the curve (AUC) value of 
0.97 accompanied by positive and negative predictive values of 95% and 91% 
respectively 
2011 
Preis et al. 
 
[394] 
EUS-FNA 
10 PDAC; 3 NP surgical 
samples; validated in 95 
PDAC and 11 normal EUS-
FNAs. 
Fluorescence-based ISH 
using LNA-modified DNA 
probes against various miRs 
was used followed by co-
detection of proteins 
(cytokeratin 19 and amylase) 
by immunohistochemistry 
(IHC) on the same FFPE 
sections to confirm miR 
expression in true ductal 
cells. 
 
UP: miR-10b 
and 21 
 Reproducible system for assessing the spatial distribution of miRNAs in PDAC EUS-
FNA samples 
 High miR-10b patients have an unfavourable prognosis and low miR-10b patients 
may benefit most from multimodality neoadjuvant treatment 
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2010 
Sadakari et al. 
 
[443] 
Aspirate 
from pre-
operative 
ERCP 
Pancreatic juice samples: 16 
PDAC, 5 CP; RT-qPCR used 
to measure miRNAs 
UP: miR-21 and 
155 
 High miR-21 and miR-155 in ERCP pancreatic juice samples from PDAC compared 
to CP; also confirmed in FFPE samples 
2010 
Hanoun et al.  
 
[436] 
EUS-FNA 
39 PDAC, 20 CP 
DNA was extracted from 
EUS-FNA biopsy samples to 
determine the methylation 
level of the region encoding 
miR-148a. 
 
Hyper- 
methylation of 
DNA region 
encoding 
miR-148a; 
low mature miR-
148a 
 Hypermethylation of miR-148a was able to differentiate PDAC from CP with 90% 
specificity and 46.2% sensitivity (90.4% positive predictive value and 47.4% 
negative predictive value) 
2009 
Habbe et al. 
 
[429] 
Aspirate 
from 
surgical 
resection 
15 non-invasive IPMNs 
matched NP. 
 
MiR-155 and miR-21 (most 
overexpressed) evaluated by 
LNA-ISH in 64 archival 
IPMNs. 
 
MiR-155 and miR-21also 
measured in pancreatic juice 
from 10 resected IPMNs and 
5 non-neoplastic controls. 
 
UP: miR-21, 100, 
107, 155, 181a, 
181c, 210, 221, and 
223. 
 
miR-155 as a 
biomarker for 
IPMN 
 
 10 up-regulated miRNAs >3-fold in IPMNs compared to normal pancreas (all 10 
miRNAs are also overexpressed in PDAC) 
 miR-21 and 155 could not discriminate between IPMN adenoma, borderline or 
carcinoma-in-situ lesions 
 miR-155 increased expression in IPMN with intestinal or pancreatobiliary type 
epithelium vs. gastric foveolar lining 
 Up-regulation of miR-155 in 60% of IPMN pancreatic juice samples vs. 0% in normal 
controls 
2009 
Torrisani et al. 
 
[286] 
EUS-FNA 
12 PDAC (ineligible for 
surgery due to advanced 
disease or unfit), 3 normal. 
Pre-let-7a (down-
regulated) 
 Pre-let-7a expressed in tissue adjacent to tumour and normal but massively reduced 
in PDAC 
 Confirmed in surgical specimens by in situ hybridisation as mature let-7 localised to 
pancreatic acini adjacent to PDAC, but not in stromal or cancerous cells 
2008 
Szafranska et 
al. 
 
[337] 
EUS-FNA 
11 PDAC, 1 PET, 1 atypical, 
3 normal pancreata (from 
same patient). 
Cytopathologist assessed 
the adequacy of the 
samples; 4.9µg RNA isolated 
after 3 FNA needle passes 
Original 2-miRNA 
PDAC classifier: 
high miR-196a and 
low miR-217 
 TaqMan miRNA assays can be used with good accuracy on pancreatic FNA 
samples with between 5 – 50ng of RNA 
CF: cyst fluid; CT: computed-tomography; SMCA: serous microcystic adenoma; IPMN: intraductal papillary mucinous neoplasm; CEI: carcinoma-ex-IPMN; EUS-FNA: endoscopic 
ultrasound fine-needle aspiration; PET: pancreatic endocrine tumour; CP: chronic pancreatitis; RT-qPCR: quantitative real-time reverse transcriptase polymerase chain reaction; 
PNET: pancreatic neuroendocrine tumour; SPN: solid pseudopapillary neoplasm; AUC: area under the curve; LG: low grade; HG: high grade; ISH: in situ hybridisation. 
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1.5.6 PDAC-specific blood-based miRNAs  
 The absence of early detection markers for PDAC is a key factor influencing 
poor patient prognoses. The clinical use of serum CA19-9 as a diagnostic biomarker 
is limited by its lack of sensitivity and specificity and inability to distinguish carcinoma 
from benign disease. Efforts to identify a more effective blood-based marker have 
been largely unsuccessful. Blood-based miRNAs have been investigated as 
biomarkers for various cancers, in the hope that these will outperform current serum 
tumour markers, and this approach has also been used for PDAC (Table 9). 
 Unsurprisingly, the commonest dysregulated circulating miRNA in PDAC 
patients (plasma or serum) is miR-21, and others include miR-196a, 155 and 210 
[451-453]. Of note, miR-21 has been shown to distinguish PDAC from CP in isolation 
[454], or in combination with other miRNAs [381], strengthening its putative clinical 
utility as a diagnostic biomarker. In addition, 2 studies have found that high levels of 
circulating miR-21 are associated with poor OS in PDAC [380, 381].  
 The source of circulating miRNA was initially thought to be irrelevant, however 
there is increasing evidence that different blood sample preparation methods may 
affect the final concentration when measuring individual circulating miRNAs [455]. 
The serum is blood plasma without clotting factors (i.e. whole blood minus both the 
cells and the clotting factors), and a study by Wang et al. [455] found higher 
concentrations being obtained from serum compared to corresponding plasma 
samples. This difference could be due to the coagulation pathways and miRNAs 
from platelets [455]. Furthermore, debate still exists over whether miR-16 is suitable 
as an endogenous control for normalisation. miR-16 is a red blood cell expressed 
miRNA, and variations in blood cell count and/or sample haemolysis could have 
important implications for biomarker interpretation [456, 457]. Interestingly, Wang et 
al. identified miR-27a-3p (normalised to RNU6B levels) as up-regulated in peripheral 
blood mononuclear cells (PBMCs) of PDAC patients and high expression of this, 
combined with raised serum CA19-9, was able to discriminate various types of 
pancreatic cancer from benign patients with good accuracy [458]. Its use in 
discriminating PDAC may be limited however, as PBMC miR-27a-3p was found to 
also be elevated in hyperbilirubinaemia [459].  
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 The discovery of novel diagnostic blood-based biomarkers for early PDAC (at 
a surgically resectable stage) has the potential to markedly improve the overall 
outcome of this disease. These biomarkers need to be rigorously tested against 
healthy individuals and patients with benign disease. Crucially, studies have found 
commonly dysregulated miRNAs in PDAC from tissue specimens, biopsies and 
blood samples. Thus, a diagnostic signature should soon be defined. In addition, 
biomarkers that could be used to stratify patients clinically are urgently required. For 
example, indicators of metastatic spread, disease burden and response to treatment 
should be sought. Currently, panels of blood biomarkers are being tested for their 
ability to detect PDAC with better performance than any individual marker on its own. 
These have included ncRNAs (e.g. miRNAs and snRNAs), serum proteins, cfDNA, 
CTCs and serum metabolites. Recently, NGS examining DNA and RNA changes 
has offered some hope in unravelling tumour heterogeneity [460], and may allow a 
better molecular understanding of an individual patient's disease, as well as a "liquid 
biopsy" for monitoring [461].  
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Table 9 - Previous studies evaluating circulating non-coding RNAs (ncRNAs) in pancreatic ductal adenocarcinoma. 
Author / 
Ref. 
Year No. of Patients Blood 
Type Used 
ncRNA expression in 
PDAC patients 
Significance of blood ncRNA expression 
Li et al.  
[462] 
2013 PDAC (n=41) 
CP (n=35) 
HC (n=19) 
PNET (n=18) 
Serum UP: miR-1290  MiR-1290 yielded AUC of 0.96 (95% CI: 0.91-1.00), 0.81 (0.71-0.91), 0.80 (0.67-
0.93), for subjects with PDAC relative to HC, CP and PNET patients 
 
Kawaguchi  
et al. 
[463] 
2013 Pancreatic cancer (n=47) 
HC (n=30) 
Plasma UP: miR-221 
DOWN: miR-375 (P=0.064) 
 High miR-221 in pancreatic cancer and levels are reduced post-operatively. 
 MiR-221/miR-375 ratio significantly higher in pancreatic cancer vs. HCs (P<0.0001). 
 High miR-221 correlates with distant metastasis and non-resectable disease. 
Wang  
et al.  
[458] 
2013 Pancreatic cancer (n=129) 
BPD (n= 103) 
HC (n= 60) 
Peripheral 
blood mono-
nuclear cells 
UP: miR-27a-3p; -16-5p;  
-15b-5p 
 
 MiR-27a-3p able to discriminate PC from BPD and HC. 
 MiR-27a-3p + serum CA19-9 more accurate with 85.3% sensitivity and 81.6% 
specificity (AUC 0.886; 95% CI, 0.837–0.923%). 
Baraniskin  
et al.  
[464] 
2013 PDAC (n=80) 
HC (n=129)  
PDAC Mice vs. HC Mice  
(n=8 vs. 8) 
Plasma  
and  
Serum 
UP: RNU2-1f (U2 small 
nuclear RNA fragments) 
Normalized to cel-54. 
 High RNU2-1f has diagnostic accuracy of 97.5%. 
 Also elevated levels of RNU2-1f in colorectal cancer. 
Yabushita  
et al.  
[453] 
2012 PDAC Rats (n=6) 
HC Rats (n=4) 
Serum UP: miR-155; -21; -210;  
-18a; -203; -30b-5p; -31;  
-369-5p; -376; -541;  
DOWN: miR-375 
 Rats carrying the KRASG12V transgene were generated and allowed to develop 
PDAC tumours. MiRNAs were then detected in the serum and tissues.  
 A rat model of PDAC was able to identify novel candidate circulating miRNAs as 
biomarkers for human PDAC. 
Bauer et al. 
[326] 
2012 PDAC (n=45) 
CP (n=38) 
HC (n=33) 
Whole  
Blood 
87 miRNAs differentially 
expressed between PDAC 
and HC 
 With statistical learning techniques, high sensitivity and specificity (AUC values 0.973 
and 0.950) for discriminating PDAC or CP from HC. 
 Unable to discriminate PDAC and CP. 
Liu et al.  
[381] 
2012 PDAC (n=197) 
CP (n=82) 
HC (n=158) 
Serum UP: miR-20a; -21; -24;  
-25; -99a; -185; -191 
 MiRNA–based biomarker distinguishes PDAC from HC (AUC 0.992); and PDAC from 
CP (AUC 0.993). 
 High miR-21 levels associated with poor overall PDAC survival. 
Morimura  
et al. 
[465] 
2011 PDAC (n=36) 
HC (n=30) 
Plasma UP: miR-18a  MiR-18a significantly upregulated in PDAC (AUC 0.9369). 
 MiR-18a levels lower in post-operative samples, than in pre-operative samples 
(P=0.0077). 
Liu et al.  
[451] 
2012 PDAC (n=140) 
CP (n=111) 
HC (n=68) 
Plasma UP: miR-16; -21; -155; 
-181a; -181b; -196a; -210 
 MiR-16, miR-196a and CA19-9 discriminate PDAC from CP and HC (AUC 0.979; 
sensitivity, 92.0%; specificity, 95.6%); and discriminates PDAC from CP (AUC 0.956; 
sensitivity, 88.4%; specificity, 96.3%). 
LaConti  
et al. 
[423] 
2011 PDAC (n=6) 
HC (n=8) 
GI cancers (n=12) 
Plasma UP: miR-100a; -10  Panel of 9 miRNAs (miR-100a, 10, 155, miR-199, miR- 221, miR- 21, miR- 210, miR- 
223, miR- 16) distinguishes PDAC from HC and other GI cancers. 
Li et al.  
[466] 
2010 PDAC (n=45) 
CP (n=11) 
HC (n=32) 
Serum UP: miR-200a; -200b  PDAC distinguished from HC with miR-200a and miR-200b (AUC 0.86 and 0.85 
respectively). 
 No difference in miRNA expression between PDAC and CP. 
Wang et al.  
[452] 
2009 PDAC (n=49) 
HC (n=36) 
Plasma UP: miR-21; -210; -155; 
-196a 
 Combination of 4 miRNAs detects PDAC vs. HC with AUC 0.82 (95% CI, 0.70-0.94). 
Kong et al.  
[454] 
2010 PDAC (n=35) 
CP (n=15) 
HC (n=15) 
Serum UP: miR-21; -155; -196a 
(no difference: miR-181a,  
-181b, -221, -222) 
 MiR-21 can differentiate PDAC from CP (P<0.003) and from HC (P<0.001). 
 MiR-155 and miR-196a can differentiate PDAC and CP from HC. 
PDAC, pancreatic ductal adenocarcinoma; CP, chronic pancreatitis; HC, healthy control; AUC, area under curve; PNET, pancreatic neuroendocrine tumour 
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1.6 Modulation of miRNAs as Anti-Cancer Therapeutics 
1.6.1 miRNA Theory versus Reality  
The modulation of miRNAs by either inhibition or replacement may be the 
next important therapeutic strategy in PDAC. Down-regulation of target oncogenes 
by replacement of TS-miRs, or de-repression of tumour suppressor genes by 
silencing oncomiRs could reduce tumour growth, slow progression and prevent 
metastasis. MiRNAs have one-to-many and many-to-one relationships with their 
gene targets [467]. Therefore, miRNA-modulating therapy affecting a single miRNA 
could simultaneously modify a number of relevant gene pathways within a tumour, or 
even multiple targets in the same pathway [468], in both cases leading to significant 
biological effects on the pathological phenotype.  
Accordingly, a new class of drugs that specifically target small RNA pathways 
via replacement of TS-miRs with synthetic or viral vector encoded miRNA mimics or 
antisense-mediated inhibition of oncomiRs are currently in development. 
Unfortunately, the manipulation of miRNAs can lead to unpredictable "off-target" 
effects with adverse consequences, and these concerns must be addressed before 
such therapies can be safely used in clinical practice. Some possible solutions may 
be using a number of miRNAs at lower concentrations to target a single gene, 
thereby enhance the specificity of silencing (a combinatorial effect), or selecting a 
miRNA that targets multiple genes within a single pathway, in order to consolidate 
silencing and reduce undesired effects [469].  
Developing approaches to deliver miRNA-modulating agents directly to target 
tissues is also a major difficulty. Barriers to miRNA systemic delivery include: rapid 
degradation of RNA by serum and tissue nucleases, rapid renal clearance, and 
entrapment in the capillary system [470]. In addition, the delivered miRNA needs to 
access the target organ with high tissue-specificity [471], enter the cells, and reach 
the gene target(s) in its active form [470]. This process can be further hindered by 
the low cellular uptake of RNA due to its high molecular weight and negative charge, 
uptake by scavenger macrophages and ineffective cell internalisation / endocytosis 
and release from the endosome in target cells [472]. Thus, industry has been 
 124 
 
challenged by the development of miRNA formulations with the unique properties to 
overcome these hurdles. Strategies being employed to modulate miRNA activity for 
therapeutic purposes and measures being used to overcome potential obstacles will 
now be discussed.  
 
1.6.2 miRNA Inhibition 
1.6.2.1 Antisense oligonucleotides (ASO) against miRNAs 
MiRNA antagonists must selectively hybridise with their endogenous mature 
miRNA target, usually via complete complementarity, thereby blocking its function in 
RISC and preventing an interaction between the miRNA and its target gene [470, 
473]. The most basic examples are antisense oligonucleotides (ASO) which consist 
of a ‘naked’ single-stranded molecule that inhibits a miRNA via complementary 
binding. However, ‘naked’ oligomers are relatively unstable and are easily degraded 
by endogenous RNases, resulting in their limited efficacy by systemic administration. 
These ASO have now been chemically modified and shown to specifically and 
efficiently inhibit miRNAs in vitro and in vivo [474]. These modifications can improve 
hybridisation affinity for the target RNA, provide resistance to nuclease degradation, 
or activation of other proteins involved in terminating their action [474]. Indeed, ASO 
with 2′sugar modifications (including 2′-O-methyl (2′-OMe), 2′-O-methoxyethyl (2′-
MOE), 2′-flouro (2′-F), and LNA), as well as phosphorothioate backbone 
modifications can be effective miRNA inhibitors. In addition, these alterations or 
conjugation to carrier moieties can delay plasma clearance and promote uptake into 
tissues, which is necessary for in vivo delivery to be successful [474]. ASO have 
already been shown to inhibit oncomiRs such as miR-21 and miR-221 in vitro, 
resulting in de-repression of their targets (PTEN, RECK and CDKN1B) and reduced 
proliferation, increased apoptosis and improved sensitivity to GEM [413, 475]. 
1.6.2.2 AntagomiRs 
There are two popular types of antagomiR that are commercially available: 
anti-miRNA oligonucleotides (AMO or anti-miRs) and LNAs. An AMO is a single-
stranded ASO (17 to 22 nt in length) modified by the addition of a 2’-OMe group. 
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Conjugation of a cholesterol to the 3′ end (increasing their affinity with the plasma 
membrane and facilitating into cells) can produce a more stable AMO for in vivo use 
[474, 476]. Indeed, Krutzfelt et al. [477] demonstrated that a single intravenous (IV) 
injection of an antagomiR designed to target cholesterol-regulating miR-122 in mice, 
resulted in prolonged miR-122 silencing in the liver and a significant decrease in 
serum cholesterol levels. In tumour biology, Ma et al. [395] went on to show that 
systemic delivery of an antagomiR against miR-10b in a mouse BC model prevented 
metastatic spread. Furthermore, a single IT injection of antagomiR-221/222 into 
melanoma xenografts in nude mice has been shown to significantly inhibit tumour 
progression with no documented toxicity [478], and an intraperitoneal (IP) injection of 
antagomiR-182 could reduce hepatic metastases in another melanoma mouse 
model [479]. Recently, multiple-target AMOs (MTg-AMO) have been engineered, 
which can target multiple miRNAs simultaneously [480]. This will enable the 
validation of a combinatorial, targeted effect against crucial oncomiRs in various 
tumour types and will be an important step in developing anti-cancer miRNA-based 
therapeutics [476].  
LNAs are ASOs that contain a ribose moiety that is functionally locked into a 
C3’-endo conformation, via the addition of a methylene bridge which confers greater 
stability, increased miRNA-binding affinity and lower toxicity [473, 476]. There have 
already been some promising results silencing miRNAs in vivo, using systemic tiny 
LNA antagomiRs in rodents, non-human primates and more recently human patients 
[481-483]. LNA antagomiRs against miR-122 were first shown to reduce serum 
cholesterol levels in healthy and obese mice, as well as healthy non-human 
primates. These 15-nt LNA antagomiRs are complementary to and bind with a high 
affinity and specificity for the 5′ region of mature miR-122. Since miR-122 is also 
essential for Hepatitis C virus (HCV) RNA replication, systemic delivery of LNA 
antagomiRs against miR-122 (SPC3649 aka Miravirsen, Santaris Pharma) in HCV-
infected chimpanzees was next found to lead to prolonged 300-fold suppression in 
HCV viraemia [482]. Subsequent Phase I single-dose safety studies in humans 
demonstrated that Miravirsen had limited toxicity and a clear dose-dependent 
pharmacology, therefore allowing Phase II studies to continue, making it the first 
miRNA-modulating therapy to reach this stage [484]. Recently, Miravirsen has been 
evaluated in a Phase 2a study [483]. In this randomised, double-blind, placebo-
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controlled trial [483], 36 patients with chronic HCV infection were enrolled, of which 9 
received the placebo and the remainder were treated with Miravirsen. Janssen et al. 
[483] found that five weekly subcutaneous injections of Miravirsen successfully 
produced a dose-dependent and prolonged decrease in HCV RNA levels in patients 
with chronic HCV genotype 1 infection. This landmark study is yet to be replicated 
with inhibition of a cancer-related miRNA, but gives support to the emergence of 
anti-cancer miRNA-modulating therapeutics in the future. 
1.6.2.3 miRNA sponges 
Another novel approach for reducing mature miRNA levels is the use of 
vector-encoded RNA molecules, or ‘miRNA sponges’. The sponge RNAs contain 
multiple partially complimentary 3’UTR binding sites, which competitively bind to 
miRNAs of interest, liberating their gene targets from repression by these miRNAs. 
They can be designed to carry a number of different binding sites (>20), therefore 
enabling simultaneous inhibition of multiple members of a miRNA cluster or different 
miRNAs acting on the same target [485]. This was initially an advantage over ASO, 
which only target single miRNAs, until the advent of MTg-AMO [480]. Furthermore, 
sponge RNAs can be stably integrated into the genome, enabling the development 
of transgenic animals and stable cell lines which are functionally deficient in certain 
miRNAs.  
Onyeagucha et al. [486] demonstrated that the S100P/RAGE receptor 
signalling pathway induces expression of the oncogenic miR-155, and that loss of 
miR-155 function by a miR-155 sponge decreased colon cancer cell growth, motility, 
and invasion in vitro. Valastyan et al. [487] orthotopically implanted BC MCF7-RAS 
cells stably expressing a sponge vector targeting the anti-metastatic miR-31 into 
mice. Accordingly, they found that miR-31 sponge-expressing MCF7-RAS cells 
metastasised to the lungs in significant numbers compared to empty vector cells in 
control animals. Similarly, our group has recently shown that the anti-metastatic miR-
23b is a central effector of cytoskeletal remodelling, modulating focal adhesion and 
reducing cell motility and invasion, by directly regulating several genes involved in 
these processes [488]. Using BC cells stably expressing a miR-23b sponge vector 
implanted into the mammary fat pad in nude mice, we found that miR-23b inhibition 
resulted in enhanced tumour growth and increased metastases in draining LNs 
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[488]. Whilst these results are encouraging, a number of important factors make 
sponge RNAs unsuitable for therapeutic use in humans, including the risk of 
insertional mutagenesis in target cells, and vector size resulting in poor 
biodistribution, which limits their systemic use.  
 
1.6.3 miRNA Replacement 
In contrast, the restoration of lost TS-miR expression can be achieved by 
delivery of miRNA mimics or viral vectors [489], both of which have been shown to 
produce positive results in experimental animal models of cancer [180, 490]. Other 
approaches include the use of nanoparticle delivery systems are being tested in pre-
clinical [471], and more recently, clinical models [491]. These methods may be a 
more efficacious and less toxic strategy than inhibiting oncomiRs.  
1.6.3.1 miRNA mimics 
Basic miRNA replacement therapies are similar to siRNA therapeutics, in that 
miRNA mimics and siRNAs are both short double-stranded oligonucleotides and 
both act downstream of RISC, thus requiring the enzymatic functions of cellular 
RISC to be catalytically active, in order for the intended mRNA to be targeted [472]. 
Certain chemical modifications, similar to those used for the antagomiRs, can be 
made to the oligonucleotides to reduce degradation. While antagomiRs are relatively 
permissive to chemical modifications, miRNA mimics must still be incorporated into 
the RISC such that modifications added to improve properties, such as stability, run 
the risk of loss of functionality. Takeshita et al. [492] used tail vein injections to 
administer a chemically modified miR-16 precursor (a TS-miR known to be down-
regulated in prostate cancer) or control mimic to a mouse model of bony metastatic 
prostate cancer. The miRNA mimic was complexed with Atelocollagen (Koken, 
Tokyo, Japan; also see our methods section 2.2.15), which promoted sustained 
delivery of miR-16 into the bone metastases and was detected in tumour tissue for 
>3 days after IV injection. Accordingly, growth of the bony metastases was reduced 
in miR-16-treated mice, compared to control treated animals. 
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1.6.3.2 miRNA delivery by viral vectors 
Another method of supplementation of exogenous miRNAs is through the use 
of adeno-associated viruses (AAVs) that allow the persistent transcription and 
expression of miRNAs at high levels in target tissues, with a low risk of insertional 
mutagenesis compared to other viral delivery systems [351]. Due to the availability of 
a number of different AAV serotypes that show natural tropism for different organs, a 
high degree of tissue-specificity can be achieved [493]. Kota et al. found that down-
regulation of miR-26a is associated with HCC, and found that tail vein injection of a 
miR-26a-expressing AAV into a murine HCC model successfully suppressed 
tumourigenesis [180]. Interestingly, although approximately 90% of hepatocytes 
were transduced with miR-26a in this model, there were no signs of hepatotoxicity or 
dysregulation of other endogenously expressed miRNAs [180]. It should be noted, 
however, that AAVs can cause undesired immune responses and so far, these 
vectors have not been used in human studies. Other important proofs-of-principle for 
miRNA replacement therapy have been demonstrated in preclinical animal models of 
cancer using the let-7 family and miR-34a.  
Let-7 levels are reduced in non–small cell lung cancer (NSCLC) relative to 
normal lung tissue, and inversely correlate with the expression of the RAS 
oncoprotein (frequently activated in this type of cancer) [270]. In fact, let-7 directly 
suppresses members of the RAS oncogene family and loss of let-7 function leads to 
an increase in RAS protein levels. Other important tumour-promoting genes directly 
targeted by let-7 include HMGA2, MYC, cyclin D, CDK6, and CDC25A and reduced 
let-7 levels allow the de-repression of these oncogenic factors [494]. Functional 
studies in vitro, as well as mouse models of lung cancer, have shown that the re-
expression of let-7 mimics reduces cancer cell proliferation and the growth of 
existing lung tumours in vivo the animal [494]. Accordingly, intranasal instillation of a 
lentiviral vector expressing let-7a reduced the number and size of tumours in a 
KRASG12D induced mouse model of lung cancer, validating the function of let-7 as a 
tumour suppressor, and that its replacement has potential therapeutic benefits [495]. 
Another study showed similar results, again with lungs of LSL-KRASG12D mice 
treated by intranasal instillation of an adenovirus expressing a let-7a hairpin (Ad-let-
7) which resulted in reduced lung tumour load at 7 weeks post-infection [496].  
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Kasinski and Slack [376] went one step further and used a therapeutically 
resistant mutant KRAS and p53 mutant mouse lung cancer model as the basis for 
their experiments. Impressively, they found that restoring miR-34a levels using a 
miR-34a-expressing lentivirus (administered intra-tracheally) at the same time as 
transgene activation, which normally induces lung tumours at 10 weeks post-
activation, had little to no evidence of tumourigenesis, and that lentivirus-induced 
miR-34a also prevented further progression of preformed tumours. These data 
support the pursuit of miR-34 replacement as a therapy against human lung cancer. 
1.6.3.3 miRNA delivery using nanovectors 
There have been many recent advances in non-viral miRNA delivery using 
nanovectors, which could be more efficient for the systemic distribution and delivery 
of miRNAs to cancerous tissues [470]. These include the complexation, 
encapsulation and conjugation of miRNAs with various vehicles [470, 476]. 
Nanoparticles are positively charged structures with diameters of 45-70nm that can 
be used to administer negatively charged miRNAs / mimics to target tissues. This 
structure confers greater miRNA stability, allows their slow release for prolonged 
mRNA targeting and avoids the possible immunogenicity associated with AAVs. 
These favourable characteristics suggest their potential to be administered 
intravenously to human patients. 
Hu et al. [497] have recently conjugated CC9 (a specific tumour-homing and 
penetrating bifunctional peptide) with miR-34a-delivering therapeutic 
nanocomplexes. They demonstrated effective in vivo inhibition of tumour growth and 
the induction of cancer cell apoptosis in an orthotopic xenograft mouse model of 
PDAC after biweekly IV injections for 2 weeks [497]. Restoring miR-34 levels was 
found to inhibit target gene expressions such as E2F3, BCL2, MYC and cyclin D1, 
inducing cell cycle arrest, apoptosis, and suppressing migration [497]. Pramanik et 
al. [498] have complexed miRNAs with lipid-based nanoparticles to deliver miR-34a 
or the miR-143/145 cluster to also treat PDAC xenografts. This method was 
successful at the systemic restoration of these TS-miRs, and resulted in reduced 
tumour growth with minimal side-effects [498]. MiR-143 and 145 target KRAS; whilst 
active KRAS activates RAS-responsive element binding protein 1 (RREB1), which 
then directly inhibits the transcription of miR-143/145 [498]. Consequently, Pramanik 
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et al. [498] showed that miR-143/145 overexpression down-regulated both KRAS 
and RREB1 levels, whilst miR-34a down-regulated SIRT1, CD44 and ALDH in vivo.  
In April 2013, the first human clinical trial examining the use of miRNA mimics 
as anti-cancer agents was started[491]. Mirna Therapeutics (Austin, Texas, USA) 
launched a Phase 1 trial that is recruiting patients with liver cancer and metastatic 
cancer with liver involvement for treatment with MRX34, a synthetic miRNA mimic of 
miR-34 [491]. MRX34 is a double-stranded oligonucleotide delivered using a 
liposome-based nanoparticle, called Smarticles [491]. These Smarticles have been 
shown to increase uptake into tumours, and are tissue specific, as liposomes 
naturally accumulate within the liver [491]. Preclinical studies have shown that 
MRX34 restores the tumour suppressive effect of miR-34a and induces apoptosis of 
cancer cells in vitro and in vivo [491]. Results are eagerly awaited, and will pave the 
way for the modulation of miRNA levels in other human cancers.  
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1.7 Aims & Objectives  
At the time of starting this project there was little published research that 
described miRNAs as biomarkers for determining pancreatic malignant 
transformation or prognosis. Therefore, our aims were to: 
 
Chapter 3 - Investigate miRNAs expressed in pancreatic benign cystic tumours 
(BCTs) compared to PDAC 
 To describe miRNAs involved in the malignant transformation of these pre-
malignant lesions into PDAC. 
 To compare the differences in miRNA expression between low malignant and 
high malignant potential BCTs. 
 To examine the gene targets of any identified miRNAs and their potential role 
in malignant transformation and early PDAC tumourigenesis. 
 To discover miRNAs that may help to stratify these pancreatic BCTs. The 
identification of diagnostic miRNA biomarkers that can aid the clinical 
differentiation of these pre-malignant lesions would allow for early surgical 
intervention and better outcomes. 
 
Chapter 4 - Establish a miRNA signature of PDAC progression 
 To determine the most crucial miRNAs involved in PDAC tumourigenesis by 
performing an integrated molecular analysis of the PDAC miRNome and 
transcriptome using fresh surgical specimens from patients. 
 To correlate any identified miRNAs with tumour clinicopathologic features and 
patient survival outcomes, thereby helping to define a prognostic miRNA 
signature. 
 To investigate the role of modulating a combination of miRNAs as an anti-
cancer therapeutic for human PDAC using mouse models. 
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1 Materials used  
2.1.1 Pancreatic cancer cell lines 
Table 10 - Pancreatic cancer cell-lines. 
 
 
Table 11 - Transfection media and reagents. 
Transfection Media Additives Transfection reagent   Storage 
 
Normal growth medium 
 
 
Opti-MEM
® 
I Reduced 
Serum Medium (Gibco
®
) 
 
 
No 
 
 
No 
 
HiPerFect Transfection Reagent (Qiagen, 
West Sussex, UK) 
 
Lipofectamine
®
 2000 Reagent (Invitrogen, 
Life Technologies Ltd, Paisley, UK) 
 
 
4°C 
 
 
4°C 
    
Cell Type Media Additives Storage 
 
PANC-1 
 
DMEM  
(Dulbecco’s Modified 
Eagle’s Medium) 
(Sigma-Aldrich) 
 
2mM Glutamine 
50 units/ml Penicillin 
50μg/ml Streptomycin 
10% FCS 
 
4°C, media used within 
one month 
 
MIA PaCa-2 
 
 
50% RPMI  
50% DMEM  
 
 
 
2mM Glutamine 
50 units/ml Penicillin 
50μg/ml Streptomycin 
10% FCS 
 
4°C, media used within 
one month 
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2.1.2 Buffers and Solutions  
Table 12 - Buffers and reagents. 
Reagent Recipe Storage 
 
PBS (Phosphate 
buffered Saline) 
 
EDTA-Trypsin 
 
 
5 PBS (Dulbecco A) (OXOID) dissolved  
in 500ml of ddH20 
 
2.5g/l Trypsin in 0.02% EDTA (Sigma-Aldrich) 
 
 
4°C 
 
 
4°C 
75% Ethanol 
 
1M Tris-HCl 
 
 
SDS (Sodium Dodecyl 
Sulphate) loading 
buffer (2x) 
 
10x SDS PAGE  
Running buffer 
 
10x Transfer buffer 
 
 
TBS 10x 
(Tris-Buffered Saline) 
 
 
TBST buffer 
(TBS/ Tween
®
 20) 
 
Blocking solution  
3% BSA 
 
NP-40 lysis buffer 
 
75ml Ethanol added to 25ml of ddH20 
 
60.5g Tris in total of 500ml ddH20 and adjusted to 
desired pH with pure HCl 
 
125mM Tris-Cl pH 6.8, 20% glycerol,  
4% SDS, 100mM DTT,  
0.04% (w/v) bromophenol blue 
 
10g SDS, 30.3g Tris, 144.1g glycine dissolved in  
1l of ddH20 
 
30.3g Tris, 144,1g glycine dissolved  
in 1l of ddH20 
 
24.23g Trizma HCl, 80.06 g 
NaCl dissolved in 1l of ddH20 and 
adjusted pH to 7.6 with pure HCl 
 
100ml of TBS 10x, 900ml ddH20,  
1ml Tween
®
 20 (BDH) 
 
5% dried skimmed milk powder in TBST 
3g bovine serum albumin dissolved in 100ml of 
TBST 
30 ml of 5 M NaCl, 100 ml of 10% NP-40, 50 ml of 
1 M Tris (pH 8.0), and 820 ml of ddH2O 
Room temperature 
 
Room temperature 
 
 
Room temperature 
 
 
 
500μl aliquots at 4°C 
 
 
Room temperature 
 
 
Room temperature 
 
 
 
Room temperature 
 
 
4°C  
4°C  
 
4°C  
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2.1.3 Antibodies and probes 
Table 13 - Antibodies. 
PRIMARY ANTIBODIES 
Antibody Dilution Company Dilution buffer 
 
Monoclonal rabbit GAPDH 
 
Monoclonal mouse KRAS  
 
Monoclonal mouse BCL2 (ab692) 
 
Monoclonal mouse CRK (610035) 
 
Monoclonal mouse PDCD4 
 
Monoclonal mouse NEDD4L 
 
Monoclonal mouse BTG2 
 
Monoclonal mouse SORBS2 
 
 
1/10,000 
 
1/50 
 
1/100 
 
1/5000 
 
1:1000 
 
1:200 
 
1:1000 
 
1:250 
 
abcam
®  
sc137179 
Santa-Cruz 
sc-30 
abcam
®
 
ab692 
BD Ltd. 
610035 
abcam
® 
ab51495 
Sigma 
HPA024618 
Sigma 
AV33561 
Sigma 
SAB4200183 
 
Blocking buffer  
 
Blocking buffer 
 
Blocking buffer 
 
Blocking buffer 
 
Blocking buffer 
 
Blocking buffer 
 
Blocking buffer 
 
Blocking buffer 
 
SECONDARY ANTIBODIES 
Antibody Dilution Company Dilution buffer 
 
Polyclonal goat anti-rabbit 
IgG/HRP 
 
Polyclonal goat anti-mouse 
IgG/HRP 
 
 
1/2500 
 
 
1/2500 
 
Dako 
 
 
Dako 
 
Blocking buffer 
 
 
Blocking buffer 
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2.1.4 Primers 
Table 14 - RT-qPCR primer sequences. 
All the primers were synthesised by Sigma-Aldrich (Dorset, UK). 
 
PRIMER SEQUENCES 
Gene Forward (5’ to 3’) Reverse (5’ to 3’) 
 
KRAS 
 
 
CATGGACTGTGTCCCCACG 
 
TGACTAACCAATGCATGACAACACT 
 
 
Table 15 - Primer sequences for plasmid constructs. 
 
2.1.5 Plasmid vectors 
Table 16 - List of plasmid vectors. 
 
KRAS_A_WT  
Sense CGCGCAGCGACAGTAGGATTTTTCAAACCTGGTATGAATAGAGC 
Antisense AGCTGCTCTATTCATACCAGGTTTGAAAAATCCTACTGTCGCTG 
KRAS_A_MUT 
Sense CGCGCAGCGACAGTAGGATTTTTCAAACCTGGATAGAATAGAGC 
Antisense AGCTGCTCTATTCTATCCAGGTTTGAAAAATCCTACTGTCGCTG 
KRAS_B_WT 
Sense CGCGCGTGCTTTCTTTTGTGGGACATATGCAGTGTGATCCAGGC 
Antisense AGCTGCCTGGATCACACTGCATATGTCCCACAAAAGAAAGCACG 
KRAS_B_MUT 
Sense CGCGCGTGCTTTCTTTTGTGGGACATATGCAGACAGATCCAGGC 
Antisense AGCTGCCTGGATCTGTCTGCATATGTCCCACAAAAGAAAGCACG 
Plasmid ID Gene Company 
pMIR-REPORT
TM
 
miRNA Expression 
Vector 
 
KRAS_A_WT; KRAS_A_MUT; 
KRAS_B_WT; KRAS_B_MUT 
Invitrogen, Life Technologies Ltd, 
Paisley, UK 
pRL-TK Vector E2241 
 
Renilla Luciferase Promega, Madison, WI, USA 
pLightSwitch_3’UTR 
Go Clone vector 
S806055 
RenSp Luc-hsa-RGS2-
3’UTR 
SwitchGear Genomics, Menlo Park, 
CA 
S806591 
RenSp Luc-hsa-BNIP3-
3’UTR 
S810507 
RenSp Luc-hsa-NEDD4L-
3’UTR 
S810530 
RenSp Luc-hsa-PDCD4-
3’UTR 
S812869 
RenSp Luc-hsa-BTG2-
3’UTR 
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2.1.6 Patient tissue samples used in Chapter 3 
Following written informed consent, specimens were obtained from 58 
individuals who underwent pancreatic resection for a cystic tumour or known PDAC 
between May 1999 and November 2010 at the Hammersmith Hospital, London, UK. 
During this period, 4 FFPE and 9 fresh samples of normal pancreas (NP) were also 
collected from pancreatic resection following trauma. After macroscopic examination, 
10 µm thick sections were obtained from the paraffin blocks for the FFPE tumour 
samples (n=43) as in previous studies [277, 371]. For the FFPE microarray there 
were: serous microcystic adenoma (SMCA; n=7), mucinous cystic neoplasm (MCN; 
n=6), intraductal papillary mucinous neoplasm (IPMN; n=7), carcinoma-ex-IPMN 
(CEI; n=9) and PDAC (n=14). Our histopathologist removed any adjacent normal 
acinar or adipose tissue with a scalpel. In addition, several sections (3 to 5) were 
taken from each block in order to ensure that a representative sample was obtained. 
Fresh tissue samples (n=24; NP, n=9; PDAC, n=15) collected at surgery were 
immediately placed in RNALater RNA Stabilization Reagent solution (Qiagen, 
Hilden, Germany) and stored at room temperature for 2-3 hours before being frozen 
at -80°C. The immunohistochemical analysis was performed on FFPE samples: NP, 
n=12; PDAC, n=12; and SMCA, n=12 (an additional 5 cases of SMCA were available 
at this time). Further detailed clinicopathological information about the patients is 
provided in Appendix 1. 
 
2.1.7 Patient tissue samples used in Chapter 4 
Three independent, nonoverlapping patient tumour cohorts were used. 
Specimens were obtained from individuals undergoing pancreaticoduodenectomy 
(PD) for PDAC between 2004 and 2010 at Hammersmith Hospital, London, UK. The 
initial cohort consisted of 9 PDAC and 9 nonmalignant fresh pancreas samples that 
were used for miRNA and mRNA microarray profiling. These were immediately 
macrodissected at the time of surgery, placed directly in RNAlater stabilization 
solution (Qiagen, Hilden, Germany), stored at room temperature for 2-3 hours and 
then frozen at -80°C. This was done to prevent any degradation and ensure high 
quality RNA for the subsequent molecular profiling. Hematoxylin and eosin staining 
was used for histological confirmation of cancer and to determine the cellularity of 
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representative sections. A specialist pancreatic pathologist (Dr Raida Ahmad, 
Hammersmith Hospital) reviewed the slides, and tissue for RNA isolation was 
verified to contain ≥60% neoplastic cells.  
The second cohort (n=91) consisted of patients who underwent PD at Pisa 
University Hospital (Italy) and Hammersmith Hospital (UK) between 2000 and 2010. 
Tumours were isolated by LCM [347] from FFPE blocks and were used as a 
validation cohort for quantitative real time reverse transcription-PCR (RT-qPCR) of 
miRNA expression.  
The third patient data set (n=121) was a tissue microarray (TMA) of PDACs 
from patients who underwent resection with curative intent between 1995 and 2009 
at the surgical department of Friedrich-Schiller University (Germany) and was used 
as an immunohistochemistry (IHC) validation cohort.  
Complete clinicopathological, follow-up and recurrence data were available 
from prospectively maintained databases. Overall cancer-specific survival (OS) was 
examined for the RT-qPCR and TMA cohorts. Written informed consent was 
obtained from all patients, and ethical approval was provided by each hospital’s 
research ethics committee. Further detailed clinicopathological information about the 
patients is provided in Appendix 2. 
 
2.2 Methods used  
2.2.1 Ethical approval 
 Analysis of miRNAs in historical stored FFPE and fresh surgical specimens 
was approved by a UK national research ethics committee (Camden & Islington 
REC, London; 09/H0722/77) and by Imperial College Healthcare NHS Trust in the 
UK and the ethics committee of Pisa University Hospital in Italy. All animal 
experimental procedures were conducted under the UK Home Office Project License 
number PPL 70/7256.  
 138 
 
2.2.2 Cell culture and transfection 
2.2.2.1 Growing and passaging pancreatic cancer cells 
PANC-1 and MIA PaCa-2 pancreatic cells were purchased from the European 
Collection of Cell Cultures (ECACC). PANC-1 cells were chosen as they are an 
epithelial type cell, whilst MIAPaCa-2 cells are more mesenchymal [499]. PANC-1 
and MIA PaCa-2 pancreatic cells were cultured in 150 cm2 flasks maintained at 37°C 
in a humidified 5% CO2 incubator (Table 10 and Table 11). Cells were routinely 
passaged when a confluency of ~90% was reached depending on the doubling time 
of each cell line. To passage the cells, medium was aspirated, cells were washed 
once with warmed PBS solution and then trypsinised with EDTA-trypsin at 37°C for 3 
to 10 minutes to allow them to detach. Media containing foetal calf serum (FCS) was 
added to inactivate the trypsin and cell clumps were disrupted through gentle 
pipetting. The obtained liquid suspension containing the cells was transferred into a 
15ml sterile centrifuge tube and centrifuged for 4 minutes at 1300 rpm. After 
centrifugation, the supernatant was aspirated and cell pellet was re-suspended in the 
appropriate volume of medium. The resulting suspension was split to the desired 
dilution (normally 1:5 to 1:7) into new flasks and fresh media was added. Cells were 
used between passages 4 to 20 in all experiments. The two primary cell cultures 
from PDAC patients (LPc006 and LPc167) were maintained as previously described 
[500].  
2.2.2.2 Transient cell transfection 
For mature miRNA overexpression and inhibition:  
PANC-1 and Mia PACA-2 cell lines were plated in 100mm tissue culture 
plates at 1.5 x 106 cells suspended in 7ml of medium (proportionately less for 6-well 
plates and 24-well plates). Cells were allowed to adhere and grown at 37°C with 5% 
CO2. After 24 hours, 10nM to 30nM of each precursor miRNA (pre-miR) 
oligonucleotide (Applied Biosystems, Cheshire, UK) or pre-miR-negative control; NC 
(for the control experiment) or alternatively 30nM to 90nM of each miRNA inhibitor 
(anti-miR) or the anti-miR-NC was added to 0.5ml of medium without additives and 
20µl/plate of HiPerFect Transfection Reagent (Qiagen, Hilden, Germany) and gently 
mixed. The transfection solution was then incubated for 9 minutes at room 
temperature (RT) to allow the formation of transfection complexes. After incubation, 
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the transfection complexes were added drop-wise onto the cells and the plates were 
gently swirled to ensure uniform distribution in each plate. The cells with the 
transfection complexes were then incubated under their normal growth conditions for 
24 to 48 hours. The transfection with each miRNA precursor was performed in 
duplicate for both protein and RNA extraction. For miRNA effects on target protein 
levels and the effects of gain-of-function on cell-proliferation (Chapter 4), the final 
concentration of pre-miR was kept constant (30 nmol/L or 30nM) for either single, 
triple pre-miR transfection or the pre-miR-NC (e.g. for 3 pre-miRs the concentration 
was 10 nM for each and 30 nM was used for the pre-miR-NC). 
 For 3’UTR reporter transfection:  
 MIA PaCa-2 cells were seeded onto 24-well plates (10 × 105 cells per well) the 
day before transfections were performed. Cells (80% confluent) were co-transfected 
with pRL-TK luciferase reporters (50 ng/well), pMIR-REPORT firefly luciferase (150 
ng/well) (Table 16), and the miRNA precursor (i.e. pre-miR-126) at 100 nM using 
Lipofectamine® 2000 (Invitrogen, Paisley, UK). To prepare the transfection 
complexes, these were added in 50µl Opti-MEM® I Medium, gently mixed and 
incubated for 5 minutes at RT. After incubation, the oligonucleotide solutions were 
combined with the appropriate volume of Lipofectamine® 2000, gently mixed and 
incubated for 20 minutes at RT to allow complex formation to occur. The complexes 
were then added drop-wise to each well containing cells and medium, and then 
incubated under normal growth conditions for 48 hours. Each transfection was 
performed in triplicate and also in three independent experiments.  
 In addition, the 3’UTRs of cancer-relevant tumour suppressors cloned into 
pLightSwitch_3UTR GoClone vectors (SwitchGear Genomics, Menlo Park CA, USA) 
(Table 16) were used to confirm direct target binding. The day before transfections 
were performed, PANC-1 cells were seeded onto 24-well plates (15 × 10
5 cells per 
well) in antibiotic free media in triplicate per construct. Cells (80% confluent) were 
co-transfected with pLightSwitch_3UTR luciferase reporters (150 ng/well) and the 
relevant pre-miR (100 nM) or a non-targeting negative control using Lipofectamine 
2000® (Invitrogen). Again, complexes were added drop-wise to each well containing 
cells and medium, and then incubated under normal growth conditions for 24 hours. 
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2.2.3 Performing 3’UTR Luciferase Reporter Assay 
For pMIR-REPORT and pRL-TK reporters, the MIA PaCa-2 cells were lysed 
after 48 hours with 50µl/well of the Cell Culture Passive Lysis Buffer (5x) (Promega, 
Southampton, UK) and placed on a bench agitator at for 30 minutes at RT. The 
firefly and renilla luciferase luminescence signals were measured using the Dual-Glo 
Luciferase Assay System (Promega, Southampton, UK). For this, lysates were 
transferred into an OptiPlate-96-well microplate and mixed with 50µl/well of Dual-
GloTM Luciferase Reagent. After 10 minutes, the microplate was sealed and the 
firefly luciferase activity was measured in a GLOMAX 96 Microplate Luminometer 
(Promega, Southampton, UK). The measure of renilla luciferase luminescence was 
carried out by adding 50µl/well of Dual-GloTM Stop & Glo® reagent following the 
manufacturer’s instructions. After 10 minutes, the reading of renilla luminescence 
was taken by the luminometer. The ratio between the firefly and renilla luminescence 
measurements was then calculated and an average of the triplicates determined. 
For pLightSwitch_3UTR GoClone vectors, the PANC-1 cells were lysed after 
24 hours using the Cell Culture Passive Lysis Buffer (Promega, Southampton, UK). 
The LightSwitch Assay System (Switchgear Genomics, Menlo Park, CA) was then 
used for luciferase signal detection following the manufacturer instructions. After a 30 
minute incubation period (covered from light), the signal from each well was read in a 
GLOMAX 96 Microplate Luminometer (Promega, Southampton, UK) and the 
average luciferase intensity was calculated for pre-miR replicates and then divided 
by the average for negative control replicates. 
 
2.2.4 Plasmid constructions  
For KRAS 3’UTR reporters construction, complementary oligonucleotides 
(Sigma Aldrich Ltd., Dorset, UK) containing the miR-126 recognition elements (MRE) 
were annealed and successively cloned into the Mlu1 and HindIII sites of the multiple 
cloning site (MCS) of pMIR-REPORT firefly luciferase vector (Applied Biosystems, 
Cheshire, UK). A KRAS 3’-UTR containing two wild-type (named KRAS_A_WT and 
KRAS_B_WT) and two mutated (named KRAS_A_MUT and KRAS_B_MUT) miR-
126 binding sites were used to produce the constructs. The sequences of all primers 
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used for plasmid construction are reported in Table 15. In brief, double digestion of 
the blunt-ends of the amplicons was performed by using HindIII and Mlu1 restriction 
enzymes (New England BioLabs; NEB, MA, USA) at 37°C overnight. All the primers 
used for the amplification of 3’UTRs were designed by adding a HindIII-specific 
restriction site on the 5’end, and a Mlu1-specific restriction site on the 3’ end, in order 
to allow the amplicons to be cloned into the MCS of the pMIR-REPORT firefly 
luciferase vector. The ligation reaction was then carried out by incubating each 
amplicon with the linearized pMIR-REPORT firefly luciferase vector (at a ratio of 3:1) 
and 1µl of T4 DNA Ligase (NEB) at 16°C overnight. 
 
2.2.5 Laser capture microdissection 
 In order to ensure that cell-type specific miRNA levels could be assessed, 
LCM was performed as previously described (Figure 10). LCM was performed using 
the PALM MicroBeam LCM system (Carl Zeiss, Munich, Germany).  
FFPE slides of PDAC and adjacent NP were stained with H&E and reviewed 
with a specialist pancreatic pathologist. Area of NP and PDAC were then marked 
with permanent marker on the glass cover-slip. FFPE blocks corresponding to each 
H&E slide were then cut (5-10 sections, each 10 μm thick). Sections were then 
loaded onto specialised metallic membrane slides (MembraneSlide1.0 PEN, Carl 
Zeiss) under RNase-free conditions. PEN membrane is polyethylene-naphthalene, a 
special membrane slide coating which allows very easy cutting and transfer of large 
tissue regions after LCM. PEN membrane slides were also incubated in dry heat at 
180°C for 4 hours to completely inactivate any RNases prior to use). These were 
then stained with haematoxylin only (dark blue colour; Figure 10) and stored at -
20°C until required. The LCM was then performed using the H&E cover-slip as a 
“map” for the corresponding membrane slide sections (Figure 10). The PALM 
system cuts the tissue area required and catapults the specimen into an adhesive 
cap on an Eppendorf, which is then sealed and stored until required.  
Total RNA was then isolated from the LCM samples using the miRNeasy Mini 
Kit (Qiagen, Hilden, Germany) as per the manufacturer’s instructions. A volume of 
150μl of Buffer PKD (proteinase K digestion; Qiagen) was added to the Eppendorf 
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tubes containing the LCM elements in the adhesive cap. Proteinase K (10μl) was 
then added and the tubes were inverted to allow contact between the reagents and 
the samples on the adhesive surface. The samples were then digested by placing 
the tubes upside down in an incubator at 56°C overnight, after which they were 
vortexed and heated at 80°C for 15 minutes in a heat block and then incubated on 
ice for 3 minutes. Following this, 16 μl of DNase Booster Buffer (Qiagen) and 10 μl of 
DNase I stock solution (Qiagen) were added and the samples were mixed gently by 
inverting the tubes which were then centrifuged briefly to collect any residual liquid 
from the sides of the tubes. The samples were then incubated at RT for 15 minutes, 
and the lysates were transferred to a new 1.5ml microcentrifuge tube. RBC solution 
(320μl; Qiagen) was then added to adjust the binding conditions and the lysates 
were mixed thoroughly. Next, 720μl of 100% ethanol was added to the samples, 
which were then mixed well by pipetting. Next, 700μl of the sample was transferred 
to an RNeasy MinElute spin column (Qiagen) placed in a 2 ml collection tube and 
centrifuged for 15 s at ≥10000 rpm. The flow-through was discarded and this step 
was repeated until the entire sample had passed through the spin column. Following 
this, 500μl of Buffer RPE (Qiagen) were added to the RNeasy MinElute spin column 
which was then centrifuged for 15 seconds at ≥10000 rpm to wash the spin column 
membranes. The flow-through was then again discarded and the RNeasy MinElute 
spin columns were then placed in a new 2 ml collection tube. The spin columns were 
then centrifuged at full speed for 5 minutes with their lids opened and the flow-
through in the collections tubes was discarded. The RNeasy MinElute spin columns 
were placed into new 1.5 ml collection tubes and 30μl of RNase-free water was 
added for elution. The collection tubes were closed and centrifuged for 1 minute at 
full speed to elute the RNA. The RNA solution was then stored at -20°C until 
required. 
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Figure 11 - Laser capture microdissection of normal pancreas and PDAC. 
(A) Haematoxylin & Eosin (H&E) staining of normal pancreas. Haematoxylin only (dark blue) 
staining of (B) normal pancreatic tissue and (C) PDAC before and after LCM (left to right 
shows the area marked on the computer screen to direct the laser prior to LCM, then after 
the LCM procedure and finally the cut areas in the cap of the Eppendorf). 
 
 
2.2.6 RNA extraction 
2.2.6.1 RNA isolation from clinical specimens 
FFPE archival samples were deparaffinized with xylene and total RNA was 
collected using the miRNeasy Mini Kit (Qiagen, Hilden, Germany) according to the 
manufacturer's instructions (see above). Fresh tissue stored in RNALater was 
crushed in liquid nitrogen and subsequent powder lysed in Trizol Reagent 
(Invitrogen, Paisley, UK), followed by RNA isolation according to the manufacturer's 
instructions (see below for brief description).  
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Fresh tissue samples were obtained at the time of surgical resection, 
immersed in RNALater (RNA stabilising solution; Qiagen, Hilden, Germany) and 
frozen at -80°C. When required, they were crushed in liquid nitrogen and the 
subsequent powder lysed in Trizol (Invitrogen, Paisley, UK) reagent. RNA isolation 
was carried out according to the manufacturer's instructions. The quality of isolated 
RNA was analysed on the Agilent 2001 Bioanalyzer (Agilent Technologies Inc., CA, 
USA). To assess RNA integrity, RNA integrity numbers (RINs) are calculated by 
Agilent software. A RIN of ≥7 is sufficient RNA quality for RNA microarray 
analyses.[501] The RINs for our patient RNA samples used for the initial molecular 
profiling in Chapter 4 were between 8.70 and 10.  
2.2.6.2 RNA extraction from cells 
Buffers and reagents used are seen in 2.1. Cells were plated in 100mm tissue 
culture dishes for the pre-miRs overexpression, were allowed to adhere and grown 
for 48 hours. To avoid RNase contamination, filter tips and sterile Eppendorf tubes 
were used and benches and work gloves were carefully cleaned with RNaseZap® 
(Ambion) spray. The plate was placed on ice, medium was aspirated, and cells were 
washed twice with cold PBS. Cells were scraped in 1ml cold PBS, halved into two 
Eppendorf tubes for both RNA and protein extraction and then centrifuged for 5 
minutes at 1300 rpm. The supernatant was removed and one of the two cell pellets 
was lysed with 1ml of Trizol reagent (Invitrogen, Paisley, UK) through pipetting. 
Under the safety hood, 200µl of chloroform per 1ml of Trizol reagent was added to 
the lysates and the tube shaken vigorously. The samples were vortexed for 15 
seconds, incubated at RT for 2 to 3 minutes, and then centrifuged at 12,000 x g for 
15 minutes at 2 to 8°C. Following centrifugation, each mixture separates into lower 
red, phenol-chloroform phase, an interphase, and a colourless upper aqueous 
phase. RNA remains exclusively in the aqueous phase. Each aqueous phase was 
transferred carefully without disturbing the interphase into fresh Eppendorf tubes. 
The total RNA was precipitated from the aqueous phases by mixing with 500µl of 
isopropyl alcohol and incubating for 10 minutes at RT. The mixtures were then 
incubated overnight at -80°C to allow small RNA precipitation.  
After incubation, the RNA precipitates were centrifuged at 12,000 x g for 10 
minutes at 2 to 4°C to form a pellet on the side and bottom of the tube. The 
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supernatants were removed, and the RNA pellets were washed by adding 1ml of 
75% ethanol and mixed by vortex. The samples were centrifuged at 7,500 x g for 5 
minutes at 2 to 8°C. The supernatants were removed and any residues of ethanol 
were partially air-dried. Finally, the RNA pellets were resuspended in an appropriate 
volume of RNAse-free water. Subsequently, RNA concentration was measured at 
260nm and 280nm wavelengths, using a NanoDrop ND-100-Spectrophotometer 
(NanoDrop Technologies). The RNA quality was also determined on non-denaturing 
agarose gel electrophoresis. For each RNA that was isolated, two intensive bands at 
approximately 4.5 and 1.9 kb were observed at the transilluminator. These bands 
represent 28S and 18S rRNA and indicate successful RNA preparation. 
 
2.2.7 Quantitative real-time Reverse Transcription-PCR  
2.2.7.1 cDNA synthesis 
For mature miRNAs, reverse transcription was performed using the TaqMan 
MicroRNA Reverse Transcription Kit (Applied Biosystems, Life Technologies Ltd, 
Paisley, UK). Total RNA (10ng) was mixed with 7µl of master mix and 3µl of 
microRNA-specific RT TaqMan stem–loop primers (Applied Biosystems) in a 48-well 
PCR plate (Thermo Scientific, Abgene®, Leicestershire, UK). The samples were 
incubated in the Applied Biosystems Veriti 96-Well Thermal Cycler at 16°C for 30 
minutes to allow primer annealing, followed by 30 minutes at 42°C for the elongation 
step, and 5 minutes at 85°C to inactivate the reverse transcriptase (Figure 12).  
For gene expression, the cDNA was synthesised by using the Superscript III 
First Strand cDNA synthesis system (Invitrogen, Life Technologies Ltd, Paisley, UK). 
For this, 1 µg of purified DNase-treated RNA was mixed with 50nM of the reverse 
primer of each primer set (Table 14) and incubated in a Veriti 96-Well Thermal 
Cycler at 70°C for 10 min to allow RNA denaturation, and then place on ice to allow 
primer annealing. Reverse transcriptase and dNTPs were then added to the RNA 
and incubated at 50ºC for 50 min, and then at 85ºC for 10 min in a Veriti 96-Well 
Thermal Cycler. After RT cycles, the cDNA samples were placed in ice and then 
prepared for real-time qPCR. 
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2.2.7.2 Quantitative real-time PCR (RT-qPCR) 
For miRNAs a selection of miRNAs were chosen for validation based on 
statistical significant high levels of logarithmised fold change seen in the microarrays, 
as well as their functionally relevance and known potential roles in tumourigenesis. 
Duplicate samples and validated endogenous controls (snRNA U6, U47 and miR-
191) were used throughout. Expression levels of each miRNA were evaluated using 
comparative threshold cycle (Ct) method as normalized to a control (2 –ΔΔCt). The 
relative expression levels of each miRNA were calculated between tissue / cell types 
/ treatments. The cDNA previously created is used in the real-time PCR reaction. A 
mixture of forward and reverse primers and a dual-labelled probe (TaqMan®, Applied 
Biosystems, Leicestershire, UK) are used to amplify and detect the cDNA target. The 
probe has a reporter dye on the 5' end and a quencher on the 3' end. If the target 
sequence is present during the PCR, the probe binds to the target sequence. During 
the extension stage of the PCR cycle, the reporter dye is released by the 5' 
exonuclease activity of Taq polymerase, and because the reporter and quencher 
have been separated, the fluorescence from the reporter dye is detected [502].  
In order to amplify mature miRNAs, for a single reaction, 1ng of relative cDNA 
template was distributed in a Fast Optical 96-well reaction plate (Applied 
Biosystems), followed by the appropriate volume of a master mix. The master mix 
was prepared by combining 10μl of 2x TaqMan® Universal PCR Master Mix, No 
UNG Amperase® (Applied Biosystems) with 1μl of the relative 20x Real Time 
TaqMan probe (Applied Biosystems), by adding ddH2O to a final volume of 15.57μl 
per single reaction. Each reaction was done in triplicate. The plate was then sealed 
using the Optical Adhesive Cover Starter Kit (Applied Biosystems) and centrifuged 
(2,000 x g) for 30 seconds at RT. Quantitative real-time PCR (qPCR) was performed 
with a 7900 HT Fast Real-Time PCR System (Applied Biosystems) with a thermal 
cycling program as follow: a first stage of 10 minutes at 95°C, followed by 40 cycles 
of 15 seconds at 95°C and 1 minute at 60°C. Finally, data were analysed using 
qBasePlus software (Biogazelle). 
For gene expression, either the TaqMan® system was used or total RNA 
was reverse transcribed using Superscript III Reverse Transcriptase (Invitrogen, Life 
Technologies Ltd, Paisley, UK) and cDNA transcripts were amplified by qPCR using 
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SYBR Green (Applied Biosystems, Leicestershire, UK). Triplicate samples were 
used and levels were normalised to GAPDH using primers described in Castellano et 
al [342]. When TaqMan primer and probe sets (Applied Biosystems) were used, 
transcripts were quantified by using the expression of the gene RPLPO (aka 36B4) 
as the endogenous RNA control.  
 
 Reproduced from [502]. 
 
2.2.8 Protein extraction and Western blotting 
2.2.8.1 Protein extraction 
Whole cell lysates were prepared in Nonidet P-40 (NP-40) lysis buffer [50 mM 
Tris/HCl, pH 8.0, 150 mM NaCl, 10% (vol/vol) glycerol, 1% Nonidet P-40, 5 mM DTT 
(DTT), 1 mM EDTA, 1 mM EGTA, 50 µM leupeptin, and 30 µg/mL aprotinin]. After 
treatment, cells plates were placed on ice and cells were washed once with cold 
PBS. Cells were scraped in 1ml cold PBS, halved into two Eppendorf tubes for both 
RNA and protein extraction and centrifuged for 5 minutes at 1300 rpm. The 
supernatant was removed and one of the two cell pellets was lysed in 30 to 60μl of 
NP-40 lysis buffer and protease inhibitor cocktail solution (Roche, Diagnostic Ltd, 
West Sussex, UK). Eppendorf tubes containing cell lysates were placed on a rotator 
Figure 12 - Amplification of 
miRNAs using TaqMan 
primers and probes. 
(A) Ligation of hairpin loop 
primer to mature miRNA. (B) 
Reverse transcription to cDNA 
product. (C) Real-time PCR 
amplification of cDNA with 
forward and reverse primers 
and use of a TaqMan probe for 
detection. Key: Q, quencher; R, 
reporter dye.  
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for 15 minutes at 4°C. Centrifugation of the lysates at maximum speed (13,000 rpm) 
for 15 minutes at 4°C allowed the separation of protein from the insoluble elements. 
The supernatants containing proteins were transferred into new Eppendorf tubes and 
subsequently subjected to protein quantification. 
2.2.8.2 Protein quantification  
The protein concentration in the supernatants was determined using Bradford 
Reagent (BioRad, Berkeley, CA, USA) diluted tenfold in dH2O. In reading cuvettes, a 
standard solution and a solution used as “blank” were prepared by adding 1µl of 
1mg/ml BSA (Invitrogen) and 1µl of the NP-40 working lysis buffer in 1ml of diluted 
Bradford Reagent respectively. Protein samples were diluted 1:10 and 1µl was 
added in 1ml of diluted Bradford Reagent. Absorbance readings were measured at 
595nm using a Beckman DU® 530 Life Science UV/Visible spectrophotometer. Upon 
collection of the data, the concentration of the unknown samples was determined 
based on standard absorbance value. The protein samples were then prepared for 
the SDS-polyacrylamide gel electrophoresis: 3µg/µl of protein samples were mixed 
with SDS Loading Buffer (2x) and boiled at 95°C for 5 minutes. Samples were then 
stored at -20°C until required. 
2.2.8.3 SDS-polyacrylamide gel electrophoresis 
Both 15% resolving acrylamide and 4% stacking gels were prepared manually 
as required. Once Spectra™ rainbow marker (Fermentas, Thermo Scientific, 
Leicestershire, UK) and the protein samples (10µl) were loaded; electrophoresis was 
carried out for 3 to 4 hours at 80V. Proteins were separated by SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE) and run in running buffer.  
2.2.8.4 Western blotting 
The proteins were transferred to a Hybond C super nitrocellulose membrane 
(GE Healthcare, Bucks, UK) for 1.5 hours at 100V in transfer buffer using a Mini-
PROTEAN® Tetra Cell (BioRad). The membrane was stained with Ponceau S 
solution (Fluka, Sigma-Aldrich, Dorset, UK) to check if the transfer had been 
successful. The membrane was washed once for 10 minutes with ddH20 in order to 
remove the staining and then blocked with blocking buffer at RT for 1 hour. The 
membrane was transferred into the primary antibody solution and left at 4°C 
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overnight. TBST was used to wash the membrane for three times (10 minutes each). 
An IgG/HRP (horseradish peroxidise) secondary antibody diluted in blocking solution 
was then added and the membrane incubated at RT for 1 hour. The membrane was 
again washed 3 times with TBST and 1ml + 1ml (per membrane) of the Enhanced 
Chemiluminescence (ECL) detection system (GE Healthcare) was used for 
visualisation. The emitted fluorescence was detected using Hyperfilm ECL (GE 
Healthcare) on SRX-101A x-ray developer. Band intensities were then measured by 
the image analysis Image Processing and Analysis in Java (Image J) program 
(National Institutes of Health; available free at http://rsbweb.nih.gov/ij/) or 
chemiluminescence was detected and quantified by the Fusion FX7 image 
acquisition system (Vilber Lourmat, Germany). Antibodies used can be seen in Table 
13. 
 
2.2.9 febit miRNA microarray  
The microarray we used is applicable and has been validated for FFPE 
samples [503]. Total RNA was extracted (as mentioned previously) and the samples 
were analysed with the Geniom Realtime Analyzer (GRTA) using the Geniom 
Biochip MPEA Homo sapiens (both by febit biomed gmbh, Germany). The probes on 
the biochip are designed as the reverse complements of all major mature human 
miRNAs (866 miRNAs) as published in the Sanger miRBase version 13.0 (March 
2009) [128]. The probes are synthesized with 7 intra-array replicates for each miRNA 
to increase the statistical confidence and to compensate for potential positional 
effects. This microarray combined with the fully automated GRTA platform allows for 
measuring miRNA signatures and ensures a high degree of reproducibility [504]. 
Samples were labeled by microfluidic-based enzymatic on-chip labeling of miRNAs 
(MPEA) [505]. Following hybridization for 16 hours at 42°C, the biochip was washed 
automatically and a program for signal enhancement was processed with the GRTA. 
Resulting detection pictures were evaluated using the Geniom Wizard Software (febit 
biomed gmbh, Germany).  
The miRNA microarray aimed to detect differential expression between tissue 
types. The mean expression values for each miRNA on the microarray were first 
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background subtracted and normalised before analysis. Global background 
subtraction corrects for several experimental factors that may cause a systematic 
spatial variability on a microarray. Following this, the 7 replicate intensity values of 
each miRNA were summarised by their median value. Quantile normalisation was 
then performed across all the different arrays [506]. These microarray data are 
presented as the median relative miRNA expression levels observed and the median 
logarithmised fold changes between tissue types.  
A hierarchical clustering heatmap was created using the 35 miRNAs with the 
highest variability in order to separate the data graphically. This was done because if 
all the miRNAs were used then there would be no reliable image, since most are 
contributing more noise than signal. To detect whether partitioning was significant, a 
3x3 contingency table consisting of the 3 main groups of tissue type (PDAC, CEI and 
BCT), was analysed using Fisher’s Exact test [507]. A P<0.05 was considered a 
significant clustering result.  
We used Limma which is a test for differential expression analysis of data 
arising from microarray experiments. Empirical Bayes and other methods are used to 
borrow information across genes, making the analyses ideal for experiments with a 
small number of arrays [508, 509]. The resulting P-values were adjusted for multiple 
testing by the Benjamini-Hochberg method [510, 511]. A log fold change for a 
deregulated miRNA with a limma adjusted P<0.05 was considered statistically 
significant. Tables 17 to 20 demonstrate the microarray results for the 30 most 
deregulated probes (detected by highest absolute value of logarithmised fold 
changes) in each tissue comparison.  
 
2.2.10 miRNA and mRNA expression profiling 
2.2.10.1 Gene expression profiling (cDNA microarray)  
Gene expression analysis was performed using the Affymetrix Human Gene 
1.0 ST Array interrogating 28,869 well-annotated transcripts (Affymetrix, Santa Clara, 
CA, USA). The GeneChip Human Gene 1.0 ST array is a whole transcript–based 
array for gene expression profiling [512]. Its design is based on a subset of probes 
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from the Human Exon 1.0 ST array (Affymetrix) and includes well-annotated exons, 
based on RefSeq (www.ncbi.nlm.nih.gov/refseq), Ensembl (www.ensembl.org) and 
putative complete coding sequences from GenBank 
(www.ncbi.nlm.nih.gov/genbank), as well as some unannotated probe sets.  
2.2.10.2 miRNA Nanostring analysis 
The Nanostring nCounter Human miRNA Expression Array 
(http://www.nanostring.com/) was used to obtain miRNA expression profiles [243]. 
The NanoString miRNA panel contains 654 probes for human miRNAs. Total RNA 
(100 ng) was used as input for nCounter miRNA sample preparation reactions and 
these were performed according to manufacturer's instructions (NanoString 
Technologies). Small RNA sample preparation involves the ligation of a specific DNA 
tag onto the 3′ end of each mature miRNA. These tags normalise the melting 
temperatures (Tms) of the miRNAs and provide a unique identification for each 
miRNA species in the sample. Excess tags were then removed, and the resulting 
material was hybridised with a panel of miRNA: tag-specific nCounter capture and 
barcoded reporter probes. Hybridised probes were then purified and immobilised on 
a streptavidin-coated cartridge using the nCounter Prep Station (NanoString 
Technologies). Data collection was carried out on the nCounter Digital Analyser 
(NanoString Technologies) following the manufacturer's instructions to count 
individual fluorescent barcodes and quantify target RNA molecules present in each 
sample. For each assay, a high density scan (600 fields of view) was performed. 
2.2.10.3 miRNA expression data processing 
Raw intensity values of the Nanostring nCounter Human miRNA Expression 
Arrays for 18 samples were quantile-normalised using function 'normalise.quantiles' 
from the R/Bioconductor package 'preprocessCore'. Normalised intensity values for 
654 human miRNAs were then filtered to discard low-intensity features (i.e. to avoid 
over-scoring changes in expression) by requiring mean signal intensity in at least 
one condition (i.e. cancer or normal samples) to be >500 on the linear scale (n=56 
miRNAs passing filter). This filtering on abundance is common practice, done to 
increase the power of the test for differential expression (i.e. by reducing the number 
of multiple tests performed). From miRNA studies it has emerged that generally as 
few as 10-15 miRNAs account for up to 90% of the total amount of mature miRNA 
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molecules of a cell. Abundance levels in our normalised miRNA microarray data 
ranged from 0 to over 99000 on a linear scale and we chose 500 as a reasonable 
arbitrary threshold to ensure good expression of a given miRNA in at least one 
condition and avoid evaluation of differential expression for those miRNAs always 
expressed at low levels. 
2.2.10.4 Gene expression data processing 
The Affymetrix Human Gene 1.0 ST array was used to profile gene expression 
in 12 samples. Preprocessing of microarray raw data (i.e. quantile normalisation, 
summarisation, generation of present/absent calls and detection P-values) was 
performed using functions from the R/Bioconductor package xps. A microarray can 
contain thousands of spots, with each one containing a few million copies of identical 
DNA molecules that uniquely correspond to a probe set, which in turn interrogates a 
given transcript. The binding of a probe set to its target, due to sequence 
complementarity, results in a fluorescence signal that is proportional to the extent of 
bound molecules from each spot. Thus, a signal intensity measure can be obtained 
and used to compare mRNA abundance across different arrays (i.e. experimental 
conditions). However, before comparing gene expression levels across arrays, it is 
necessary to process raw data in order to remove any systematic bias inherent to 
the microarray experiment (e.g. differential efficiency of the fluorescent dye, different 
amounts of starting RNA material, background noise, differences in hybridisation 
reactions and conditions and different scanner settings). A reliable and commonly 
used method to reduce this technical, rather than biological, variability is quantile 
normalisation. This technique makes the distribution of expression intensities of each 
array identical. This is done to make intensity values comparable across different 
arrays and we assume that the distribution of gene expression measures does not 
change across arrays (i.e. range of abundance should be the same). It works by 
taking some indicative points, or quantiles, at regular intervals from the overall 
distribution function and dividing the sample population into equally numerous 
subsets. Next, after splitting the distribution, genes in the upper or lower range of 
intensities are transformed into the same distribution shape in order to have a 
common distribution of intensities. This is done as you would expect the 
frequency/proportion of poorly and highly expressed genes to be the same, whilst 
the expression of individual genes can change across the analysed arrays (i.e. 
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experimental conditions). Parameter settings passed to function 'rma' to perform 
Robust Multi-array Average (RMA) normalisation were as follows: 
background="antigenomic" (i.e. internal control probe sets used to estimate the array 
background signal), option="transcript",exonlevel="core+affx". RMA is a well-
established method [513] to perform the standard preprocessing steps of Affymetrix 
arrays. These include: background adjustment (i.e. definition of the background 
intensity value by using internal control probe sets), intra-array normalisation (i.e. 
normalisation of the signal intensity values across repeated probe set spots on the 
array), and summarisation procedures (i.e. summary quantification of a single 
intensity value for each probe set represented on the array based on the fitting of a 
linear model to the intra-array normalised data). Finally, present/absent calls and P-
values were obtained applying function 'dabg.call' from the same xps package. For 
each probe set, this function generates a detection P-value based on comparing the 
perfect match (PM) probe intensity values to the intensity distribution provided by 
background probes sharing the same GC-content as the PM probe under 
consideration. The same function was also used to compute summary expression 
levels for transcript clusters (i.e. probe sets mapping to the same transcript cluster 
identifier). 
Normalised and transcript-cluster summarised expression data (n=28,926 
transcript cluster ids) were then filtered to remove low-intensity features as well as 
features lacking unambiguous annotation to a gene symbol (i.e. probe sets that are 
associated with no gene symbol or cannot be mapped to exactly one gene symbol). 
Generic filtering details were as follows: (A) require Affymetrix 'Present' call in all 
samples (n=23,204 transcript-cluster ids passing filter); (B) require unique mapping 
to a gene symbol according to the current NetAffx (the official Affymetrix on-line 
resource database storing array annotations and thus enabling the correlation of 
array results with array design and annotation information) release note (Release 32, 
June 2011) (n=19,449 transcript-cluster ids passing filter). Overall 16,934 transcript 
cluster ids, interrogating 16,148 unique genes, passed the generic filtering and were 
used in further analyses. 
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2.2.10.5 Differential expression analysis 
Two sample t-tests (function 't.test' from the R package 'stats') were applied to 
each Affymetrix transcript-cluster identifier and miRNA identifier included in our 
filtered expression datasets to compare expression in cancer and normal samples. 
The P-values were adjusted to account for multiple testing using the Benjamini-
Hochberg method (function ‘p.adjust' from the R package 'stats’). An adjusted P 
value <0.05 was considered significant.  
 
2.2.11 Oncomine and GEO2R analysis 
 Oncomine’s gene search function was used to assess the differential expres-
sion of a selected gene across all available datasets (updated September 2012; 
https://www.oncomine.org/resource/login.html). We searched for PDCD4, BTG2, and 
NEDD4L in human cancer using the following threshold values: P value of <0.05, 
fold change of 1.5 and gene rank in the top 10% among all differentially expressed 
genes. Oncomine then listed all differential expression analyses in which these 
genes were included. For each listed analysis, the statistical results were provided 
and linked to the original microarray dataset. We then examined the 8 PDAC 
datasets for each transcript. Next, using GEO2R [514], we examined a recently 
published dataset (GSE28735 [515] ) that became publically available from July 
2012 and is not yet included in the Oncomine database. This dataset contains 
microarray gene-expression profiles for 45 pairs of tumour and adjacent non-tumour 
tissues from 45 patients with PDAC. We searched for each gene (BTG2, 
transcript_cluster_id 7908917; PDCD4, transcript_cluster_id 7930454; and NEDD4L, 
transcript_cluster_id 8021376) and extracted expression values for each pair of 
patient samples. 
2.2.12 Gene ontology (GO) and KEGG pathway analyses of mRNA 
expression 
We used the GeneAnswers Bioconductor package to perform enrichment 
analysis of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and GO 
terms (biological process) upon the list of protein-coding genes deregulated in PDAC 
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(Benjamini-Hochberg adjusted t-test P-value <0.05). The reference set for the 
functional enrichment used by the package is the human annotated genes. Adjusted 
P-values <0.05 were taken as significant. A selection of the top enriched GO 
biological processes and KEGG pathways for genes can be seen in Figure 30. 
Cytoscape (http://www.cytoscape.org/) is an open source software platform 
for visualising complex networks and integrating these with any type of attribute data. 
This software was used to visualise the putative tumour suppressor network 
regulated by miR-21, 23a and 27a (Figure 43). Using Panther 
(http://www.pantherdb.org/), the union set of putative target genes of miR-21, miR-
23a or miR-27a/b, based on the occurrence of one or more seeds for at least one of 
these miRNAs in the mRNA 3'UTR and opposite regulation in cancer (i.e. up-
regulation of the miRNA; down-regulation of the mRNA), were annotated to GO 
biological processes (pie chart can be seen in Figure 44). 
 
2.2.13 Computational analyses of miRNA-mRNA interactions to 
identify functionally relevant miRNAs 
To prioritise functionally relevant miRNAs in PDAC for further experimental 
studies, we performed a seed enrichment analysis that was tissue and tumour 
specific. MiRNAs are predominantly negative regulators of mRNA expression and 
the seed region (i.e. nucleotides 2-7 at the 5' end of the mature miRNA sequence) 
plays a dominant role in target mRNA recognition [205]. We tested our lists of 
deregulated genes in PDAC for enriched frequency (Fisher’s one-tailed exact test) of 
mRNAs carrying a seed match in their 3'UTR for each mature miRNA significantly 
deregulated in our initial cohort and in accordance to the anti-regulation paradigm. 
We specifically tested seed enrichment of up-regulated miRNAs among down-
regulated mRNAs and vice versa.  
 A database of 3'UTR sequences for protein-coding mRNAs in our dataset was 
created querying the Ensembl gene database (Homo sapiens genes GRCh37.p8) by 
using the R/Bioconductor interface [516] to the BioMart data portal 
(http://www.biomart.org/). The list of identifiers used to retrieve 3'UTR sequences 
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included 15,488 RefSeq 'NM' identifiers (http://www.ncbi.nlm.nih.gov/RefSeq/) ('NM' 
identifies for a single protein coding transcript) matching 14,900 unique Entrez Gene 
ids (http://www.ncbi.nlm.nih.gov/gene). NetAffx release note (Release 32, June 
2011) was used to annotate the transcript cluster ids in our filtered expression 
dataset to RefSeq 'NM' identifiers. After removing RefSeq ids lacking an available 
3'UTR sequence, as well as entries with annotated 3'UTR sequence shorter than 
100 nucleotides (because these are more likely to originate from incomplete gene 
annotation rather than to constitute genuine 3'UTR sequences), we removed residual 
redundancy, due to the existence of multiple annotated sequences, by retaining only 
one 3'UTR sequence for each Entrez Gene identifier. The resulting database used 
for the seed enrichment analysis includes 13,885 3'UTR sequences matching as 
many unique Entrez Gene ids and is available on request.  
 We recorded in the above 3'UTR sequence database all occurrences of short 
sites which perfectly complement the miRNA seed region (both position 2 to 7: '6-
mer seed' and position 2 to 8: '7-mer seed') of our list of differentially expressed 
miRNAs (Figure 28A) using the R/Bioconductor package 'microRNA' and functions 
there-in. To evaluate overlap with existing target predictions and help prioritize a list 
of putative target genes for experimental validation, we used the miRanda-mirSVR 
database (release of August 2010; 'Good mirSVR score' dataset; 
http://www.microrna.org/microrna/home.do) [230] (i.e. we highlighted those 
interactions identified from our investigations based on the simple presence of seed 
that are also predicted by the miRanda-mirSVR algorithm). Figure 31 shows results 
of the seed match analysis for up-regulated miRNAs (n=18, Benjamini-Hochberg 
adjusted t-test P-value <0.05) and top down-regulated mRNAs (n=152, Benjamini-
Hochberg adjusted t-test P-value <0.05; log-ratio of mean signal intensity in cancer 
vs. normal ≤ -1; mean signal intensity in cancer and/or normal samples ≥500). 
 Based on the model that miRNAs act as negative regulators of target mRNAs, 
we assayed our lists of deregulated genes and miRNAs in PDAC for enrichment in 
the frequency of mRNAs carrying a seed match (i.e. site complementary to the 
miRNA seed region) in their 3'UTR compared to remaining genes and in accordance 
to the anti-regulated paradigm. One-tailed Fisher's exact test was used to test for the 
enriched proportion of mRNAs with a seed match (i.e. complementary to the miRNA 
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seed region) in their 3'UTR in the selected group (i.e. down-regulated genes when 
testing with up-regulated miRNAs and up-regulated genes when testing with down-
regulated miRNAs) compared to the rest of the gene list (all-but-down-regulated 
genes or all-but-up-regulated genes, respectively). We selected for a Benjamini-
Hochberg adjusted P-value <0.05 and an absolute log-ratio of ≥1 of PDAC vs. NP 
samples mean intensity signal to define lists of top deregulated genes to be used in 
the analysis (n=1,328 deregulated genes: 348 down-regulated genes, 980 up-
regulated genes) (Figure 28B). Test results for 6-mer and 7-mer seeds are shown in 
Table 24. To prioritise miRNAs for investigation, we chose the 3 miRNAs that were 
significant at the 6-mer level (i.e. miR-21, miR-23a and miR-27a). At the 7-mer level, 
only miR-23a was significant (based on a cut-off of P<0.05). Both miR-27a and miR-
27b were significantly enriched in our seed enrichment analysis (Table 24). We 
chose to use miR-27a as a molecular treatment and biomarker, as both these 
miRNAs have identical seed regions (from nt 2-8; http://www.mirbase.org) and are 
therefore able to target the same mRNAs. Actually the only difference between these 
two miRNAs is one nt (http://www.mirbase.org; Figure 13). Even if an undiscovered 
mechanism makes the change in that single nt relevant for their regulation of gene 
targets, we chose miR-27a as it has been previously shown to be important in 
PDAC. 
 
Figure 13 - Mature miR-27a has the same seed region as miR-27b. 
The seed region is highlighted in orange and the single nucleotide that differs between the 
two miRNAs is shown in red. 
 
Gene targets with a 7-(oligo) mer or a conserved seed match in vertebrates 
were chosen for further investigation. MEDLINE and Google Scholar were searched 
in order to identify tumour suppressors from the enriched list that are known to be 
involved in gastrointestinal or PDAC tumourigenesis. 
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2.2.14 Array data deposition 
Raw and processed array expression data has been deposited at the Gene 
Expression Omnibus (GEO) repository (http://www.ncbi.nlm.nih.gov/geo/) which is 
publically accessible. We can confirm all details are MIAME compliant. The data for 
Chapter 3 are under accession number GSE29352; and the data for Chapter 4 are 
under accession number GSE41372 (miRNA and gene microarray). 
 
2.2.15 In vivo studies 
We performed an in vivo tumourigenicity assay in nude mice bearing 
orthotopic human PDAC xenografts. Four-week-old female BALB/c nude mice were 
purchased (Charles River Laboratories, Margate, UK) and maintained in specific 
pathogen-free conditions. To create the subcutaneous human PDAC tumour 
xenograft model, MIA PaCa-2 or PANC-1 cells were subcutaneously, bilaterally 
inoculated (5x106 cells suspended in a 1:1 mixture of 10% FBS-DMEM/Matrigel [BD 
Biosciences], at a total volume of 0.1 mL per site) into the flanks of athymic mice. 
The animals were monitored for activity, physical condition, determination of body 
weight and measurement of tumour volume [1/2 x (the major axis) x (the minor axis) 
2] twice a week. 
To measure the tumours accurately, mice were given a quick inhalation 
general anesthetic with isoflurane and oxygen to ensure that the mice were still and 
digital calipers were used. When the tumours reached a volume of 50mm3 (Day 0; 
approximately 2 weeks after the initial inoculation with PDAC cells), mice were 
randomised into 2 groups (n=6 in each group) to receive IT injections of anti-miRs 
(group 1: anti-miR-NC to the left flank and anti-miR-21 to the right flank; group 2: 
anti-miR-NC to the left flank and anti-miR-21/23a/27a to the right flank).  
Atelocollagen (Atelogene Local Use; Koken, Tokyo, Japan) has been shown 
recently to be a useful system for the efficient delivery of siRNA and miRNA 
molecules into tumours in vivo [517-519]. It has been pretreated with pepsin to 
remove the telopeptides thereby reducing most of the collagen’s antigenicity 
http://www.kokenmpc.co.jp/english/support/tecnical/collagen/index.html). 
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Atelocollagen has not been found to have any unspecific toxic effects on cell growth 
[518]. Complexes of the indicated anti-miR or anti-miR-Negative Control (NC) with 
atelocollagen were prepared according to the manufacturer's instructions. The final 
concentration of anti-miR was 12 µM in a 50 µL injection volume for each tumour (for 
the triple combination each anti-miR was 4 µM).  
One IT injection was administered every week for 3 weeks, followed by a 3 
week rest period, then another treatment cycle and finally mice were sacrificed 3 
weeks after the last IT injection. The whole experiment lasted 12 weeks. Tumours 
were harvested, immediately snap frozen in liquid nitrogen and stored at -80°C until 
required. To perform the IT injection, mice were given a quick inhalation general 
anesthetic with isoflurane and oxygen. The site of injection was disinfected and 
forceps were used to hold the tumour. The needle was then directly inserted and the 
tumour was penetrated until the tip reached the center. The solution was then slowly 
pushed into the tumour. The needle was then slowly pulled back, but not out of the 
tumour, and left in the tumour for about 20 seconds. Finally, the needle was slowly 
pulled out of the tumour and the puncture site in the skin pinched with fine forceps to 
avoid any leakage. No death, loss of body weight or gross adverse effects occurred 
in the mice as a result of treatment with the anti-miR-atelocollagen complexes. 
Ethical constraints prevented xenografts growing past 400mm3. 
2.2.16 Immunohistochemical analysis 
Either sections (4 μm) from FFPE blocks of PDAC surgical resections were 
prepared for immunohistochemical examination (Chapter 3) or sections from a 
tissue microarray (TMA) were used. The validation PDAC TMA used in Chapter 4 
has been previously detailed [520] and represents an independent, nonoverlapping 
cohort of patients.  
After deparaffinisation and rehydration, antigen retrieval was performed by 
boiling in 10 mmol/l of citrate buffer (pH 6.0) for 10 min. After inhibition of 
endogenous peroxidase activity for 30 min with methanol containing 0.3% H2O2, the 
sections were blocked with 2% BSA in PBS for 30 min and incubated with antibodies 
against same antibodies used for Western blotting (Table 13). The immune complex 
was visualised with the Dako REAL EnVision Detection System, Peroxidase/DAB, 
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Rabbit/Mouse (Dako, Cambridgeshire, UK), according to the manufacturer’s 
procedure. The nuclei were counterstained with hematoxylin. Representative 
photographs were taken and two pathologists (Dr Raida Ahmad and Dr Patrizia 
Cohen) scored the slides for protein expression. 
In order to accurately describe the extent of immunohistochemical (IHC) 
staining of a tumour core within the TMA (Chapter 4), the degree of IHC staining in 
each sub-cellular compartment in tumour cells was captured for each analyte. Thus 
we captured the percentage of tumour cells stained at each intensity level. An 
intensity scale ranging from 0 for no staining to 3+ for the most intense staining was 
used. This information was used to calculate a variable (H-Score), more continuous 
than simply positive versus negative[521]. This semi-quantitative H-score is more 
representative of the staining of the entire tumour on the section. The H-Score is 
calculated for staining of each sub-cellular compartment using the following formula:  
H-Score = (% at 0) * 0 + (% at 1+) * 1 + (% at 2+) * 2 + (% at 3+) * 3 
The H-score produces a continuous variable that ranges from 0 to 300. The median 
H-score was then used to dichotomise patients into those with high or low protein 
expression. Survival curves and analyses were performed as described before. 
 
2.2.17 Cell proliferation assay  
In order to assess the effects of miRNAs on cell growth, PANC-1 and MIA 
PaCa-2 PDAC cells were seeded onto 24-well plates (2.5 × 104 and 5 × 104 cells 
per well respectively) in triplicate. LPc006 and LPc167 PDAC cells were seeded onto 
24-well plates (both 2 × 104 cells per well) in triplicate. The day after, cells were 
transfected with either miRNA inhibitor (anti-miR) or a non-targeting negative control 
inhibitor (anti-miR-NC; Applied Biosystems). The final concentration was kept 
constant (90 nM) for either single, double or triple anti-miR transfection and the anti-
miR-NC (e.g. for 2 anti-miRs the final concentration was 45 nM for each and 90 nM 
was used for the anti-miR-NC). To measure the cell proliferation in culture, the 
numbers of cells were counted manually after 1, 2, 3, 4 and 5 days of incubation 
using a hemacytometer (Hawksley, West Sussex, UK) [522]. This was done in 
combination with trypan blue to stain dead cells in the culture sample.  
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2.2.18 Statistical analyses 
The differential miRNA expression between tissues for all RT-qPCR and 
Western blotting data was analyzed using the parametric t-test (unpaired, 1-tailed for 
validation, otherwise unpaired, 2-tailed was used) with GraphPad Prism 5.0 
(GraphPad Software Inc, San Diego, California). The immunohistochemistry data 
was analysed using a 3x3 contingency table and the Fisher’s exact test (2-tailed). 
Where required, the P-values were adjusted for multiple testing with the Bonferroni 
correction. Experiments were performed at least three times. Values represent the 
mean of triplicate samples and standard deviations (SD) of the mean unless 
indicated otherwise. Cell-proliferation experiments were analysed by one-way 
ANOVA adjusted by Tukey test. All reported P-values were rated significant if <0.05. 
2.2.19 Survival analyses  
Functionally relevant miRNAs were measured in patient samples (n=91). 
Each miRNA was also associated with clinicopathological data. The χ2 test was used 
for univariate comparisons between 2 groups. Then by dichotomising expression of 
individual miRNAs into high and low expression, using the median value as a cut-off, 
we associated expression with overall cancer-specific survival (OS) following 
pancreaticoduodenectomy (PD) surgery (i.e. from date of surgery to date of death or 
follow-up). Survival curves were constructed using the Kaplan-Meier method and 
differences in survival were compared by log-rank test. In this way, high and low risk 
groups based on miRNA expression profiles were determined. Thus survival analysis 
was done using a univariate log-rank test for each clinical covariate to assess their 
influence on outcome. A multivariate Cox proportional hazard regression analysis 
was then used to adjust for competing risk factors and the significant HRs (with 95% 
CIs) were reported as an estimate of survival risk. Univariate predictors with two-
sided P values ≤0.05 were included in the multivariate model and backward 
elimination was applied to obtain a final model; two-sided P values ≤0.05 were 
considered significant. All statistical analyses were done using SPSS 20.0 (IBM, 
SPSS). 
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CHAPTER 3: miRNAs Targeting Oncogenes are 
Down-Regulated in Pancreatic Malignant 
Transformation from Benign Cystic Tumours 
 
3.1 Background 
Cystic lesions of the pancreas can be either inflammatory or proliferative 
[523]. Differentiation between low and high-risk pre-malignant tumours can be 
difficult and the consequences of missing the chance for a curative procedure in 
patients who are suitable for pancreatic surgical resection can be devastating [523]. 
To prevent this, many centres recommend routine excision of all suspicious 
pancreatic cystic lesions exposing patients with benign disease to the unnecessary 
risks associated with major pancreatic surgery [523]. The incidence of pancreatic 
benign cystic tumours (BCT) is increasing due to the liberal use and improved 
resolution of cross-sectional imaging and they are often identified coincidentally 
[524-526]. However, none of the currently available imaging modalities are reliable 
enough to distinguish benign from malignant lesions [527, 528]. As a result, the 
management of this condition is often controversial and time consuming, and there 
are regularly updated guidelines to help clinicians [529].  
Out of the true cystic tumours, the most encountered are serous 
cystadenomas (32%-39%), mucinous cystic neoplasms (MCNs) (10%-45%), and 
intraductal papillary mucinous neoplasms (IPMNs; 21%-33%) [530]. These can be 
further classified into non-mucinous tumours with low malignant potential, such as 
the serous microcystic and macrocystic adenomas (SMCAs), and those with high 
malignant potential, such as IPMNs and MCNs (Figure 14) [530-532]. The latter 
have the potential to give rise to in situ or invasive carcinoma, via an adenoma-
carcinoma sequence [524, 532, 533].  
IPMNs are mucinous cystic lesions that is connected to the native pancreatic 
(main or side-branch) ducts [534]. In contrast, MCNs are separate from the ductal 
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system [534, 535]. Main branch IPMN lesions carry the highest percentage of 
malignancy, ranging between 57-92% and side-branch IPMN between 6-46% [535, 
536]. Invasive malignancy arising on the background of an IPMN, termed carcinoma-
ex-IPMN (CEI), is more common in main branch IPMN and approaches 60% [535]. 
In comparison to IPMN lesions, MCNs have a malignant potential ranging from 6-
36% [532, 537]. 
Currently, there is an urgent need to develop better techniques to diagnose 
PDAC at an early stage, that are also capable of differentiating benign from pre-
malignant and malignant pancreatic cystic tumours. A correct preoperative diagnosis 
and evaluation of pancreatic benign cystic tumours (BCT) is crucial for clinical 
decision-making to sieve out those lesions that are already malignant or have a high-
risk malignant potential for whom urgent surgical intervention is required [538]. In this 
study [539], we attempted to identify miRNAs markers of malignant transformation in 
pancreatic BCTs.  
 
 
 Figure 14 - Cystic tumours of the pancreas classified according to origin. 
Our study concentrated on the tumours of epithelial origin in order to identify miRNAs which 
may be involved in the development of early neoplasia and pancreatic ductal 
adenocarcinoma (PDAC).  
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3.2 Results section 
3.2.1 Microarray expression profiles reveal general miRNA down-
regulation in PDAC compared to low malignant potential Benign 
Cystic Tumours 
In order to distinguish the various types of pancreatic cystic tumour (Figure 
14), miRNA expression profiling was performed using total RNA derived from FFPE 
tissues of low and high malignant potential BCT and adenocarcinoma (CEI and 
PDAC). The miRNA microarray (febit) aimed to detect differential expression 
between pancreatic tumour types (Tables 17-20). The comparisons were: 
 
 PDAC versus Serous Microcystic Adenoma (SMCA; low malignant 
potential) 
 PDAC versus Mucinous Cystic Neoplasm (MCN; high malignant 
potential) 
 PDAC versus IPMN (high malignant potential) 
 PDAC versus Carcinoma-Ex-IPMN (CEI) 
 
 It has already been described that PDAC is mainly characterised by miRNA 
up-regulation. Bloomston et al. identified 30 miRNAs up-regulated and 3 down-
regulated in PDAC compared to NP tissue [325]. This suggested that miRNA up-
regulation represents an important event for PDAC progression, but interestingly, 
comparing the miRNA expression levels between the low malignant potential BCT 
and PDAC, we observed general miRNA down-regulation in PDAC (Table 17).  
Hierarchical clustering based on the expression of these miRNAs correctly 
aggregated benign and PDAC cases. The first cluster consists of 80% PDAC, 20% 
CEI and no BCT samples and thus contains predominantly PDAC samples. The 
second cluster contains 41% PDAC, 41% BCT and 18% CEI samples and finally the 
third cluster contains 14% PDAC, 24% CEI and 62% BCT samples, thus consists 
predominantly of BCT samples (Figure 15A). The detected partitioning and 
clustering was statistically significant (P=0.034).  
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Next, miRNA expression profiles of PDAC were compared between different 
types of BCT (Table 17-20) to observe whether it would be possible to distinguish 
between them. Although no significant differential expression of miRNAs was 
identified between the BCT subgroups (i.e. IPMN vs. MCN or SMCA; IPMN vs. CEI – 
data not shown), 21 miRNAs were down-regulated and none were up-regulated in 
PDAC compared to SMCA (low malignant potential BCT; Table 17). Similar results 
were seen when the pooled BCT were compared to PDAC (data not shown). 
 
 
 
Table 17 - Microarray results for PDAC vs. Serous Microcystic Adenoma (SMCA). 
The 30 most deregulated probes (detected by highest absolute value of logarithmised fold 
changes) for PDAC (g1) vs. SMCA (g2; low malignant potential tumour). There is 
widespread down-regulation of miRNAs in PDAC (limma adjp indicates the P-value adjusted 
for multiple testing).  
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Table 18 - Microarray results for PDAC vs. Mucinous Cystic Neoplasm (MCN). 
The 30 most deregulated probes (detected by highest absolute value of logarithmised fold 
changes) for PDAC (g1) vs. MCN (g2; high malignant potential tumour). No significant 
difference in miRNA expression profile was shown between these 2 tissue types (limma adjp 
indicates the P-value adjusted for multiple testing).  
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Table 19 - Microarray results for PDAC vs. Intraductal Papillary Mucinous Neoplasm 
(IPMN). 
The 30 most deregulated probes (detected by highest absolute value of logarithmised fold 
changes) for PDAC (g1) vs. IPMN (g2; high malignant potential tumour). No significant 
difference in miRNA expression profile was shown between these 2 tissue types (limma adjp 
indicates the P-value adjusted for multiple testing).  
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Table 20 - Microarray results for Carcinoma Ex-IPMN (CEI) vs. PDAC. 
The 30 most deregulated probes (detected by highest absolute value of logarithmised fold 
changes) for PDAC (g1) vs. IPMN (g2; high malignant potential tumour). No significant 
difference in miRNA expression profile was shown between these 2 tissue types (limma adjp 
indicates the P-value adjusted for multiple testing).  
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Figure 15 - A subset of miRNAs are down-regulated in PDAC compared to Benign 
Cystic Tumours (BCT). 
(A) Hierarchical Clustering Heatmap was created to detect possible clusters in rows 
(transcripts) and columns (samples) of the normalised expression matrix. For this analysis 
we used the 35 miRNAs with highest overall variability. As the heatmap shows, with its 
dendrogram on top and the contingency table at the bottom, we detected three clusters 
indicated by the solid blue lines. As indicated in the table underneath the heatmap, the first 
cluster consists of 80% PDAC, 20% CEI and no BCT samples and thus contains 
predominantly PDAC samples. The second cluster contains 41% PDAC, 41% BCT and 18% 
CEI samples. Subdividing it into two additional clusters, as indicated by the dashed blue 
lines, we see that the left part consists predominantly of CEI, whilst the right part entails a 
slight enrichment for BCT samples. Finally, the third cluster contains 14% PDAC, 24% CEI 
and 62% BCT samples, thus consists predominantly of BCT samples (P=0.034). (Red 
indicates high intensity; green indicates low intensity; PDAC, Pancreatic Ductal 
Adenocarcinoma; CEI, Carcinoma-Ex-IPMN; BCT, Benign-Cystic-Tumours). (B) miR-21 (C) 
miR-126 and (D) miR-16 were measured using RT-qPCR, performed on the 43 FFPE 
tissues in order to validate the microarray data. Samples included: SMCA (n=7), MCN (n= 
6), IPMN (n=7), and CEI (n=9) and PDAC (n=14). (Results presented as mean±SEM; 
***P=0.003, **P=0.02 and *P=0.05 respectively). MiRNA levels were normalised to 
endogenous U6 and U47 snRNAs and miR-191 levels. 
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3.2.2 RT-qPCR validates the microarray results  
To confirm the microarray results, we performed TaqMan RT-qPCR and 
normalised miRNA expression levels using snRNA U6, snoRNA U47 and also miR-
191 (as this miRNA did not change across tumour types in the microarray). All of the 
controls reached the same statistical significance. Since their deregulation is 
important for cancer progression, miR-21 [306, 313], miR-126 [540] and miR-16 
[541] were selected for further RT-qPCR validation, furthermore miR-126 and miR-
16 have not been well studied in PDAC. Let-7 was not validated as the role of the let-
7 family in PDAC has been previously reported [286]. RT-qPCR was performed with 
the same RNA as used in the microarray. Interestingly, this revealed that there was 
no significant change of miR-21 between the BCT types (Figure 15B), whilst miR-
126 and miR-16 were significantly down-regulated in PDAC compared to SMCA (low 
malignant potential BCT; Figures 15C and D).  
 
3.2.3 miR-21 is up-regulated in PDAC and SMCA compared to non-
tumour samples 
As miR-21 is well described as being up-regulated in PDAC compared to 
normal tissues [325], we used NP to confirm the up-regulation of miR-21 in PDAC 
and to examine expression levels of the other selected miRNAs. RNA from a panel 
of fresh non-tumourous and PDAC tissues samples (n=24) was extracted in order to 
measure miRNA expression levels by RT-qPCR. We confirmed that miR-21 was 
significantly up-regulated in PDAC (P<0.001) compared to NP (Figures 16A). 
However, no significant changes were found in the expression levels of miR-126 and 
miR-16 between fresh NP and PDAC tissues (Figures 16B and C), but we did 
confirm by RT-qPCR that there was significant down-regulation of miR-126 and miR-
16 between SMCA (low malignant potential BCT) and PDAC in the FFPE samples 
(Figures 15C and D). 
In order to investigate the similar miR-21 levels in BCTs and PDAC, we 
performed a further RT-qPCR validation by using the same RNA from the FFPE 
SMCA samples and some RNA isolated from paraffinised fresh NP samples. 
Interestingly, using these FFPE NP samples we confirmed that miR-21 was up-
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regulated in PDAC (n=14), as well as in SMCA (n=7), compared to NP (n=4; Figure 
17). This indicates that the expression of miR-21 is an early event, and may be able 
to initially increase pancreatic cell proliferation, but not malignant transformation. 
 
 
Figure 16 - miR-21, 126 and 16 levels in 
fresh normal pancreas compared to 
PDAC measured by RT-qPCR. 
(A) miR-21, (B) miR-126 and (C) miR-16 
were measured using RT-qPCR in order to 
compare PDAC to normal pancreas for the 
miRNAs of interest. MiR-21 is 
overexpressed in PDAC compared to normal 
pancreas tissue (*** P<0.001). MiR-126 and 
miR-16 expression levels were not 
significantly different between PDAC and 
normal pancreas. MiRNA levels were 
normalised to endogenous U6 and U47 
snRNAs and miR-191 levels. Samples 
included: normal pancreas (n=9) and PDAC 
(n=15). Box and Whiskers indicate median, 
minimum and maximum. 
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3.2.4 miR-16, miR-126 and let-7d modulate the expression of 
pancreatic cancer oncogenes 
Our microarray analysis revealed that many of the miRNAs found to be down-
regulated in PDAC compared to SMCA (low malignant potential BCT) potentially 
regulate the expression of genes which promote malignant transformation. PDAC is 
characterised by the deregulation of many proto-oncogenes, among which KRAS is 
a driver [542], but others such as HMGA2, BCL2 and CRK can also be critical [542-
545]. Using TargetScan, we identified that miR-16 and miR-126 have highly 
conserved binding sites in the 3’UTRs of BCL2 and CRK respectively (Figure 18). 
As we could not see miR-126 and miR-16 down-regulated in our fresh PDAC 
samples compared to NP (Figures 16B and C), we performed data-mining of a 
publically available dataset (GSE24279) of miRNA expression profiling results which 
contains a large cohort of PDAC (n = 136) and NP tissue samples (n=22). These 
data revealed that both miR-16 and miR-126 levels are significantly reduced in 
PDAC (Figure 19A and C). 
Next, we found that KRAS and BCL2 protein levels are significantly up-
regulated in PDAC patients (Figure 20A and B). Although no significant change was 
observed at the mRNA level for KRAS (Figure 20C), suggesting that post-
transcriptional regulation may be occurring in PDAC which could be mediated by the 
miRNA pathway. Moreover, it is already known that KRAS and HMGA2 are 
repressed by the let-7 family (family of miRNAs that we also found to be down-
Figure 17 - RT-qPCR confirmed miR-21 
overexpression in PDAC and SMCA 
compared to normal pancreas. 
This suggests that miR-21 overexpression 
may be an early event in the formation of 
pancreatic BCT from normal pancreas. MiR-
21 was unable to differentiate PDAC from 
SMCA and therefore it may be questionable 
as a future biomarker of PDAC. RNA was 
isolated from FFPE samples for all 3 tissue 
types. MiRNA levels were normalised to 
endogenous U6 and U47 snRNAs and miR-
191 levels. Results presented as 
mean±SEM. 
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regulated in PDAC; highlighted in black in Table 17) in PDAC and other cancers 
[546]. The levels of KRAS mRNA have also been found to vary widely in CRC 
despite consistent up-regulation of KRAS protein levels [547].  
However, we could not find any significant difference in CRK protein levels 
when comparing NP and PDAC patient samples (Figure 20A and B). We therefore 
performed immunohistochemical analysis using a larger sample size, also containing 
SMCA cases, to stain for CRK protein directly on the tissue. This identified increased 
CRK protein levels in PDAC compared to the BCT and NP, indicating a possible 
regulatory role of miR-126 in pancreatic tumours. Representative sections of CRK 
protein levels in the different pancreatic tissues can be seen in Figure 21. Analysis 
using Fisher’s Exact test indicated a statistically significant difference in CRK 
staining intensity between PDAC, NP and SMCA (P=0.0048).  
 
Figure 18 - miRNAs that putatively interact with 3’UTR of CRK, KRAS and BCL2 genes 
using TargetScan algorithm. 
MiR-126 putatively interacts with CRK 3’UTR and miR-15a/16 with BCL2 3’UTR (BLACK 
boxes). MiR-126 and let-7 are not predicted to target the KRAS 3’UTR. However, miR96, 
217 and 143/145 have been shown to interact with KRAS 3’UTR (BLACK boxes). 
Interestingly, KRAS is also a predicted target of miR-27a (GREEN boxes; see Chapter 4). 
Figure adapted from the TargetScan website. 
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Figure 19 - Data-mining confirms that miR-16 and miR-126 are down-regulated in 
PDAC compared to normal pancreas. 
Using a publically available dataset (GSE24279) we examined (A) miR-16, its family 
member (B) miR-15a and (C) miR-126 expression in a large cohort of PDAC patients and 
normal pancreas samples. This dataset contains miRNA expression profiling results from 
tissue samples: PDAC (n = 136), and normal pancreas (n=22). Due to an approximate 
normal distribution, the non-parametric Mann-Whitney U test was used to compare miRNA 
levels between tissue-types. Patients included in this study were of stages II, III and IV. 
Scatterplots are shown for each miRNA and the horizontal line represents the median 
expression level and inter-quartile range (***P<0.001). 
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Figure 20 - BCL2, CRK and KRAS expression levels in PDAC and normal pancreatic 
tissue. 
(A) Western Blots showing protein levels of BCL2, CRK, KRAS and GAPDH in PDAC (n=9) 
fresh tissue samples compared to normal pancreas (n=9). (B) Bar chart showing mean 
relative protein levels of the Western Blots analyzed by densitometric scanning after 
normalisation to GAPDH (*BCL2 levels in PDAC vs. Normal P=0.03; **KRAS levels in PDAC 
vs. Normal P=0.0003). (C) RT-qPCR performed on the same fresh tissue samples showing 
KRAS mRNA levels in PDAC (n=6) compared to normal (n=6) after normalisation to GAPDH 
(mean±SD). 
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Figure 21 - Immunohistochemical analysis of CRK expression in pancreatic tissues. 
Paraffin sections were analysed using anti-CRK antibody and counterstained with 
haematoxylin. Cytoplasmic staining (brown) was observed in PDAC and normal pancreas, 
but not in SMCA. Original photographs were taken at magnification 20x. Staining intensity 
was measured as 0 for no expression, 1+ for weak expression and 2+ for moderate 
expression. Bar charts indicate the % in each category for each tissue type. A 3x3 
contingency table was created and analysed using the Fisher’s Exact test to reveal a 
significant difference between the 3 tissue types (i.e. increased CRK expression in PDAC > 
normal pancreas > SMCA; P=0.0048). 
 
Thus, our investigations have shown that miR-16 and miR-126 are down-
regulated in PDAC (Table 17; Figure 19A and C), and accordingly that their targets, 
BCL2, KRAS and CRK are up-regulated or de-repressed in PDAC (Figure 20A, 20B 
and 21). It is known that miR-16 regulates BCL2 expression and acts as a tumour 
suppressor miRNA (TS-miR) in prostate cancer and chronic lymphocytic leukemia 
(CLL) [257]. Thus, indicating that there may be a role for miR-16 loss in pancreatic 
tumourigenesis. Furthermore, it has been shown that miR-126 directly regulates the 
expression of CRK in NSCLC [548], gastric [549] and BC [550], and we showed 
elevated expression of CRK in PDAC compared to NP and SMCA (Figure 21). CRK 
is a component of the focal adhesion complex that is involved in integrin signalling 
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and high levels of CRK have been associated with an aggressive phenotype of 
carcinomas [550]. Therefore, failure to repress expression of this oncogene by loss 
of miR-126 may be important in pancreatic neoplasia. 
In order to evaluate whether any of these miRNAs down-regulate the 
expression of these oncogenes in PDAC, the miRNAs were first overexpressed, by 
transfecting mimics into MIA PaCa-2 and PANC-1 PDAC cell-lines followed by 
Western blot analysis. Overexpression of miR-16 down-regulated BCL2 expression 
compared to the overexpressed negative control in both MIA PaCA-2 (Figure 22A 
and B) and PANC-1 cell lines (Figure 23A). Furthermore CRK levels were reduced 
by miR-126 overexpression in the same cell lines (Figure 22A, 22B, and 23A) and 
surprisingly, KRAS was down-regulated not only by let-7d (used as a positive 
control), but also by miR-126 in MIA PaCa-2 cells (Figure 22A and B).  
As it is well documented that the tumour suppressor let-7 family regulates 
KRAS in PDAC [286, 354], lung cancer [270], CRC [352] and BC [353], we 
concentrated our investigations on miR-126 as a novel KRAS targeting miRNA in 
PDAC (Figure 18). To this end we performed loss-of-function experiments using 
specific miRNA inhibitors to further validate this finding. We demonstrated that in 
contrast to miR-126 overexpression, the inhibition of mature miR-126 increases both 
KRAS and CRK protein levels in MIA PaCa-2 cells (Figure 22C and D), but not in 
PANC-1 cells (Figure 23C). However, we could not see any difference in KRAS 
mRNA levels after transfection with either pre-miR-126 or anti-miR-126 (Figure 22E 
and 23B); this suggests that miR-126 probably acts by inhibiting protein translation, 
rather than degrading the KRAS mRNA. The data herein demonstrate that the down-
regulation of multiple miRNAs in PDAC may contribute to malignant transformation.  
  
 178 
 
 
Figure 22 - Down-regulated miRNAs allow increased expression of crucial PDAC 
oncogenes. 
(A) Western Blots showing expression levels of BCL2, CRK and KRAS oncogenes in MIA 
PaCa-2 cells. Transfection was performed for 48 hours with precursor miR-16, miR-126 and 
let-7d. GAPDH was used as an endogenous loading control. These are representative blots 
derived from three biological replicates (NC, negative control). (B) Densitometric western 
analysis. Bar diagram of density ratio (protein / GAPDH). Negative control (NC) was set to 1 
(*P<0.05; **P<0.01). (C) Western Blots showing increased expression of CRK and KRAS 
oncogenes in MIA PaCa-2 cells after silencing of miR-126 using anti-miR (100nM) 
transfection for 48 hours; (D) Densitometric Western analysis. Bar diagram of density ratio 
(protein / GAPDH). Negative control (NC) was set to 1 (*P<0.05; **P<0.01). (E) The relative 
expression of KRAS mRNA after pre-miR-126 or anti-miR-126 was analyzed using RT-
qPCR. GAPDH was used as a housekeeping control. All data are shown as mean±SD. 
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Figure 23 - Expression levels of BCL2, CRK and KRAS oncogenes in PANC-1 cells. 
(A) Western Blots showing protein levels of BCL2, CRK, KRAS after transfection for 48 
hours with precursor miR-16, miR-126 and let-7d (miRNA mimics). (B) The relative 
expression of KRAS mRNA after pre-miR-126 or anti-miR-126 transfection was analysed 
using RT-q PCR and remained unchanged compared to negative control. GAPDH was used 
as a housekeeping control. All data are shown as mean±SD. (C) Western Blots showing 
protein levels of CRK and KRAS after transfection for 48 hours with miRNA inhibitor (anti-
miR-126). GAPDH was used as an endogenous loading control for all blots. These are 
representative blots derived from three biological replicates (NC, negative control). 
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3.2.5 miR-126 regulates KRAS protein translation by interacting 
with a “seedless” motif in its 3’UTR 
We found that overexpression of miR-126 reduces and conversely its 
silencing increases KRAS protein levels (Figure 22A-D). In order to evaluate 
whether miR-126 directly regulates KRAS, we performed a bioinformatic search of 
potential miR-126 interaction sites in the KRAS mRNA. Using the RNA22 software 
[237] (see section 1.3.1.1 for more detail) and the entire KRAS transcript as the 
input sequence, we predicted two miR-126 binding sites in the 3’UTR with “seedless” 
characteristics (Figure 24A). This means that these interaction sites do not have 
“canonical” features of complete interaction between the 5’ seed region of the 
miRNA [229] and the 3’UTR of the gene, which is known to be important, but not 
essential, for the regulation of the target genes [551]. But instead G-U wobbles were 
present in the complementarity between gene and miRNA seed sequence (Figure 
24A). Interestingly, these two regions appeared evolutionally conserved across 
many species (Figure 24A) and more importantly it has been recently demonstrated 
that miRNAs can regulate gene expression also using "seedless" pairing [551]. For 
these reasons, we went on to clone the two sites that we termed KRAS_A_WT and 
KRAS_B_WT into the 3’UTR of pMIR-REPORT construct along with a mutated 
version of each (Table 15) and co-expressed them with the pre-miR-126 in MIA 
PaCa-2 cells. Overexpression of miR-126 decreased luciferase activity only when 
co-expressed with KRAS_A_WT and not its mutated version (KRAS_A_MUT), and 
neither KRAS_B_WT or its mutated counterpart (KRAS_B_MUT) (Figure 24B). This 
indicated that miR-126 directly regulates KRAS post-transcriptional levels by 
interacting with at least one “seedless” site within the KRAS 3’UTR.  
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Figure 24 - KRAS is experimentally validated as a direct target of miR-126 in PDAC 
cells. 
(A) Putative miR-126 binding sequences in the 3′-UTR of KRAS mRNA. Two different 
fragments from the 3′UTR region of KRAS were cloned downstream of the luciferase 
reporters and named as wild-type (KRAS_A_WT and KRAS_B_WT). Two mutated versions 
of the miR-126 binding site were also generated (KRAS_A_MUT and KRAS_B_MUT); the 
mutated nucleotides of the miR-126 binding site are underlined. Boxed areas represent 
conserved complementary nucleotides of the miR-126 seed sequence in various species 
(Hsa, human; Ptr, chimpanzee; Mml, rhesus; Mmu, mouse; Laf, elephant; Gga, chicken). 
*indicates that KRAS_B_WT is conserved in 16 species. (B) Luciferase reporter assay. Each 
of the 4 plasmids (150ng) and a Renilla luciferase reporter (50ng) were co-transfected into 
MIA PaCa-2 cells with precursor miR-126 (100nM). Luciferase activity was assayed 48 
hours after transfection. All experiments were independently repeated at least three times; 
the results are presented as mean±SD (**P<0.01).  
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3.3 Discussion 
In this study, for the first time, we examined global miRNA expression in all 
the epithelial macroscopic pancreatic BCT (i.e. SMCA, MCN and IPMN), compared 
to PDAC and CEI, by performing a microarray analysis to explore the miRNA-based 
relationship between these lesions. Although the pancreas specific miRNome and 
how it is modified in PDAC has been extensively investigated [325] (Table 4), there 
have been only a limited number of studies that have looked at miRNA expression in 
these pancreatic pre-malignant lesions [442, 444, 445, 449] (Table 7), indicating an 
urgent need for further investigation. The results from our microarray lead us to 
discover two miRNAs, miR-16 and miR-126, as regulators of important PDAC 
oncogenes such as BCL2, CRK and KRAS. 
 
3.3.1 miRNAs can differentiate between benign and malignant 
pancreatic lesions 
We screened for the expression of 866 human miRNAs in 43 pancreatic BCT 
and cancerous lesions using a high-throughput microarray. We hypothesised that by 
profiling a large number of miRNAs, there may be a possibility of creating a panel of 
miRNAs that are differentially expressed, which could subsequently be used as a 
scoring system for diagnosis. Surprisingly, we failed to show any significant changes 
in miRNA expression patterns between the various types of pancreatic BCT (data 
not shown), indicating that miRNA changes may not be obviously involved in 
transitions between the different BCT types in vivo. Thus, whilst we were unable to 
define a miRNA signature for each BCT for potential diagnostic use, there were 
some striking findings from the microarray and its subsequent validation, as will be 
discussed. However, with regards to the microarray experiment, the following should 
be taken into account: 
 Firstly, the various pancreatic BCT are very rare (prevalence reported in the 
literature as between 0.2–2.6% in the asymptomatic general population [552]) 
and the tissues are difficult to obtain as few patients undergo surgical 
resection. This is reflected in our small sample sizes. Thus, whilst we found 
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that there were no statistically significant deregulated miRNAs between many 
of the groups, this is probably a Type II error. 
 Secondly, the FFPE samples used for the microarray were macrodissected 
prior to RNA isolation and LCM was not used. This could have also 
confounded our results since the cellular source of the miRNAs may have 
been contaminated and not indicative of the cystic lesion itself.  
 Thirdly, a major flaw in our study design was that we did not include NP tissue 
in the microarray. These data were therefore difficult to interpret in the context 
of other studies in the literature, as we could not know the miRNAs levels in 
non-neoplastic cells in comparison to the BCTs and PDAC (Figure 15). 
During our subsequent validation experiments, NP was obtained at a later 
date in order to verify miRNA expression levels compared to BCT and PDAC 
(Figure 16 and 17). 
 
More recent studies have demonstrated that miRNA differences can be 
detected between benign and malignant pancreatic cystic tumours. Ryu et al. [445] 
used RT-qPCR to measure miR-21, 155, 17-3p, 191, and 221 in 40 pancreatic cysts. 
The mucinous cysts included 11 IPMN, 3 CEI and 10 MCNs, whilst the non-
mucinous cohort included 11 SCMAs and 5 other benign cysts. They found that up-
regulation of miR-21, 221 and 17-3p can differentiate mucinous vs. non-mucinous 
cystic lesions (i.e. high vs. low malignant potential). Matthaei et al. [444] performed 
high-throughput screening of BCTs (LCM FFPE samples and cyst fluid samples 
included in array). Their FFPE samples included 10 low-grade IPMN and 12 high-
grade and the cyst fluid specimens consisted of 4 SCMAs, 3 low-grade IPMNs, and 
4 high-grade IPMNs. Their microarray identified a 9 miRNA signature (miR-24, 30a-
3p, 18a, 92a, 342-3p, 99b, 106b, 142-3p and 523-3p) that could distinguish 
pancreatic cyst pathology implying the need for surgical resection (i.e. high risk of 
malignancy; high grade IPMNs, pancreatic neuroendocrine tumours [PNET] and 
solid pseudopapillary neoplasms [SPN]) versus low risk lesions that can be 
conservatively managed (i.e. low grade IPMNs and SMCAs). This signature had a 
sensitivity of 89%, and a specificity of 100% (area under the curve, AUC of 1). 
Interestingly, this study did not demonstrate miR-21 to be significantly predictive of 
risk for malignant transformation [444]. Of note, this study did not investigate MCNs 
 184 
 
or SCMAs, and we did not include PNET in our study as these are not cancers of the 
exocrine pancreas. Similarly, whilst SPN are indeed exocrine pancreatic tumours, we 
did not have any samples available for our microarray. 
Panarelli et al. [442] examined expression of 5 miRNAs (miR-21, 221, 181b, 
196a and 217) in FNA biopsy samples (in FFPE) from PDAC (n=38) and benign 
lesions (n=11; comprising CP, n=2; SMCA, n=2; and pancreatic pseudocysts, n=7). 
Using a logistic regression model, they identified a new miRNA classifier (miR-
221+2*miR-196a) which correctly predicted malignancy in 89% of FNA biopsies 
(using cytology as the standard) [442]. However, their model misclassified 3 benign 
cytology specimens as positive for malignancy, and 1 of 9 cancers as negative for 
malignancy [442]. They concluded that the sensitivity and specificity may be 
improved by using fresh biopsies and/or including additional miRNAs in future 
analyses [442]. 
Finally, Henry et al. (Bloomston’s group) [441] performed a custom TaqMan 
microarray of 379 most common miRNAs in 42 pancreatic duct fluid aspirates from 
BCTs. The samples profiled included SCMAs, IPMN, MCN and CEI, although we are 
not told the exact numbers of each, and for their final analysis, BCT were grouped 
into benign, pre-malignant or malignant. They excluded non-neoplastic samples (i.e. 
NP, simple cysts, pseudocysts or CP), PNET or SPN. For their analysis they used 
two miRNAs that were most consistently expressed among all 42 samples as their 
housekeeping genes for normalisation. They found that between benign, pre-
malignant and malignant there was up-regulation of: let-7b, miR-27b, miR-92a, 99a, 
100, 125b, 145 and 483; and down-regulation of miR-212 [441]. Interestingly, and 
similar to our results (Table 17), they found primarily reduced miRNA expression in 
the malignant samples, whilst most of the differentially expressed miRNAs reported 
in PDAC are increased [441]. This may be due to pancreatic BCTs secreting 
different miRNAs into the cystic fluid (i.e. into the centre of the lesion or pancreatic 
duct)[441]. Indeed, during the macrodissection of our BCTs, there certainly would 
have been some cystic fluid trapped in the FFPE process / block, and this may have 
constituted more of the sample than the cyst wall itself, perhaps contributing to our 
findings. Henry et al. [441] also considered that the apparent reduction in miRNAs in 
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the cystic fluid of benign compared to malignant lesions is an artefact of the RNA 
yield; however this should have been corrected during normalisation.  
Other studies have concentrated their attempts specifically on IPMNs only, the 
type of BCT with high malignant potential and also often the most difficult to manage 
clinically. These have revealed that there is indeed a change in miRNA expression 
between NP to IPMN adenoma to adenocarcinoma (CEI) [429, 430]. Recently, 
Lubezky et al. [428] performed macrodissection of FFPE tissues (10 LG IPMN, 5 MG 
IPMN, 5 HG IPMN, 10 CEI, and 5 PDAC), followed by a microarray of 846 miRNAs. 
They found up-regulation of miR-21 and miR-155, but also raised miR-708 and 
reduced miR-217 levels occur during IPMN malignant transformation. Subsequently, 
high tumoural miR-21 levels in CEI have been shown to be associated with poor 
survival outcomes for patients that have had surgical resection [430].  
Thus, miRNA screening has been able to determine miRNA signatures for 
these pre-malignant BCTs, although this has been more often by targeted RT-qPCR, 
rather than by miRNA microarray. Other explanations for our failure to recognise 
miRNA alterations for many of the BCT types could be a lack of sensitivity of the febit 
microarray; screening of too many miRNAs (we looked at 866 miRNAs, whilst Henry 
et al. [441] and Matthaei et al. [444] profiled 379 and 750 miRNAs respectively); and 
the normalisation techniques or statistical analyses used. For example, the methods 
used to adjust for multiple testing may have been too stringent. As miRNAs have 
now been shown to be stable in various biofluids, it seems that profiling fresh fluid 
and/or solid biopsies is a better method for determining the miRNA signatures of 
pancreatic BCT, and these results will hopefully be more easily translatable to 
clinical use. Although, whilst this may identify clinically useful biomarkers, the 
miRNAs present in the cystic fluid cannot be assumed to correlate with those that 
are differentially expressed in the tissues, and vice versa, therefore these may not be 
the best therapeutic targets or explain neoplastic changes [441].  
In our microarray, we did notice, however, albeit with a few exceptions, that 
after unsupervised hierarchical clustering of the data, the PDAC samples tended to 
cluster together and remain well separated from the BCT (Figure 15A). Therefore, 
we concentrated on establishing any differences in miRNA expression between the 
different BCT and PDAC (i.e. benign vs. truely malignant lesions; Tables 17-20). 
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Interestingly, we observed a widespread miRNA down-regulation in PDAC compared 
to SMCA (Table 17), the most benign lesion that rarely progresses to invasive 
adenocarcinoma. Notably, in our study we have profiled the miRNA expression of 
the largest number of SMCAs (n=7) to date (Tables 7 and 8) [442, 444, 449]. This 
again highlights the rarity of these tumours, but also shows that if there had been a 
better pre-operative marker for benign disease, these patients could have avoided 
pancreatic surgery. 
In addition, we observed that many of the miRNAs down-regulated in PDAC 
vs. SMCA (Table 17) belong to the same family or cluster. Being that the probes 
used in the microarray are randomly located on the platform, we regard this as 
validation of our findings. For example, among the miRNAs that we found to be 
down-regulated, miR-15a forms a cluster with miR-16, miR-29a with miR-29b, and 
miR-143 with miR-145 and each cluster is expressed as a unique primary transcript. 
Amongst the down-regulated miRNAs in our microarray (Table 17), there are many 
already described as tumour suppressors, due to their inhibition of known oncogenes 
in PDAC and other cancers. We found general miR-29 family member down-
regulation in PDAC. Amongst their targets are DNMT3A and 3B-methyltransferases, 
whose levels can increase because of the loss of miR-29, causing CpG island 
hypermethylation and cancer, if these are located in the promoter regions of tumour 
suppressor genes [235, 553]. Furthermore, pan-cancer integrated analyses have 
shown that loss of the miR-29 family occurs in a wide range of cancer types and is 
frequently associated with up-regulation of TET1 and TDG, resulting in active DNA 
demethylation processes that could facilitate tumourigenesis [235]. In PDAC, low 
miR-29 tumoural expression has recently been associated with poor prognosis after 
surgical resection, suggesting that its loss characterises aggressive tumour biology 
[387].  
We also found down-regulation of let-7 family members (let-7f, let-7d, let-7c, 
let-7a, let-7i) (Table 17), which are already described as negative regulators of 
KRAS and HMGA2 oncogenes, whose increased activity is very important during 
PDAC progression [270, 291]. Indeed, let-7 alters several signalling pathways in 
cancer, including mitotic signalling, cell cycling, angiogenesis, cell adhesion and 
migration [554]. Accordingly, Torrisani et al. showed that let-7 is reduced by ~60% in 
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surgically resected PDAC compared to NP, and that levels of let-7 precursor are 
down-regulated in pre-operative PDAC EUS-FNA biopsies [286]. They went on to 
demonstrate that let-7 overexpression slows PDAC cell proliferation in vitro, with 
concomitant reduction in KRAS and MAPK phosphorylation levels, but found that its 
replacement failed to inhibit PDAC tumour progression in vivo [286]. This indicates 
that modulating more than one miRNA is probably required to alter a malignant 
phenotype in vivo. Finally, we observed down-regulation of both miR-143 and miR-
145, which have recently been described as being transcriptionally down-regulated 
by the RAS signaling pathway, and in turn directly targets KRAS in PDAC [361]. This 
feed-forward mechanism potentiates oncogenic RAS signaling [361]. As KRAS is 
one of the main genetic promoters of PDAC [542], and HMGA2 expression levels are 
associated with the malignant phenotype in pancreatic exocrine tissue [545], down-
regulation of these miRNAs (i.e. let-7 and miR-143/145) could help to enhance the 
expression of these genes. Furthermore, we observed an up-regulation of KRAS 
protein, but no change in its mRNA levels, when comparing NP to PDAC (Figure 
20), indicating that the post-transcriptional regulation of KRAS may be an essential 
step in pancreatic tumourigenesis. 
Of the miRNAs down-regulated in PDAC compared to SMCA, we chose to 
further investigate miR-21, 16 and 126, as the first has well known roles in human 
cancers, whilst the others have not been well described in PDAC. 
 
3.3.2 miR-21 down-regulation as an early event in pancreatic 
neoplasia 
We next validated the microarray findings by RT-qPCR, however, to our 
surprise we found miR-21 levels were similar in PDAC and SMCA (Figure 16A), 
despite the latter being a benign tumour. We further confirmed this by performing 
RT-qPCR analysis again, but with the addition of some NP samples (Figure 17). 
This showed that miR-21 levels were certainly raised in both the adenoma and 
adenocarcinoma compared to NP (Figure 17). Thus, since miR-21 has been 
previously demonstrated to be overexpressed in PDAC compared to NP [325], and 
we established that it is not deregulated in PDAC compared to a low malignant 
potential BCT, a possible explanation is that its up-regulation is an early event which 
 188 
 
is important for benign neoplasm formation from normal tissue. Indeed, Du Rieu et 
al. [422] examined samples of non-pathologic pancreatic ducts and microscopic 
pancreatic precursor PanIN lesions from a KRASG12D mouse model and from human 
FFPE samples adjacent to PDAC. They showed that miR-21 deregulation occurs in 
the most advanced PanIN-3 lesions, before they become invasive PDAC [422]. Yu et 
al. [421] performed a similar study, but examined LCM human PanINs. They found 
that miR-21 expression is elevated even earlier, in PanIN-2 lesions compared to 
PanIN-1 and NP [421]. Similarly, miR-21 levels have been shown to rise in benign 
IPMN adenomas from NP, although higher expression is typically seen in CEI and 
PDAC [429, 430, 449]. Furthermore, miR-21 up-regulation has been seen in early 
neoplasia in other tissue types, such as colonic adenoma [555] and breast epithelium 
atypia [556]. 
We could not observe an up-regulation of miR-21 in PDAC compared to 
SMCA (Figure 17). However, some of the studies already discussed did not find 
miR-21 significantly raised in their malignant lesions either [441, 444, 450]. Focusing 
on miR-21, Croce’s group have also examined 80 PDAC in more detail and found 
that it is significantly overexpressed in PDAC, but that its expression does not 
correlate with tumour size, nodal status or T stage [357]. We observed that its up-
regulation from normal tissue is almost certainly a very early event that occurs in the 
low malignant potential BCT we studied and this may occur even earlier than 
previously described (i.e. in a very low malignant potential lesion, compared to the 
known PanIN or IPMN sequences) [422, 429]. This suggests that miR-21 induces 
pancreatic cell proliferation, but is not yet sufficient to induce malignant 
transformation, perhaps also due to other tumour suppressors controlling the cells' 
fate in this instance.  
3.3.3 Role of miR-16 and miR-126 in PDAC 
3.3.3.1 KRAS is a novel target for miR-126 
Mutations that result in a constitutively active KRAS are found in >95% of 
PDAC and are thought to be a crucial initiating event for this disease [557]. 
Furthermore, PDAC continues to be "addicted" to KRAS for epithelial differentiation 
and cell viability, indicating that finding new KRAS regulators is an important step for 
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advancing our understanding of pancreatic tumour biology [558]. We found a down-
regulation of miR-126 in PDAC (Table 17 and Figure 19), with increased expression 
of KRAS (Figure 20A and B). Importantly, RAS, which is a key target for the let-7 
family, is not predicted by traditional bioinformatic algorithms to be a putative target 
of this miRNA family (Figure 18); yet Johnson et al. [270] elegantly showed that 
human NRAS, KRAS, and HRAS 3′UTRs have nine, eight, and three let-7 family 
complementary sites respectively, which are functionally significant. On this basis, 
we hypothesised that there may be a possible role for miR-126 in regulating KRAS, 
even though there were no canonical binding sites identified on TargetScan (Figure 
18).  
The RNA22 is a pattern-based algorithm (see section 1.3.1.1) that is distinct 
from other prediction tools for miRNA-mRNA interactions (heteroduplexes), as it 
does not use experimentally validated heteroduplexes for training [237]. Instead it 
relies only on the reverse complement of mature miRNA sequences to perform 
pattern discovery in a target sequence of interest to thereby identify candidate 
microRNA target sites [237]. Once a miRNA binding site has been located, the 
strength of the RNA-RNA heteroduplex can be computed [237]. Notably, RNA22 
does not require the presence of the exact reverse complement of a miRNA seed in 
a putative target, therefore it permits bulges and G:U wobbles in the seed region of 
the heteroduplex, helping to discover non-canonical binding sites in 3'UTRs [237]. 
Recently, Xia et al. [559] examined “non-canonical” miRNA interactions using 
molecular dynamics simulations of the crystal structure of the Ago-miRNA-mRNA 
ternary complexes. They found that many modifications, such as combinations of 
multiple G:U wobbles, bulges and mismatches in the seed region, are functionally 
acceptable and whilst giving rise to some conformational changes, they do not affect 
the stability of the ternary complex [559]. Thus, RNA22 is ideal for discovering the 
spectrum of “seedless” miRNA targets. 
Using the RNA22 algorithm, we subsequently identified two possible “non-
canonical” binding sites in the KRAS 3’UTR (Figure 24A). We found that miR-126 is 
able to directly regulate KRAS, inhibiting its protein translation by interacting with a 
“seedless” site within its 3’UTR (Figure 24B). This suggests that its down-regulation 
in PDAC could participate in the progression of PDAC because of reduced post-
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transcriptional repression and a subsequent increase in KRAS protein. Interestingly, 
miR-126 expression was down-regulated in PDAC compare to SMCA (a low 
malignant potential BCT) and previous studies have shown that these BCT lesions 
are devoid of the KRAS mutation [560, 561]. Conversely, the more malignant 
potential BCTs (i.e. IPMN and MCN) have been shown to have oncogenic mutated 
KRAS more frequently [562, 563] and we show these lesions had no significant 
difference in miR-126 expression when compared to PDAC (Tables 18-20). 
Interestingly, for progression from microscopic PanIN to macroscopic BCT to 
adenocarcinoma, these mucinous lesions require a KRAS (G12D) mutation, followed 
by loss of heterozygosity (LOH) of SMAD4 and mutation of TP53 or p16/CDKN2A 
[564]. Strikingly, miR-126 levels have been shown to be down-regulated very early in 
pancreatic neoplasia with lower levels in PanIN-3 lesions compared to NP (Figure 
10) [421]. As we show miR-126 up-regulation occurs in SMCA, this raises the 
possibility of replacement miRNA therapy for those patients with low miR-126 in their 
BCT or PDAC at the time of pre-operative biopsy or maybe even as an adjuvant 
treatment after surgical resection to prevent disease recurrence. In addition, as 
KRAS expression is wild-type in SMCA [560, 561], then perhaps raised miR-21 
levels in these BCTs (Figure 17) are insufficient on their own (i.e. without loss of 
miR-126 and miR-16) to cause malignant progression past adenomatous change. 
3.3.3.2 miR-126 targets CRK in PDAC  
Whilst we did not see significant down-regulation of miR-126 compared to NP 
(Figure 16B), most likely a Type II statistical error, our subsequent data-mining 
analysis confirmed its reduction in PDAC (Figure 19C), and we also found a 
reduction in SMCA lesions (Figure 15C). MiR-126 has been described as down-
regulated in various tumours compared to non-cancerous tissues including breast, 
lung, stomach, cervix, bladder, and prostate [540]. MiR-126 has also been shown to 
be a tumour suppressor in gastric cancer, as it can inhibit tumour growth and 
metastasis in vitro and in vivo [549]. This effect was partially mediated by down-
regulation of CRK [549]. Using gain-of-function and loss-of-function approaches, we 
showed that CRK is also regulated by miR-126 in PDAC in the more mesenchymal 
and metastatic Mia PaCa-2 cells (Figure 22A-D), compared to PANC-1 cells (Figure 
23).  
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SRC tyrosine kinase promotes non-anchored cell growth and migration. 
Importantly, SRC activation and CRK-associated substrate (Cas) phosphorylation is 
an important promoter of PDAC anchorage-independence and tumour progression 
[544]. Cas is an important component of the integrin signalling network and after 
phosphorylation by SRC, it can bind to a number of proteins, including CRK and 
PI3K [550]. Specifically, the Cas/CRK association acts to induce cell migration which 
then leads to tumour cell invasion [550]. Furthermore, SRC induces miR-224 
expression and suppresses miR-126 in BC to promote non-anchored cell growth and 
migration [550]. The mechanism by which SRC is able to directly suppress miR-126 
is unknown, but ultimately results in the augmentation of CRK expression, and the 
promotion of tumour progression [550]. Interestingly, MYC may also suppress miR-
126 to promote tumourigenesis [550].  
Recently, Hamada et al. [565] have confirmed miR-126 as indeed down-
regulated in PDAC patient samples and cell lines. Furthermore, they showed that it 
has tumour suppressive effects by targeting ADAM9, thereby enhancing cancer cell 
invasion by modulating tumour-stromal cell interactions. Accordingly, re-expression 
of miR-126 reduced cellular migration and invasion in PDAC cell lines [565]. Thus, 
the miR-126/ADAM9 axis has been established to control migration and invasion in 
PDAC, as well as reversal of EMT (Figure 25) [565]. In other tumours, restoration of 
miR-126 expression suppresses the growth of CRC cells (by targeting PI3K) [566, 
567] and inhibits the growth of lung cancer in vitro and in vivo (by down-regulating 
VEGF) (Figure 25) [568]. As miR-126 has been shown to modulate the activity of 
PI3K at the level of signal initiation by limiting p85β levels in normal epithelium [566], 
its loss may amplify the PI3K signal, which is known to cause PDAC cell proliferation 
and survival. Therefore, miR-126 acts as a tumour-suppressor miRNA (TS-miR) in 
most cancers, but has also been placed at the heart of complex metastatic 
pathways, acting as a suppressor of proliferation and metastasis in BC [569].  
In 2008, Tavazoie and colleagues first identified miR-335, miR-206 and miR-
126 as metastasis-suppressor miRNAs in BC [569]. In that study, miR-126 
restoration was found to reduce tumour growth and proliferation, whereas miR-335 
expression reduced cell migration and invasion. Most recently miR-126 has been 
affirmed as a central miRNA governing metastatic initiation and colonisation in BC 
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[570, 571]. The Tavazoie group have shown that loss of miR-126 in BC cells causes 
a minimal increase in mammary tumour volume, but significantly promotes the 
development of metastases in distant organs (i.e. lung, liver, brain and bone) in 
mouse models [571]. MiR-126 acts in a non-cell autonomous way to regulate 
endothelial cell recruitment to metastatic BC cells. It inhibits this recruitment by 
directly targeting three pro-angiogenic genes (IGFBP2, PITPNC1, and MERTK) 
without affecting the actual tumour growth (Figure 25) [570, 571]. Therefore, loss of 
miR-126 and induction of these pro-angiogenic targets allows metastatic cells to 
establish endothelial and vessel interaction crucial for initiation and colonisation of 
secondary sites [571].  
These data indicate that miR-126 may be an ideal molecular target for PDAC 
therapy (Figure 25), not only for preventing tumourigenesis, but also for controlling 
disease spread. Further in vivo studies are urgently required to assess whether 
replacing this miRNA can truely reduce PDAC progression and metastasis. In 
addition, further clinical assessments are required to investigate whether miR-126 
can be used as a diagnostic or prognostic marker in PDAC. In BC, miR-126 
suppresses the expression of a set of genes that are strongly correlated with 
metastatic relapse, and low miR-126 expression is associated with reduced 
metastatic-free survival [571]. Thus, it appears that down-regulation of miR-126 is 
important for the progression of pancreatic and other cancers; however many of the 
mechanisms that might account for this remain unknown.  
3.3.3.3 miR-16 targets anti-apoptotic BCL2 in PDAC 
For the first time, we established that miR-16 targets BCL2 in PDAC (Figures 
22A, 22B and 23A). Furthermore, we showed that the miR-16 is down-regulated in 
PDAC compared to NP (Figure 19A) and adenomatous (Figure 15D) patient 
samples. MiR-15a and miR-16 have a common seed sequence and share 80% 
complementarity, and we found that miR-15a was also significantly down-regulated 
in PDAC compared to NP (Figure 19B) and SMCA (Table 17). MiR-15a/16 are often 
down-regulated in CLL [256], gastric [572], ovarian [573] and prostate cancers [490] 
and act as TS-miRs that target and down-regulate the anti-apoptotic gene BCL2, 
therefore loss of miR-15a/16 allows cells to avoid apoptosis [257] (also see section 
1.4.1). BCL2 is overexpressed in human PDAC [574, 575] and we confirmed this 
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(Figure 20A and B). Interestingly, Bottoni et al. [576] found that miR-15a and miR-
16 were expressed at lower levels in pituitary adenomas as compared to normal 
pituitary tissue. Moreover, their expression was inversely correlated with tumour 
diameter, suggesting that these miRNAs might influence tumour growth [576]. 
Unfortunately, we did not have enough RNA material remaining to further examine 
miR-16 expression in our adenomas (SCMA and IPMN) compared to NP. 
Other important miR-16 target genes include WNT3A (which increases β-
catenin protein abundance and activates other survival and proliferation pathways 
via ERK and AKT) and CCND1 (encoding cyclin D1; an important regulator of G1 to 
S phase progression), whose functions are directly associated with cancer 
progression and invasion [490, 577]. Bonci et al. [490] showed that silencing miR-
15a/16 by injection of antagomiRs into normal mouse prostates results in prostate 
hyperplasia with disruption of glandular acini associated and CCND1 and WNT3A 
up-regulation. Thus indicating that loss of miR-15a/16 could be an early event even 
in the prostatic tumourigenic process and also in the absence of BCL2 expression 
[490]. After the loss of miR-15a and miR-16 in tumours, larger amounts of BCL2 and 
WNT3A then enhance prostate cell growth by inhibiting apoptosis [490]. CCND1 and 
WNT3A are able to promote cell proliferation after down-regulation of miR-15a/16, 
whereas an increase in WNT3A expression alone appears responsible for enhanced 
migration and invasiveness typical of advanced prostate cancer [490]. Accordingly, 
studies have shown that restoration of miR-16 in vivo can cause prostate tumour 
regression and necrosis after intra-tumoural injection [490], and even attenuation of 
disease progression in a metastatic model after systemic delivery [492].  
Our results are comforted by a recent study by Basu et al. who have also 
demonstrated that BCL2 is targeted by miR-16 in vitro. In addition, they found that 
overexpression of miR-16 significantly decreased the clonogenic survival and 
proliferation of PDAC cells over a 2 week period. Furthermore, previous work using 
siRNAs against BCL2 in PDAC has shown that silencing this gene alone can 
enhance apoptosis and suppress cell proliferation in vitro and in vivo [575]. 
Therefore, miR-16 replacement appears to be an attractive therapeutic option for 
PDAC. 
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Figure 25 - miR-126 targets several genes and pathways involved in tumour 
progression and metastasis in human malignancies. 
Mir-126 has many oncogenic targets in PDAC that are released by its down-regulation, 
including KRAS, ADAM9 and CRK (pathways highlighted in GREEN). Key: PolyA, poly A 
tail; m7G, 7-methylguanosine cap; ORF, open reading frame. Modified from [570]. 
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3.3.4 Summary 
The differential diagnosis of pancreatic BCTs remains a clinical challenge. A 
better understanding of the natural history of these lesions is considered central to 
understanding the risk of malignant transformation. The principal aim of this study 
was to investigate differences in miRNA expression between the low and high 
malignant potential BCTs, and also primary PDAC.  
We observed significantly down-regulated miRNAs in PDAC compared to low 
malignant potential BCT, such as miR-16, miR-126 and let-7d, which could be 
confirmed by RT-qPCR and were demonstrated to target known PDAC oncogenes 
such as BCL2, CRK and KRAS. We thus demonstrate that miRNAs have the 
potential to be used to differentiate pancreatic BCT from malignant PDAC (Figure 
26). Given the shortcomings of our microarray, it would be appropriate to undertake 
further miRNA studies on these low and high malignant potential BCTs and validate 
candidate miRNAs in larger cohorts, ideally in the prospective and multicentric 
setting. The assessment of fresh cystic tumour and PDAC biopsies would be 
appropriate to ensure the best RNA quality and most accurate patient data. 
For the first time we have shown that KRAS is directly targeted by miR-126 by 
binding to a "seedless" site in its 3'UTR. Although the luciferase reporter assay that 
we designed to validate the interaction between KRAS and miR-126 only contained 
a small part of the binding site from the 3’UTR of KRAS. This was done to show that 
the miR-126-KRAS interaction can occur at a “non-canonical” biding site. However, it 
would be important to validate this with the entire 3’UTR in a repeat luciferase 
reporter assay. As the majority of PDAC are driven by activated KRAS, the re-
expression of this miRNA, along with other miRNAs known to also negatively 
regulate this crucial oncogene (i.e. let-7 family, miR-96 [578], 143 and miR-217 
[359]), may provide a novel therapeutic strategy. 
Furthermore, we have shown that miR-21 up-regulation may be an early 
event that induces normal non-proliferative cells into benign proliferative cells. 
Dysregulation of other miRNAs or proteins involved in PDAC, which still need to be 
characterised, could explain this proliferative, but non-malignant event. 
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This study adds to and supports the current knowledge regarding the role of 
miRNAs in early pancreatic tumourigenesis and provides further avenues for basic 
and translational research. 
 
 
Figure 26 - Flow chart of miRNA expression profiling in pancreatic BCTs and miRNA 
target acquisition. 
FFPE, formalin-fixed paraffin embedded tissue; **indicates that RNA could not be isolated 
from 1 sample; RT- qPCR, quantitative reverse transcription polymerase chain reaction. 
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CHAPTER 4: miRNAs Co-operatively Inhibit a 
Network of Tumour Suppressor Genes to Promote 
Pancreatic Tumour Growth and Progression 
 
4.1 Background 
Although the PDAC miRNome has been extensively profiled [325, 356, 387, 
579] (Table 4), it remains unclear which differentially expressed miRNAs are the 
most important in tumourigenesis (Tables 5 and 6). In Chapter 3, we have shown 
that oncomiR-21, an oncogene in PDAC [325, 383, 387] and other tumour types 
[580], is not only up-regulated in PDAC, but also in a pancreatic BCT compared to 
NP [539]. This indicated that elevated miR-21 levels may be an early event in 
pancreatic adenomas and malignant tumour formation.  
However, many other miRNAs have been identified as prominently 
dysregulated in PDAC (Table 4), but knowing which miRNAs exert the most 
influence on the PDAC transcriptome, thereby contributing to sustained tumour 
growth and progression is unknown. In addition, whilst the diagnostic signature for 
PDAC has been over-investigated, the ideal prognostic miRNA signature for clinical 
use is yet to be described.  
We hypothesised that the miRNAs regulating the majority of transcripts in 
PDAC are likely to be crucial for tumour progression and therefore may be novel 
biomarkers and/or targets for molecular therapy.  
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4.2 Results section  
4.2.1 Differentially Expressed miRNAs and mRNAs between PDAC 
and normal pancreas 
To evaluate important miRNA-mRNA interactions in PDAC, we performed an 
integrated molecular analysis (Figure 27). The initial molecular profiling (miRNA and 
mRNA) was performed on FF tumour samples derived from 9 patients with 
resectable PDAC, who underwent surgical resection by pancreaticoduodenectomy 
(PD) with curative intent, and samples of NP tissue. Appendix 2 summarises their 
clinical and histopathological characteristics. All patients had American Joint 
Committee on Cancer (AJCC) stage 2B tumours with positive LNs, and there were 
positive microscopic resection margins (R1) in 56%. Specific molecular alterations 
identified through that integrated genomic profiling were then validated in separate 
cohorts by RT-qPCR (n=91) and immunohistochemistry (n=121), in which the 
clinicopathologic and survival characteristics were largely overlapping (also 
Appendix 2).  
Expression profiles assayed by miRNA nCounter array in these 9 PDAC and 
normal samples highlighted 22 significantly differentially expressed miRNAs in 
malignant tissue (Benjamini-Hochberg adjusted t-test, P<0.05) (Figure 28A). Most 
miRNAs implicated in PDAC are up-regulated compared to NP [325] and our miRNA 
signature was consistent with this (Figure 28A and Table 21). We also appreciated 
a down-regulation of miR-216a and miR-217 in our PDAC samples, which is 
characteristic and seen previously in several studies (see section 1.5.1.1). 
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Figure 27 - An overview of our integrated molecular profiling based study for PDAC. 
The Seed Match Analysis is shown in Figure 29 and the Seed Enrichment Analysis can be 
seen in Table 23. 
 
Next, we identified differentially expressed genes in the same PDAC samples 
using a high throughput cDNA microarray, which revealed a set of 4,700 significantly 
changing genes (Benjamini-Hochberg adjusted t-test P<0.05; Figure 28B). We 
validated several of those genes previously described in PDAC (Tables 22 and 23) 
using RT-qPCR confirming that our cDNA microarray had accurately differentiated 
malignant from NP tissue (Figure 29). To understand the wide-range of altered 
mRNA transcripts in PDAC and to further demonstrate the reliability of our methods, 
we performed gene ontology (GO) and KEGG pathway enrichment analyses of the 
differentially-expressed genes. This allowed a global view of the transcriptome that is 
under miRNA regulation in PDAC. Most of the terms and pathways were closely 
related to tumourigenesis (Figure 30A and B). 
 
 200 
 
 
 
Figure 28 - miRNAs and mRNAs Differentially Expressed in PDAC vs. Normal 
Pancreas.  
(A) Heatmap showing miRNA expression across 18 samples for 22 differentially expressed 
miRNAs (selection: Benjamini-Hochberg adjusted t-test P-value <0.05). (B) Heatmap 
showing gene expression across 12 samples for 1,328 top differentially expressed mRNAs 
(selection: t-test adjusted P<0.05 and absolute log-ratio of cancer vs. normal samples mean 
intensity signal ≥1).The heatmaps in panel (A) and (B) report relative levels of miRNA or 
gene expression in a green [lower expression] to red [higher expression] scale. Whilst the 
seed-enrichment analysis was used to investigate up-regulated miRNAs in PDAC, we also 
identified miRNA-mRNA interactions between down-regulated miRNAs and up-regulated 
genes. 
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Table 21 - Comparison of our miRNA signature of PDAC with other expression 
profiling studies from the literature. 
amiR-199a-3p and 199a-5p have also been identified as endogenous miRNA drivers of 
metastasis in other tumour types [581]. 
Up-regulated in 
PDAC 
Noted in prior study 
(refs) 
Down-regulated in 
PDAC 
Noted in prior study 
(refs) 
let-7i [277, 387, 582, 583] miR-216a 
 
[277, 337, 356, 387, 
583] 
 
miR-21 
 
[276, 277, 325, 357, 
387, 583] 
 
miR-217 
 
[337, 356, 359, 387, 
583] 
 
miR-23a 
 
[277, 325, 387] 
 
miR-630 no 
miR-27a 
 
[277, 350, 355, 387, 
402]  
 
miR-744 no 
miR-27b 
 
no 
 
  
miR-99a 
 
[277, 325] 
 
  
miR-100 
 
[276, 277, 325, 387, 
583] 
 
  
miR-125b 
 
[276, 277, 325, 583] 
 
  
miR-142-3p 
miR-142-5p 
 
[387] 
 
  
miR-143 
 
[277, 325, 337, 387, 
583] 
 
  
miR-145 
 
[277, 337, 387, 583] 
 
  
miR-199a-3p 
miR-199a-5p 
[277, 325, 387] 
a
   
miR-223 
 
[277, 325, 387] 
 
  
miR-342-3p 
no 
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Table 22 – Comparison of our gene signature of PDAC with Oncomine and literature data. 
Comparison of most significantly deregulated genes in our cDNA array of PDAC with the top 100 
deregulated genes from the 8 profiling datasets in Oncomine and other meta-analyses. Key: yellow 
indicates gene was validated by RT-qPCR in Figure 29. 
Up-regulated 
in PDAC in 
Oncomine 
Up-
regulated 
in our 
PDACs 
Noted in 
meta-
analyses 
(refs) 
Down-
regulated 
in PDAC in 
Oncomine 
Down-
regulated 
in our 
PDACs 
Noted in 
meta-
analyses 
(refs) 
S100P Yes [584] AMY2B No  
CDH3 Yes  CCDC69 Yes  
GPRC5A Yes  PTPRS Yes  
AHNAK2 Yes  CIRBP Yes  
COL11A1 Yes  C6 No  
LEMD1 No  SIDT2 Yes  
SLC2A1 No  SYNGR1 No  
FN1 Yes [585] PDCD4 Yes  
LAMC2 Yes  GRB10 Yes  
HIST1H2AC No  DPEP1 Yes  
PKM2 No  SLC25A45 No  
MMP11 No  CTRL Yes  
SFN Yes  PNLIPRP2 No  
POSTN Yes [584] NR5A2 Yes  
THBS2 Yes  KIAA2022 Yes  
MYOF Yes  KIAA1324 Yes  
VCAN Yes  LOC338799 No  
ECT2 Yes  RNF212 Yes  
ATP2C1 Yes  LGALS2 No  
AMIGO2 Yes  CLU No  
GJB2 No  FLRT2 No  
MTMR11 Yes  ACACB Yes  
ENO2 No  MCOLN3 Yes  
SOX4 No  GSTA2 Yes  
FBXO32 Yes  KLK3 Yes  
FAM164A Yes  P2RX1 Yes  
IGFBP3 Yes  BACE1 Yes  
C1S Yes  CTNND2 Yes  
PLEK2 Yes  ACADL Yes  
LEF1 Yes  SLC1A2 Yes  
TOP2A Yes  TMED6 Yes  
TRIB2 Yes  PNLIPRP1 No  
LIMS1 Yes  PRLR Yes  
LMO4 No  DMRTC1 No  
RPL32P16 No  DEFB118 No  
INPP4B Yes  EPHX2 Yes [586] 
KLF7 Yes  GP2 Yes  
CEACAM5 Yes [584] WNT6 No  
LOXL2 No  CD209 No  
NQO1 Yes  SNRPN No  
CALD1 Yes  RAMP1 Yes  
OLFML2B Yes  FGL1 Yes [585] 
CSTB Yes [586] TSPY1 No  
CXCL5 No  RBP1 Yes  
PHLDA2 No  LOC158960 No  
CACNB3 No  PAK3 Yes  
CDH11 Yes  TTN Yes  
FAM110A No  GSTA3 Yes  
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ISG15 No  C12orf39 Yes  
PLOD2 Yes  GSK3A No  
DGKH Yes  SLC4A4 Yes  
PLAC8 Yes  CLCNKB No  
C16orf75 No  C20orf56 No  
KYNU Yes  GATM Yes [585] 
PLAUR Yes  ANPEP Yes  
LAMA3 Yes  ENPP1 Yes  
KIAA1217 Yes  CASZ1 No  
ZDHHCC7 No  KCNJ16 Yes  
S100A10 Yes  ACAT1 Yes  
P4HA1 No  HIST1H2AC No  
PLOD3 No  MT1B No  
MBOAT2 Yes  C21orf2 No  
MATN3 No  PDIA2 Yes [585] 
GPR124 No  MMP2A No  
BIK No  AOX1 Yes  
CKLF No  SH3BGR Yes  
ARNTL2 Yes  GPR155 Yes  
SULF1 Yes  FGFR1 Yes  
TGFB1I1 No  DLL1 Yes  
MET Yes  CABC1 No  
SLC16A3 No  XBP1 Yes  
IL1R2 Yes  DPT Yes  
ENTPD1 Yes  FAM41AY2 No  
DPYSL3 Yes  PTGER3 No  
LOC100289175 No  FAM41AY1 No  
OPN3 No  GATA2 Yes  
KIAA0101 No  LOC283481 No  
IFI27 Yes  CLPS Yes  
TMCC1 No  GATA4 Yes  
S100A11 Yes  BNIP3 Yes  
GSK3B Yes  GSG1 Yes  
HOXB7 No  GH1 Yes  
TPRG1 Yes  UBE2G2 No  
TGM2 Yes  MYLIP No  
EGLN3 No  PAH Yes  
C22orf9 No  C6orf89 No  
IGFBP5 Yes [586] GRB14 Yes  
KIF20A No  KLKB1 No  
PCDH7 Yes  IGFN1 No  
C1orf107 No  PRSS1 No  
COL1A1 Yes  PDK4 No  
C5orf13 Yes [586] RGN Yes  
CD55 Yes  PECI No  
GABRP No  LOC387647 No  
CEACAM6 Yes  EPB41L4B Yes  
LCN2 Yes [584] NFIA No  
RAP2B No  HOMER2 Yes  
ADAM8 No  RPL7AP36 No  
MPZL1 Yes  PAIP2B Yes  
CEP170 Yes  TNXB No  
Yes 62%  Yes 58%  
No 38%  No 42%  
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Table 23 - Other known significantly deregulated genes in PDAC identified by our 
cDNA microarray. 
Key: yellow indicates gene was validated by RT-qPCR in Figure 29. 
 
  
Up-regulated in 
PDAC 
Noted in prior 
studies (refs) 
Down-regulated 
in PDAC 
Noted in prior 
studies (refs) 
SPARC [584, 587] NRCAM [587, 588] 
MMP7 [584] BCAT1 [586] 
ITGB2 [587] C5 [586] 
FBN1 [586, 589] SSFA2 [586] 
ARPC3 [587] F11 [586] 
ARHGDIB [587] CRAT [586, 589] 
COL1A2 [586, 587] MKNK1 [586] 
LAMA4 [586] CADPS [587] 
ZEB1 [590, 591] CHRNA2 [587] 
ZEB2 [591] CYB5 [587] 
SNAI2 [398]  DUSP1 [587] 
ADAM9 [584] FGFR2 [587] 
CXCR4 [584, 589, 592] FXYD2 [587] 
RBMS1 [587] HGD [587] 
COL5A2 [586] HS6ST [587] 
ECM1 [586] IMPA2 [587, 589] 
MYL9 [586] MAT1A [587] 
PMP22 [586] MYOM1 [587] 
RCN1 [586] PHKA2 [587] 
MSN [586] P4HB [589] 
EPS8 [586] PABPC4 [589] 
CLIC1 [586] SERPINA4 [587] 
LTBP1 [585] SERPINA6 [587] 
ANXA2 [584] SERPINI2 [589] 
CASP3 [584] TPD52L1 [587] 
CENPF [584] UGT2B7 [587] 
PTGS2 [584] TPST2 [589] 
FXYD3 [584] AKR7A3 [589] 
EPHA4 [587] GUCA1A [589] 
LGALS3 [584, 589] MAPK8IP1 [589] 
MGLL [589] DEFA4 [589] 
RARRES3 [589]   
KRT19 [589]   
CTSB [584]   
CTSE [584, 589]   
CTSK [586]   
COL3A1 [589]   
PTGIS [589]   
ITGB6 [589]   
PFKP [589]   
OLFML2B [589]   
KCNK1 [589]   
MYH11 [589]   
CBLB [589]   
CPM [589]   
CD58 [589]   
PSMB8 [589]   
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4.2.2 Validation of PDAC cDNA array 
In order to validate our cDNA microarray, we compared the gene expression 
from our PDAC samples to the top 100 up-regulated and down-regulated genes in 
PDAC found across the 8 datasets found on the Oncomine website 
(https://www.oncomine.org/resource/login.html), and also to three previous meta-
analyses [584-586] of dysregulated genes in PDAC (Table 22). We found our PDAC 
samples had 62% of the up-regulated and 58% of the down-regulated genes when 
compared to the top 100 up- and down-regulated genes in the 8 Oncomine datasets 
(Table 22).  
We also noted other genes significantly dysregulated in our cDNA microarray 
that have been previously identified as differentially expressed in PDAC and are 
considered important (Table 23). For example, genes known to be down-regulated in 
PDAC included: PDCD4, GATM, BNIP3, LIFR, NrCAM, EPHX2, FGL1, PDIA2 and 
SERPINI2. Programmed cell-death 4 (PDCD4) is a well-documented tumour 
suppressor in PDAC [593]. Glycine amidinotransferase (GATM) has been identified 
as down-regulated and a marker of PDAC in several independent studies [585]. 
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) is a hypoxia-
inducible proapoptotic member of the BCL2 family [594] and has decreased 
expression in PDAC compared to NP due to BNIP3 promoter hypermethylation 
[595]. Leukemia inhibitory factor receptor (LIFR) has recently been shown to be a 
new metastasis suppressor [596]. Neuronal cell adhesion molecule (NrCAM) is an 
immunoglobulin-like cell-adhesion molecule (Ig-CAM) that has an inhibitory role in 
tumour progression and is consequently downregulated in invasive/metastatic PDAC 
compared with well/moderately differentiated tumour tissue [588, 597]. Serpin 
peptidase inhibitor, clade I, member 2 (SERPINI2) is a serine protease inhibitor that 
is specific to the pancreas and its down-regulation may play a role in PDAC 
development or progression [598].  
Conversely, and also comparable to previous studies, we saw the following 
genes were significantly up-regulated in PDAC: ZEB1/2, SNAI2, S100P, MUC4, 
SULF1, SPARC, FN1, POSTN, CEACAM5, IGFBP5, CXCR4, ADAM9 and MMP11. 
The ZEB1/2 proteins and SLUG (encoded by SNAI2) are transcriptional repressors 
of E-cadherin and involved in PDAC progression and metastasis, as well as in 
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several other cancers [369]. S100 calcium binding protein P (S100P) has been 
shown to be involved in early neoplasia (e.g. PanIN-3 lesions – see Figure 1B), as 
well as PDAC cell growth, invasiveness and survival [599]. Secreted protein acidic 
and rich in cysteine (SPARC) is expressed and secreted by PDAC-associated 
peritumoural fibroblasts as a matricellular regulator of tumourigenesis [600] and 
stromal SPARC expression may be a biomarker of outcome for GEM plus nab-
paclitaxel combination regimens [103].  
In order to demonstrate the validity of our cDNA microarray, we chose 5 
genes that are dysregulated in PDAC (Tables 22 and 23) and quantified their 
expression by RT-qPCR. These were GATM, ZEB2, SNAI2, S100P and NrCAM. The 
expression of all these genes was confirmed to be in the same direction as the initial 
cDNA array and the literature, thereby further validating our initial molecular profiling 
(Figure 29).  
 
Figure 29 - Validation of PDAC cDNA microarray by RT-qPCR. 
Relative mRNA expression of GATM, ZEB2, NrCAM, S100P and SNAI2 was measured in 
the same normal and PDAC samples (n=9 for both) that were used for the initial molecular 
profiling. The expression of all these genes was confirmed to be in the same direction as the 
initial cDNA microarray. Gene expression was normalised to RPLPO expression as an 
endogenous control (*P<0.05; **P<0.01). 
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Figure 30 - Top enriched biological processes and pathways for genes in our PDAC 
samples. 
(A) Gene Ontology (GO) terms and (B) Kyoto Encyclopedia of Genes and Genomes 
(KEGG) pathways were identified for genes in our PDACs with a Benjamini-Hochberg 
adjusted P-value <0.05. We confirmed a significant enrichment of GO terms involved in 
cancer, including the apoptotic process (P=1.74 x 10-9), cell proliferation (P=1.30 x 10-7), cell 
differentiation (P=5.95 x 10-14) and angiogenesis (P=6.42 x 10-5). We also confirmed a 
significant enrichment of KEGG terms, such as pathways in cancer (P=1.09 x 10-8) and 
pancreatic cancer (P=8.93 x 10-6), as well as terms more relevant to PDAC such as 
regulation of the actin cytoskeleton (P=3.85 x 10-9), axon guidance (P=3.22 x 10-3) and TGF-
β signalling (P=4.16 x 10-3). 
 
4.2.3 Three miRNAs regulate functionally relevant targets in PDAC  
Seeking to generate hypotheses on putatively functional and disease-relevant 
miRNA-mRNA interactions, we used one-tailed Fisher's exact tests to assay lists of 
differentially expressed genes for enrichment of miRNA seed matches (Table 24). 
Early studies have shown that perfect complementarity at the “seed region”, is a 
principal determinant of target recognition [601]. Taking advantage of the mRNA 
expression profile to reduce the test space of PDAC expressed genes; we used a 
seed-match based statistical analysis to highlight putative regulatory networks 
irrespective of conservation limits imposed by target prediction algorithms. The seed 
match analysis (Figure 31) examined the presence and “score” or length of a seed 
match between the top up-regulated miRNAs and down-regulated mRNAs observed 
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in PDAC samples compared to controls (the opposite, that is down-regulated 
miRNAs and up-regulated mRNAs was also investigated; Figure 32). The seed 
enrichment analysis suggested that some of the most down-regulated mRNAs may 
be cooperatively regulated by different up-regulated miRNAs, and revealed 18 up-
regulated miRNAs that potentially down-regulate 136 transcripts (with at least one 6-
(oligo)-mer match). Notably, the most significantly enriched miRNAs were miR-21, 
miR-23a and miR-27a (Table 24); therefore we selected these as suitable 
candidates for further investigation in PDAC.  
Next, we identified novel miRNA-tumour suppressor gene interactions in 
PDAC for these three miRNAs, amongst the top down-regulated transcripts. We 
found that these over-expressed miRNAs preferentially target tumour suppressors 
and selected five interesting genes for further validation (Figure 31 and 33), 
including three known tumour suppressors in PDAC (i.e. PDCD4, SORBS2 and 
BNIP3) and two known tumour suppressors in other cancers that had never been 
studied in PDAC (i.e. BTG2 and NEDD4L). Therefore, these miRNA-mRNA 
interactions allowed us to prioritise important miRNAs for further investigation in 
PDAC. 
 
 
  
  
 
 
Figure 31 - Seed match analysis reveals a miRNA-mRNA regulatory network (up-regulated miRNAs associated with down-regulated 
genes) in PDAC. 
Heatmap showing seed match analysis for 18 up-regulated miRNAs and 152 top down-regulated genes in PDAC vs. Normal Pancreas. 
Colored cells highlight the presence of a miRNA seed reverse-complementary match in the 3'UTR sequence of the crossing gene. Seeds: '6-
mer seed'=nucleotides 2-7 in the miRNA mature sequence; ‘7-mer seed'=nucleotides 2-8 in the miRNA mature sequence; 'predicted 
interaction'=predicted functional interaction based on miRanda-mirSVR [230]. For each colored cell at the intersection of a row (up-regulated 
miRNA) with a column (down-regulated mRNA), the colour identity and meaning are: dark red [miRanda-mirSVR predicted interaction]; medium 
red [7-mer seed]; light red [6-mer seed]; yellow [no seed]. Feature selection: miRNAs: up-regulated miRNAs (Benjamini-Hochberg adjusted t-
test P-value <0.05). MiRNAs belonging to the same miRNA family (i.e. having the same seed sequence) are collapsed in the heatmap to 
remove redundancy (18 up-regulated miRNAs → 15 unique miRNA families shown in the heatmap). Messenger RNAs: top down-regulated 
mRNAs (Benjamini-Hochberg adjusted t-test P-value <0.05; log-ratio of mean signal intensity in cancer vs. normal ≤ -1; mean signal intensity in 
cancer and/or normal samples ≥ log2(500)). Only mRNAs with at least 1 seed-complementary match for any of the up-regulated miRNAs are 
shown in the heatmap (152 unique down-regulated mRNAs → 136 mRNA with at least 1 seed match). Blue arrows indicate miRNA-mRNA 
interactions chosen for further validation. 
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Figure 32 - Seed match analysis reveals up-regulated genes associated with down-regulated miRNAs in PDAC. 
Heatmap showing seed match analysis for 4 PDAC down-regulated miRNAs and 325 top up-regulated genes. Coloured cells highlight the 
presence of a miRNA seed reverse-complementary match in the 3'UTR sequence of the crossing gene. Seeds: '6-mer seed'=nucleotides 2-7 in 
the miRNA mature sequence; ‘7-mer seed'=nucleotides 2-8 in the miRNA mature sequence; 'predicted interaction'=predicted functional 
interaction based on miRanda-mirSVR.[230] For each coloured cell at the intersection of a row (up-regulated miRNA) with a column (down-
regulated mRNA), the color identities are: dark red [miRanda-mirSVR predicted interaction]; medium red [7-mer seed]; light red [6-mer seed]; 
yellow [no seed]. Feature selection: miRNAs: down-regulated miRNAs (Benjamini-Hochberg adjusted t-test P-value <0.05). Messenger RNAs: 
top up-regulated mRNAs (Benjamini-Hochberg adjusted t-test p-value < 0.05; log-ratio of mean signal intensity in cancer vs. normal ≥ 1; mean 
signal intensity in cancer and/or normal samples ≥ log2(500)). Only mRNAs with at least 1 seed-complementary match for any of the down-
regulated miRNAs are shown in the heatmap. 
 Table 24 – miRNA Seed Enrichment Analysis of differentially expressed genes in 
PDAC 
Up-regulated miRNAs, down-regulated genes 
miRNA 
6-mer seed 
P value 
miRNA 
7-mer seed 
P value 
hsa-miR-27a 0.004 hsa-miR-23a 0.038 
hsa-miR-27b 0.004 hsa-miR-21 0.057 
hsa-miR-23a 0.015 hsa-miR-27a 0.094 
hsa-miR-21 0.020 hsa-miR-27b 0.094 
hsa-miR-142-5p 0.028 hsa-miR-145 0.098 
hsa-miR-199a-3p 0.140 hsa-miR-142-5p 0.111 
hsa-miR-143 0.211 hsa-miR-199a-3p 0.128 
hsa-miR-100 0.327 hsa-miR-223 0.226 
hsa-miR-99a 0.327 hsa-miR-142-3p 0.230 
hsa-miR-145 0.339 hsa-miR-143 0.414 
hsa-miR-142-3p 0.357 hsa-miR-100 0.571 
hsa-let-7i 0.501 hsa-miR-99a 0.571 
hsa-miR-342-3p 0.607 hsa-miR-150 0.751 
hsa-miR-223 0.850 hsa-let-7i 0.760 
hsa-miR-125b 0.929 hsa-miR-199a-5p 0.826 
hsa-miR-150 0.941 hsa-miR-199b-5p 0.826 
hsa-miR-199a-5p 0.992 hsa-miR-125b 0.905 
hsa-miR-199b-5p 0.992 hsa-miR-342-3p 0.985 
Down-regulated miRNAs, up-regulated genes 
miRNA 
6-mer seed 
P value 
miRNA 
7-mer seed 
P value 
hsa-miR-630 0.009 hsa-miR-217 0.030 
hsa-miR-216a 0.220 hsa-miR-630 0.107 
hsa-miR-217 0.952 hsa-miR-216a 0.757 
hsa-miR-744 1.000 hsa-miR-744 1.000 
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Figure 33 - miRNA recognition elements (MREs) for miR-21, miR-23a and miR-27a 
seeds in the 3’UTRs of the 5 genes chosen for further validation.  
MREs are based on miRanda-mirSVR target predictions (November 2012; 
http://www.microrna.org/microrna/home.do) [230]. PDCD4 was chosen as a positive control. 
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4.2.4 Key tumour suppressors are direct targets of miR-21, miR-23a 
and miR-27a  
To validate the selected genes as important miRNA targets, we used cloned 
3’UTR regions of these transcripts in luciferase reporter vectors and co-expressed 
them with precursor miRNAs (pre-miRs) in PANC-1 cells. Reduced luciferase levels, 
upon miRNA overexpression, were detected for four of the five genes chosen and 
verified a direct miRNA-mRNA interaction (Figure 34A). We then transfected both 
PANC-1 and MIA PaCA-2 cells with the pre-miRs, either individually or in 
combination and performed immunoblots to assess and confirm changes at the 
protein level. Consistent with the above findings, we observed a reduction in the 
endogenous levels of three of the four proteins with their predicted targeting miRNAs 
(Figure 34B). Notably, BTG2 was undetectable in PANC-1 cells (Figure 34B). 
Strikingly, when all three pre-miRs (10nM for each; total of 30nM) were co-
transfected into MIA PaCa-2 cells, this translated into significantly reduced BTG2 
protein levels compared to pre-miR-21 alone (30nM), suggesting that these miRNAs 
functionally cooperate in the post transcriptional regulation of BTG2, despite being 
over-expressed at a lower extent (Figure 34B). Whilst we demonstrated an 
interaction between miR-23a and SORBS2 by luciferase assay (Figure 34A), protein 
levels were reduced in only one PDAC cell-line after miR-23a overexpression and for 
this reason we did not consider it further (Figure 34B). 
 
Therefore, in accordance with our seed match analysis (Figure 31) and the 
miRanda-mirSVR target predictions [230], we validated that miR-21 regulates 
PDCD4; miR-21 and miR-27a regulate BTG2; and miR-23a regulates NEDD4L 
(Figure 33). 
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Figure 34 - Validation of miR-21, miR-23a and miR-27a targets by luciferase reporter 
assay and immunoblotting. 
(A) Luciferase activity derived from the indicated 3′UTR reporter constructs following co-
transfection into PANC-1 cells with control mimic (pre-miR-NC) or mature miRNA mimics 
(pre-miRs). Error bars represent standard deviations from three independent transfections, 
each measured in triplicate (*P<0.05; **P<0.01). (B) Western Blot analysis of indicated 
protein expression after overexpression of the individual mature miRNAs (30nM) or all three 
in combination (10nM each) for 72 hours in PANC-1 and MIAPaCa-2 cells. BTG2 was not 
detectable in PANC-1 cells. GAPDH was used as an endogenous loading control. Fold 
changes in protein expression levels normalised for GAPDH using ImageJ software are 
shown underneath each relative protein plot. These are representative Western Blots from 
three independent experiments. 
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4.2.5 Inhibition of the triple miRNA combination reduces tumour 
growth more efficiently than silencing an individual miRNA in vitro 
or in vivo  
To verify the role of miR-21, miR-23a and miR-27a in PDAC tumourigenesis, 
we used antisense miRNA inhibitors (anti-miRs) in various combinations to examine 
the effect of loss-of-function on cell-proliferation (Figure 35A). After 5 days there 
was significant reduction in proliferation upon inhibition of miR-21, miR-27a, miR-
21/23a or miR-21/27a in PDAC cell lines. However, co-expression of anti-miRs 
against miR-21, miR-23a and miR-27a (i.e. triple miRNA combination) had a 
stronger effect on reducing the growth of both PDAC cell-lines (60% reduction in 
PANC-1 and 40% in MIA PaCa-2; P<0.001 for both compared to anti-miR-NC), as 
opposed to an individual anti-miR or double combinations (Figure 35A). This effect 
was also seen in primary PDAC cell cultures grown from LCM patient tumours (69% 
reduction in LPc006 and 57% in LPc167; P<.001 for both compared to anti-miR-NC; 
Figure 35B). Conversely, we found an increase in proliferation upon gain-of-function 
by co-expressing either pre-miRs for the triple combination, compared to individual 
pre-miRs or double combinations (66% increase in PANC-1 and 36% in MIA PaCa-
2; P<.001 for both compared to pre-miR-NC; Figure 35C). 
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Figure 35 - Ectopic modulation of miR-21/23a/27a regulates PDAC cell proliferation. 
(A) PANC-1 and MIA PaCa-2 cells were transfected with anti-miR-NC (Negative Control) 
(blue line) or anti-miR-21, anti-miR-23a and anti-miR-27a either individually (90nM) or in 
different combinations (various color lines; 45nM each for 2 anti-miRs or 30nM each for all 3 
anti-miRs) on day 0 and cells were counted on the days indicated. The data are expressed 
as means ± standard deviations (SD; *P<0.05; ***P<0.001). Line graphs are all from the 
same experiments, but have been split into different plates to view the growth curves better; 
anti-miR-NC can be seen in each for easy comparison. (B) LPc006 and LPc167 cells 
(primary cell cultures from LCM PDACs) were transfected with anti-miR-NC (blue line) or 
anti-miR-21, anti-miR-23a and anti-miR-27a either individually (90nM; various color lines) or 
in triple combination (orange line; 30nM each for all 3 anti-miRs) on day 0 and cells were 
counted on the days indicated. The data are expressed as means ± SD (*P<0.05; **P<0.01; 
***P<0.001). (C) PANC-1 and MIAPaCa-2 cells were transfected with pre-miR-NC (Negative 
Control; blue line) or pre-miR-21, pre-miR-23a and pre-miR-27a either individually (30nM) or 
in different combinations (various color lines; 15nM each for 2 pre-miRs or 10nM each for all 
3 pre-miRs) on day 0 and cells were counted on the days indicated. The data are expressed 
as means ± SD (*P<0.05; **P<0.01; ***P<0.001). All cultures for these experiments were 
performed in triplicate. Figure continues on the next page. 
A 
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To investigate the potential anti-tumour activity of these three miRNAs in vivo, 
subcutaneous human PDAC xenografts using two different cell-lines (MIA PaCa-2 
and PANC-1) were grown in nude mice (n=6 for each experimental and control 
group). OncomiR-21 induces cell growth in many human cancers, including PDAC, 
and miR-21 loss enhances apoptosis and reduces cell proliferation [602]. This 
suggests that a miR-21 inhibitor could be used as a potential anti-cancer drug [603]. 
We treated the two groups of PDAC xenografts by weekly IT injection with either 
anti-miR-21 or anti-miR-21/23a/27a complexed with Atelocollagen (first dose given 
on Day 0) to evaluate whether the triple combination was more effective. 
In MIA PaCa-2 xenografts, anti-miR-21 administration caused significant 
suppression of tumour growth by day 21 (i.e. after 3 consecutive doses), compared 
with the administration of the anti-miR-NC complexes (Figure 36Ai). However, this 
tumour suppressive effect was lost for the rest of the experiment (Figure 36Ai). 
Conversely, a reduction in tumour volume was observed for xenografts treated with 
anti-miR-21/23a/27a by day 7 (i.e. after only 1 dose; Figure 36Aii), and this 
reduction was sustained significantly to day 21 and up to the end of the experiment, 
even despite a 3 week rest period before the second treatment cycle. By 10 weeks, 
the MIA PaCa-2 xenografts treated with the triple combination of anti-miRs were 
significantly smaller than those that were administered anti-miR-NC or anti-miR-21 
alone (Figure 36Aiii). Furthermore, and consistent with our findings, tumours treated 
with anti-miR-21/23a/27a showed a significant increase or de-repression of PDCD4, 
BTG2 and NEDD4L by immunoblotting compared to those treated with anti-miR-NC 
(Figure 36Aiv). Tumours from mice injected with anti-miR-21 only, had significant 
de-repression of PDCD4, indicating the efficiency of this treatment (Figure 37). It is 
important to note that anti-miRs can sequester their miRNAs without causing 
degradation [474]. Therefore, measuring miRNA levels is not always a reliable 
measure of miRNA inhibition, and consequently the targets were examined. This in 
vivo experiment was next repeated using PANC-1 cells. This confirmed a reduction 
in tumour volume in xenografts treated with anti-miR-21/23a/27a (Figure 36Bii) that 
was significant for the duration of the experiment compared to anti-miR-NC or anti-
miR-21 alone (Figure 36Bi). Accordingly, xenografts treated with anti-miR-
21/23a/27a were visibly smaller and weighed less than those that were administered 
anti-miR-NC or anti-miR-21 (Figure 36Biii and 36C). 
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Figure 36 - Co-inhibition of miR-21/23a/27a suppresses PDAC tumour growth in vivo. 
(Figure legend continues on the next page). 
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Figure 36 - Co-inhibition of miR-21/23a/27a suppresses PDAC tumour growth in vivo. 
(A) Growth curves of xenografts formed after implantation of MIA PaCa-2 cells (5x106) into 
BALB/c nude mice treated with (i) anti-miR-21/atelocollagen or (ii) anti-miR-
21/23a/27a/atelocollagen compared to each relative control (anti-miR-NC/atelocollagen 
complexes). The volume of the tumours at day 0 was 50mm3, which was when intratumoural 
(IT) injections were started. The data at each time point are expressed as means ± SD of 6 
tumours in each experimental group (*P<0.05; **P<0.01). (iii) Photographs illustrating 
representative features of MIAPaCa-2 xenografts at the end of the experiment after 6 
treatments with anti-miR-NC vs. anti-miR-21 or anti-miR-21/23a/27a. Mice treated with anti-
miR-21/23a/27a all had visibly smaller xenografts at the end of 10 weeks; (iv) The co-
inhibition of miR-21/23a/27a allows the de-repression of crucial PDAC tumour suppressors 
in vivo. Representative Western Blots of protein expression from mice xenografts confirmed 
our direct targets by loss-of-function in vivo and densitometric quantification of protein levels 
(n=6 vs. 6 mice). GAPDH was used as an endogenous loading control. Fold changes in 
protein expression levels normalised for GAPDH using ImageJ software are shown 
underneath each relative protein plot. Bar diagram indicates density ratio (protein / GAPDH). 
Data are shown as means ± SD (*P<0.05). Negative control (anti-miR-NC) was set to 1. (B) 
Tumour xenografts from PANC-1 cells (5x106) treated by IT injection of (i) anti-miR-NC vs. 
anti-miR-21 and (ii) anti-miR-NC vs. anti-miR-21/23a/27a. (iii) Photographs illustrating 
representative features of mouse tumours derived from PANC-1 cells at the end of the 
experiment. (C) Treated PANC-1 xenografts were excised at week 10. Tumours were (i) 
photographed (each index in the ruler represents 1 mm) and (ii) tumour weight was 
evaluated.  
 
Figure 37 - Expression of PDCD4 (a miR-21 target) in mice xenografts after anti-miR-
21 intratumoural injections. 
At the end of 10 weeks, PDCD4 was significantly de-repressed confirming that the anti-miR-
21 treatment had an effect. Representative Western blots of protein expression from mice 
xenografts. GAPDH was used as an endogenous loading control. Fold changes in protein 
expression levels normalised for GAPDH using ImageJ software are shown underneath 
each relative protein plot. Bar diagram indicates density ratio (protein / GAPDH; anti-miR-21 
(n=6) vs. anti-miR-NC (n=6)). Data are shown as mean ± SD (*P<0.05). Negative control 
(anti-miR-NC) was set to 1. 
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Collectively, these results indicate that the synergistic inhibition of these three 
miRNAs suppresses the growth of human PDAC cells in vivo more effectively than 
inhibition of oncomiR-21 alone. This may be due in part to the release of PDCD4, 
BTG2 and NEDD4L from post-transcriptional regulation by these miRNAs, although 
certainly many other miRNA-mRNA interactions exist (Figure 31). 
 
4.2.6 Ex vivo analysis reveals high expression of miR-21, miR-23a 
and miR-27a is associated with aggressive tumour behavior and 
poor survival after PDAC resection 
Using a cohort of LCM PDAC samples (n=91), we found a statistically 
significant association between elevated miR-21 levels and poorly differentiated 
tumours (high vs. low grade; P=0.044), but no other clinicopathological parameters 
(Table 25). Whereas, low levels of all three miRNAs was associated with less 
microscopic tumour infiltration into the surgical resection margin (R0 vs. R1; 
P=0.028; Table 25), an indication of less invasive disease, rather than better surgical 
technique [604] and reduced perineural invasion (P=0.012; Table 25). 
Next, we examined the prognostic value of measuring miR-21, miR-23a and 
miR-27a in the above patient cohort. The majority of the patients with a high doublet 
miRNA expression (i.e. miR-21/23a: miR-21/27a; or miR-23a/27a) were found to 
also be in the high triple miRNA combination expression group (Table 26). Thus, few 
patients have an isolated high expression of two of the miRNAs without up-regulation 
of the third one also (Table 26). Indeed, biologically none of the doublet treatments 
were as effective as the triple miRNA combination or oncomiR-21 alone at 
modulating cellular proliferation in vitro.  
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Table 25 - Correlation Between miR-21 and miR-21/23a/27a Expression with 
Clinicopathologic Variables in the Validation Cohort 
 
Table 26 - Expression of Components of the Triple miRNA Combination (miR-
21/23a/27a) in the RT-qPCR Validation Cohort (n=91) 
 
 
Variables 
All cases  
n=91 (%) 
Low 
miR-21 
n (%) 
High 
miR-21 
n (%) 
Χ
2 
(2-tailed) 
P values 
Low miR-
21/23a/27a 
n (%) 
High miR- 
21/23a/27a 
n (%) 
Χ
2 
(2-tailed) 
P values 
  45 (49.4) 46 (50.6)  64 (70.3) 27 (29.7)  
Age, y 
65 
>65  
 
40 (44) 
51 (56) 
 
21 (52.5) 
24 (47.1) 
 
19 (47.5) 
27 (52.9) 
0.606 
 
31 (77.5) 
33 (64.7) 
 
9 (22.5) 
18 (35.3) 
0.185 
Sex  
Male 
Female 
 
48 52.7) 
43 47.3) 
 
24 (50) 
21 (48.8) 
 
24 (50) 
22 (51.2) 
0.912 
 
33 (68.8) 
31 (72.1) 
 
15 (31.2) 
12 (27.9) 
0.727 
Grade
a
 
Low  
High 
 
39 42.9) 
52 57.1) 
 
26 (66.7) 
19 (36.5) 
 
13 (33.3) 
33 (63.5) 
0.044
d
 
 
30 (76.9) 
34 (65.4) 
 
9 (23.1) 
18 (34.6) 
0.233 
Lymph-node 
status
b
 
N0 
N1 
 
6 (6.6) 
85 (93.4) 
 
3 (50) 
42 (49.4) 
 
3 (50) 
43 (50.6) 
0.978 
 
3 (50) 
61 (71.8) 
 
3 (50) 
24 (28.2) 
0.259 
Tumour size
c
, mm 
30 
>30  
 
21 (41.2) 
30 (58.8) 
 
10 (47.6) 
15 (50) 
 
11 (52.4) 
15 (50) 
0.867 
 
13 (61.9) 
19 (63.3) 
 
8 (38.1) 
11 (36.7) 
0.917 
Lymphovascular 
invasion  
No 
Yes 
 
33 (36.3) 
58 (63.7) 
 
14 (42.4) 
31 (53.4) 
 
19 (57.6) 
27 (46.6) 
0.312 
 
22 (66.7) 
42 (72.4) 
 
11 (33.3) 
16 (27.6) 
0.564 
Perineural 
invasion  
No  
Yes 
 
27 (29.7) 
64 (70.3) 
 
15 (55.6) 
30 (46.9) 
 
12 (44.4) 
34 (53.1) 
0.449 
 
24 (88.9) 
40 (62.5) 
 
3 (11.1) 
24 (37.5) 
0.012
d
 
Resection margin  
R0 
R1 
 
53 (58.2) 
38 (41.8) 
 
30 (56.6) 
15 (39.5) 
 
23 (43.4) 
23 (60.5) 
0.107 
 
42 (79.2) 
22 (57.9) 
 
11 (20.8) 
16 (42.1) 
0.028
d
 
Adjuvant therapy  
No 
Yes 
 
21 (23.1) 
70 (76.9) 
 
11 (52.4) 
34 (48.6) 
 
10 (47.6) 
36 (51.4) 
0.759 
 
14 (66.7) 
50 (71.4) 
 
7 (33.3) 
20 (28.6) 
0.675 
AJCC, American Joint Committee on Cancer; miRNA expression was defined as high or low in 
terms of above or below the median expression respectively.
a
High grade tumours were poorly 
differentiated, compared to low grade which were moderately or well differentiated; Data on 
b
lymph-
node status and 
c
tumour size were analyzed for the 51 patients from the London cohort only. 
d
Statistically significant.  
 
miR-
21 
miR-
23a 
miR-
27a 
miR- 
21/23a 
Isolated 
miR-21/23a 
miR-
23a/27a 
Isolated 
miR-
23a/27a 
miR-
21/27a 
Isolated 
miR-
21/27a 
miR- 
21/23a/27a 
n 
(%) 
Low 
45 
(49.5) 
 
High 
46 
(50.5) 
Low 
45 
(49.5) 
 
High 
46 
(50.5) 
Low 
45 
(49.5) 
 
High 
46 
(50.5) 
Low 
57 
(62.6) 
 
High 
34 
(37.4) 
Rest 
84 (92.3) 
 
High 
7 (7.7) 
Low 
57 (62.6) 
 
High 
34 (37.4) 
Rest 
84 (92.3) 
 
High 
7 (7.7) 
Low 
56 
(61.5) 
 
High 
35 
(38.5) 
Rest 
83 (91.2) 
 
High 
8 (8.8) 
Low 
64 (70.3) 
 
High 
27 (29.7) 
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Kaplan–Meier univariate analyses of OS indicated that high expression of 
miR-21, miR-23a and miR-27a (Figure 38A-C) and their combinations (Figure 39A-
D; Table 27), as well as high tumour grade (median 14.8 vs. 29.9 months, P=0.001) 
and positive resection margin status (R1; median 11.0 vs. 25.2 months, P=0.006) 
were associated with poor OS (Table 27). Notably, patients with high miR-21 
expression alone had significantly worse OS, compared to those with low miR-21 
expression (median 12.4 vs. 27.8 months, P<0.001; Figure 38A). However, patients 
with high miR-21/23a/27a expression had even shorter OS rates, compared to low 
expressors (median 8.5 vs. 25.2 months, P<0.001; Figure 39D). To confirm that 
other significantly expressed miRNAs from our PDAC signature did not confer a 
comparable prognostic value, we randomly selected three different up-regulated 
miRNAs (miR-142-3p, miR-199-3p and miR-342-3p) for further validation in patient 
samples. The expression of these three miRNAs was not associated with OS, either 
individually or in triple combination (Figure 40A-D), indicating that our seed 
enrichment analysis helped to discover a triple combination of miRNAs (miR-
21/23a/27a) that are functionally relevant in PDAC in vivo.  
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Figure 38 - Overall survival among PDAC patients depending on tumoural miR-21, 
miR-23a or miR-27a expression. 
The prognostic value of the individual miRNAs that make up the triple miRNA combination 
were assessed in the London and Italian patients cohorts (n=91). High expression of (A) 
oncomiR-21, (B) miR-23a or (C) miR-27a was associated with poor survival (P<0.001, 
P=0.008, P=0.008, respectively). MiRNA expression levels were measured by RT-qPCR and 
patients were dichotomised into high or low expression groups using the median expression 
value for each miRNA. Figures in bold indicate the median overall survival (OS) in months 
(mo). P values are based on the univariate log-rank test. 
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Figure 39 - Overall survival among PDAC patients depending on tumoural double and 
triple miRNA expression.  
The prognostic value of the double and triple miRNA combinations were assessed in the 
London and Italian patients cohorts (n=91). (A) High expression of miR-21 and miR-23a was 
associated with poor overall survival (P<0.001). (B) High expression of miR-21 and miR-27a 
was associated with poor overall survival (P<0.001). (C) High expression of miR-23a and 
miR-27a was associated with poor overall survival (P=0.001). (D) High expression of all 
three miRNAs versus low expression was associated with poor overall survival (P<0.001). 
MiRNA expression levels were measured by RT-qPCR and patients were dichotomised into 
high or low expression groups using the median expression value for each miRNA. Figures 
in bold indicate the median overall survival (OS) in months (mo). P values are based on the 
univariate log-rank test. 
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Figure 40 - Overall survival among PDAC patients depending on tumoural miR-142-3p, 
miR-199a-3p or miR-342-3p expression or their combination. 
The prognostic value of three other miRNAs that were found to be up-regulated in PDAC 
(Table 21), but not significant in the seed enrichment analysis (Table 24), was assessed in 
the Italian patient cohort (n=40). High expression of (A) miR-142-3p, (B) miR-199a-3p, or (C) 
miR-342-3p was not associated with any survival difference. And neither was the (D) 
combination of these three miRNAs. MiRNA expression levels were measured by RT-qPCR 
and patients were dichotomised into high or low expression groups using the median 
expression value for each miRNA. Figures in bold indicate the median overall survival (OS) 
in months (mo). P values are based on the univariate log-rank test. 
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4.2.7 Multivariate analysis identifies the elevated expression of the 
triple miRNA combination as independently prognostic in PDAC 
To further evaluate the hazard of death associated with high tumoural levels 
of these 3 miRNAs, we performed a Cox regression analysis that included variables 
significantly associated with OS at univariate analysis. Prior to this, we noted that the 
expression of these three miRNAs and their combinations are highly correlated with 
the triple miRNA combination (i.e. Pearson Correlation >0.5; Table 27) and are 
therefore redundant variables. The inclusion of correlated predictor variables 
destabilises a regression model; therefore we chose to only include miR-21/23a/27a, 
as we demonstrated that this combination was the most effective at regulating 
tumour growth in vitro and in vivo. Our multivariate model revealed that high miR-
21/23a/27a expression is an independent predictor of poor outcome (HR=3.21; 1.78-
5.78; Table 27), indicating potential future use as a prognostic signature.  
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Table 27 - Univariate and multivariate analyses for overall survival in patients with 
PDAC (n=91) including clinical covariates and miRNA expression 
Prognostic factor 
 
 
 
mOS 
(months) 
Univariate 
analysis 
(Log 
Rank) 
P value 
Pearson 
Correlation 
Multivariate 
model 
(Cox 
regression) 
P value 
Hazard Ratioa 
(95% CI) 
Age (65 vs. >65 y)  25.2/21.1 0.251    
Sex (male vs. female)  20.3/25.2 0.269    
Grade (high vs. low)  14.8/29.9 0.001e 0.125 0.008f 2.16 (1.22-3.83) 
Lymph Node statusb  
(N0 or N1) 
 
16.1/21.1 0.486 
 
  
AJCC Stagec  
(Stage IIA vs. IIB) 
 
16.1/20.3 0.508 
 
  
Tumour Sized  
(<30 vs. ≥30mm) 
 
23.3/20.3 0.861 
 
  
Adjuvant 
chemotherapy 
(yes or no) 
 23.9/14.0 0.091e 
 
-0.044 
 
  
Resection Margin 
status 
(R1 or R0) 
 11.0/25.2 0.006e 
 
0.230 
 
0.042f 1.77 (1.02-3.07) 
Perineural invasion 
(yes or no) 
 16.1/26.6 0.106e 
 
0.264 
 
  
LVI (yes or no)  20.3/23.3 0.438    
miR-21 (high vs. low)  12.4/27.8 0.000e 0.642   
miR-23a (high vs. low)  14.8/23.9 0.008e 0.642   
miR-27a (high vs. low)  15.2/25.2 0.008e 0.642   
miR-21/23a (high vs. 
low) 
 
10.1/25.2 0.000e 
0.841 
  
miR-23a/27a (high vs. 
low) 
 
10.1/25.2 0.001e 
0.841 
  
miR-21/27a (high vs. 
low) 
 
12.4/27.8 0.000e 
0.822 
  
miR-21/23a/27a  
(high vs. low) 
 
8.5/25.2 0.000e 1g 0.000f 3.21 (1.78-5.78) 
mOS, median overall survival; LVI, lymphovascular invasion;  
a
HR
 
<1 first level of the covariate is associated with good outcome, >1 first level of the covariate is 
associated with poor outcome;  
Data on 
b
lymph-node status, 
c
AJCC stage and 
d
tumour size were available and analyzed by log rank 
test for the London cohort only (n=51) and not considered for the multivariate analysis. 
e
Variables with a P value <0.25 by log-rank test were considered for suitable for inclusion in the 
multivariate model.  
f
Statistically significant.  
 g
Pearson Correlation was used to analyse correlations between the triple miRNA combination and the 
other variables. Those that were highly correlated (i.e. Rho >0.5) were considered redundant and not 
all included in the multivariate model. 
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4.2.8 NEDD4L, PDCD4 and BTG2 are targeted by the miRNAs in the 
triple combination and are clinically relevant in PDAC 
To illustrate the importance of NEDD4L, PDCD4 and BTG2 in PDAC, we 
performed data-mining using Oncomine and also compared mRNA expression levels 
between matched PDAC and NP patient samples using the GEO2R software in 
Gene Expression Omnibus (GEO). Consistent with our findings, all three transcripts 
were significantly down-regulated in PDAC (Table 28; Figure 41A). Using an 
additional recently added dataset (GSE28735 [515]), this was even true in 45 paired 
samples (PDAC vs. NP) from the same patients (Figure 41B-D).  
 
Table 28 – Down-regulation of BTG2, PDCD4 and NEDD4L transcripts in clinical 
PDACs (based on Oncomine analyses of 8 datasets) 
Dataset (Ref) n Clinical 
samples 
BTG2 PDCD4 NEDD4L 
Logsdon Pancreas 
[605] 
27 PDAC vs. normal  
P=7.910
–9
, 
fc –9.112 
P=2.3010
–4
,  
fc –22.714 
N/A 
Segara Pancreas  
[606] 
17 PDAC vs. normal  
P=8.6310
–5
,  
fc –5.092 
P=1.1910
–6
,  
fc –2.225 
P=8.1810
–4
,  
fc –1.574 
Pei Pancreas 
[607] 
52 
PDAC vs. normal 
(matched) 
P=1.9410
–4
,  
fc –3.278 
P=2.3710
–6
,  
fc –2.982 
P=0.002, 
fc –2.106 
Badea Pancreas 
[608] 
78 
PDAC vs. normal 
(matched) 
P=1.14x10
–7
,  
fc –1.952 
P=3.58x10
–10
, 
fc –1.906 
P=3.10x10
–8
,  
fc –1.819 
Grutzmann Pancreas 
[609] 
25 PDAC vs. normal  
P=0.027, 
fc –1.298 
NS NS 
Iacobuzio-Donahue 
Pancreas 2 
[610] 
36 PDAC vs. normal NS 
P=2.96x10
–6
,  
fc –1.835 
P=0.002, 
fc –3.235 
Ishikawa Pancreas  
[611]  
49 PDAC vs. normal  NS NS NS 
Bucholz Pancreas  
[612] 
38 PDAC vs. normal  NS NS NS 
Key: fc, fold change; NS, non-significant; N/A, not available. 
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Figure 41 - Data-mining confirms BTG2, PDCD4 and NEDD4L as clinically important in 
PDAC. 
(A) Summary of BTG2, PDCD4 and NEDD4L mRNA expression in PDAC compared with 
normal pancreas (from Oncomine; datasets updated as of September 2012). In total there 
were 8 cDNA microarray datasets available in Oncomine. Red colour indicates up-
regulation, whilst blue indicates down-regulation in cancer vs. normal. The highlighted 
number (yellow) indicates the number of datasets for which that finding was significant 
(P<0.05). Using GEO2R, the dataset GSE28735 was search for (B) BTG2 (C) PDCD4 and 
(D) NEDD4L. All three transcripts were found to be significantly down-regulated in PDAC vs. 
matched normal pancreas from the same patients. Data are shown as means ± SD. 
 
Next, we examined the expression of these three proteins by immunostaining 
in a tissue microarray containing a large number of PDAC patients (n=121), to reveal 
their influence on clinicopathologic characteristics and survival after PDAC resection 
(Table 29; Figure 42). As the miRNA-mRNA interactions had already been 
confirmed in the same patient samples in our initial molecular profiling, this cohort 
was used to further validate the clinical relevance of these genes. Non-neoplastic 
pancreatic ductal epithelium showed intense nuclear PDCD4 and cytoplasmic BTG2 
protein expression (Figure 42A). However, antibodies against NEDD4L that were 
 231 
 
able to detect protein for Western blotting did not appear to stain above background 
in immunohistochemistry assays (data not shown). Semi-quantitative analysis of 
protein expression showed low expression of BTG2 in 73.6% (89/121) and low 
PDCD4 in 67.8% (82/121) of patients. Statistical analysis revealed that low BTG2 
expression was associated with significantly lower OS, than high BTG2 expression 
(median 15.0 vs. 19.0 months, P=0.046; Figure 42B). Reduced BTG2 levels were 
also significantly associated with high tumour stage (pT3/4, P=0.034; Table 29). In 
addition, reduced levels of PDCD4 were also significantly associated with poor OS 
(median 15.0 vs. 18.0 months; P=0.024; Figure 42C). 
 
Table 29 - Correlation of Clinicopathologic Variables with PDCD4 or BTG2 Expression 
Levels in PDAC (n=121) 
Variables 
All cases 
n=121 
(%) 
BTG2 (cytoplasmic)  
Χ
2 
(2-tailed) 
P values 
PDCD4 (nuclear) Χ
2 
(2-tailed) 
P values 
Low 
BTG2 
n (%) 
High  
BTG2 
n (%) 
Low 
PDCD4 
n (%) 
High 
PDCD4 
n (%) 
  89 (73.6) 32 (26.4)  82 (67.8) 39 (32.2)  
Age, y 
65 
>65 
 
69 (57) 
52 (43) 
 
48 (53.9) 
41 (46.1) 
 
21 (65.6) 
11 (34.4) 
 
0.252 
 
44 (53.7) 
38 (46.3) 
 
25 (64.1) 
14 (35.9) 
 
0.278 
Sex 
Male 
Female 
 
67 (55.4) 
54 (44.6) 
 
47 (52.8) 
42 (47.2) 
 
20 (62.5) 
12 (37.5) 
 
0.344 
 
45 (54.9) 
37 (45.1) 
 
22 (56.4) 
17 (43.6) 
 
0.874 
Differentiation grade
a
 
Low 
High 
 
 
43 (35.8) 
77 (64.2) 
 
 
30 (33.7) 
59 (66.3) 
 
 
13 (41.9) 
18 (58.1) 
 
0.411 
 
30 (37) 
51 (63) 
 
13 (33.3) 
26 (66.7) 
 
0.692 
Lymph-node status 
N0 
N1 
 
37 (30.6) 
84 (69.4) 
 
30 (33.7) 
59 (66.3) 
 
7 (21.9) 
25 (78.1) 
 
0.213 
 
27 (32.9) 
55 (67.1) 
 
10 (25.9) 
29 (74.4) 
 
0.416 
pT category  
1-2 
3-4 
 
32 (26.4) 
89 (73.6) 
 
19 (21.3) 
70 (78.7) 
 
13 (40.6) 
19 (59.4) 
 
0.034
b
 
 
18 (22) 
64 (78) 
 
14 (35.9) 
25 (64.1) 
 
0.104 
Lymphovascular 
invasion  
No 
Yes 
 
 
55 (48.2) 
59 (51.8) 
 
 
39 (47) 
44 (53) 
 
 
16 (51.6) 
15 (48.4) 
 
 
0.660 
 
 
39 (50.6) 
38 (49.4) 
 
 
16 (43.2) 
21 (56.8) 
 
 
0.459 
Perineural invasion  
No 
Yes 
 
52 (55.9) 
41 (44.1) 
 
33 (51.6) 
31 (48.4) 
 
19 (65.5) 
10 (34.5) 
 
0.209 
 
33 (53.2) 
29 (46.8) 
 
19 (61.3) 
12 (38.7) 
 
0.460 
Resection margin  
R0 
R1 
 
115 (95) 
6 (5) 
 
83 (93.3) 
6 (6.7) 
 
32 (100) 
0 (0) 
 
0.132 
 
77 (93.9) 
5 (6.1) 
 
38 (97.4) 
1 (2.6) 
 
0.403 
Adjuvant therapy  
No 
Yes 
 
58 (48.7) 
61 (51.3) 
 
46 (52.3) 
42 (47.7) 
 
12 (38.7) 
19 (61.3) 
 
0.194 
 
40 (50) 
40 (50) 
 
18 (46.2) 
21 (53.8) 
 
0.694 
AJCC, American Joint Committee on Cancer; 
a
High grade tumours were poorly differentiated, 
compared to low grade which were moderately or well differentiated. 
b
Statistically significant. 
 232 
 
 
Figure 42 - Immunohistochemical analyses of the expression of tumour suppressors 
BTG2 and PDCD4 in PDAC reveals loss of expression is associated with poor overall 
survival. 
Immunohistochemical analyses were performed on a tissue microarray of resected PDAC 
cases (n=121). (A) Non-neoplastic pancreatic ductal epithelium showed intense nuclear 
PDCD4 and cytoplasmic BTG2 expression compared to PDAC cores on the TMA. (B) 
Reduced BTG2 expression (targeted by miR-21 and miR-27a) predicts poor overall survival 
(OS) in PDAC. Kaplan–Meier (KM) curves are shown for groups dichotomised according to 
the H-score of low (red) versus high (blue) BTG2 expression on the TMA. (C) Reduced 
PDCD4 expression (targeted by miR-21) also predicts poor OS in PDAC. Again, KM curves 
are shown for groups dichotomised according to the H-score of low (purple) versus high 
(blue) PDCD4 expression on the TMA. Statistical differences were analysed using the log-
rank test.  
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4.3 Discussion 
4.3.1 Integrated molecular analysis identifies miRNA-mRNA 
interactions in PDAC 
miRNAs have broad specificity, therefore one or a few target mRNAs cannot 
fully explain the functional properties of a particular miRNA [613]. Their effects are 
more likely the result of the regulation of several targets participating in multiple 
biological pathways. MiRNAs therefore have clinical potential as diagnostic and 
predictive markers and as novel molecular targets in PDAC.  
Recently, Ma et al. [388] have performed a robust meta-review of the profiled 
PDAC miRNome and validated a 10 miRNA signature as a diagnostic tool. This was 
based simply on the frequency and consistency between previous microarray 
studies, and identified a miRNA meta-signature for recognising PDAC, which 
includes up-regulation of miR-21, 23a, 31, 100, 143, 155, and 221; with down-
regulation of miR-148a, 217 and 375 [388]. This diagnostic meta-signature was then 
successfully validated by RT-qPCR using 78 PDAC and adjacent NP samples [388]. 
Furthermore, the meta-signature was found to be associated with extremely relevant 
GO processes, known to be crucial to pancreatic tumourigenesis, including cell-cell 
adhesion, TGF-β signalling, axonal guidance WNT signalling; EGFR signalling and 
RAS pathway [388]. Of these frequently dysregulated miRNAs in PDAC, they found 
that high miR-21; high miR-31 and low miR-375 were associated with poor OS 
independent of other clinicopathologic variables [388].  
We have described the role of miRNAs in PDAC tumourigenesis and 
highlighted the importance of a combination of three miRNAs (miR-21, 23a, and 27a) 
as a therapeutic target, a concept that could be used successfully to reduce tumour 
progression in other cancers. The importance of miR-21/23a/27a was revealed 
through a seed enrichment analysis (Table 24), combining miRNA and mRNA 
expression profiling, which identified a PDAC specific miRNA-mRNA regulatory 
network, an approach that has never been performed in PDAC before.  
Increasing experimental evidence supports the miRNA mechanism of target 
degradation, rather than translational repression, thus the integration of target 
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predictions with miRNA and gene expression profiles has been proposed to improve 
the detection of functional miRNA–mRNA relationships [614]. Since miRNAs tend to 
down-regulate target mRNAs, the expression profiles of genuinely interacting pairs 
are expected to be anti-correlated. Based on this, we investigated the 3'UTRs of the 
significantly down-regulated genes for enriched frequency of a seed match for each 
up-regulated miRNA in matched PDAC patient samples (Table 24). In this way, we 
were able to prioritise miRNAs that may have the most influence over the PDAC 
transcriptome (i.e. miRNAs targeting the majority of down-regulated genes). We 
were then able to identify a subset of putative, tissue specific, functional mRNA 
targets of a dysregulated miRNA for further experimental validation by evaluating 
overlap with existing target predictions on the miRanda-mirSVR database (Figure 
31). 
In order to improve target acquisition accuracy, several studies have now 
used these integrated approaches to analyse miRNA-mRNA profiles in various 
human malignancies, the goal as always being to identify novel biomarkers and 
therapeutic targets for each tumour [615]. Integrated analyses have now been 
performed in breast, ovarian, colorectal, stomach and haematological cancers [615, 
616]. Indeed, the analysis of matched miRNA–mRNA profiles (miRNA and gene 
expression profiles quantified on exactly the same set of biological samples) has 
been shown to have a remarkable advantage over in silico target predictions and un-
matched miRNA–mRNA expression profile integration [614].   
As described later, we chose to experimentally validate some of the miRNA–
mRNA interactions generated by our integrated analysis. However, in order to 
validate theses type of network analyses there are several other possibilities. Firstly, 
computational algorithms now exist that can combine miRNA and mRNA data sets to 
perform a web-based integrated analysis. MMIA [617] integrates miRNA and mRNA 
expression data with predicted miRNA target information for analysing miRNA-
associated phenotypes and biological functions by gene set analysis. Whilst MAGIA 
(miRNA and genes integrated analysis) [614], is a novel web tool that allows to 
integrate target predictions and gene expression profiles using different relatedness 
measures either for matched or un-matched expression profiles, using miRNA–
mRNA bipartite networks reconstruction, gene functional enrichment and pathway 
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annotations for results browsing. We would expect both of these tools to highlight 
miR-21/23a/27a as functionally important in PDAC. Secondly, further validation and 
insight into the miRNAs identified by our network analysis could be gained by 
performing advanced techniques like high-throughput sequencing of RNAs isolated 
by crosslinking immunoprecipitation (AGO HITS-CLIP or AGO PAR-CLIP), both of 
which identify functional protein–RNA interaction sites [249]. The miRNAs are co-
immunoprecipitated with AGO proteins and bound RNA fragments, which are then 
sequenced by high-throughput methods thereby yielding information on miRNP 
binding sites. These data can then be used to create transcriptome-wide interaction 
maps. When combined with miRNA-expression based arrays, subsequent message 
degradation and therefore functionality can also be determined [618]. These 
methods should therefore provide a new approach to understanding the role of 
miRNAs in PDAC tumourigenesis.  
Nevertheless, we found several miRNA-mRNA putative interactions in PDAC, 
allowing us to prioritise miRNAs for further investigation. We then performed in vitro, 
in vivo and ex vivo studies to fully understand the underlying mechanisms of the 
enriched miRNAs in PDAC. The cooperative inhibition of these miRNAs significantly 
reduced tumour growth both in vitro and in vivo (using PDAC xenografts grown in 
nude mice). We demonstrated this in two different PDAC cell lines (PANC-1 and MIA 
PaCa-2) and also in primary cell cultures derived from patient tumours (LPc006 and 
LPc167). Interestingly, these primary cell cultures have reduced sensitivity to 
standard chemotherapeutic agents used for PDAC, with LPc006 and LPc167 having 
increased chemoresistance to 5-FU and GEM respectively [500]. Thus, the triple 
anti-miR combination may have a role in treating chemoresistant patients, but this 
would require further investigation. There have already been several studies 
demonstrating the role of miR-21 in PDAC chemoresistance, and its inhibition is 
indeed beneficial (Table 6). For the first time, we show that the combined inhibition 
of oncogenic miRNAs could be potentially used as a therapy for PDAC. However, 
additional animal and human studies are warranted. 
MiRNAs are consistently dysregulated in human cancers and have major 
roles as either oncogenes or tumour suppressor genes. Bioinformatic analysis has 
greatly improved our ability to predict bona fide miRNA targets and this is based 
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mainly on the evolutionarily conserved seed matches in the mRNA 3′ UTR. However, 
due to the sophistication of miRNA-mRNA interactions, and the small effect exerted 
by an individual miRNA, few miRNA targets have been functionally validated [472]. 
The computational prediction programs developed can identify putative miRNA 
targets, but these suffer from high false positives and due to a whole genome 
approach, cannot identify tissue/tumour specificity of regulation. False negatives also 
occur due to the low-throughput nature of the query design (i.e. gene by gene or 
miRNA by miRNA) [619].  
Donahue et al. [579] used a multi-platform, survival-based, analysis of 
molecular changes of PDAC to discover clinically useful biomarkers. A composite 
score predictive for survival was calculated for individual genes taking into account 
DNA copy number variations (CNVs) and any regulation by miRNAs. They used 
snap FF surgical specimens of PDAC (n=25) and non-malignant pancreas (n=7) for 
their multiple array platforms. They found 186 up-regulated and 314 down-regulated 
genes that were able to dichotomise patients into 2 highly significant prognostic 
groups (median DFS 7.7 vs. 25.3 months). Similarly, 31 miRNAs were able to 
differentiate 2 prognostic groups (median DFS 9 vs. >36 months). Unsurprisingly, 
none of the miRNAs in their signature overlapped with ours. CNVs associated with 
68 genes were also able to differentiate patient survival. For example, a CNV on 
chromosome 10, resulting in deletion of the tumour-suppressor PDCD4 locus (known 
to also be targeted by miR-21) was identified in 10 patients and found to be 
correlated with poor prognosis. Whilst an amplification on chromosome 20, causing 
amplification of the SRC locus, also predicted worse prognosis in those with low-
grade tumours (SRC is known to suppress miR-126 expression – see 3.3.3.2). As 
there was a large number of PDAC patients included in their integrated analysis, 
they were also able to correlate gene expression with survival. Our initial molecular 
profiling unfortunately didn’t contain enough PDAC samples (n=9) to allow this type 
of analysis (Appendix 2). Donahue et al. [579] found that the following were 
associated with poor OS: up-regulation of EGFR due to low miR-646; low 
PI3KR1/p85α p85α (normally antagonises PI3K/AKT signalling) due to high miR-
519d; and low CBL due to high miR-125a-3p. These and other interactions 
highlighted need further validation [620]. An explanation for lack of concordance with 
our results could be that their PDAC samples only contained >30% tumour cell 
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content, in order to distinguish between cancer cell from stromal cell signatures, 
compared to the >60% tumour cell content that we defined for our study. 
Furthermore, our samples were all from resectable stage IIB PDAC patients 
(Appendix 2), whilst their cohort contained stage I (5%), stage II (26%) and locally 
advanced, unresectable stage III (69%) patients. Thus, although their sample size 
was larger than ours, one could argue that their molecular signature of PDAC may 
be inferior, especially with regards to those patients undergoing potentially curative 
surgical resection.  
In our integrated molecular profiling [390], and the meta-profiling study of 
PDAC by Ma et al. [388], tumours were macrodissected and as a result there were 
miRNAs consistently identified as dysregulated in PDAC vs. NP (i.e. up-regulation of 
miR-21, 23a, 100, and 143; down-regulation of miR-217). This does raise the 
question whether molecular profiling studies should use LCM to dissect out the 
tumour cell compartment or not? Any biopsy or FNA of a pancreatic tumour will not 
sample only cancerous cells but additionally some of the desmoplastic stroma. 
Therefore, it seems reasonable that profiling is based on "bulk" tumour, as 
biomarkers discovered could be translated more easily into clinical practice. On the 
other hand, in order to identify molecular aberrations in vivo and then work 
backwards to reveal tumourigenic mechanisms and possible targets that could be 
"druggable", then it is advisable to investigate cell-specific genomic changes. 
Interestingly, Kadera et al. [389] have shown that miR-21 expression is also 
increased within the stromal compartment, which is known to be responsible for the 
aggressive nature of PDACs. They conclude that "anti-miR-21 may represent a novel 
therapeutic strategy for dual targeting of both tumour and stroma in PDAC" [389]. 
Other differences between the various profiling studies of PDAC (Tables 4 and 21) 
are likely to be due to the use of different microarrays platforms, and this was one of 
the key reasons that Ma et al. [388] state for aggregating selected independent 
miRNA lists in order to reach a pooled conclusion. In addition, different stages of 
disease were included in each microarray. Nevertheless, both the meta-profiling by 
Ma et al. [388] and our miRNA profiling (Table 21) found miR-23a upregulated in 
PDAC, along with its family member miR-27a, as well as miR-21.  
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The recent genetic and molecular profiling of large tumour populations 
generated by TCGA has now enabled an integrated molecular analysis of various 
human cancer types, thereby leading to the "ultimate" pooled conclusion [235, 331]. 
Unfortunately these analyses have not included PDAC as yet, since the data only 
became publically available in December 2013. The analysis by Hamilton et al. [331] 
combined TCGA profiling with HITS-CLIP data to reveal pan-tumour miRNA drivers 
of cancer including miR-17, 18, 19, 93, 130, 210 and 455 [331]. They found that a 
miR-17-19-130 pan-cancer oncomiR superfamily was able to target the PI3K, TGF-β 
and p53 pathways, by co-targeting SMAD4, ZBTB4, TGFβR2 and PTEN tumour 
suppressors [331]. These data reinforce that certain gene pathways have common 
aberrations across cancers, but also that miRNA expression can be tumour specific. 
Indeed, of these only miR-210 is commonly seen as up-regulated in PDAC (5 studies 
in Table 21). Importantly, they noted that miR-21 is the most highly expressed 
miRNA in these cancers, whilst miR-143 is the most highly expressed in normal 
tissues [331]. Conversely, we saw miR-143 up-regulation in our and 5 other previous 
PDAC microarrays (Table 21). 
We defined miRNAs and mRNAs whose expression was significantly 
deregulated in PDAC compared to NP. By mapping 3’UTR complementary seed 
match occurrences, potentially linking up-regulated miRNAs with down-regulated 
mRNAs, we highlighted possible instances of co-regulation (Figure 31). This was 
based on the principle that mammalian miRNAs have been shown to predominantly 
act through the destabilisation of target mRNAs. Indeed, lower mRNA levels account 
for more than 84% of the decreased protein production [621]. Since our analysis was 
based on the fact that miRNAs lower mRNA levels, we may have missed a 
percentage of targets on which the miRNAs only act by decreasing protein 
translation. Furthermore, “non-canonical” targets would have not been highlighted by 
our methods. Recent re-evaluation of the rules that govern miRNA-target base 
pairing, by high-throughput mapping of RNA-RNA interactions, has now estimated 
that ”non-canonical” seed interactions (i.e. G:U pairs; or up to one nt mismatch or 
bulge) are more common than perfect base pairing than previously thought (63% vs. 
37%) [622]. Therefore, potentially important miRNA-mRNA interactions could have 
been missed by our seed enrichment analysis of PDAC. 
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Figure 43 - Interaction network for miR-21, miR-23a and miR-27a in PDAC. 
Cytoscape visualisation software [623] was used to display putative functional interaction 
network for miR-21/miR-23a/miR-27a. Nodes: [red] PDAC up-regulated miR-21, miR-23a 
and miR-27a; [green] PDAC top down-regulated genes. Edges between miRNA and gene 
nodes are drawn whenever a seed match in the gene 3'UTR is present according to our 
seed match analysis and miRanda-mirSVR target predictions (Figure 31). Grey circles 
indicate genes chosen for validation. 
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Even so, our integrated analysis demonstrated that 18 miRNAs are 
significantly up-regulated in resectable PDAC (Table 21) and highlighted that some 
of the transcripts may be co-regulated by multiple up-regulated miRNAs (Figure 31). 
We found enriched seed sequences in 152 down-regulated transcripts in the same 
tumour samples. In particular, miR-21, 23a and 27a expression levels are elevated in 
PDAC and showed significantly enriched frequency of seed matches among top 
down-regulated genes, including important tumour suppressors (Table 24; Figure 
31). This indicated that these miRNAs may be important in PDAC progression 
targeting a tumour suppressor gene network (Figure 43). Indeed, examining the set 
of putative target genes of miR-21, 23a and/or 27a, we observed several GO 
processes relevant to tumourigenesis such as apoptosis, cell adhesion, cell cycle 
and cellular organisation (Figure 44). We experimentally validated some of the 
miRNA-mRNA interactions in vitro and confirmed by loss-of-function, in our xenograft 
model, that PDCD4 is repressed by miR-21, BTG2 by miR-21 and miR-27a, and 
NEDD4L by miR-23a (Figure 36 and 37).  
 
 
Figure 44 – Gene Ontology annotations for the putative target genes of the miR-
21/23a/27a combination. 
Using Panther, the union set of putative target genes of miR-21, 23a and/or 27a, based on 
the occurrence of one or more seeds for at least one of these miRNAs in the mRNA 3'UTR 
and opposite regulation in cancer (i.e. up-regulation of the miRNA; down-regulation of the 
mRNA), were annotated to GO biological processes. 
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4.3.2 PDCD4 validated as a miR-21 target in PDAC 
Of the target genes chosen for validation from our seed-match analysis 
(Figure 31 and 33), the function of PDCD4 has been well defined in PDAC and 
other cancers [593]. PDCD4 inhibits neoplastic transformation and must be down-
regulated for malignant progression to occur [624]. In normal tissues, PDCD4 
mediates multiple biologic processes, such as cell cycle progression and cell 
survival, and interacts with the translation initiation factors eIF4A and eIF4G, thereby 
inhibiting protein translation [625]. Thus, PDCD4 is a tumour suppressor which 
regulates multiple proteins that are involved in tumour progression and 
differentiation. PDCD4 is able to inhibit invasion and metastasis in CRC by regulating 
SP1/SP3-mediated u-PAR expression, a gene known to be involved in cancer 
proliferation and progression [625]. Furthermore, Talotta et al. [322] have described 
a miR-21-PDCD4-AP-1 pathway that can control neoplastic invasion in RAS-
inducible cells. They found that oncomiR-21 is a transcriptional target of the AP-1 
complex in response to the RAS oncoprotein [322]. The AP-1-induced miR-21 then 
down-regulates PDCD4, and to a lesser extent PTEN [322] (Figure 45). PDCD4 
itself has been identified as a powerful inhibitor of AP-1 activity, thus its down-
regulation contributes to the increase of AP-1 activity, revealing a novel AP-1 
autoregulatory mechanism in RAS transformation [322]. As both AP-1 and KRAS are 
activated in PDAC, this pathway may also be important for pancreatic 
tumourigenesis.  
Whilst not novel, the interaction between miR-21 and PDCD4 [384, 593, 626] 
confirmed the robustness of our seed-match analysis (Figure 31), serving as a 
positive control. Indeed, we found that PDCD4 is a functional target of miR-21 in 
vivo, as miR-21 inhibition caused de-repression of PDCD4 (Figure 36A and 37). 
Interestingly, Frankel et al. [305] demonstrated that knock-down of PDCD4 by RNAi 
was insufficient on its own to increase cancer cell proliferation compared to controls, 
however this was able to rescue the reduction in proliferation seen after miR-21 
inhibition. This suggests that miR-21 needs to regulate a multitude of genes to 
effectively enhance tumour growth. Indeed, miR-21 overexpression has been shown 
to potentiate RAS signalling in a CAG-miR-21; KRASLA2 (high miR-21 and oncogenic 
KRAS) mouse model of NSCLC, by inhibiting of antagonists of the RAS/MEK/ERK 
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pathway, including SPRY1, SPRY2, BTG2, and PDCD4 [627]. Furthermore, Hatley 
et al. [627] show that several miR-21 target genes are tumour suppressors involved 
in apoptosis, including APAF11, PDCD4, RHOB and FASLG (Figure 45). 
Surprisingly, this autoregulatory loop between RAS and miR-21 has never been 
investigated in PDAC, and neither has the direct effect of PDCD4 inhibition on cell 
growth. 
Clinically, Nagao et al. [384] have recently demonstrated a strong association 
between high miR-21 expression levels and down-regulated nuclear PDCD4 
expression. Furthermore, they showed a significant association between poor OS 
and low PDCD4 expression in the same PDAC patients [384]. We have confirmed 
this in a larger PDAC patient cohort (n=121, Table 29; Figure 42), further indicating 
the importance of miR-21 regulating PDCD4 in vivo.  
 
4.3.1 BTG2 is a tumour suppressor regulated by miR-21 and 27a in 
PDAC 
BTG2 is a p53 transcriptional target gene and thus has considerable anti-
proliferative activity [628]. The tumour suppressive role of BTG2 is supported by its 
down-regulation in several cancers, including kidney, breast and prostate 
adenocarcinomas [629]. However, its role in PDAC has not been elucidated. BTG2 is 
an early growth response gene that connects the p53 and retinoblastoma (RB) cell 
cycle regulatory pathways in human tumourigenesis [629]. It is a major downstream 
effector of p53-dependent proliferation arrest that acts by inhibiting the expression of 
CCND1, the phosphorylation of RB, and G1 to S progression [629] (Figure 45). 
BTG2 inhibition has also been revealed to cooperate with oncogenic RAS in inducing 
cell transformation [629], which is highly relevant for PDAC carcinogenesis. 
Interestingly, the tumourigenic phenotype acquired by cells as a result of BTG2 
inactivation and RAS signalling does not always require inactivation of p53 (e.g. in 
prostate and RCC) [629, 630]. Ficazzola et al. [630] hypothesised that loss of BTG2 
in this instance may be due to an unknown post-transcriptional modification. Since 
then, several studies have now demonstrated that BTG2 is regulated by various 
miRNAs in human cancers: including miR-32 [631] and miR-21 [632] in prostate 
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adenocarcinoma; miR-21 in laryngeal carcinoma [633]; miR-21 in NSCLC [627] and 
miR-21 in melanoma [634].  
With regards to BTG2s' function in vivo, Yanagie et al. [635] found that the 
deduced amino acid sequence of TOB revealed significant homologies to the BTG1 
and BTG2 gene products. Subsequently, they performed intraperitoneal injection of 
an adenoviral vector containing TOB, in order to up-regulate TOB, into PDAC 
peritonitis mouse models [635]. They found that re-expressing this tumour 
suppressor caused PDAC disease regression and no intra-abdominal tumour 
deposits or bloody ascites were found compared to control mice [635]. Interestingly, 
we also saw TOB1 (a BTG family member) as a target of miR-21 and miR-27a, 
containing 6-mer seeds for both and also good miRanda-mirSVR prediction scores 
(Figure 31 and 43). 
 
Figure 45 - Proposed model of mode of action for miR-27a interacting with BTG2 
causing pancreatic tumourigenesis. 
Key: nuclear factor κB, NF-κB; the ARF tumour suppressor is transcribed from an Alternate 
Reading Frame of the INK4a/ARF locus (CDKN2A); cyclin D1, CCND1; programmed cell 
death 4, PDCD4; Sprouty 2, SPRY2; B-cell translocation gene 2, BTG2; Apoptotic protease 
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activating factor 1, APAF1; Fas Ligand, FASLG; RAS homolog gene B, RHOB; activator 
protein 1 TF, AP-1. 
 
For the first time, we confirmed the direct interaction of miR-21 with the BTG2 
3′UTR in PDAC, and validated miR-27a as a new miRNA that also directly regulates 
this gene (Figure 33 and 34). Synergistically, these two miRNAs reduced the 
expression of BTG2 at the protein level more effectively than overexpression of miR-
21 only (Figure 34B). This is consistent with a previous demonstration that multiple 
miRNAs have a larger effect on translation of a protein [636] and indicates that a 
combination of miRNAs could be a new more effective approach in cancer 
therapeutics. In addition to our microarray, we examined various published datasets 
(Table 28; Figure 41) and identified BTG2 as consistently down-regulated in PDAC. 
Moreover, reduced BTG2 protein expression was associated with poor OS in our 
large cohort of surgically resected PDAC patients (Table 29; Figure 42). Clearly, 
further investigations for the role BTG2 in PDAC are warranted. 
 
4.3.2 NEDD4L is a novel tumour suppressor in PDAC and is 
regulated by miR-23a 
NEDD4L encodes the principal E3 ubiquitin ligase that selectively targets 
activated, linker phosphorylated SMAD2/3 for dephosphorylation and degradation, 
thereby regulating signal termination of the canonical TGF-β pathway [637], which is 
known to have an important role in PDAC progression and metastasis [638]. In 
addition, NEDD4L associates with TGF-βRI receptor via SMAD7, and induces its 
ubiquitin-dependent degradation also [639]. Therefore, loss of NEDD4L antagonism 
may enhance the TGF-β signalling pathway (Figure 46) [640]. The increased 
expression of TGF-β (an endogenous inhibitor of cell growth) is usually accompanied 
by a loss in the growth inhibitory response to TGF-β in human cancers [639]. The 
actual mechanisms for up-regulation of TGF-β are unknown; however, defects in 
TGF-β pathway components (e.g. changes in receptors, TGF-β-related-signal 
transduction/gene activation, and TGF-β-regulated cell cycle proteins) leads to loss 
of growth regulation, tumour cell survival and oncogenesis [639]. Accordingly, 
depletion of NEDD4L leads to the enhanced TGF-β responsiveness of cells [637, 
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639]. As such, overexpression of NEDD4L may result in resistance to growth 
inhibition by TGF-β. 
Other mechanisms exist by which down-regulation of NEDD4L can increase 
tumour progression. In particular, NEDD4L is also down-regulated by N-MYC 
downstream-regulated gene-1 (NDRG1) in PDAC cells [641]. Interestingly, reducing 
NDRG1 levels also results in a decrease in PTEN and SMAD4 tumour suppressor 
levels, and perturbation of the RAS and PI3K pathways [641]. Thus, decreased 
expression of NDRG1 and thereby down-regulation of NEDD4L, increases the 
malignant potential of pancreatic tumours. Accordingly, up-regulation of NDRG1 has 
been shown to inhibit PDAC tumour growth in vivo, in part by these mechanisms, but 
also by causing up-regulation the cyclin-dependent kinase inhibitor p21CIP1/WAF1 and 
down-regulation of cyclin D1 [642].  
In PDAC, the aberrant activation of WNT signalling, revealed by the nuclear 
localisation of β-catenin, occurs in 30–65% of tumours [643]. Mechanistically, 
inhibition of the WNT pathway results in reduced PDAC cell proliferation and survival 
[644]. A recent report has shown that NEDD4L inhibits both the canonical and non-
canonical WNT pathways, in part by inducing Dishevelled (DVL2) degradation [645]. 
As the canonical and non-canonical WNT pathways diverge down-stream from DVL, 
its regulation is of great significance for proper WNT signal transduction [645]. 
Furthermore, Tanksley et al. [646] found that NEDD4L can also inhibit canonical 
WNT signalling at or below the level of β-catenin. Thus, NEDD4L is an essential 
negative regulator of WNT signalling, a pathway known to be active in PDAC (Figure 
46). 
Loss of NEDD4L expression has been identified in the progression of various 
tumours, including prostate cancer, gastric cancer, CRC and malignant glioma [646-
649]. We have now established that NEDD4L expression is also reduced in PDAC 
(Figure 31 and 41). However, how NEDD4L is regulated under physiological and 
pathological conditions is currently unknown. Cho et al. [650] investigated mRNA 
and miRNA expression in interstitial lung diseases which are thought to have several 
pathological features similar to lung cancer. They found miR-23a/24-2/27a cluster 
overexpression, as well as up-regulation of ZEB1, a crucial marker of EMT [650]. 
They also discovered that there are two E-box motifs (i.e. presumptive binding sites 
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for ZEB1) in the distal promoter of the miR-23a/24-2/27a cluster locus, raising the 
possibility that ZEB1 regulates or co-regulates the transcription of these miRNAs 
[650]. 
 
Figure 46 – Proposed model of mode of action for miR-23a interacting with NEDD4L 
causing pancreatic tumourigenesis. 
WNT signalling mediates its effect by binding to Fizzled receptors and Low-density 
lipoprotein receptor-related protein (LRP) 5/6 co-receptors. This causes activation of 
intracellular Dishevelled (DVL), which inhibits Adenomatous polyposis coli (APC), Axin and 
glycogen synthase kinase-3 (GSK3), resulting in the stabilisation and nuclear translocation 
of β-catenin. This then induces gene transcription via LEF/TCF family of transcription 
factors. Figure modified from [651].  
 
Accordingly, they showed that overexpression of ZEB1, in the well-
characterised Madin-Darby canine kidney (MDCK) epithelial cell line, causes the 
levels of miR-23a, 24 and 27a to increase dramatically [650]. Thus, they proposed 
that that loss of NEDD4L could be involved in interstitial lung disease progression by 
increasing ZEB1-mediated EMT, through miR-23a/24-2/27a cluster inhibition of 
NEDD4L protein levels, thus enhancing TGF-β signalling and contributing to disease 
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persistence [650]. It is well known that TGF-β can also induce ZEB1 expression, with 
changes in miR-200 family and E-cadherin expression finally resulting in EMT [344]. 
Reports have also found that TGF-β can induce members of the miR-23a/24-2/27a 
cluster in HCC [652] and lung cancer [653]. Cao et al. [653] also showed that miR-
23a overexpression leads to EMT by down-regulating E-cadherin. Indeed, CDH1 has 
a poorly conserved 8-mer seed for miR-23a (Targetscan). However, they failed to 
show 3’UTR interaction and their results may be due to an indirect effect (e.g. via 
NEDD4L regulation), even though TGF-β treatment followed by anti-miR-23a 
transfection partly rescued E-cadherin levels [653]. More recently, Zheng et al. [654] 
have demonstrated in gastric and colorectal cancers that FASL signalling causes an 
interaction between AP-1 and NFAT4 and subsequent binding to the miR-23a 
promoter leading to increased miR-23a expression. MiR-23a then directly inhibits E-
cadherin expression, through interaction at its 3'UTR, causing EMT and enhanced 
cell invasion and metastasis in vitro and in vivo respectively [654]. Loss of E-
cadherin is the hallmark of EMT and in PDAC this is known to be associated with 
enhanced invasion and migration in vitro [655] and also with higher tumour grade, 
increased chemoresistance and worse prognosis in patients [366]. Therefore, it is 
possible that the miR-23a-NEDD4L interaction can affect two important oncogenic 
pathways (WNT and TGF-β) and lead to PDAC progression (Figure 30B and 46). 
For the first time, we have demonstrated that reduced NEDD4L is a feature of PDAC 
and this may partly be due to post-transcriptional modification by miR-23a (Figures 
31, 33, 34 and 41).  
The clinical significance of reduced NEDD4L in PDAC is unknown, and 
unfortunately, we were unable to successfully examine its expression in our TMA 
(Figure 42). However, data exists for other tumour types. Sakashita et al. [651] have 
recently performed an integrated microarray analysis between comparative genomic 
hybridisation and gene expression with LCM in NSCLC. They identified that reduced 
NEDD4L expression was significantly correlated with copy number loss [651]. 
Furthermore, they established that low NEDD4L expression was significantly 
associated with poor clinicopathological factors, such as excessive smoking history, 
high grade, LN metastasis, and advanced pathological and T stages [651]. 
Accordingly, they found that low NEDD4L expressors had significantly shorter OS 
after surgical resection [651]. Similarly, Gao et al. [647] examined NEDD4L 
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expression in gastric cancer and found that those patients with low tumoural 
NEDD4L also had more advanced disease (LN metastasis, lymphatic and venous 
invasion) and that reduced expression was an independent predictor for poor OS. 
Thus, loss of NEDD4L seems to be a feature of many cancers and of an aggressive 
phenotype [646-649, 651]. However, NEDD4L has also been reported to be up-
regulated in hepatoma [651], prostate [656] and gallbladder cancer [657]. The 
reasons for NEDD4L having “two faces” are unknown, but may be due to the 
different dependency on TGF-β signalling during EMT and tumourigenesis. 
Thus, although we have shown that BTG2 and NEDD4L are regulated by 
members of the triple miRNA combination (miR-21/23a/27a), very little is known 
about the gene pathways and networks that they are involved in to cause pancreatic 
tumourigenesis. As such, additional experiments are warranted to help delineate 
their roles in PDAC. Such investigations may include knock-down by siRNA to 
assess the effects on proliferation and tumourigenicity in vitro, as well as 
investigating their role in EMT and metastasis in vivo. Furthermore, it is clear that the 
triple miRNA combination targets other important tumour suppressors in PDAC 
(Figure 43) and other cancers. 
 
4.3.4 miR-21, 23a and 27a regulate multiple targets in PDAC and 
other cancers 
We validated PDCD4 as a miR-21 target in PDAC. However, miR-21 also 
regulates PTEN, TPM1, TIMP3 and Maspin, resulting in the inhibition of apoptosis 
and promoting aggressive behaviour in PDAC [215, 325, 384, 404]. Surprisingly, 
PTEN also has two 7-mer seeds for miR-23a that are well conserved across species 
(Figure 47A), indicating that it is possibly co-regulated by miR-21 and 23a in PDAC. 
We also saw LRP1B, a member of the lipid transporter family, which is commonly 
mutated in human cancer [656], as a novel target of miR-21 (Figure 31 and 43), 
containing both a 6-mer and 7-mer seed. This newly recognised tumour suppressor 
interacts with uPAR to inhibit cell migration [656] and also regulates the actin 
cytoskeleton via the CDC42/RHOA pathway. Silencing of LRP1B causes increased 
cell migration and invasion in vitro [639], whilst overexpression of LRP1B inhibits 
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tumour formation in nude mice [656]. Thus, LRP1B inhibition by high miR-21 levels 
could contribute to the aggressive and early metastatic nature of PDAC.  
Members of the miR-23a/24-2/27a cluster are known to be up-regulated in 
many other malignancies, including leukaemias, CRC, breast, gastric, lung, 
hepatocellular, and bile duct cancers [654, 658-660]. Whilst, the context-dependent 
functions of this cluster in tumourigenesis are still under investigation, recent studies 
have elucidated several tumourigenic and metastatic mechanisms for these miRNAs. 
MiR-27a has been shown to down-regulate ZBTB10, which de-represses SP TFs 
and SP-dependent genes (including survivin, VEGF and VEGFR1) that are 
associated with cancer-cell survival, growth and angiogenic responses in PDAC 
[661]. Furthermore, Ma et al. showed that inhibition of miR-27a results in the 
suppression of cell growth, colony formation and migration in PDAC (PANC-1 and 
MIA PaCa-2 cells) [662], effects that are mediated via the regulation of its tumour 
suppressor target SPRY2, which is an antagonist of the RAS/MAPK signalling 
pathway (Figure 45) [662]. Interestingly, Acunzo et al. [660] have shown that 
hepatocyte growth factor (HGF) binds to its membrane receptor, MET, and induces 
miR-23a/24-2/27a cluster expression through TF ELK1 in NSCLC. Moreover, miR-
27a can then down-regulate MET and EGFR, by either directly targeting their 3′ 
UTRs, or indirectly by regulating SPRY2. Meanwhile, Li et al. [659] showed that EGF 
induces the expression of MYC, which promotes miR-23a/24-2/27a cluster 
expression and subsequently decreases SPRY2, thus promoting BC cell migration 
and invasion and subsequent hepatic metastases. Interestingly, MYC is known to be 
over-expressed in PDAC also [663]. The SPRY2 3'UTR was found to have functional 
binding sites for miR-23a, 24-2 and 27a in BC [659]. Importantly, SPRY2 contains a 
7-mer seed for miR-23a that is well conserved among multiple vertebrate species 
(Figure 47B). Furthermore, SPRY2 is also regulated by miR-21 in CRC [314]. These 
data suggest that SPRY2 could be co-operatively regulated by the triple miRNA 
combination (miR21/23a/27a) in PDAC contributing to its aggressive phenotype 
(Figure 45 and 47B).  
Remarkably, expression of LIFR (a new metastatic suppressor [596]) was 
also reduced in our PDAC samples, and contains a highly conserved 7-mer seed for 
miR-27a, as well as 7-mer seeds for miR-21 and miR-23a (Figure 47C). Similarly, 
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the adhesion molecule, Nr-CAM, was also down-regulated in our specimens and 
contains 7-mer seeds for miR-21, 23a and 27a (Figure 29, 31 and 47D). Nr-CAM is 
lost in poorly differentiated PDAC [588, 597]. These interactions deserve attention.  
Jahid et al. [664] found that miR-23a and 27a are involved in CRC 
progression, and are both highly expressed in colon cancer stem cells (CCSCs). 
MiR-23a was found to promote migration and invasion of CRC cells and CCSC, 
whereas miR-27a increased cellular proliferation. They validated that metastasis 
suppressor 1 (MTSS1) is a direct miR-23a target and that the E3 ubiquitin ligase 
FBXW7, which targets oncogenic proteins for degradation such as NOTCH, MYC, c-
JUN, is a direct miR-27a target [664]. Looking at patient specimens, expression 
levels of miR-23a were up-regulated in stage I/II CRCs vs. pre-invasive adenomas 
and carcinoma in situ. Thus, miR-23a expression is specifically higher in CRCs from 
patients with locally invasive (stage I/II) disease. In comparison, miR-27a levels were 
higher in all CRCs vs. adenomas and CIS. The most remarkable results come from 
their in vitro and in vivo experiments. They found that miR-27a overexpression 
increased cell proliferation and clonogenicity in vitro, whilst its silencing significantly 
reduced xenograft tumour volumes in a CRC mouse model. Conversely, miR-23a 
knockdown had only a modest effect at reducing cell proliferation and clonogenicity 
in vitro, and silencing it in vivo had no effect on xenograft tumour volume. They went 
on to discover that the main role for miR-23a is in regulating CCSC migration and 
invasion, due to down-regulation of its target MTSS1, rather than proliferation. 
Furthermore, knockdown of both miR-23a and 27a increased the OS of their mice. 
These data have major implications for our findings, and the regulation of MTSS1 
and FBXW7 should be examined in PDAC also. 
Thus, there are many genes which may be regulated by the triple miRNA 
combination and therefore deserve further investigation in PDAC (Figure 31 and 
43). Surprisingly, miR-23a is up-regulated in PDAC in several reports (Table 21), but 
there have been no previous studies investigating its functional role in pancreatic 
tumourigenesis. For the first time, we show that miR-23a, and its family member 
miR-27a, are part of an important functional interactome in PDAC. Strikingly, it 
appears that all three miRNAs (miR-21/23a/27a) are collectively involved in 
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regulating crucial genes in a tumour suppressor network that may drive PDAC 
progression (Figure 43). 
 
4.3.5 miR-21, 23a and 27a inhibition as a novel PDAC therapy  
 Our data on the functional characterisation of the triple combination of miR-
21/23a/27a suggests that their silencing results in a synergistic reduction in tumour 
growth in vitro and in vivo through the positive regulation of their tumour suppressor 
targets (Figure 36). However, we did not find a significant difference in anti-miR-21 
treated mice (Figure 36). The inhibition provided by our methods was functional, as 
we confirmed de-repression of one of the miR-21 target genes, PDCD4 (Figure 37). 
This reinforces the finding that a single miRNA, gene or pathway is unlikely to be a 
reliable target for therapy or predictor of progression for this molecularly complex 
disease [450]. Moreover, the unique triple combination may be used further to 
investigate the biology of PDAC with respect to individual patient prognosis and 
response to anti-cancer therapies. 
  Previous in vivo studies have found that transiently transfected MCF7 BC 
cells with anti-miR-21 (50 nM) that are subsequently injected into the mammary fat 
pads of female nude mice grow substantially slower, compared to the NCs, with 
reduced tumour weight at the end of 4 weeks and reduced cell proliferation 
confirmed by Ki-67 staining [316]. However, Yan et al. [643] used a peptide 
backbone anti-miR-21 (100 nM), thought to provide longer lasting inhibition, to 
transiently transfect MCF7 BC cells prior to fat pad injection, and found that after 9 
days of xenograft growth, anti-miR-21 only had a subtle inhibitory effect on tumour 
volume [643]. Whilst miR-21 levels were reduced in these tumours, no miR-21 
targets were assessed to confirm functional knockdown in vivo [643]. Zhu et al. [644] 
treated more metastatic MDA-MB-231 BC cells with anti-miR-21 and injected them 
systemically via the tail vein into young female nude mice. After 3 weeks they 
harvested the lungs to assess metastatic spread and found that miR-21 silencing in 
vivo significantly reduced the number of lung nodules [643]. Overall these data 
confirm that miR-21 inhibition has a role in reducing tumour progression in vivo. 
However, these studies all performed transient transfection, rather than regular IT 
injection of anti-miR-21 as in our experiments (Figure 36).  
 252 
 
  
Figure 47 - The 3’UTRs of other important tumour suppressors contain miRNA 
recognition elements (MREs) for miR-21, miR-23a and miR-27a.  
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Figure 47 - The 3’UTRs of other important tumour suppressors contain miRNA 
recognition elements (MREs) for miR-21, miR-23a and miR-27a.  
Using the miRanda-mirSVR target predictions (November 2012; 
http://www.microrna.org/microrna/home.do)[230], we identified MREs for the three miRNAs 
in important tumour suppressor genes including (A) PTEN, (B) SPRY2, (C) LIFR and (D) 
NrCAM. Of note, mirSVR is a machine learning method for ranking miRanda-
predicted miRNA target sites by a down-regulation score, the suggested mirSVR score cut-
off for reporting target sites is -0.1 or lower. The PhastCons score measures the 
conservation of nucleotide positions across multiple vertebrates [665]. 
  
Zhu et al. [310] have gone on to grow mammary fat pad xenografts and 
perform two IT injections of anti-miR-21 (50 nM; each one week a part) over a 4 
week period. They found that tumours treated with anti-miR-21 grew slower than 
controls, although data are not shown in their report [310]. They did however find 
that anti-miR-21 IT injections had a functional effect, confirming de-repression of 
tropomyosin 1 (TPM1) [310]. Furthermore, Sicard et al. [412] have shown that stable 
knockdown of miR-21, by single IT injections of LVs antisense to miR-21, strongly 
inhibits progression in their PDAC mouse models (MIA PaCa-2 cell xenografts). 
However, LV gene therapy can have possible genotoxic effects, such as insertional 
mutagenesis, activation of proto-oncogenes in healthy cells or even the generation of 
aberrant transcripts, and therefore is not yet a safe option for human patients [412, 
666].   
 Compared to these studies, our in vivo anti-miR experiments had the 
advantage of repeatedly injecting anti-miRs IT on a weekly basis for 10 weeks, 
thereby allowing a prolonged period of inhibition, whilst recreating a typical 
”chemotherapy-like” regimen (Figure 36). Evidently, our anti-miR/atelocollagen 
complexes had long-lasting effects, were stable in vivo and able to overcome the 
tumour microenvironment (Figure 36 and 37). Despite this, we saw only a mild 
reduction in PANC-1 xenograft volume after anti-miR-21 treatment, but instead a 
much more pronounced fall in tumour growth after silencing the miR-21/23a/27a 
combination (Figure 36). This suggests that PDAC can continue to grow in vivo even 
with a degree of miR-21 inhibition, but the additional targeting of other oncogenic 
pathways, by reducing miR-23a and 27a levels, is fatal. Importantly, this effect was 
observed with the individual doses of the three anti-miRs being much smaller than 
that used when anti-miR-21 was delivered on its own. This may have the advantage 
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of less ”off-target” effects seen silencing a single miRNA with high concentrations of 
anti-miR, whilst maintaining anti-cancer benefits of the treatment [667]. 
 Finally, as the pancreas is a difficult organ to access easily and PDAC is often 
a systemic disease at presentation, methods other than IT injection would also have 
to be considered for delivering miRNA therapeutics. However, a phase I clinical trial 
in 24 advanced and/or metastatic PDAC patients at the University Hospital, Toulouse 
(TherGAP; ClinicalTrials.gov NCT01274455), has shown that a gene therapy product 
can be safely delivered by IT injections via the transgastric or transduodenal route 
using EUS guidance [412]. Although EUS may not be the most agreeable or risk-free 
procedure for patients, the IT delivery of therapeutic miRNA-modulating agents 
against PDAC could soon be a possibility. This may have the value of not only 
providing local tumour control, but also at directly enhancing sensitivity to known 
cytotoxics (e.g. GEM). 
  
4.3.6 Using miR-21, 23a and 27a s as prognostic markers in PDAC 
 Clinical data confirmed previous reports that high miR-21 expression can be 
utilised as a marker for poor OS (Figure 38A; Table 27) [383, 387]. However, we 
found for the first time that miR-23a and 27a also have prognostic value in PDAC 
(Figure 38B and C). Interestingly, these individual miRNAs and their doublet 
expressions were unsurprisingly highly correlated with the triple combination (Table 
27). Cox regression indicated that high expression of the miR-21/23a/27a 
combination was a strong independent predictor of short OS among PDAC patients 
(Figure 39D; Table 27) and was also associated with a more aggressive tumour 
phenotype (more microscopic tumour infiltration at the resection margin and 
increased perineural invasion; Table 25). Thus, this combination may be a more 
powerful and robust prognostic signature than measuring oncomiR-21 alone in 
PDAC. 
 Indeed, miR-23a levels have recently been found to increase during CRC and 
gastric cancer progression [654]. Raised miR-23a expression has also been shown 
to be associated with advancing clinical stage, depth of invasion and LN metastasis 
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in CRC [668]. Zheng et al. [654] found that miR-23a was a surrogate marker of EMT, 
and that patients with high miR-23a levels and low E-cadherin expression had much 
shorter OS rates. We also found that patients with high miR-23a levels had reduced 
OS in PDAC. Notably, our patients (n=91) were all stage IIA and IIB (i.e. resectable 
disease) and it would be interesting to examine miR-23a, as well as miR-21 and 27a 
levels, in stage III or IV PDAC patients.  
Furthermore, miR-27a expression has been shown to be an independent 
prognostic factor of OS and DFS in BC patients, and high levels correlated with 
tumour size, LN metastases and distant deposits [641]. The prognostic significance 
of miR-27a overexpression has also been revealed in other carcinomas. In gastric 
cancer, Liu et al. [642] identified a serum-based 5 miRNA signature (miR-1, 20a, 
27a, 34 and 423-5p) for detection. High levels of this signature, which included miR-
27a, was strongly associated with advanced clinical stages of this disease [642]. 
Whilst in osteosarcoma, a separate signature (miR-16, 142-5p, 29b, 181 and 27a) 
was predictive of metastasis and response to chemotherapy [645]. Indeed, increased 
expression of miR-27a at pre-treatment biopsy was found to be prognostic of 
metastatic disease [645]. In acute lymphoblastic leukaemia, a signature of miR-708, 
223 and 27a was also associated with relapse-free survival [669]. Finally, in ovarian 
cancer, Eitan et al. [670] identified 5 miRNAs (miR-27a, 23a, 30c, 199a-3p and let-
7g) to be over-expressed in chemoresistant tumours. Incredibly, they next found that 
all the members of the miR-23a/24-2/27a cluster, as well as miR-21, were 
associated with poor OS and DFS [670]. In stage III ovarian cancers, high miR-27a 
was found to be an independent prognostic factor for poor OS [670]. Interestingly, 
pan-cancer analyses  have shown that there are common miRNA signatures 
amongst cancers, as well as those that are more tumour-type specific [331].  
 MiR-21 has been shown to cause chemoresistance to GEM, in PDAC (Table 
6). As a result, several studies have shown that high expression of miR-21 is 
associated with poor response to adjuvant chemotherapy, resulting in reduced 
survival [382, 383, 387]. Thus, whilst we have demonstrated that increased 
expression of the triple combination (miR-21/23a/27a) can enhance PDAC tumour 
growth in vitro and in vivo, it may be that the dramatic reduction in OS that we see in 
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high expressing patients is also due to adjuvant chemotherapy failure. The roles of 
miR-23a and 27a in PDAC chemoresistance need to be urgently investigated. 
 
4.3.7 Summary  
In this study [390], we investigated miRNAs up-regulated in PDAC, and found 
that miR-21, 23a and 27a have an increased frequency of seed sequence matches 
among those genes significantly down-regulated in the cancer cells. Of those genes, 
we experimentally demonstrated that PDCD4, BTG2 and NEDD4L are direct targets 
of miR-21, 23a and 27a, and that silencing these miRNAs exerts a combinatorial 
effect on the reduction of cell proliferation. Concurrent targeted silencing of these 
miRNAs, by IT treatment in immunodeficient mouse models, stunted in vivo tumour 
growth. This indicated that inhibition of the triple combination is required as an 
effective therapeutic strategy for PDAC, and we were able to further elucidate some 
of the mechanism for this. We demonstrated an association between high triple 
miRNA expression and poor survival in an independent cohort of PDAC patients, 
suggesting that these miRNAs regulate crucial tumour suppressors in vivo and are 
clinically relevant. Our results identified a combination of three oncomiRs that 
promotes PDAC growth and provide evidence that the co-inhibition of multiple 
miRNAs holds promise for the development of novel cancer therapies. These data 
also suggest that strategies focusing only on individual miRNAs and their pathways 
in PDAC are likely to be flawed.  
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CHAPTER 5: CONCLUSIONS 
Since their discovery in 1993, there has now been a ”miRNA revolution” in 
molecular oncology and most human cancers have been profiled and classified by 
distinctive miRNA signatures. Alterations in miRNA expression and function 
contribute to cancer development through a multitude of mechanisms and miRNAs 
are able to act as tumour suppressors or oncogenes in a tissue/tumour specific 
manner. From this, the diagnostic value and therapeutic potential of miRNAs has 
been realised. 
In this thesis, we have examined the role of miRNAs in pancreatic 
tumourigenesis, including early malignant changes (Chapter 3) and disease 
progression (Chapter 4). Based upon previous expression profiling studies, a 
diagnostic miRNA signature for PDAC appears to exist. Studies have now 
concentrated on determining the use of miRNAs as biomarkers for the detection of 
early changes of malignant transformation in PDAC precursor lesions (i.e. PanINs 
and BCTs) with some success. We have shown that miRNAs can differentiate 
between low malignant potential precursor BCTs and PDAC (low miR-16, 126 and 
let-7), but that caution should be applied to interpreting levels of miR-21, as this may 
be up-regulated early in some cystic tumours (i.e. SMCA). Our studies have 
highlighted that miRNAs can be measured in pancreatic BCTs, and that a subset of 
can distinguish those lesions with less malignant potential. These data support the 
further investigation of miRNAs for the pre-operative classification of pancreatic 
lesions, by using samples taken from either the pancreatic duct at ERCP (fluid 
aspirate) or the cystic/solid lesion itself at EUS-FNA. 
 Surprisingly, whilst the diagnostic PDAC miRNome has been well profiled, a 
prognostic miRNA signature is missing. We have performed an integrated molecular 
profiling of PDAC, a technique now being used more often, to determine the impact 
of dysregulated miRNAs on the PDAC transcriptome, in an attempt to prioritise 
miRNAs that may be the most influence on disease progression. Indeed, modulating 
the expression of a single miRNA can influence an entire gene network and thereby 
modify complex disease phenotypes. We identified a triple combination of up-
regulated oncomiRs (miR21/23a/27a) targeting a tumour suppressor network and 
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whose inhibition was consequently able to diminish tumour growth in a mouse model 
of PDAC. 
 Where key driver mutations, such as KRAS and TP53, are absent in PDAC, 
other gene mutations in their pathways can account for the loss of cell cycle control 
and increased proliferation required for PanIN growth and progression to PDAC [58]. 
Thus, as a single miRNA can target many genes, and many different miRNAs can 
have the same gene target, it is possible that the increase of a small number of 
crucial oncomiRs or the loss of a few TS-miRs could drive PDAC. 
Indeed, it is clear that miR-21 has an important role in pancreatic 
tumourigenesis. However, whilst the mechanisms of miR-23 and 27a have been 
investigated in other tumour types, their role in PDAC progression remains to be 
explained. We have shown that inhibition of these two miRNAs, along with miR-21 
silencing, seems to provide an enhanced antitumourigenic effect. We were able to 
confirm two novel tumour suppressor targets for these oncomiRs, BTG2 and 
NEDD4L, whose loss of action appears to have an important role in several 
oncogenic pathways in PDAC, including TGF-β, RAS and WNT signalling. Future 
large scale genomic profiling studies, including results from the recent TCGA project, 
will expand our understanding of the genetic heterogeneity that underlies PDAC and 
detail the interactive role of miRNAs in tumourigenesis. This could lead to 
“personalised medicine”, whereby specific gene pathways and processes are 
targeted on a patient-to-patient basis.  
MiRNAs hold potential as robust biomarkers to enhance the detection and 
management of pancreatic tumours through their assessment in blood and biopsies, 
and also surgical specimens. Currently, it remains uncertain if miRNAs can be used 
to reliably help detect PDAC pre-operatively, identify high-risk pre-malignant 
neoplasms and/or stratify patients for various anti-cancer treatments, whether that is 
surgery, chemotherapy and/or radiation. However, our results have contributed to 
the growing body of evidence. The next step will be to use these diagnostic and 
prognostic miRNA biomarkers within prospective trials to ascertain if they can 
“personalise” outcome prediction and ultimately aid clinical decision-making. 
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5.1 Future directions 
Whilst the results presented in this thesis have highlighted some important 
miRNA-mRNA interactions in PDAC tumourigenesis, it would be interesting to 
investigate a few aspects further: 
Defining the anti-tumourigenic and anti-metastatic effects of silencing miR-23a 
and 27a in PDAC 
Surprisingly, there is very little known about the precise molecular events 
behind PDAC metastatic spread, which is the main cause of mortality in the vast 
number of cases. However, there have been a few miRNAs validated to target genes 
involved in metastasis (e.g. miR-21 and miR-200 in EMT). From our results it is still 
unclear how miR-23a and 27a can influence PDAC tumour growth and patient 
outcomes. Whilst we have shown a tumour suppressor network that appears to be 
targeted by the triple miRNA combination (miR-21/23a/27a) in PDAC, many miRNA-
mRNA interactions remain to be validated. There can be two possibilities: firstly, the 
triple miRNA combination is involved in disease progression, by causing increased 
proliferation, invasion, motility, cell-survival, stemness and other properties required 
of cells undergoing metastasis, and/or secondly, up-regulation of these miRNAs is 
able to provide considerable resistance to known PDAC anti-cancer drugs.  
Therefore, additional in vitro studies should be performed to assess the anti-
tumourigenic effects of the triple anti-miR combination, such as colony growth 
assays; cell cycle distribution using flow-cytometry; Annexin and caspase 3/7 activity 
assays to assess apoptosis rates; and invasion and migration assays to assess 
metastatic ability. In addition, terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL; detects DNA fragmentation by labeling the terminal end of nucleic 
acids), a measure of apoptotic programmed cell death, could be used to stain treated 
PDAC xenografts or treated tumours from GEMMs.  
Additionally, the functional consequences of our miRNAs could be further 
investigated ex vivo in additional patient samples through immunohistochemical 
staining of tumour sections, for various protein targets, and concomitant ISH, to 
assess the expression and cellular localisation of the miRNAs. This would provide 
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visual confirmation of the resultant reduction of target protein expression for each up-
regulated miRNA in the same patient samples. As the triple miRNA combination may 
be involved in metastasis, correlation of their expression with EMT protein markers 
could also be performed (e.g. E-cadherin, ZEB1 and the miR-200 family). 
Finally, the role of miR-23a and 27a in chemoresistance has been proven in 
other tumour types. Therefore, we would also like to assess the effects of their 
overexpression and silencing, with and without anti-miR-21, on the responsiveness 
to GEM and other anti-cancer drugs in vitro and in vivo. 
Investigating miRNAs in PDAC intratumour heterogeneity and metastasis 
There are some major limitations of our data in light of current interests in the 
sequencing of human tumours in order to identify therapeutic targets or biologic 
pathways of significance. We performed integrated molecular profiling on a single 
region within each PDAC tumour, and whilst this may be sufficient for the 
identification of miRNAs and genes altered during carcinogenesis, it will not 
accurately capture the extent of genetic heterogeneity within that neoplasm, and 
therefore does not reflect any areas undergoing subclonal evolution and preparation 
for metastasis [66]. Therefore, based on our data, affecting miRNAs and altering 
their target gene levels based on a single region biopsy may permit expansion of 
resistant subclonal populations already present in the patient, thereby leading to 
resistance and subsequent progression [66]. The multiple subclones in each patient, 
all with potentially differing therapeutic weaknesses, would need to be targeted for 
effective management of metastatic disease. 
Intratumoural heterogeneity has been reported in a number of solid cancers, 
including PDAC. More recently, complex DNA copy number microarrays and NGS 
techniques have provided powerful techniques for exploring clonal diversity, tumour 
evolution, and development of treatment resistance. For example, genomic variation 
has been used to track dispersal of pancreatic metastases to secondary organs and 
estimate time course of disease [91]. Furthermore, analysis of individual parts of 
solid tumours and their comparison has identified distinct populations of tumour cells 
(subclones) within individual patient samples  [66]. These studies provide insight into 
rates of genomic change in an evolving cancer, and crucially, help to define genes 
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associated with tumour progression and possibly treatment failure. We would 
therefore like to embark on a large study investigating the role of miRNAs in clonal 
evolution during PDAC progression: 
1. First, to assess baseline miRNome changes during PDAC spread, we would 
use a known mouse model of PDAC metastasis, based on human cancer cell 
lines, to obtain primary tumours, as well as LN and liver metastases (the two 
commonest sites) [671]. 
2. Next, we would obtain fresh surgical specimens of PDAC from patients. Part 
of the tumour sample would be frozen until required and the remainder used 
to perform intrapancreatic implantation into nude mice, to again create 
orthotopic xenografts [672]. These patient tumour derived xenografts would 
be allowed to metastasise and then the deposits and primary tumours would 
again be harvested. 
3. Finally, all the samples would be subjected to deep-sequencing for transcripts 
and small RNAs in order to determine the alterations in the miRNome and 
transcriptome. Data analysis would then allow us to define important miRNAs 
involved in PDAC metastasis that could also be further investigated as targets 
to prevent disease spread.  
The results from this study may help illuminate drivers of intratumour heterogeneity 
and the genetic events that permit drug resistance and/or metastasis.  
Defining the PDAC interactome 
Further investigations studying the interactions between miRNAs and genes 
in PDAC are required. These should include the use of NGS, such as HITS-CLIP 
and PAR-CLIP, and will provide a unique opportunity to fully understand the 
miRNome structure and function in PDAC. Hopefully findings from such studies will 
offer new insights into the genetic and signalling pathways in PDAC. These data 
could also eventually be translated into improving anti-cancer drug response. 
 262 
 
Prospective studies investigating the diagnostic potential of miRNAs in bile 
samples and EUS-FNAs from suspicious lesions  
The hope of identifying biomarkers for PDAC screening purposes is still a long 
way off. However, investigations into improving pre-treatment assessment (either 
before surgery, neoadjuvant chemotherapy or palliative measures) have room for 
improvement. We have shown that miRNAs can potentially be used to determine 
aggressive tumour biology, and with an every decreasing list of candidates, the idea 
of measuring specific miRNAs in bile or EUS-FNA samples from patients with 
suspicious pancreatic lesions is soon to be translated into real clinical practice. To 
this end, we have embarked on two studies: 
1. The role of miRNAs in pre-operative bile samples for diagnosing and 
differentiating PDAC, CCA and gallstone disease [673]. We have 
prospectively collected bile samples obtained at ERCP from patients with 
benign and malignant biliary obstruction and are currently measuring miRNAs 
to assess their ability to differentiate these pathologies. 
2. The role of miRNAs in pre-operative EUS-FNAs for diagnosing PDAC and 
differentiating low from high potential BCTs. We have prospectively collected 
EUS-FNAs from pancreatic BCTs and PDACs and are assessing levels of 
miR-21, 126 and let-7d, as well as other miRNAs. 
A meta-analysis of miRNAs with prognostic relevance in PDAC. 
 Finally, we are performing a systematic review and meta-analysis of the 
current studies, including our own, that have associated miRNA expression with 
patient survival outcomes. This will hopefully provide a pooled conclusion about the 
best prognostic miRNA biomarkers to use in future clinical trials. 
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APPENDICES 
Appendix 1 - Clinicopathological Characteristics of Patients with Benign and 
Malignant Pancreatic Cystic Tumours in Chapter 3. 
MiRNA expression profiling and validation was performed on 58 pancreatic tumour samples; 
43 formalin-fixed paraffin-embedded (FFPE) tumour samples were analysed by miRNA 
microarray and RT-qPCR using TaqMan probes; a further 24 fresh surgical specimens 
(normal pancreas n=9 and PDAC n=15) were used to validate the results using RT-qPCR. 
Samples available for immunohistochemical (IHC) analysis were normal pancreas n=12, 
PDAC n=12 and SMCA n=12. Non-tumourous tissue was obtained during pancreatic trauma 
surgery (continued on the next page).  
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BENIGN CYSTIC TUMOUR PDAC NORMAL TOTAL 
 SMCA MCN IPMN CEI Adenocarcinoma 
 
 
 
        
 FFPE n=7 in 
microarray; 
n=12 in IHC 
FFPE n=6 FFPE n=7 FFPE 
n=9 
FFPE n=14; fresh 
n=15 
FFPE n=12; 
fresh n=9 
n=63 
Sex 
Female 8 6 4 6 13 6 37 (58.7) 
Male 4 0 3 3 16 7 26 (41.3) 
Age 
(median, 
range) 
63 (39-78) 50 (24-72) 68 (53-77) 
70 (41-
76) 
67 (30-82) - - 
Tumour Size 
(cm; 
median, 
IQR) 
4.3 (3.3) 3.0 (8.2) 2.4 (4.6) 3.3 (2.4) 2.7 (1.5) - - 
Tumour (pT) stage (%) 
0 - - - 0 0 - 0 
1 - - - 0 1 (3.4) - 1 (2.6) 
2 - - - 1 (11.1) 1 (3.4) - 2 (5.3) 
3 - - - 7 (77.8) 14 (48.3) - 21 (55.3) 
4 - - - 0 9 (31.0) - 9 (23.7) 
Biopsy only - - - - 3 (10.3) - 3 (7.9) 
Missing - -  1 (11.1) 1 (3.4) - 2 (5.3) 
Nodal Status (%) 
Negative - - - 5 (55.6) 8 (27.5) - 13 (34.2) 
Positive - - - 4 (44.4) 17 (58.6) - 21 (55.3) 
Biopsy only - - - - 3 (10.3) - 3 (7.9) 
Missing - - - - 1 (3.4) - 1 (2.6) 
Resection Status (%) 
R0 - - 4 (57.1) 5 (55.6) 15 (48.2) - 24 (63.2) 
R1 - - 3 (42.9) 4 (44.4) 11 (37.9) - 18 (47.4) 
Biopsy only - - - - 3 (10.3) - 3 (7.9) 
Perineural Invasion (%) 
Negative - - - 3 (33.3) 5 (17.2) - 8 (21.1) 
Positive - - - 5 (55.6) 18 (62) - 23 (60.5) 
Biopsy only - - - - 3 (10.3) - 3 (7.9) 
Missing - - - 1 (11.1) 3 (10.3) - 4 (10.5) 
Lymphovascular Invasion (%) 
Negative - - - 5 (55.6) 4 (13.8) - 9 (23.7) 
Positive - - - 3 (33.3) 21 (72.4) - 24 (63.2) 
Biopsy only - - - - 3 (10.3) - 3 (7.9) 
Missing - - - 1 (11.1) 1 (3.4) - 2 (5.3) 
Distal Recurrence (%) 
No - - - 7 (77.8) 20 (69) - 27 (71.1) 
Yes - - - 2 (22.2) 9 (31) - 11 (28.9) 
Local Recurrence (%) 
No - - - 6 (66.7) 10 (34.5) - 16 (42.1) 
Yes - - - 3 (33.3) 19 (65.5) - 22 (57.9) 
Disease Progression (%) 
No - - - 3 (33.3) 12 (41.4) - 15 (39.5) 
Yes - - - 6 (66.7) 17 (58.6) - 23 (60.5) 
Mortality (%) 
Alive All alive All alive 6 (85.7) 4 (44.4) 11 (37.9) - 21 (55.3) 
Dead - - 
a
1 (14.3) 5 (55.6) 18 (62.1) - 24 (44.7) 
SMCA, serous microcystic adenoma; MCN, mucinous cystic neoplasm; PDAC, Pancreatic 
Adenocarcinoma; IPMN, Intraductal papillary mucinous neoplasm; CEI, Carcinoma-ex-IPMN; IQR, 
interquartile range; 
a
Non-disease related death (cardiac disease), RT-qPCR, Quantitative Reverse 
Transcription Polymerase Chain Reaction. 
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Appendix 2 - Clinicopathological and Treatment Characteristics of the PDAC Patient 
Cohorts in Chapter 4. 
Variables Subcategory 
Initial PDAC 
resection 
cohort (fresh) 
n (%) 
Validation 
qPCR cohort 
(FFPE) 
n (%) 
Validation 
IHC Cohort 
(TMA) 
n (%) 
  
All cases  9 91 121 
 
  
Age, y 65 3 (33.3) 40 (44) 69 (57)   
 >65 6 (66.7) 51 (56) 52 (43)   
Sex Male 6 (66.7) 48 (52.7) 67 (55.4)   
 Female 3 (33.3) 43 (47.3) 54 (44.6)   
Differentiation 
grade 
Low 
High 
5 (55.6) 
4 (45.4) 
39 (42.9) 
52 (57.1) 
43 (35.8) 
77 (64.2) 
  
       
Lymph-node 
status 
Absent (N0) 
Present (N1) 
0 (0) 
9 (100) 
6 (6.6) 
85 (93.4) 
37 (30.6) 
84 (69.4) 
  
       
AJCC stage I 0 (0) 0 (0) 9 (7.4)   
 IIA 0 (0) 6 (6.6) 26 (21.5)   
 IIB 9 (100) 85 (93.4) 79 (65.3)   
 III/IV 0 (0) 0 7 (5.8)   
Tumour Size, mm 30 2 (22.2) 21
a 
(41.2) N/A   
 >30 7 (77.8) 30
a 
(58.8) N/A   
Lymphovascular 
invasion 
No 0 (0) 33 (36.3) 55 (45.5)   
 Yes 9 (100) 58 (63.7) 59 (48.8)   
 
unknown 0 (0) 0 (0) 7 (5.8) 
  
Perineural 
invasion 
No 1 (11.1) 27 (29.7) 52 (43) 
  
 Yes 8 (88.9) 64 (70.3) 41 (33.9)   
 unknown 0 (0) 0 (0) 29 (23.9)   
Resection margin 
status 
Negative (R0) 4 (45.4) 53 (58.2) 115 (95)   
 Positive (R1) 5 (55.6) 38 (41.8) 6 (5)   
Survival (months) mOS 13.1 21.1 16.0   
 mDFS 2.1 14.3 11.5   
Status at 
Follow-up 
alive 2 (22.2) 31 (34.1) 0 (0)   
 dead 7 (77.8) 60 (65.9) 121 (100)   
Adjuvant therapy No 3 (33.3) 21 (23.1) 58 (47.9)   
 Yes 6 (66.7) 70 (76.9) 61 (50.4)   
 unknown 0 0 2 (1.7)   
PDAC, pancreatic ductal adenocarcinoma; FFPE, formalin-fixed paraffin embedded; IHC, 
immunohistochemistry; TMA, tissue microarray; AJCC, American Joint Committee on Cancer; data on 
a
tumour size were available for the 51 patients from the London cohort only; N/A, not available; mOS, 
median overall survival; mDFS, median disease-free survival. 
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Abstract
Background: MicroRNA (miRNA) expression profiles have been described in pancreatic ductal adenocarcinoma (PDAC), but
these have not been compared with pre-malignant pancreatic tumors. We wished to compare the miRNA expression signatures
in pancreatic benign cystic tumors (BCT) of low and highmalignant potential with PDAC, in order to identify miRNAs deregulated
during PDAC development. The mechanistic consequences of miRNA dysregulation were further evaluated.
Methods: Tissue samples were obtained at a tertiary pancreatic unit from individuals with BCT and PDAC. MiRNA profiling
was performed using a custom microarray and results were validated using RT-qPCR prior to evaluation of miRNA targets.
Results: Widespread miRNA down-regulation was observed in PDAC compared to low malignant potential BCT. We show
that amongst those miRNAs down-regulated, miR-16, miR-126 and let-7d regulate known PDAC oncogenes (targeting BCL2,
CRK and KRAS respectively). Notably, miR-126 also directly targets the KRAS transcript at a ‘‘seedless’’ binding site within its
39UTR. In clinical specimens, miR-126 was strongly down-regulated in PDAC tissues, with an associated elevation in KRAS
and CRK proteins. Furthermore, miR-21, a known oncogenic miRNA in pancreatic and other cancers, was not elevated in
PDAC compared to serous microcystic adenoma (SMCA), but in both groups it was up-regulated compared to normal
pancreas, implicating early up-regulation during malignant change.
Conclusions: Expression profiling revealed 21 miRNAs down-regulated in PDAC compared to SMCA, the most benign lesion
that rarely progresses to invasive carcinoma. It appears that miR-21 up-regulation is an early event in the transformation
from normal pancreatic tissue. MiRNA expression has the potential to distinguish PDAC from normal pancreas and BCT.
Mechanistically the down-regulation of miR-16, miR-126 and let-7d promotes PDAC transformation by post-transcriptional
up-regulation of crucial PDAC oncogenes. We show that miR-126 is able to directly target KRAS; re-expression has the
potential as a therapeutic strategy against PDAC and other KRAS-driven cancers.
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Introduction
Pancreatic cancer is the 4th commonest cause of cancer-related
death accounting for 33,000 deaths per year in the US [1,2,3] and
at least 6,000 deaths per year in the UK [4]. Currently surgical
resection remains the only treatment associated with the potential
for cure [5]. However, most patients have locally advanced or
metastatic disease at presentation and are therefore not surgical
candidates [3,6]; the actual resection rate is less than 10% [7].
Routine imaging techniques such as computed tomography (CT)
or magnetic resonance imaging (MRI) are not sensitive enough to
detect pancreatic cancer at an early stage [2]. In addition, patients
continue to be diagnosed with advanced disease because currently
there are no tumor markers that allow reliable screening at a
potentially curable stage.
Cystic lesions of the pancreas can be either inflammatory or
neoplastic [8,9]. The epithelial benign cystic tumors (BCT) of the
pancreas have the potential to transform into invasive pancreatic
ductal adenocarcinoma (PDAC) (Figure S1). Clinical differentia-
tion between low and high-risk pre-malignant BCT can be difficult
and the consequences of missing the chance for a curative
procedure in patients who are suitable for pancreatic surgical
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resection can be devastating [8]. BCT are divided into non-
mucinous and mucinous variants: serous microcystic adenomas
(SMCA), which are non-mucinous tumors, have a very low-
malignant potential (,2%) and very rarely progress to PDAC
[10]; intraductal papillary mucinous neoplasms (IPMN) are
mucinous tumors that are connected to the native pancreatic
ducts (main or side-branch) [11]; whilst the mucinous cystic
neoplasms (MCN) are separate from the ductal system [11,12].
Main branch IPMN lesions carry the highest malignant potential,
ranging between 57 to 92% and side-branch IPMN between 6 to
46% [12,13]. MCNs have a high-malignant potential ranging
from 6 to 36% [14,15]. Out of the BCT, the most often en-
countered are the SMCA (32%–39%), MCNs (10%–45%), and
IPMNs (21%–33%) [16]. The latter have more potential to give
rise to in situ or invasive PDAC, via an adenoma-carcinoma
sequence [3,5,14]. Invasive malignancy arising on the background
of an IPMN is termed Carcinoma-Ex-IPMN (CEI) and is more
common in main pancreatic duct IPMN [12,15,17]. A correct
preoperative diagnosis and evaluation of pancreatic BCT is crucial
for clinical decision-making to sieve out those tumors that are
already malignant or have a high-risk of malignant potential for
which urgent surgical intervention is required [17].
MiRNAs are a recently recognized class of non-coding short
RNAs from 17 to 25 nucleotides in length that play a role in post-
transcriptional gene regulation [18]. Expression profiles of human
miRNAs have demonstrated that many miRNAs are deregulated
in cancer and these profiles will help further establish molecular
diagnosis, prognosis and therapy. Several studies have demon-
strated a different miRNA expression profile in PDAC compared
to normal tissues [2,19,20]. However, the profiles of miRNA
production in PDAC precursor lesions remain largely unknown.
In this report, miRNA expression signatures in low and high-
risk pre-malignant pancreatic BCT were investigated. Further-
more, the role of oncogene targeting miRNAs in the regulation of
malignant transformation from BCT was assessed and KRAS was
identified as a direct target of miR-126. Ultimately, identification of
miRNA markers for the clinical differentiation of these pre-
malignant BCT would allow for early surgical resection to improve
outcomes.
Methods
Tissue samples
Analysis of miRNAs in historical stored formalin-fixed paraffin
embedded (FFPE) and fresh surgical specimens was approved by a
UK national research ethics committee (London; 09/H0722/77)
and by Imperial College Healthcare NHS Trust. Following written
informed consent, specimens were obtained from 58 individuals
who underwent pancreatic resection for a cystic tumor or known
PDAC between May 1999 and November 2010 at the Hammer-
smith Hospital, London, UK. During this period, 4 FFPE and 9
fresh samples of normal pancreas were also collected from
pancreatic resection following trauma. After macroscopic exam-
ination, 10 mm thick sections were obtained from the paraffin
blocks for the FFPE tumor samples (n = 43) as in previous studies
[19,21,22]. For the FFPE microarray there were: SMCA (n= 7),
MCN (n=6), IPMN (n=7), CEI (n= 9) and PDAC (n= 14). Our
histopathologist removed any adjacent normal acinar or adipose
tissue with a scalpel. In addition, several sections (3 to 5) were
taken from each block in order to ensure that a representative
sample was obtained. Fresh tissue samples (n = 24; normal
pancreas n= 9, PDAC n=15) collected at surgery were immedi-
ately placed in RNALater RNA Stabilization Reagent solution
(Qiagen, Hilden, Germany) and stored at room temperature for 2–
3 hours before being frozen at 280uC. The immunohistochemical
analysis was performed on FFPE samples: normal pancreas n= 12,
PDAC n=12 and SMCA n=12 (an additional 5 cases of SMCA
were available at this time). Further detailed clinicopathological
information about the patients is provided in Table S1.
Cell culture and transfection
PANC-1 and MIA PaCa-2 pancreatic cells were purchased
from the European Collection of Cell Cultures (ECACC). Both
were maintained in 50% DMEM and 50% RPMI supplemented
with 10% FCS, 1% penicillin/streptomycin, and 1% glutamine.
When the cells were ready for transfection, they were plated in 6
well plate the day before and then transfected with precursor
miRNA (pre-miR) or miRNA inhibitor (anti-miR) (Applied
Biosystems, Cheshire, UK) for 48 hours using HiPerFect Trans-
fection Reagent (Qiagen, Hilden, Germany) before lysis, RNA and
protein extraction.
RNA Isolation
FFPE samples were deparaffinized with xylene and total RNA
was collected using the miRNeasy Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions. Fresh
tissue stored in RNALater was crushed in liquid nitrogen and
subsequent powder lysed in Trizol Reagent (Invitrogen, Paisley,
UK), followed by RNA isolation according to the manufacturer’s
instructions.
miRNA Microarray
The microarray we used is applicable and has been validated for
FFPE samples [23]. Total RNA was extracted (as mentioned
previously) and the samples were analyzed with the Geniom
Realtime Analyzer (GRTA) using the Geniom Biochip MPEA
Homo sapiens (both by febit biomed gmbh, Germany).
The probes on the biochip are designed as the reverse
complements of all major mature human miRNAs (866 miRNAs)
as published in the Sanger miRBase version 13.0 (March 2009)
[24,25]. The probes are synthesized with 7 intra-array replicates
for each miRNA to increase the statistical confidence and to
compensate for potential positional effects. This microarray
combined with the fully automated GRTA platform allows
for measuring miRNA signatures and ensures a high degree of
reproducibility [26]. Samples were labeled by microfluidic-based
enzymatic on-chip labeling of miRNAs (MPEA) [27]. Following
hybridization for 16 hours at 42uC, the biochip was washed
automatically and a program for signal enhancement was processed
with the GRTA. Resulting detection pictures were evaluated using
the Geniom Wizard Software (febit biomed gmbh, Germany).
We have deposited the raw data at GEO under accession
number GSE29352, we can confirm all details are MIAME
compliant.
RT-qPCR
A selection of miRNAs were chosen for validation based on
statistical significant high levels of logarithmized fold change seen
on the microarray, as well as their known potential roles in
tumorigenesis. Extracted total RNA was used to perform RT-
qPCR using Taqman mature miRNA primers and probes
(Applied Biosystems, Cheshire, UK). Briefly, RNA was reverse
transcribed followed by qPCR on a 7900 HT Fast Real-Time
PCR System (both by Applied Biosystems, Cheshire, UK).
Duplicate samples and endogenous controls (U6, U47 and miR-
191) were used throughout. Expression levels of each miRNA were
evaluated using the comparative threshold cycle (Ct) method as
MiRNAs in Benign vs. Malignant Pancreatic Tumors
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normalized to a control (2 2DCt). The relative expression levels of
each miRNA were calculated between tissue types.
For gene expression analysis, total RNA was reverse transcribed
using Superscript III Reverse Transcriptase (Invitrogen, Paisley,
UK) and cDNA transcripts were amplified by qPCR using SYBR
Green (Applied Biosystems, Cheshire, UK). Triplicate samples
were used and levels were normalized to GAPDH using primers
described in Castellano et al [18]. KRAS primer sequences were
from Kent et al [28].
Luciferase Reporter Assay
For KRAS 39UTRs reporter construction, complementary
oligonucleotides (Sigma Aldrich Ltd., Dorset, UK) containing
the miR-126 recognition elements (MRE) plus 10 nucleotides on
each side were annealed and successively cloned into the Mlu1 and
HindIII sites of the multiple cloning site (MCS) of pMIR-
REPORT Firefly Luciferase vector (Applied Biosystems, Cheshire,
UK). KRAS 39-UTR containing two wild-type (named KRA-
S_A_WT and KRAS_B_WT) and two mutated (named KRA-
S_A_MUT and KRAS_B_MUT) miR-126 binding sites were used
to produce the constructs. The sequences of all primers used for
plasmid construction are reported in Table S2.
MIA PaCa-2 cells were seeded onto 24-well plates (106105 cells
per well) the day before transfections were performed. Cells (80%
confluent) were co-transfected with pRL-TK luciferase reporters
(50 ng/well), pMIR-REPORT firefly luciferase (150 ng/well), and
pre-miR-126 (100 nmol/L) using Lipofectamine 2000 (Invitrogen,
Paisley, UK). After 48 hours the cells were lysed using a passive
lysis buffer (Promega, Southampton, UK) and the firefly and
Renilla luciferase luminescence signals were measured using the
Dual-Glo Luciferase Assay System (Promega, Southampton, UK).
Western Blotting
Whole cell lysates were prepared in Nonidet P-40 lysis buffer
[50 mM Tris/HCl, pH 8.0, 150 mM NaCl, 10% (vol/vol)
glycerol, 1% Nonidet P-40, 5 mM DTT (DTT), 1 mM EDTA,
1 mM EGTA, 50 mM leupeptin, and 30 mg/mL aprotinin].
Lysates were subjected to SDS/PAGE and blotted on a Hybond
C super nitrocellulose membrane (GE Healthcare, Bucks, UK).
The intensity of bands was quantified using Image J software
(National Institutes of Health). We used BCL2 (ab692) (Abcam
Plc., Cambridge, UK), CRK (610035) (BD Ltd., Oxford, UK),
KRAS (sc-30) and GAPDH (sc-137179) (Santa-Cruz Biotechnol-
ogy Inc., Santa-Cruz, USA) monoclonal mouse antibodies.
Immunohistochemistry
Sections (4 mm) from FFPE blocks were prepared for immuno-
histochemical examination. After deparaffinisation and rehydra-
tion, antigen retrieval was performed by boiling in 10 mmol/l of
citrate buffer (pH 6.0) for 10 min. After inhibition of endogenous
peroxidase activity for 30 min with methanol containing 0.3%
H2O2, the sections were blocked with 2% BSA in PBS for 30 min
and incubated with antibodies against CRK (as before). The
immune complex was visualised with the Dako REAL EnVision
Detection System, Peroxidase/DAB, Rabbit/Mouse (Dako, Cam-
bridgeshire, UK), according to the manufacturer’s procedure. The
nuclei were counterstained with hematoxylin. Representative
photographs were taken and two pathologists (R.A. and P.C.)
scored the slides for protein expression.
Statistical analysis
The miRNA microarray aimed to detect differential expression
between tissue types. The mean expression values for each miRNA
on the microarray were first background subtracted and normalized
before analysis. Global background subtraction corrects for several
experimental factors that may cause a systematic spatial variability
on a microarray. Following this, the 7 replicate intensity values of
each miRNA were summarized by their median value. Quantile
normalization was then performed across all the different arrays
[29]. These microarray data are presented as the median relative
miRNA expression levels observed and the median logarithmized
fold changes between tissue types.
A hierarchical clustering heatmap was created using the 35
miRNAs with the highest variability in order to separate the data
graphically. This was done because if all the miRNAs were used
then there would be no reliable image, since most are contributing
more background noise than signal. To detect whether partition-
ing was significant, a 363 contingency table consisting of the 3
main groups of tissue type (PDAC, CEI and BCT), was analysed
using Fisher’s Exact test [30]. A P,0.05 was considered a
significant clustering result.
Limma is a test for differential expression analysis of data arising
from microarray experiments. Empirical Bayes and other methods
are used to borrow information across genes, making the analyses
ideal for experiments with a small number of arrays [31,32]. The
resulting P-values were adjusted for multiple testing by the Benjamini-
Hochberg method [33,34]. A log fold change for a deregulated
miRNA with a limma adjusted P,0.05 was considered statistically
significant. Tables S3, S4, S5, and S6 demonstrate the microarray
results for the 30 most deregulated probes (detected by highest
absolute value of logarithmized fold changes) in each tissue
comparison.
The differential miRNA expression between tissues for all RT-
qPCR and Western blotting data was analyzed using the
parametric t-test (unpaired, 1-tailed for validation of the FFPE
samples and unpaired, 2-tailed for fresh tissue samples) with
Graphpad Prism 4.0 (Graphpad Software Inc, San Diego,
California). The immunohistochemistry data was analyzed using
a 363 contingency table and the Fisher’s Exact test (2-tailed).
Where required, the P-values were adjusted for multiple testing
with the Bonferroni correction.
Results
Microarray expression profiles reveal general miRNA
down-regulation in PDAC compared to low malignant
potential BCT
In order to distinguish the various types of pancreatic tumor,
miRNA expression profiling was performed using total RNA
derived from FFPE tissues of low and high malignant potential
BCT and ductal adenocarcinoma (CEI and PDAC). It has already
been described that PDAC is mainly characterized by miRNA up-
regulation. Bloomston et al. identified 30 miRNAs up-regulated
and 3 down-regulated in PDAC compared to normal pancreatic
tissue [20]. This suggested that miRNA up-regulation represents
an important event for pancreatic cancer progression, but
interestingly comparing the miRNA expression levels between
the low malignant potential BCT and PDAC, general miRNA
down-regulation in cancer was observed (Table S3).
Hierarchical clustering based on the expression of these miRNAs
correctly aggregated benign and PDAC cases. The first cluster
consists of 80% PDAC, 20% CEI and no BCT samples and thus
contains predominantly PDAC samples. The second cluster contains
41% PDAC, 41% BCT and 18% CEI samples and finally the third
cluster contains 14% PDAC, 24% CEI and 62% BCT samples, thus
consists predominantly of BCT samples (Figure 1A). The detected
partitioning and clustering was statistically significant (P=0.034).
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Next, miRNA expression profiles of PDAC were compared with
different types of BCT (Tables S3, S4, S5, S6) to observe whether it
would be possible to distinguish between them. Although no
significant differential expression of miRNAs was identified between
the BCT subgroups (i.e. IPMN vs.MCN or SMCA; IPMN vs. CEI),
21 miRNAs were down-regulated and none were up-regulated in
PDAC compared to SMCA (low malignant potential BCT).
RT-qPCR validates the microarray results
To confirm the microarray results, Taqman RT-qPCR and
normalized miRNA expression levels by snRNA U6, snoRNA U47
and also by miR-191 (as it did not change across tumor type in the
microarray) were used. All of the controls reached the same
statistical significance. Since their deregulation is important for
cancer progression, miR-21 [35–36], miR-126 [37] and miR-16 [38]
were selected for further analysis using RT-qPCR, furthermore
miR-126 and miR-16 have not been well studied in PDAC. RT-
qPCR was performed with the same RNA as in the microarray.
This revealed that although as expected there was no significant
change of miR-21 between the BCT types (Figure 1B), miR-126 and
miR-16 were significantly down-regulated in PDAC compared to
SMCA (low malignant potential BCT) (Figures 1C and D).
MiR-21 is up-regulated in PDAC and SMCA compared to
non-tumor samples
As miR-21 is well described as being up-regulated in PDAC
compared to normal tissues [20], we used normal pancreas to
Figure 1. A subset of miRNAs are down-regulated in PDAC compared to Benign Cystic Tumors (BCT). (A) Hierarchical Clustering Heatmap
was created to detect possible clusters in rows (transcripts) and columns (samples) of the normalized expression matrix. For this analysis we used the 35
miRNAs with highest overall variability. As the heatmap, with its dendrogram on top and the contingency table at the bottom, shows we detect three
clusters indicated by the solid blue lines. The first cluster consists of 80% PDAC, 20% CEI and no BCT samples and thus contains predominantly PDAC
samples. The second cluster contains 41% PDAC, 41% BCT and 18% CEI samples. Subdividing it into two additional clusters, as indicated by the dashed
blue lines, we see that the left part consists predominantly of CEI, while the right part entails a slight enrichment for BCT samples. Finally, the third cluster
contains 14% PDAC, 24% CEI and 62% BCT samples, thus consists predominantly of BCT samples (P=0.034). (Red indicates high intensity; green
indicates low intensity; PDAC, Pancreatic Ductal Adenocarcinoma; CEI, Carcinoma-Ex-IPMN; BCT, Benign-Cystic-Tumors). (B) miR-21 (C) miR-126 and (D)
miR-16 were measured using RT-qPCR, performed on the 43 FFPE tissues in order to validate the microarray data. Samples included: SMCA (n= 7), MCN
(n= 6), IPMN (n= 7), and CEI (n= 9) and PDAC (n=14). (Results presented as mean6SEM; *** P=0.003, ** P=0.02 and * P=0.05 respectively).
doi:10.1371/journal.pone.0032068.g001
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confirm the up-regulation of miR-21 in PDAC and to examine
expression levels of the other selected miRNAs.
RNA from a panel of fresh non-tumorous and PDAC tissues
samples (n= 24) was extracted in order to measure miRNA
expression levels by RT-qPCR. We confirmed that miR-21 was
significantly up-regulated in PDAC (P,0.001) compared to normal
pancreas (Figures 2A). Furthermore, no significant changes were
found in the expression levels of miR-126 and miR-16 between fresh
normal pancreas and PDAC tissue (Figures 2B and C), but as
confirmed by RT-qPCR, there was significant down-regulation of
miR-126 and miR-16 between SMCA (low malignant potential
BCT) and PDAC in the FFPE samples (Figures 1C and D).
In order to make a comparison with the FFPE BCT, we
paraffinized some of the normal fresh pancreas samples for RNA
extraction and RT-qPCR validation. Interestingly, in these FFPE
samples we confirmed that miR-21 was up-regulated in PDAC
(n= 14), as well as in SMCA (n= 7), compared to normal pancreas
(n = 4) (Figure 3). This indicates that the expression of miR-21 is an
early event able to increases pancreatic cell proliferation, but not
malignant transformation.
MiR-16, miR-126 and let-7d modulate the expression of
pancreatic cancer oncogenes
The current study has revealed that many of the miRNAs found
to be down-regulated in PDAC compared to SMCA (low
malignant potential BCT) can potentially regulate the expression
of genes which promote malignant transformation. PDAC is
characterized by the deregulation of many proto-oncogenes
among which KRAS, HMGA2, BCL2 and CRK are critical
[39,40,41,42]. The great majority of PDAC cases harbor a gain-
of-function mutation of KRAS that results in the generation of a
constitutively active form [39]. We show that KRAS and BCL2
protein are significantly up-regulated in PDAC patients (Figure
S2A and B). However no significant change was observed at the
mRNA level for KRAS (Figure S2C), suggesting a post-
transcriptional regulation in PDAC that could be mediated by
the miRNA pathway. Moreover, it is already known that KRAS
and HMGA2 are regulated by the let-7 family (family of miRNAs
that we found to be down-regulated in PDAC in our microarray
(Table S3)) in PDAC and other cancers [43]. The levels of KRAS
mRNA have also been found to vary randomly in colorectal
cancer despite consistent up-regulation of KRAS protein expres-
sion [44]. It is also known that miR-16 regulates BCL2 expression
and acts as a tumor suppressor in prostate cancer and chronic
lymphocytic leukemia (CLL) [45,46]. Furthermore, studies have
shown that administration of the precursor to miR-16 into a
murine model of metastatic prostate cancer results in attenuation
of disease progression [47]. Interestingly, it has been shown that
miR-126 directly regulates the expression of CRK in non-small cell
lung carcinoma [48], gastric [49] and breast cancer [50] and one
would expect PDAC to exhibit high expression of CRK if this
oncogene is repressed by miR-126 in pancreas. However, we could
not find any significant difference in CRK protein levels when
comparing normal pancreas and PDAC patient samples (Figure
S2A and B). CRK is a component of the focal adhesion complex
that is involved in integrin signalling and high levels of CRK have
been associated with an aggressive phenotype of carcinomas [50].
We therefore performed immunohistochemical analysis using a
larger sample size, also containing SMCA cases, to stain for CRK
protein directly on the tissue. This identified increased CRK
protein levels in PDAC compared to benign tissues and normal,
indicating a regulatory role of miR-126 in this tumor type.
Representative sections of CRK protein levels in the different
pancreatic tissues can be seen in Figure S3. Analysis using Fisher’s
Figure 2. RT-qPCR of selected miRNAs performed on fresh
tissues. (A) miR-21, (B) miR-126 and (C) miR-16 were measured using
RT-qPCR in order to compare PDAC to normal pancreas for the miRNAs
of interest. MiR-21 is overexpressed in PDAC compared to normal
pancreas tissue (*** P,0.001). MiR-126 and miR-16 expression levels
were not significantly different between PDAC and normal pancreas
tissue. Samples included: normal pancreas (n = 9) and PDAC (n= 15).
Box and Whiskers indicate median, minimum and maximum.
doi:10.1371/journal.pone.0032068.g002
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Exact test indicated a statistically significant difference in CRK
staining intensity between PDAC, normal pancreas and SMCA
(P=0.0048).
In order to evaluate whether any of these miRNAs down-
regulate the expression of these oncogenes in PDAC, the miRNAs
were first over-expressed, by transfecting mimics into MIA PaCa-2
and PANC-1 PDAC cell-lines followed by Western blot analysis.
Over-expression of pre-miR-16 down-regulates BCL2 expression
compared to the over-expressed negative control (Figure 4A, 4B
and Figure S4A). Furthermore CRK levels were reduced by pre-
miR-126 transfection (Figure 4A, 4B and Figure S4A) and
surprisingly, KRAS was down-regulated not only by pre-let-7d,
but also by pre-miR-126 in MIA PaCa-2 cells (Figure 4A and 4B).
As it is well documented that the tumour-suppressor let-7 family
regulates KRAS in pancreatic [51,52], lung [53], colon [54] and
breast cancers [55], we concentrated on miR-126 as a novel KRAS
targeting miRNA in PDAC. To this end we performed loss of
function experiments using specific miRNA inhibitors to further
validate this finding. We could demonstrate that in contrast to pre-
miR-126 expression, the down-regulation of miR-126 increases
both KRAS and CRK protein levels (Figure 4C and 4D). Since we
could not see any difference in KRAS mRNA levels using either
pre-miR-126 or anti-miR-126, this indicates that this miRNA
possibly acts on the protein translation step (Figure 4E). The data
herein demonstrate that the down-regulation of multiple miRNAs
in PDAC may contribute to malignant transformation.
MiR-126 regulates KRAS protein translation by
interacting with a ‘‘seedless’’ motif in its 39UTR
We show that over-expression of miR-126 reduces and
conversely its silencing increases KRAS protein levels (Figure 4A,
4B, 4C and 4D). In order to evaluate whether miR-126 directly
regulates KRAS, we performed a bioinformatic search of potential
miR-126 interaction sites in the KRAS mRNA. Using the RNA22
software [56] and the entire KRAS transcript as the input
sequence, we predicted two miR-126 binding sites in the 39UTR
with ‘‘seedless’’ characteristics (Figure 5A). This means that these
interaction sites do not have canonical features of complete
interaction between the 59 seed region of the miRNA [57] and the
39UTR of the gene that has been indicated to be important for the
regulation of the target genes [58]. But instead G-U wobbles were
present in the complementarity between gene and seed miRNA
sequence (Figure 5A). Interestingly, these two regions appeared
evolutionally conserved across species (Figure 5A) and more
importantly it has been recently demonstrated that miRNAs can
regulate gene expression also using ‘‘seedless’’ pairing [58]. For
these reasons we went on to clone the two sites that we termed
KRAS_A_WT and KRAS_B_WT into the 39UTR of pMIR-
REPORT construct along with a mutated version of each (Table
S2) and co-expressed them with the pre-miR-126 in MIA PaCa-2
cells. Over-expression of miR-126 decreased luciferase activity only
when co-expressed with KRAS_A_WT and not the mutated
version (KRAS_A_MUT) (Figure 5B). This indicates that miR-126
directly regulates KRAS at post-transcriptional levels through a
‘‘seedless’’ interaction with its 39UTR.
Discussion
Although the pancreas specific miRNAome and how it is
modified in PDAC has been extensively investigated [59], only a
limited number of studies have looked at miRNA expression in
pancreatic pre-malignant lesions [60,61] indicating an urgent need
for further investigation. Du Rieu et al. examined samples of non-
pathologic pancreatic ducts and microscopic pancreatic intraep-
ithelial neoplasia (PanIN) precursor lesions from a KRAS (G12D)
mouse model and from human FFPE samples adjacent to PDAC.
They showed that miR-21 deregulation occurs in the most
advanced PanIN-3 lesions, before they become invasive PDAC
[60]. Habbe et al. looked at the expression of 12 selected miRNAs
in IPMN compared to normal pancreas and CEI [61]. They found
10 miRNAs significantly up-regulated in IPMN compared to
normal pancreas; of which miR-21 and miR-155 were identified as
possible biomarker candidates for PDAC progression from normal
pancreas to IPMN to adenocarcinoma.
For the first time, we have examined global miRNA expression
in all the epithelial macroscopic pre-malignant pancreatic BCT
(i.e. SMCA, MCN and IPMN), compared to PDAC and CEI, by
microarray to reveal the miRNA-based relationship between these
lesions. Interestingly, with a few exceptions, PDACs tend to cluster
together and remain well separated from the BCT.
There were no significant changes in the miRNA expression
patterns between the various types of BCT, indicating that
miRNA expression changes were not involved in transitions
between the BCT types and more importantly that such transitions
were unlikely to occur in vivo. A widespread miRNA down-
regulation in PDAC was observed compared to SMCA, the most
benign lesion that rarely progress to invasive adenocarcinoma. We
observed that many of the miRNAs down-regulated in PDAC
belong to the same family or cluster. Being that the probes used in
the microarray are randomly located in the platform, we regard
this as validation of our findings. For example, among the
miRNAs that we found to be down-regulated, miR-15a forms a
cluster with miR-16, miR-24 forms a cluster with miR-23a or miR-
27b, miR-29a with miR-29b, miR-143 with miR145 and each cluster
is expressed as a unique primary transcript (Table S3).
It has widely been described that miRNA up-regulation
characterizes PDAC [19,20], whilst cancers are usually charac-
terized by general miRNA down-regulation [62]. We confirm that
miR-21 up-regulation is actually an early event that induces
Figure 3. RT-qPCR confirmed miR-21 overexpression in PDAC
and SMCA compared to normal pancreas. This suggests that miR-
21 overexpression may be an early event in the formation of pancreatic
BCT from normal pancreas. MiR-21 was unable to differentiate PDAC
from SMCA and therefore it may be questionable as a future biomarker
of PDAC. RNA was isolated from FFPE samples for all 3 tissue types.
(Results presented as mean6SEM).
doi:10.1371/journal.pone.0032068.g003
MiRNAs in Benign vs. Malignant Pancreatic Tumors
PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e32068
normal non-proliferative cells into benign proliferative cells.
Dysregulation of proteins involved in miRNA biogenesis in
PDAC, which still need to be characterized, could explain this
event. Among the down-regulated miRNAs in our microarray,
there are many already described as tumor suppressors through
inhibition of known PDAC oncogenes. We show general miR-29
family member down-regulation. Amongst their targets are
DNMT3A and 3B-methyltransferases, whose levels can increase
because of the loss of miR-29, causing CpG island hypermethyla-
tion and cancer [63]. We also show down-regulation of let-7 family
members (let-7f, let-7d, let-7c, let-7a, let-7i) (Table S3), which are
already described as negative regulators of KRAS and HMGA2
oncogenes, whose increased activity is very important during
PDAC progression [53,64]. Furthermore, we show down-regula-
tion of both miR-143 and miR-145, which have recently been
described as being transcriptionally down-regulated by the Ras
signaling pathway, that in turn directly targets KRAS oncogene in
PDAC [28]. This revealed a feed-forward mechanism that
potentiates Ras signaling [28]. This was of interest as it is well
known that KRAS is one of the main genetic promoters of PDAC
[39] and HMGA2 expression levels are associated with the
malignant phenotype in pancreatic exocrine tissue [42], which
could in part be explained by the down-regulation of these
miRNAs. Interestingly, we could see an up-regulation of KRAS
protein, but no change in mRNA levels when comparing normal
tissues to PDAC, indicating that the post-transcriptional regulation
of KRAS in PDAC may be an essential step.
Mutations that result in a constitutively active KRAS are found
in .95% of PDAC and are thought to be a crucial initiating event
for this disease [65]. Furthermore, PDAC continues to be
‘‘addicted’’ to KRAS for epithelial differentiation and cell viability,
indicating that finding new KRAS regulators is an important step
[66]. We show a down-regulation of miR-126 in PDAC, with
increased expression of KRAS. As a result, we evaluated a possible
role for miR-126 in regulating KRAS and found that it is able to
directly regulate KRAS, inhibiting its protein translation by
interacting with a ‘‘seedless’’ site within its 39UTR. This suggests
that its downregulation in PDAC could participate in the
Figure 4. Down-regulated miRNAs allow increased expression of crucial PDAC oncogenes. (A) Western Blots showing expression levels of
BCL2, CRK and KRAS oncogenes in MIA PaCa-2 cells. Transfection was performed for 48 hours with precursor miR-16, miR-126 and let-7d. GAPDH was
used as an endogenous loading control. These are representative blots derived from three biological replicates (nc, negative control). (B)
Densitometric western analysis. Bar diagram of density ratio (protein/GAPDH). Negative control (nc) was set to 1 (*P,0.05; **P,0.01). (C) Western
Blots showing increased expression of CRK and KRAS oncogenes in MIA PaCa-2 cells after silencing of miR-126 using anti-miR (100 nM) transfection
for 48 hours; (D) Densitometric Western analysis. Bar diagram of density ratio (protein/GAPDH). Negative control (nc) was set to 1 (*P,0.05;
**P,0.01). (E) The relative expression of KRAS mRNA after pre-miR-126 or anti-miR-126 was analyzed using RT-qPCR. GAPDH was used as a
housekeeping control. All data are shown as mean6SD.
doi:10.1371/journal.pone.0032068.g004
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progression of PDAC because of the subsequent KRAS increase.
MiR-126 expression was in fact down-regulated in PDAC compare
to SMCA (a low malignant potential BCT) and previous studies
have shown that these BCT lesions are devoid of the KRAS
mutation [67,68]. The high malignant potential BCT (i.e. IPMN
and MCN) have been shown to have the mutated KRAS more
frequently [69,70] and we show these lesions had no significant
difference in miR-126 expression when compared to PDAC.
Interestingly, for progression from PanIN to BCT to adenocar-
cinoma these mucinous lesions require KRAS (G12D), followed by
loss of heterozygosity of SMAD4 and mutation of p53 or p16 [71].
As we show miR-126 up-regulation occurs in SMCA, this raises the
possibility of replacement miRNA therapy for those patients with
low miR-126 in their BCT at the time of pre-operative biopsy or
even as adjuvant treatment after surgical resection to prevent
recurrence or control disease.
MiR-16 is often down-regulated in chronic lymphocytic
leukaemia [72], gastric [73], ovarian [74] and prostate cancers
as a tumor suppressor that targets and down-regulates the anti-
apoptotic gene BCL2 [45]. MiR-126 is down-regulated in various
tumors compared to non-cancerous tissues including breast, lung,
stomach, cervix, bladder, and prostate [37]. Recently, miR-126 has
been shown to be a tumor suppressor in gastric cancer as it can
inhibit tumor growth and metastasis in vivo and in vitro. This effect
was partially mediated by down-regulation of CRK [49]. SRC and
CRK-associated substrate phosphorylation is an important
promoter of PDAC anchorage-independence and tumor progres-
sion [41]. SRC is able to repress miR-126 expression levels [50]
and furthermore miR-126 has been described as a suppressor of
proliferation and metastasis in breast cancer [75]. We have
established that miR-16 targets BCL2 and miR-126 targets at least
CRK and KRAS in PDAC cell-lines. As already shown, we did
not observe any significant change in miR-16 and miR-126
expression comparing normal pancreas to PDAC using RT-
qPCR, but did find significant down-regulation of both miRNAs
in PDAC compared to a low malignant potential BCT. Whilst the
down-regulation of miR-16 has not been seen previously in PDAC
compared to normal pancreas [76], the reduction of miR-126 in
PDAC has recently been reported [77]. As both are frequently
down-regulated in several tumor types, their importance in
tumorigenesis is clear.
We could not see miR-21 as up-regulated in PDAC compared to
SMCA. Croce’s group have also examined the oncomiR-21 in more
detail in 80 PDAC specimens and found that it is significantly
overexpressed in PDAC, but that its expression does not correlate
with tumor size, nodal status or T stage [1]. We observed that its
up-regulation from normal tissue is almost certainly a very early
event that occurs in the low malignant potential BCT we studied
and this occurs even earlier than previously described [60,61].
This suggests that miR-21 induces pancreatic cell proliferation, but
it is not sufficient to induce malignant transformation. Since miR-
21 has recently been demonstrated to be up-regulated in PDAC
compared to normal tissue [20] and we show here that it is not
deregulated in PDAC compared to pre-malignant BCT, this
indicates that its up-regulation is likely to be an early event
important for benign neoplasm formation from normal tissue.
The differential diagnosis of pancreatic BCT remains a clinical
challenge. A better understanding of the natural history of these
Figure 5. KRAS is experimentally validated as a direct target of miR-126 in pancreatic cancer cells. (A) Putative miR-126 binding
sequences in the 39-UTR of KRAS mRNA. Two different fragments from the 39-UTR region of KRAS were cloned downstream of the luciferase reporters
and named as wild-type (KRAS_A_WT and KRAS_B_WT). Two mutated versions of the miR-126 binding site were also generated (KRAS_A_MUT and
KRAS_B_MUT); the mutated nucleotides of the miR-126 binding site are underlined. Boxed areas represent conserved complementary nucleotides of
the miR-126 seed sequence in various species (Hsa, human; Ptr, chimpanzee; Mml, rhesus; Mmu, mouse; Laf, elephant; Gga, chicken). *indicates that
KRAS_B_WT is conserved in 16 species. (B) Luciferase reporter assay. Each of the 4 plasmids (150 ng) and a Renilla luciferase reporter (50 ng) were co-
transfected into MIA PaCa-2 cells with precursor miR-126 (100 nM). Luciferase activity was assayed 48 hours after transfection. All experiments were
independently repeated at least three times; the results are presented as mean6SD (**P,0.01).
doi:10.1371/journal.pone.0032068.g005
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lesions is considered central to understanding the risk of malignant
transformation. We observed significantly down-regulated miR-
NAs in PDAC compared to low malignant potential BCT, such as
miR-16, miR-126 and let-7d, which could be confirmed by qRT-
PCR and target known PDAC oncogenes such as BCL2, CRK
and KRAS. We thus demonstrate that miRNAs have the potential
to be used to differentiate pancreatic BCT from malignant PDAC
(Figure 6). For the first time we have shown that KRAS is directly
targeted by miR-126 by binding to a ‘‘seedless’’ site in its 39UTR.
As the majority of PDAC are driven by activated KRAS, the re-
expression of this miRNA, along with other miRNAs known to
also negatively regulate this crucial oncogene (i.e. let-7 family, miR-
96 [78] and miR-217 [79]), may provide a therapeutic strategy for
treating this devastating disease.
Limitations
Whilst there are some striking findings from the microarray and
validation, the following should be taken into account. Firstly, the
various pancreatic BCT are very rare (prevalence reported in the
literature as between 0.2–2.6% in the asymptomatic general
population [9]) and the tissues are difficult to obtain as few patients
undergo surgical resection. This is reflected in our small sample
sizes. Thus whilst we conclude that there are no statistically
significant deregulated miRNAs between many of the groups, this
may in fact be a Type II error. Secondly, this is also true of our
validation of miR-16 and miR-126 in PDAC compared to normal
pancreas. Whilst we did not see significant down-regulation for
either of these miRNAs, this may also be a Type II error. Hamada
et al. have recently shown that miR-126 is down-regulated in
PDAC and has tumor suppressive effects by targeting ADAM9,
which enhances cancer cell invasion by modulating tumor-stromal
cell interactions. Re-expression of miR-126 reduced cellular
migration and invasion in PDAC cell lines [77]. It would be
appropriate to undertake further miRNA studies on the high
malignant potential pancreatic lesions and validate candidate
miRNAs in a larger cohort, ideally in the prospective and
multicentric setting.
Supporting Information
Figure S1 Epithelial benign cystic tumors of the pan-
creas. Our study concentrated on the tumors of epithelial origin
in order to identify miRNAs which may be involved in the
development of early neoplasia and pancreatic ductal adenocar-
cinoma (PDAC).
(TIF)
Figure S2 BCL2, CRK and KRAS expression levels in
PDAC and normal pancreatic tissue. (A) Western Blots
Figure 6. Flow chart of miRNA expression profiling in pancreatic BCTs and miRNA target acquisition. (FFPE, formalin-fixed paraffin
embedded tissue; **indicates that RNA could not be isolated from 1 sample; RT- qPCR, quantitative reverse transcription polymerase chain reaction).
doi:10.1371/journal.pone.0032068.g006
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showing protein levels of BCL2, CRK, KRAS and GAPDH in
PDAC (n= 9) fresh tissue samples compared to normal pancreas
(n = 9). (B) Bar chart showing mean relative protein levels of the
Western Blots analyzed by densitometric scanning after normal-
ization to GAPDH (*BCL2 levels in PDAC vs. Normal P=0.03;
**KRAS levels in PDAC vs. Normal P=0.0003). (C) RT-qPCR
performed on the same fresh tissue samples showing KRAS
mRNA levels in PDAC (n= 6) compared to normal (n = 6) after
normalization to GAPDH.
(TIF)
Figure S3 Immunohistochemical analysis of CRK ex-
pression in pancreatic tissues. Paraffin sections were
analyzed using anti-CRK antibody and counterstained with
hematoxylin. Cytoplasmic staining (brown) was observed in PDAC
and normal pancreas, but not in SMCA. Original photographs
were taken at magnification 206. Staining intensity was measured
as 0 for no expression, 1+ for weak expression and 2+ for moderate
expression. Bar charts indicate the % in each category for each
tissue type. A 363 contingency table was created and analyzed
using the Fisher’s Exact test to reveal a significant difference
between the 3 tissue types (i.e. increased CRK expression in
PDAC.normal pancreas.SMCA; P=0.0048).
(TIF)
Figure S4 Expression levels of BCL2, CRK and KRAS
oncogenes in PANC-1 cells. (A) Western Blots showing protein
levels of BCL2, CRK, KRAS after transfection for 48 hours with
precursor miR-16, miR-126 and let-7d (miRNA mimics). (B) The
relative expression of KRAS mRNA after pre-miR-126 or anti-
miR-126 transfection was analyzed using RT-q PCR and
remained unchanged compared to negative control. GAPDH
was used as a housekeeping control. All data are shown as
mean6SD. (C) Western Blots showing protein levels of CRK and
KRAS after transfection for 48 hours with miRNA inhibitor (anti-
miR-126). GAPDH was used as an endogenous loading control for
all blots. These are representative blots derived from three
biological replicates (nc, negative control).
(TIF)
Table S1 Clinicopathological characteristics of the
patients for each tissue type. MiRNA expression profiling
and validation was performed on 58 pancreatic tumor samples; 43
formalin-fixed paraffin-embedded (FFPE) tumour samples were
analyzed by miRNA microarray and RT-qPCR using Taqman
probes; a further 24 fresh surgical specimens (normal pancreas n=9
and PDAC n=15) were used to validate the results using RT-qPCR.
Samples available for immunohistochemical (IHC) analysis were
normal pancreas n=12, PDAC n=12 and SMCA n=12. Non-
tumorous tissue was obtained during pancreatic trauma surgery. Key:
SMCA, serous microcystic adenoma; MCN, mucinous cystic
neoplasm; PDAC, Pancreatic Adenocarcinoma; IPMN, Intraductal
papillary mucinous neoplasm; CEI, Carcinoma-ex-IPMN; IQR,
interquartile range; *Non-disease related death (cardiac disease), RT-
qPCR, quantitative reverse transcription polymerase chain reaction.
(DOC)
Table S2 Sequences of all primers used for KRAS
luciferase plasmid construction. Red ends indicate sequenc-
es appropriate for the Mlu1 and HindIII restriction enzymes.
Yellow highlighted areas indicate mutated nucleotides.
(DOC)
Table S3 Microarray results for PDAC vs. Serous
Microcystic Adenoma (SMCA). The 30 most deregulated
probes (detected by highest absolute value of logarithmized fold
changes) for PDAC vs. SMCA (low malignant potential tumor).
There is widespread down-regulation of miRNAs in PDAC
(limma adjp indicates the p- value adjusted for multiple testing).
(DOC)
Table S4 Microarray results for PDAC vs. Mucinous
Cystic Neoplasm (MCN). The 30 most deregulated probes
(detected by highest absolute value of logarithmized fold changes)
for PDAC vs. MCN (high malignant potential tumor). No
significant difference in miRNA expression profile was shown
between these 2 tissue types (limma adjp indicates the p-value
adjusted for multiple testing).
(DOC)
Table S5 Microarray results for PDAC vs. Intraductal
Papillary Mucinous Neoplasm (IPMN). The 30 most
deregulated probes (detected by highest absolute value of
logarithmized fold changes) for PDAC vs. IPMN (high malignant
potential tumor). No significant difference in miRNA expression
profile was shown between these 2 tissue types (limma adjp
indicates the p-value adjusted for multiple testing).
(DOC)
Table S6 Microarray results for Carcinoma Ex-IPMN
(CEI) vs. PDAC. The 30 most deregulated probes (detected by
highest absolute value of logarithmized fold changes) for CEI
(carcinoma on background of IPMN lesion) vs. PDAC. No
significant difference in miRNA expression profile was shown
between these 2 tissue types (limma adjp indicates the p-value
adjusted for multiple testing).
(DOC)
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Ludwig-Maximilians-University, Munich, GermanyBACKGROUND & AIMS: There has not been a broad analysis of
the combined effects of altered activities of microRNAs (miR-
NAs) in pancreatic ductal adenocarcinoma (PDAC) cells, and it
is unclear how these might affect tumor progression or patient
outcomes. METHODS: We combined data from miRNA and
messenger RNA (mRNA) expression proﬁles and bioinformatic
analyses to identify an miRNAmRNA regulatory network in
PDAC cell lines (PANC-1 and MIA PaCa-2) and in PDAC samples
from patients. We used this information to identify miRNAs that
contribute most to tumorigenesis. RESULTS: We identiﬁed 3
miRNAs (MIR21, MIR23A, and MIR27A) that acted as cooper-
ative repressors of a network of tumor suppressor genes that
included PDCD4, BTG2, and NEDD4L. Inhibition of MIR21,
MIR23A, and MIR27A had synergistic effects in reducing pro-
liferation of PDAC cells in culture and growth of xenograft tu-
mors in mice. The level of inhibition was greater than that of
inhibition of MIR21 alone. In 91 PDAC samples from patients,
high levels of a combination of MIR21, MIR23A, and MIR27A
were associated with shorter survival times after surgical
resection. CONCLUSIONS: In an integrated data analysis, we
identiﬁed functional miRNAmRNA interactions that
contribute to growth of PDACs. These ﬁndings indicate that
miRNAs act together to promote tumor progression; thera-
peutic strategies might require inhibition of several miRNAs.Keywords: Pancreatic Cancer; miRNAmRNA Interaction;
Tumorigenesis; Oncogene.
espite surgical and therapeutic advances, the 5-year*Authors share co-ﬁrst authorship. §Authors share co-senior authorship.
Abbreviations used in this paper: anti-miR, antisense miRNA inhibitor;
miRNA, microRNA; mRNA, messenger RNA; NC, negative control; OS,
overall survival; PDAC, pancreatic ductal adenocarcinoma; pre-miR,
precursor miRNA.
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http://dx.doi.org/10.1053/j.gastro.2013.10.010Dsurvival rate for pancreatic ductal adenocarcinoma
(PDAC) remains <5%.1,2 Improving our understanding of
the molecular mechanisms underpinning this aggressive
disease will allow for development of more effective treat-
ments. Additionally, ﬁnding new prognostic markers is vital,
as recent studies have indicated that prognosis is deter-
mined more by PDAC tumor biology than traditional clini-
copathologic factors.3,4MicroRNAs (miRNAs) are small noncoding RNAs impli-
cated in gene regulation.5 Some miRNAs up-regulated in
tumors can act as oncogenes (oncomiRs),6 and miRNAs
down-regulated in cancer can act as tumor suppressors.7
Expression proﬁling data have created diagnostic and
prognostic signatures that have also been applied to stratify
a variety of tumor types.6,8,9 miRNAs, therefore, have the
potential to become clinical biomarkers for human cancers
and targets for molecular therapy.10
Although the PDAC miRNome has been proﬁled exten-
sively,11–14 it remains unclear which differentially expressed
miRNAs are the most important in tumorigenesis. We have
recently shown that oncomiR-21, an oncogene in PDAC11,13,15
and other tumor types,16 is not only up-regulated in PDAC
but also in benign pancreatic cystic tumors compared with
normal pancreas,17 indicating that elevated miR-21 levels
might be an early event in pancreatic adenomas and malig-
nant tumor formation. Other miRNAs have been identiﬁed as
prominently dysregulated in PDAC,11–13,18,19 but, remarkably,
the ideal prognostic miRNA signature has yet to be described.
In this study, we investigated miRNAs up-regulated in
PDAC and found that miR-21, miR-23a, and miR-27a have an
increased frequency of seed-sequence matches among those
genes signiﬁcantly down-regulated in the cancer cells. Of
those genes, we experimentally demonstrated that PDCD4,
BTG2, and NEDD4L are direct targets and that miR-21, miR-
23a, and miR-27a exert a combinatorial effect on the
reduction of cell proliferation. Concurrent targeted silencing
January 2014 Cooperative miRNAs Induce PDAC Progression 269of these miRNAs by intratumoral treatment in immuno-
suppressed mouse models stunted in vivo tumor growth.
This indicated inhibition of the combination is required as
an effective therapeutic strategy, and further elucidated the
functional signiﬁcance of the triple miRNA combination. We
demonstrated an association between high triple miRNA
expression and poor survival in an independent cohort of
PDAC patients, suggesting that these miRNAs regulate
crucial tumor suppressors in vivo and are clinically relevant.
Our results identiﬁed a combination of 3 miRNAs that
promote tumor growth and provide evidence that the co-
inhibition of multiple miRNAs holds promise for the devel-
opment of novel cancer therapies. These data also suggest
that strategies that focus only on individual miRNAs and
their pathways in PDAC are likely to be ﬂawed.Materials and Methods
The Materials and Methods can be found in the
Supplementary Material.BA
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Differentially Expressed miRNAs and
Messenger RNAs Between PDAC and
Normal Pancreas
To evaluate important miRNAmessenger RNA (mRNA)
interactions in PDAC, we performed an integrated molecular
analysis (Supplementary Figure 1) assessing the miRNA and
mRNA expression proﬁles in the same 9 fresh clinical samples
after surgical resection (Supplementary Table 1). Expression
proﬁles assayed by miRNA nCounter array in PDAC and
normal samples highlighted 22 signiﬁcantly differentially
expressed miRNAs in malignant tissue (Benjamini-Hochberg
adjusted t test, P < .05) (Supplementary Figure 2A). Most
miRNAs implicated in PDAC are up-regulated compared with
normal pancreas,11 and our miRNA signature was consistent
with this (Supplementary Table 2).
Next, we identiﬁed differentially expressed genes in the
same PDAC samples using a high-throughput complementary
DNA microarray that revealed a set of 4700 signiﬁcantly
changing genes (Benjamini-Hochberg adjusted t test, P < .05;
Supplementary Table 3 and Supplementary Figure 2B). We
validated several of those genes described previously in PDAC
using reverse transcription quantitative polymerase chain re-
action, conﬁrming that our complementary DNA microarray
had accurately differentiated malignant from normal pancre-
atic tissue (Supplementary Tables 4 and 5 and Supplementary
Figure 3). To understand the wide range of altered mRNA
transcripts in PDAC and to further demonstrate the reliability
of our methods, we performed gene ontology and Kyoto
Encyclopedia of Genes and Genomes pathway enrichment
analyses of the differentially expressed genes. This allowed a
global view of the transcriptome that is under miRNA regula-
tion in PDAC. Most of the terms and pathways were closely
related to tumorigenesis (Supplementary Table 3 and
Supplementary Figure 4A and B).Three miRNAs Regulate Functionally
Relevant Targets in PDAC
Seeking to generate hypotheses on putatively functional
and disease-relevant miRNAmRNA interactions, we used
one-tailed Fisher’s exact tests to assay lists of differentially
expressed genes for enrichment of miRNA seed matches.
Early studies showed that perfect complementarity at the
“seed region” is a principal determinant of target recogni-
tion.20 Taking advantage of the mRNA expression proﬁle to
reduce the test space of PDAC-expressed genes; we used a
seed-matchbased statistical analysis to highlight putative
regulatory networks irrespective of conservation limits
imposed by target prediction algorithms. The seed-match
analysis (Figure 1) examined the presence and “score” or
length of a seed match between the top up-regulated miR-
NAs and down-regulated mRNAs observed in PDAC samples
compared with controls (the opposite, ie, down-regulated
miRNAs and up-regulated mRNAs, was also investigated;
Supplementary Figure 2C). The seed-enrichment analysis
suggested that some of the most down-regulated mRNAs
can be cooperatively regulated by different up-regulated
miRNAs, and revealed 18 up-regulated miRNAs that
potentially down-regulate 136 transcripts (with at least one
6-(oligo) mer match). Notably, the most signiﬁcantly
enriched miRNAs were miR-21, miR-23a, and miR-27a
(Supplementary Table 6). We identiﬁed novel miR-
NAtumor suppressor gene interactions in PDAC for these
3 miRNAs among the top down-regulated transcripts. We
found that these overexpressed miRNAs preferentially
target tumor suppressors and selected 5 interesting genes
for further validation (Supplementary Table 7), including 3
known tumor suppressors in PDAC (ie, PDCD4, SORBS2, and
BNIP3) and 2 known tumor suppressors in other cancers
that had never been studied in PDAC (ie, BTG2 and NEDD4L;
Supplementary Figure 5). Therefore, these miRNAmRNA
interactions allowed us to prioritize important miRNAs for
further investigation in PDAC.
Key Tumor Suppressors Are Direct Targets
of miR-21, miR-23a, and miR-27a
To validate the selected genes as important miRNA tar-
gets, we used cloned 30 untranslated regions of these tran-
scripts in luciferase vectors and coexpressed them with
precursor miRNAs (pre-miRs) in PDAC cell lines. This
showed reduced luciferase levels upon miRNA over-
expression for 4 of the 5 genes chosen and veriﬁed a direct
miRNAmRNA interaction (Figure 1B). We then transfected
both PANC-1 and MIA PaCA-2 cells with the pre-miRs
individually and in combination and performed immuno-
blots to assess and conﬁrm changes at the endogenous
protein level (Figure 1C). Consistent with these ﬁndings, we
observed a reduction in the levels of 3 of the 4 proteins with
their predicted targeting miRNAs (Figure 1C). Notably, BTG2
was undetectable in PANC-1 cells (Figure 1C). Strikingly,
when all 3 pre-miRs (10 nM for each; total of 30 nM) were
co-transfected in MIA PaCa-2 cells, this translated into
signiﬁcantly reduced BTG2 protein levels compared with
pre-miR-21 alone (30 nM), suggesting that even with a
Figure 1. Seed-match analysis reveals a miRNAmRNA regulatory network in PDAC vs normal pancreas. (A) Heatmap
showing seed-match analysis for 18 PDAC up-regulated miRNAs and 152 top down-regulated genes. Colored cells highlight
the presence of a miRNA seed reverse-complementary match in the 30 untranslated region (UTR) sequence of the crossing
gene. Seeds: 6-mer seed ¼ nucleotides 27 in the miRNA mature sequence; 7-mer seed ¼ nucleotides 28 in the miRNA
mature sequence; predicted interaction ¼ predicted functional interaction based on miRanda-mirSVR.21 For each colored cell
at the intersection of a row (up-regulated miRNA) with a column (down-regulated mRNA), the possible color identities (and
meanings) are: dark red (miRanda-mirSVR predicted interaction); medium red (7-mer seed); light red (6-mer seed); and yellow
(no seed). Feature selection: miRNAs: up-regulated miRNAs (Benjamini-Hochberg adjusted t test, P < .05). miRNAs belonging
to the same miRNA family (ie, having the same seed sequence) are collapsed in the heatmap to remove redundancy (18 up-
regulated miRNAs / 15 unique miRNA families shown in the heatmap). mRNAs: top down-regulated mRNAs (Benjamini-
Hochberg adjusted t test, P-< .05; log-ratio of mean signal intensity in cancer vs normal  1; mean signal intensity in cancer
and/or normal samples  log2(500)). Only mRNAs with at least 1 seed-complementary match for any of the up-regulated
miRNAs are shown in the heatmap (152 unique down-regulated mRNAs / 136 mRNA with at least 1 seed match). (B)
Validation of miR-21, miR-23a, and miR-27a targets by luciferase reporter assay and (C) immunoblotting. Luciferase activity
derived from the indicated 30UTR reporter constructs after co-transfection into PANC-1 cells with control mimic (premiR-NC)
or mature miRNA mimics (pre-miRs). Error bars represent standard deviations from 3 independent transfections, each
measured in triplicate (*P < .05; **P < .01). Western blot analysis of indicated protein expression after overexpression of the
individual mature miRNAs (30 nM) or all 3 in combination (10 nM each) for 72 hours in PANC-1 and MIAPaCa-2 cells. BTG2
was not detectable in PANC-1 cells. Glyceraldehyde-3-phosphate dehydrogenase was used as an endogenous loading
control. Representative Western blot from 3 independent experiments.
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increase the strength of BTG2 post-transcriptional regula-
tion (Figure 1C). Although we demonstrated an interaction
between miR-23a and SORBS2 by luciferase assay
(Figure 1B), protein levels were reduced in only one PDAC
cell line after miR-23a overexpression and, for this reason,
we did not consider it further (Figure 1C).
Therefore, in accordance with our seed-match analysis
(Supplementary Table 7) and the miRanda-mirSVR target
predictions,21 we validated that miR-21 regulates PDCD4;
miR-21 and miR-27a regulate BTG2; and miR-23a regulates
NEDD4L (Supplementary Figure 5).Inhibition of the Triple miRNA Combination
Reduces Tumor Growth More Efﬁciently
Than Silencing an Individual miRNA in vitro
or in vivo
To verify the role of miR-21, miR-23a, and miR-27a in
PDAC tumorigenesis, we used antisense miRNA inhibitors
(anti-miRs) in various combinations to examine the effect of
loss of function on cell proliferation (Figure 2A). After 5
days, there was a signiﬁcant reduction in proliferation upon
inhibition of miR-21, miR-27a, miR-21/23a, or miR-21/27a
in PDAC cell lines. However, coexpression of anti-miRs
Figure 2. Ectopic modulation of miR-21/23a/27a regulates PDAC cell proliferation. (A) PANC-1 and MIAPaCa-2 cells were
transfected with antimiR-NC (blue line) or antimiR-21, antimiR-23a, and anti-miR-27a either individually (90 nmol/L) or in
different combinations (various color lines; 45 nmol/L each for 2 anti-miRs or 30 nmol/L each for all 3 anti-miRs) on day 0 and
cells were counted on the days indicated. Data are expressed as means  SD (*P < .05; ***P < .001). Line graphs are all from
the same experiments, but have been split into different plates to view the growth curves better; antimiR-NC can be seen in
each for easy comparison. (B) LPc006 and LPc167 cells (primary cell cultures from laser-microdissected PDACs) were
transfected with antimiR-NC (blue line) or antimiR-21, antimiR-23a, and antimiR-27a either individually (90 nmol/L;
various color lines) or in triple combination (orange line; 30 nmol/L each for all 3 anti-miRs) on day 0 and cells were counted on
the days indicated. Data are expressed as means  SD (*P < .05; **P < .01; ***P < .001). (C) PANC-1 and MIAPaCa-2 cells were
transfected with premiR-NC (blue line) or premiR-21, premiR-23a, and premiR-27a either individually (30 nmol/L) or in
different combinations (various color lines; 15 nmol/L each for 2 pre-miRs or 10 nmol/L each for all 3 pre-miRs) on day 0 and
cells were counted on the days indicated. Data are expressed as means  SD (*P < .05; **P < .01; ***P < .001). All cultures for
these experiments were performed in triplicate.
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combination) had a stronger effect on reducing the growth
of both PDAC cell lines (60% reduction in PANC-1 and 40%
in MIA PaCa-2; P < .001 for both compared with antimiR-
negative control [NC]), as opposed to an individual anti-miR
or double combinations (Figure 2A). This effect was also
seen in primary PDAC cell cultures grown from laser
microdissected patient tumors (69% reduction in LPc006
and 57% in LPc167; P < .001 for both compared with
antimiR-NC; Figure 2B). Conversely, we found an increase
in proliferation upon gain of function after coexpression of
pre-miRs for the triple combination, compared with indi-
vidual pre-miRs or double combinations (66% increase inPANC-1 and 36% in MIA PaCa-2; P < .001 for both
compared with premiR-NC; Figure 2C).
To investigate the potential anti-tumor activity of these 3
miRNAs in vivo, subcutaneous human PDAC xenografts us-
ing 2 different cell lines (MIA PaCa-2 and PANC-1) were
grown in nude mice (n ¼ 6 for each experimental and
control group). OncomiR-21 induces cell growth in many
human cancers, including PDAC, and miR-21 loss enhances
apoptosis and reduces cell proliferation.22 This suggests an
miR-21 inhibitor could be used as a potential anti-cancer
drug.23 We treated the 2 groups of PDAC xenografts with
weekly intratumoral injection with either antimiR-21 or
antimiR-21/23a/27a complexed with atelocollagen (ﬁrst
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bination was more effective. In MIA PaCa-2 xenografts,
antimiR-21 administration caused signiﬁcant suppression
of tumor growth by day 21 (ie, after 3 consecutive doses),
compared with administration of the antimiR-NC com-
plexes (Figure 3A). However, this tumor suppressive effect
was lost for the rest of the experiment (Figure 3A).
Conversely, a reduction in tumor volume was observed for
xenografts treated with antimiR-21/23a/27a by day 7 (ie,
after only 1 dose) (Figure 3A), and this reduction was sus-
tained signiﬁcantly to day 21 and up to the end of the
experiment, despite a 3-week rest period before the second
treatment cycle. By 10 weeks, the MIA PaCa-2 xenografts
treated with the triple combination of anti-miRs were
signiﬁcantly smaller than those that were administered
antimiR-NC or antimiR-21 alone (Figure 3A). In addition,
and consistent with our ﬁndings, tumors treated with
antimiR-21/23a/27a showed a signiﬁcant increase or
de-repression of PDCD4, BTG2, and NEDD4L by immuno-
blotting compared with those treated with antimiR-NC
(Figure 3A). Tumors from mice injected with antimiR-21
only had signiﬁcant de-repression of PDCD4, indicating the
efﬁciency of this treatment (Supplementary Figure 6). This
in vivo experiment was also performed using PANC-1 cells.
This conﬁrmed a reduction in tumor volume in xenografts
treated with antimiR-21/23a/27a that was signiﬁcant for
the duration of the experiment compared with antimiR-NC
or antimiR-21 alone (Figure 3B). Accordingly, xenografts
treated with antimiR-21/23a/27a were visibly smaller
and weighed less than those that were administered
antimiR-NC or antimiR-21 (Figure 3B and C).
Collectively, these results indicate that the synergistic
inhibition of these 3 miRNAs suppresses the growth of hu-
man PDAC cells in vivo more effectively than inhibition of
oncomiR-21 alone. This might be due in part to the release
of PDCD4, BTG2, and NEDD4L from post-transcriptional
regulation by these miRNAs, although certainly many
other miRNAmRNA interactions exist (Figure 1 and
Supplementary Table 7).Figure 3. Co-inhibition of miR-21/23a/27a suppresses PDAC t
grafts after transplantation into BALB/c nude mice treated w
complexes. The volume of the tumors at day 0 was 50 mm3, whic
time point are expressed as means  SD of 6 tumors in each exp
(arrows) of antimiR-21 caused signiﬁcant growth suppression
However, this reduction in xenograft tumor volume surprisingly
despite 3 additional treatments. (ii) In contrast, intratumoral i
resulted in a reduction in xenograft tumor volume after only 1 tre
to sustain a signiﬁcant reduction during the next 70 days compa
on day 28 during the treatment rest period. (iii) Photographs illus
end of the experiment after 6 treatments with antimiR-NC v
antimiR-21/23a/27a all had visibly smaller xenografts at the en
release of crucial PDAC tumor suppressors in vivo. Representat
conﬁrming our direct targets by loss of function in vivo and de
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was us
density ratio (protein to GAPDH). Data are shown as means  S
Tumor xenografts from PANC-1 cells treated by intratumoral inje
vs antimiR-21/23a/27a. (iii) Photographs illustrating representa
the end of the experiment. (C) Treated PANC-1 xenografts were e
in the ruler represents 1 mm) and (ii) tumor weight was evaluatEx vivo Analysis Reveals High Expression of
miR-21, miR-23a, and miR-27a Is Associated
With Aggressive Tumor Behavior and Poor
Survival After PDAC Resection
Using a cohort of microdissected PDAC samples (n ¼
91), we found a statistically signiﬁcant association between
elevated miR-21 levels and poorly differentiated tumors
(high vs low grade; P ¼ .044), but no other clinicopatho-
logical parameters (Supplementary Table 8). Low levels of
all 3 miRNAs were associated with less microscopic tumor
inﬁltration into the surgical resection margin (R0 vs R1; P ¼
.028; Supplementary Table 8), an indication of less invasive
disease rather than better surgical technique24 and reduced
perineural invasion (P ¼ .012; Supplementary Table 8).
Next we examined the prognostic value of measuring
miR-21, miR-23a, and miR-27a in this patient cohort. The
majority of patients with high doublet miRNA expression
(ie, miR-21/23a:miR-21/27a, or miR-23a/27a) were found
to also be in the high triple miRNA combination expression
group (Supplementary Table 9). Few patients have isolated
high expression of 2 of the miRNAs without up-regulation of
the third one also (Supplementary Table 9). Biologically,
none of the doublet treatments was as effective as the triple
miRNA combination or oncomiR-21 alone at modulating
cellular proliferation in vitro. Kaplan-Meier univariate ana-
lyses of overall survival (OS) indicated that high miR-21,
high miR-23a, and high miR-27a expression and their
combinations (Figure 4A and B; Supplementary
Figure 7AE), as well as high tumor grade (median, 14.8
vs 29.9 months; P ¼ .001) and positive resection margin
status (R1; median, 11.0 vs 25.2 months; P ¼ .006), were
associated with poor OS. Notably, patients with high miR-21
expression alone had signiﬁcantly worse OS compared with
those with low miR-21 expression (median, 12.4 vs 27.8
months; P < .001; Figure 4A). However, patients with high
miR-21/23a/27a expression had even shorter OS compared
with those with low triple miRNA expression (median, 8.5
vs 25.2 months; P < .001; Figure 4B). To conﬁrm that otherumor growth in vivo. (A) Growth curves of MIAPaCa-2 xeno-
ith anti-miRNA/atelocollagen or antimiR-NC/atelocollagen
h was when intratumoral injections were started. Data at each
erimental group (*P < .05; **P < .01). (i) Intratumoral injections
of MIA PaCa-2 xenografts compared with the antimiR-NC
could not be sustained for the duration of the experiment
njections (arrows) of the antimiR-21/23a/27a combination
atment (by day 7). Additional intratumoral injections were able
red with antimiR-NC. Note the suppression of tumor growth
trating representative features of MIAPaCa-2 xenografts at the
s antimiR-21, or antimiR-21/23a/27a. Mice treated with
d of 10 weeks. (iv) Co-inhibition of miR-21/23a/27a allows the
ive Western blots of protein expression from mice xenografts
nsitometric quantiﬁcation of protein levels (n ¼ 6 vs 6 mice)
ed as an endogenous loading control. Bar diagram indicates
D (*P < .05). Negative control (antimiR-NC) was set to 1. (B
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Figure 4. Overall cancer-speciﬁc survival among PDAC patients depending on tumoral miRNA expression. (A) High
expression of oncomiR-21 was associated with poor survival (P < .001). (B) High expressors of the triple miRNA combination
(miR-21, miR-23a, and miR-27a) had shorter survival (P < .001). miRNA expression levels were measured by reverse tran-
scription quantitative polymerase chain reaction and patients were dichotomized into high- or low-expression groups using the
median value. Figures in bold indicate the median overall survival in months. P values are based on log-rank test.
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did not confer a comparable prognostic value, we randomly
selected 3 different up-regulated miRNAs (miR-142-3p,
miR-199-3p, and miR-342-3p) for further validation in pa-
tient samples. Expression of these 3 miRNAs was not
associated with OS, either individually or in combination
(Supplementary Figure 8AD), indicating that our seed-
enrichment analysis helped to discover a triple combina-
tion of miRNAs (miR-21/23a/27a) that are functionally
relevant in PDAC in vivo.Multivariate Analysis Identiﬁes the Elevated
Expression of the Triple miRNA Combination
as Independently Prognostic in PDAC
To further evaluate the hazard of death associated with
high tumoral levels of these miRNAs, we performed a Cox
regression analysis that included variables signiﬁcantly
associated with OS at univariate analysis. Before this, we
noted that the expression of these 3 miRNAs and their
combinations are highly correlated with the triple miRNA
combination (data not shown) and are therefore redundant
variables. The inclusion of correlated predictor variables
destabilizes a regression model, therefore, we chose to only
include miR-21/23a/27a, as we demonstrated that this
combination was the most effective at regulating tumor
growth in vitro and in vivo. Our multivariate model revealed
that high miR-21/23a/27a expression is an independent
predictor of poor outcomes (hazard ratio ¼ 3.21; 95%
conﬁdence interval: 1.785.78; Table 1), indicating poten-
tial future use as a prognostic signature.NEDD4L, PDCD4, and BTG2 Are Targeted
by miRNAs in the Triple Combination and Are
Clinically Relevant in PDAC
To illustrate the importance of NEDD4L, PDCD4, and
BTG2 in PDAC, we performed data mining using Onco-
mine and also compared mRNA expression levels be-
tween matched malignant and normal pancreas patient
samples using the GEO2R software in Gene Expression
Omnibus. Consistent with our ﬁndings, all 3 transcripts
were signiﬁcantly down-regulated in PDAC
(Supplementary Figure 9A and Supplementary Table 10).
Using an additional recent dataset (GSE2873525), this was
even true in 45 paired samples (PDAC vs normal
pancreas) from the same patients (Supplementary
Figure 9BD). Next, we examined the expression of
these 3 proteins by immunostaining in a tissue micro-
array containing a large number of PDAC patients
(n ¼ 121), to reveal their inﬂuence on clinicopathologic
characteristics and survival after PDAC resection
(Supplementary Table 11 and Supplementary Figure 10).
As the miRNAmRNA interactions had already been
conﬁrmed in the same patient samples in our initial
molecular proﬁling, this cohort was used to further
validate the clinical relevance of these genes. Non-
neoplastic pancreatic ductal epithelium showed intense
nuclear PDCD4 and cytoplasmic BTG2 expression
(Supplementary Figure 10A). However, antibodies against
NEDD4L that were able to detect protein for Western
blotting did not appear to stain above background in
immunohistochemistry assays (data not shown). Semi-
quantitative analysis of protein expression showed low
Table 1. Multivariate Analysis for Overall Survival of Clinical Covariates and miRNA Expression Levels in Patients With PDAC
(n¼91)
Prognostic factor mOS (months) Hazard ratioa (95% CI)
Multivariate model
(Cox regression)
P value
Grade (high vs low) 14.8/29.9 2.16 (1.22–3.83) .008b
Resection margin status (R1 or R0) 11.0/25.2 1.77 (1.02–3.07) .042b
miR-21/23a/27a (high vs low) 8.5/25.2 3.21 (1.78–5.78) .000b
mOS, median overall survival.
aHR <1 ﬁrst level of the covariate is associated with good outcome, >1 ﬁrst level of the covariate is associated with poor
outcome.
bStatistically signiﬁcant.
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in 67.8% (82 of 121) of patients. Statistical analysis
revealed that low BTG2 expression was associated with
signiﬁcantly lower OS than high BTG2 expression (me-
dian, 15.0 vs 19.0 months; P ¼ .046; Supplementary
Figure 10B). Reduced BTG2 levels were also signiﬁ-
cantly associated with high tumor stage (pT3/4; P ¼ .034;
Supplementary Table 11). In addition, reduced levels of
PDCD4 were signiﬁcantly associated with poor OS (me-
dian, 15.0 vs 18.0 months; P ¼ .024; Supplementary
Figure 10C).BA
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miRNAs have broad speciﬁcity, therefore, one or a few
target mRNAs cannot fully explain the functional properties
of a particular miRNA.26 Their effects are more likely the
result of the regulation of several targets participating in
multiple biological pathways. miRNAs have clinical potential
as diagnostic and predictive markers and as novel molecular
targets in PDAC.
We describe here the role of miRNAs in PDAC tumori-
genesis and highlighted the importance of a combination of
3 miRNAs (miR-21, miR-23a, and miR-27a) as a therapeutic
target, a concept that could be used successfully to reduce
tumor progression in other cancers. The importance of miR-
21/23a/27a was revealed through a seed-enrichment
analysis combining microarray miRNA and mRNA expres-
sion proﬁling, which identiﬁed the PDAC-speciﬁc miR-
NAmRNA regulatory network, an approach that has never
been performed in PDAC before. We found several miR-
NAmRNA putative interactions in PDAC, allowing us to
prioritize miRNAs for further investigation. We then per-
formed in vitro, in vivo, and ex vivo studies to fully under-
stand the underlying mechanisms of the enriched miRNAs in
PDAC. The cooperative inhibition of these miRNAs signiﬁ-
cantly reduced tumor growth both in vitro and in vivo
(using PDAC xenografts grown in nude mice). We demon-
strated this in 2 different PDAC cell lines (PANC-1 and
MIAPaCa-2) and also in primary cell cultures derived from
patient tumors (LPc006 and LPc167). Interestingly, these
primary cell cultures have reduced sensitivity to standard
chemotherapeutic agents used for PDAC, with LPc006 andLPc167 having increased chemoresistance to 5-ﬂuorouracil
and gemcitabine, respectively.27 The triple anti-miR combi-
nation might have a role in treating chemoresistant patients,
but this would require further investigation. For the ﬁrst
time, we show that the combined inhibition of oncogenic
miRNAs could potentially be used as a therapy for PDAC.
However, additional animal and human studies are
warranted.
We deﬁned miRNAs and mRNAs, the expressions of
which were signiﬁcantly deregulated in PDAC compared
with normal pancreas. By mapping 30 untranslated region
complementary seed-match occurrences, potentially link-
ing up-regulated miRNAs with down-regulated mRNAs,
we highlighted possible instances of co-regulation. This
was based on the principle that mammalian miRNAs have
been shown to predominantly act through the destabili-
zation of target mRNAs. Indeed, lower mRNA levels ac-
count for >84% of the decreased protein production.28,29
Because our analysis here was based on the fact that
miRNAs lower mRNA levels, we might have missed a
percentage of targets on which the miRNAs only act by
decreasing protein translation. We demonstrated that 18
miRNAs are signiﬁcantly up-regulated in PDAC and high-
lighted that some of the transcripts might be co-regulated
by multiple up-regulated miRNAs. We found enriched
seed sequences in 152 down-regulated transcripts in the
same tumor samples. In particular, miR-21, miR-23a, and
miR-27a expression levels are elevated in PDAC and
showed signiﬁcantly enriched frequency of seed matches
among top down-regulated genes, including important
tumor suppressors. This indicated that these miRNAs
might be important in PDAC progression targeting a tu-
mor suppressor gene network. We experimentally vali-
dated some of these interactions in vitro and conﬁrmed by
loss-of-function in our xenograft model, that PDCD4 is
repressed by miR-21, BTG2 by miR-21 and miR-27a, and
NEDD4L by miR-23a. In addition, these miRNAs target
other important tumor suppressors in PDAC and various
human cancers.
miR-21 targets PTEN, TPM1, TIMP3, and Maspin, result-
ing in the inhibition of apoptosis and promoting aggressive
behavior in PDAC.11,30,31 Surprisingly, PTEN also has two
7-mer seeds for miR-23a that are well conserved across
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PANCREASspecies (Supplementary Figure 11A), indicating that it is
possibly co-regulated by miR-21 and miR-23a in PDAC. miR-
27a targets ZBTB10, which de-represses Sp transcription
factors and Sp-dependent genes that are associated with
cancer-cell survival, growth, and angiogenic responses in
PDAC.32 In addition, inhibition of miR-27a results in sup-
pression of cell growth and migration in PDAC,33 effects that
are mediated via the regulation of its tumor suppressor
target Spry2.33 Spry2 is also regulated by miR-21 in colo-
rectal cancer34 and contains a conserved 7-mer seed for
miR-23a among multiple vertebrate species (Supplementary
Figure 11B), suggesting that Spry2 might be cooperatively
regulated by these 3 miRNAs in PDAC. Remarkably,
expression of LIFR (a new metastatic suppressor35) was
reduced in our PDAC samples, and contains a highly
conserved 7-mer seed for miR-27a and 7-mer seeds for miR-
21 and miR-23a (Supplementary Figure 11C). Similarly, the
adhesion molecule Nr-CAM, was also down-regulated in our
specimens and contains 7-mer seeds for miR-21, miR-23a,
and miR-27a (Supplementary Figure 11D). These and other
genes regulated by the triple miRNA combination deserve
further investigation in PDAC (Figure 1 and Supplementary
Table 7). Surprisingly, miR-23a is up-regulated in PDAC in
several reports (Supplementary Table 2), but there have
been no previous studies investigating its functional role in
pancreatic tumorigenesis. For the ﬁrst time, we show that
miR-23a and its family member miR-27a are part of an
important functional interactome in PDAC. Strikingly, it
appears that all 3 miRNAs (miR-21/23a/27a) are collec-
tively involved in regulating crucial genes in a tumor sup-
pressor network implicated in PDAC progression
(Supplementary Figure 12).
Finally, clinical data conﬁrmed previous reports that
high miR-21 expression can be used as a marker for poor
OS (Figure 4A),13,15 however, we found that miR-23a and
miR-27a also have prognostic value (Supplementary
Figure 7A and B), and these individual miRNAs and
their doublet expressions are, not surprisingly, highly
correlated with the triple combination. Cox regression
indicated that high expression of the miR-21/23a/27a
combination was a strong independent predictor of
short OS among PDAC patients (Table 1), and was also
associated with a more aggressive tumor phenotype (low
expressors had less microscopic tumor inﬁltration at the
resection margin and reduced perineural invasion;
Supplementary Table 8). This combination might be a
more powerful prognostic signature than measuring
oncomiR-21 alone.
Our data on the functional characterization of the triple
combination of miR-21/23a/27a suggest that increased
expression results in a synergistic reduction in tumor
growth in vitro and in vivo through the negative regulation
of their tumor suppressor targets. This reinforces the
ﬁnding that a single miRNA, gene, or pathway is unlikely to
be a reliable target for therapy or predictor of progression
of this molecularly complex disease.36 In addition, this
unique combination can be used to investigate the biology of
PDAC with respect to individual patient prognosis and
response to anti-cancer therapies.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
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Supplementary Materials and
Methods
Clinical Specimens
Three independent, nonoverlapping patient tumor cohorts
were used. Specimens were obtained from individuals under-
going pancreaticoduodenectomy for PDAC between 2004 and
2010 at Hammersmith Hospital, London, UK. The initial cohort
consisted of 9 PDAC and 9 nonmalignant fresh pancreas sam-
ples thatwere used formiRNA andmRNAmicroarray proﬁling.
Thesewere immediatelymacrodissected at the time of surgery,
placed directly in RNALater stabilization solution (Qiagen, Hil-
den, Germany), stored at room temperature for 23 hours, and
then frozen at 80C. This was done to prevent any degrada-
tion and ensure high-quality RNA for the subsequentmolecular
proﬁling.H&Estainingwasused forhistological conﬁrmationof
cancer and to determine the cellularity of representative sec-
tions. A specialist pancreatic pathologist (RA) reviewed the
slides, and tissue for RNA isolation was veriﬁed to contain
60%neoplastic cells. The second cohort (n¼ 91) consisted of
patients who underwent pancreaticoduodenectomy at Pisa
University Hospital (Italy) and Hammersmith Hospital (UK)
between 2000 and 2010. Tumors were isolated by laser
microdissection1 from formalin-ﬁxed parafﬁn-embedded
blocks and were used as a validation cohort for reverse tran-
scription quantitative polymerase chain reaction (RT-qPCR) of
miRNA expression. The third patient dataset (n ¼ 121) was a
tissue microarray (TMA) of PDACs from patients who under-
went resection with curative intent between 1995 and 2009 at
the surgical department of Friedrich-Schiller University
(Germany) and was used as an immunohistochemistry valida-
tion cohort. Complete clinicopathological, follow-up, and
recurrence data were available from prospectively maintained
databases. Cancer-speciﬁc OS was examined for the RT-qPCR
and TMA cohorts. Written informed consent was obtained
from all patients, and ethical approval was provided by each
hospital’s research ethics committee.
Clinicopathologic Characteristics of the
PDAC Patient Cohort
The initial molecular proﬁling (miRNA and mRNA) was
performed on fresh frozen tumor samples derived from 9
patients with resectable PDAC who underwent surgical
resection by pancreaticoduodenectomy with curative intent
and samples of normal pancreas tissue. Supplementary
Table 1 summarizes their clinical and histopathological
characteristics. All patients had American Joint Committee
on Cancer stage IIB tumors with positive lymph nodes and
56% had positive resection margins (R1). Speciﬁc molecular
alterations identiﬁed through that integrated genomic
proﬁling were then validated in separate cohorts by RT-
qPCR (n ¼ 91) and immunohistochemistry (n ¼ 121) in
which the clinicopathologic and survival characteristics
were largely overlapping (Supplementary Table 1).
Total RNA Isolation
Fresh tissue stored in RNALater (Qiagen) was crushed in
liquid nitrogen and the subsequent powder lysed in Trizol
(Invitrogen, Paisley, UK) reagent and RNA isolation was
carried out according to manufacturer’s instructions. The
quality of isolated RNA was analyzed on the Agilent 2001
Bioanalyzer (Agilent Technologies Inc., Santa Clara, CA). To
assess RNA integrity, RNA integrity numbers are calculated
by Agilent software. An RNA integrity number of 7 is
sufﬁcient RNA quality for RNA microarray analyses.2 The
RNA integrity numbers for our patient RNA samples used
for the initial molecular proﬁling were between 8.70 and 10.
Formalin-ﬁxed parafﬁn-embedded samples were deparafﬁ-
nized with Xylene and total RNA was collected using the
miRNeasy Mini Kit (Qiagen) according to manufacturer’s
instructions.
Gene Expression Analysis
Gene expression proﬁling was performed using
the Affymetrix Human Gene 1.0 ST Array interrogating
28,869 well-annotated transcripts (Affymetrix, Santa Clara,
CA). The GeneChip Human Gene 1.0 ST array is a whole-
transcriptbased array for gene expression proﬁling.3 Its
design is based on a subset of probes from the Human
Exon 1.0 ST array (Affymetrix) and includes only well-
annotated exons based on RefSeq (www.ncbi.nlm.nih.
gov/refseq), Ensembl (www.ensembl.org), and putative
complete coding sequences from GenBank (www.ncbi.nlm.
nih.gov/genbank).
miRNA Nanostring Analysis
The Nanostring nCounter Human miRNA Expression
Array (http://www.nanostring.com/) was used to obtain
miRNA expression proﬁles.4 The NanoString miRNA panel
contains 654 probes for human miRNAs. Total RNA (100 ng)
was used as input for nCounter miRNA sample preparation
reactions and these were performed according to manu-
facturer’s instructions (NanoString Technologies). Small
RNA sample preparation involves the ligation of a speciﬁc
DNA tag onto the 30 end of each mature miRNA. These tags
normalize the melting temperatures of the miRNAs and
provide a unique identiﬁcation for each miRNA species in
the sample. Excess tags were then removed, and the
resulting material was hybridized with a panel of miRNA:
tag-speciﬁc nCounter capture and barcoded reporter
probes. Hybridized probes were then puriﬁed and immo-
bilized on a streptavidin-coated cartridge using the
nCounter Prep Station (NanoString Technologies). Data
collection was carried out on the nCounter Digital Analyzer
(NanoString Technologies) following manufacturer’s in-
structions to count individual ﬂuorescent barcodes and
quantify target RNA molecules present in each sample. For
each assay, a high-density scan (600 ﬁelds of view) was
performed.
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miRNA Expression Data Processing
Raw intensity values of the Nanostring nCounter Human
miRNA Expression Arrays for 18 samples were quantile-
normalized using function “normalize.quantiles” from the
R/Bioconductor package preprocessCore. Normalized in-
tensity values for 654 human miRNAs were then ﬁltered to
discard low-intensity features by requiring mean signal in-
tensity for the cancer and/or the normal samples to be
>500 (n ¼ 56 miRNAs passing ﬁlter).
Gene Expression Data Processing
The Affymetrix Human Gene 1.0 ST array was used to
proﬁle gene expression in 12 samples. Preprocessing of
microarray raw data (ie, normalization, generation of pre-
sent/absent calls, and detection P values) were performed
using functions from the R/Bioconductor package xps.
Parameter settings passed to function “rma” to perform RMA
normalization were as follows: background¼ “antigenomic,”
option ¼ “transcript,” and exonlevel ¼ “coreþaffx.”
Normalized and transcript-cluster summarized expression
data (n ¼ 28,926 transcript cluster ids) were then ﬁltered to
remove low-intensity features as well as features lacking
unambiguous annotation to a gene symbol. Generic ﬁltering
details were as follows: requires Affymetrix “Present” call in
all samples (n ¼ 23,204 transcript-cluster ids passing ﬁlter)
and requires unique mapping to a gene symbol according
to the current NetAffx release note (release 32, June 2011)
(n ¼ 19,449 transcript-cluster ids passing ﬁlter). Overall,
16,934 transcript cluster ids, interrogating 16,148 unique
genes, passed the generic ﬁltering and were used in further
analyses.
Differential Expression Analysis
Two-sample t test (function “t.test” from the R package
“stats”) was applied to each Affymetrix transcript-cluster
identiﬁer and miRNA identiﬁer included in our ﬁltered
expression datasets to compare expression in cancer and
normal samples. The P values were adjusted to account for
multiple testing using the Benjamini-Hochberg method
(function “p.adjust” from the R package “stats”).5 An
adjusted P value <.05 was considered signiﬁcant.
Validation of Complementary DNA
Microarray and Comparison With Published
Datasets
In order to validate our complementary DNA (cDNA)
microarray, we compared the gene expression from our
PDAC samples with the top 100 up-regulated and down-
regulated genes in PDAC found across the 8 datasets
found on the Oncomine website (https://www.oncomine.
org/resource/login.html), and also with 3 previous meta-
analyses6–8 of dysregulated genes in PDAC (see
Supplementary Tables 4 and 5). We found our PDAC sam-
ples had 62% of the up-regulated and 58% of the down-
regulated genes when compared with the top 100 up- and
down-regulated genes in the 8 Oncomine datasets
(Supplementary Table 4). We also noted other genes
signiﬁcantly dysregulated in our cDNA microarray that have
been previously identiﬁed as differentially expressed in
PDAC and are considered important (Supplementary
Table 5). For example, genes known to be down-regulated
in PDAC included PDCD4, GATM, BNIP3, LIFR, NrCAM,
EPHX2, FGL1, PDIA2, and SERPINI2. Conversely, and also
comparable with previous studies, we saw the following
genes were signiﬁcantly up-regulated in PDAC: ZEB1/2,
SNAI2, S100P, MUC4, SULF1, SPARC, FN1, POSTN, CEACAM5,
IGFBP5, CXCR4, ADAM9, and MMP11. In order to demon-
strate the validity of our cDNA microarray, we chose 5 genes
that are dysregulated in PDAC (Supplementary Tables 4 and
5) and quantiﬁed their expression by RT-qPCR. These were
GATM, ZEB2, SNAI2, S100P, and NrCAM. The expression of all
of these genes was conﬁrmed to be in the same direction as
the initial cDNA array and the literature, thereby validating
our initial molecular proﬁling (Supplementary Figure 3).
Gene Ontology and Kyoto Encyclopedia of
Genes and Genomes Pathway Analyses of
mRNA Expression
We used the GeneAnswers Bioconductor package9 to
perform enrichment analysis of Kyoto Encyclopedia of
Genes and Genomes pathways10 and Gene Ontology terms
(biological process)11 upon the list of protein-coding genes
deregulated in PDAC (Benjamini-Hochbergadjusted t test,
P < .05; Supplementary Table 3). The reference set for the
functional enrichment used by the package are the human
annotated genes. Adjusted P values <.05 were considered
signiﬁcant. A selection of the top enriched Gene Ontology
biological processes and Kyoto Encyclopedia of Genes and
Genomes pathways for genes can be seen in Supplementary
Figure 4A and B.
Computational Analyses of miRNAmRNA
Interactions to Identify Functionally Relevant
miRNAs
To prioritize functionally relevant miRNAs in PDAC for
further experimental studies, we performed a seed-
enrichment analysis that was tissue and tumor speciﬁc.
miRNAs are predominantly negative regulators of mRNA
expression and the seed region (ie, nucleotides 27 at the
500 end of the mature miRNA sequence) plays a dominant
role in target mRNA recognition.12 We tested our lists of
deregulated genes in PDAC for enriched frequency (Fisher’s
one-tailed exact test) of mRNAs carrying a seed match in
their 30 untranslated region (UTR) for each mature miRNA
signiﬁcantly deregulated in our initial cohort and in accor-
dance to the anti-regulation paradigm. We speciﬁcally tested
seed enrichment of up-regulated miRNAs among down-
regulated mRNAs and vice versa.
Details on Seed-Enrichment Analysis
A database of 30 UTR sequences for protein-coding
mRNAs in our dataset was created querying the Ensembl
gene database (Homo sapiens genes GRCh37.p8) by using
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the R/Bioconductor interface13 to the BioMart data portal
(http://www.biomart.org/). The list of identiﬁers used to
retrieve 30 UTR sequences included 15,488 RefSeq NM
identiﬁers (http://www.ncbi.nlm.nih.gov/RefSeq/) match-
ing 14,900 unique Entrez Gene ids (http://www.ncbi.nlm.
nih.gov/gene). NetAffx release note (Release 32, June
2011) was used to annotate the transcript cluster ids in our
ﬁltered expression dataset to RefSeq NM identiﬁers. After
removing RefSeq ids lacking an available 30UTR sequence, as
well as entries with annotated 30UTR sequence shorter than
100 nucleotides, we removed residual redundancy, due to
the existence of multiple annotated sequences, by retaining
only one 30UTR sequence for each Entrez Gene identiﬁer.
The resulting database used for the seed-enrichment anal-
ysis includes 13,885 30UTR sequences matching as many
unique Entrez Gene ids and is available on request.
We recorded in the 30UTR sequence database all occur-
rences of short sites that perfectly complement the miRNA
seed region (both position 2 to 7: 6-mer seed and position
28: 7-mer seed) of our list of differentially expressed
miRNAs (Supplementary Figure 2A) using the R/Bio-
conductor package microRNA and functions therein. To
evaluate overlap with existing target predictions and help
prioritize a list of putative target genes for experimental
validation, we used the miRanda-mirSVR database (release
of August 2010; Good mirSVR score dataset; http://www.
microrna.org/microrna/home.do).14 Figure 1 shows re-
sults of the seed-match analysis for up-regulated miRNAs
(n ¼ 18, Benjamini-Hochbergadjusted t test, P < .05) and
top down-regulated mRNAs (n ¼ 152, Benjamini-Hoch-
bergadjusted t test, P < .05; log-ratio of mean signal in-
tensity in cancer vs normal  1; mean signal intensity in
cancer and/or normal samples 500).
Based on the model that miRNAs act as negative regu-
lators of target mRNAs, we assayed our lists of deregulated
genes and miRNAs in PDAC for enrichment in the frequency
of mRNAs carrying a seed match (ie, site complementary to
the miRNA seed region) in their 30UTR compared with
remaining genes and in accordance to the anti-regulated
paradigm. One-tailed Fisher’s exact test was used to test
for the enriched proportion of mRNAs with a seed match (ie,
complementary to the miRNA seed region) in their 30UTR in
the selected group (ie, down-regulated genes when testing
with up-regulated miRNAs and up-regulated genes when
testing with down-regulated miRNAs) compared with the
rest of the gene list (all-but-down-regulated genes or all-but-
up-regulated genes, respectively). We selected for a
Benjamini-Hochberg adjusted P value <.05 and an absolute
log-ratio of 1 of PDAC vs normal pancreas samples mean
intensity signal to deﬁne lists of top deregulated genes to be
used in the analysis (n ¼ 1,328 deregulated genes:
348 down-regulated genes, 980 up-regulated genes)
(Supplementary Figure 2B). Test results for 6-mer and 7-mer
seeds are shown in Supplementary Table 7. To prioritize
miRNAs for investigation, we chose the 3 miRNAs that
were signiﬁcant at the 6-mer level (ie, miR-21, miR-23a, and
miR-27a). At the 7-mer level, only miR-23a was signiﬁcant
(based on a cut-off of P < .05). Both miR-27a and miR-27b
were signiﬁcantly enriched in our seed-enrichment analysis
(Supplementary Table 6). We chose to use miR-27a as a
molecular treatment and biomarker, as both these miRNAs
have identical seed regions (from nucleotides 2 to 8; http://
www.mirbase.org) and are therefore able to target the same
mRNAs. Actually, the only difference between these 2 miR-
NAs is 1 nucleotide (http://www.mirbase.org). Even if an
undiscovered mechanism makes the change in that single
nucleotide relevant for their regulation of gene targets, we
chose miR-27a because it has been previously shown to be
important in PDAC.15
mRNA Target Screening
Genes with 7-(oligo) mer or a conserved seed match in
vertebrates were chosen for further investigation. MEDLINE
and Google Scholar were next searched in order to identify
tumor suppressors from the enriched list that are known to
be involved in gastrointestinal or PDAC tumorigenesis.
Cell Culture and Transfection
PANC-1 and MIAPaCa-2 PDAC cells were purchased from
the European Collection of Cell Cultures. PANC-1 cells were
chosen because they are an epithelial-type cell, and
MIAPaCa-2 cells are more mesenchymal.16 Both were
maintained in Dulbecco’s modiﬁed Eagle medium supple-
mented with 10% fetal calf serum, 1% penicillin/strepto-
mycin, and 1% glutamine. The 2 primary cell cultures
from PDAC patients (LPc006 and LPc167) were maintained
as described previously.17 When the cells were ready for
transfection, they were plated the day before and then
transfected with precursor miRNA (Applied Biosystems,
Cheshire, UK) using HiPerfect Transfection Reagent (Qiagen)
for the indicated time before lysis, RNA and/or protein
extraction. For miRNA effects on target protein levels and
the effects of gain of function on cell proliferation, the ﬁnal
concentration of pre-miR was kept constant (30 nmol/L) for
single, triple pre-miR transfection or the premiR-NC (eg,
for 3 pre-miRs the concentration was 10 nmol/L for each
and 30 nmol/L was used for the premiR-NC).
RT-qPCR
Functionally relevant miRNAs identiﬁed by the seed-
enrichment analysis were measured in patient samples
(n¼ 91). Total RNA extracted was used to perform RT-qPCR
using Taqman mature miRNA primers and probes (Applied
Biosystems). Brieﬂy, mature miRNA expression was
measured using stem-loop reverse transcriptase primers for
miRNA cDNA synthesis followed by Taqman PCR analysis.
RNA was reverse transcribed followed by qPCR on a 7900
HT Fast Real-Time PCR System (Applied Biosystems).
Duplicate samples and an endogenous control (snRNA U6)
were used throughout. Expression levels of each miRNA
were evaluated using comparative threshold cycle (Ct)
method using the 2DDCt method with normalization to U6.
For gene expression quantiﬁcation in order to validate the
cDNA microarray, we used Taqman primer and probe sets
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(Applied Biosystems) and quantiﬁed transcripts of the gene
RPLPO (aka 36B4) as the endogenous RNA control.
Validation TMA
The PDAC TMA has been detailed previously18 and
represents an independent, nonoverlapping cohort of pa-
tients. After deparafﬁnization and rehydration, antigen
retrieval was performed by boiling in 10 mmol/L citrate
buffer (pH 6.0) for 10 minutes. After inhibition of endoge-
nous peroxidase activity for 30 minutes with methanol
containing 0.3% H2O2, the TMA sections were blocked with
2% bovine serum albumin in phosphate-buffered saline for
30 minutes and incubated with antibodies against PDCD4,
BTG2, and NEDD4L (same antibodies as before). The im-
mune complex was visualized with the Dako REAL EnVision
Detection System, Peroxidase/DAB, Rabbit/Mouse (Dako,
Cambridgeshire, UK), according to manufacturer’s proce-
dure. The nuclei were counterstained with hematoxylin.
Representative photographs were taken and the slides were
scored for protein expression by 2 blinded observers.
Semi-Quantitative Immunohistochemistry
In order to accurately describe the extent of immuno-
histochemical staining of a tumor core, the degree of
immunohistochemical staining in each subcellular
compartment in tumor cells was captured for each analyte.
We captured the percentage of tumor cells stained at each
intensity level. An intensity scale ranging from 0 for no
staining to 3þ for the most intense staining was used. This
information was used to calculate a variable (H-Score), more
continuous than simply positive vs negative.19 This semi-
quantitative H-score is more representative of the staining
of the entire tumor on the section. The H-Score is calculated
for staining of each subcellular compartment using the
following formula:
H-Score ¼ (% at 0) * 0 þ (% at 1þ) * 1 þ (% at 2þ) *
2 þ (% at 3þ) * 3.
The H-score produces a continuous variable that ranges
from 0 to 300. The median H-score was then used to
dichotomize patients into those with high- or low-protein
expression. Survival curves and analyses were performed
as described previously.
Survival Analysis
Functionally relevant miRNAs were measured in pa-
tient samples (n ¼ 91). Each miRNA was also associated
with clinicopathological data. The c2 test was used for
univariate comparisons between 2 groups. Then, by
dichotomizing expression of individual miRNAs into high
and low expression, using the median value as a cut-off, we
associated expression with cancer-speciﬁc OS after pan-
creaticoduodenectomy surgery (ie, from date of surgery to
date of death or follow-up). Survival curves were con-
structed using the Kaplan-Meier method and differences in
survival were compared by log-rank test. In this way, high-
and low-risk groups based on miRNA expression proﬁles
were determined. Survival analysis was done using a uni-
variate log-rank test for each clinical covariate to assess
their inﬂuence on outcome. A multivariate Cox proportional
hazard regression analysis was then used to adjust for
competing risk factors and the signiﬁcant hazard ratios
(with 95% conﬁdence intervals) were reported as an esti-
mate of survival risk. Univariate predictors with 2-sided P
values .05 were included in the multivariate model and
backward elimination was applied to obtain a ﬁnal model;
2-sided P values .05 were considered signiﬁcant. All sta-
tistical analyses were done using SPSS 20.0 (IBM SPSS,
Armonk, NY).
Luciferase Reporter Assays
The 30UTRs of cancer-relevant tumor suppressors cloned
into pLightSwitch_3UTR GoClone vectors (SwitchGear Geno-
mics, Menlo Park, CA) were used to conﬁrm direct target
binding. Thedaybefore transfectionswereperformed, PANC-1
cells were seeded onto 24-well plates (15 105 cells perwell)
in antibiotic-free media in triplicate per construct. Cells (80%
conﬂuent) were co-transfected with pLightSwitch_3UTR
luciferase reporters (150 ng/well) and the relevant pre-miR
(100 nmol/L) or a nontargeting negative control using Lip-
ofectamine 2000 (Invitrogen, Carlsbad, CA). After 24 hours,
cells were lysed using a passive lysis buffer (Promega, South-
ampton, UK). The LightSwitch Assay System (Switchgear
Genomics) was then used for luciferase signal detection
following manufacturer’s instructions. After a 30-minute in-
cubation period, the signal from each well was read in a
GLOMAX 96 Microplate Luminometer (Promega) and the
mean luciferase intensitywas calculated forpre-miR replicates
and then divided by the mean for negative control replicates.
Western blotting
Whole cell lysates were prepared in Nonidet P-40 lysis
buffer (50 mM Tris/HCl [pH 8.0], 150 mM NaCl, 10% [vol/
vol] glycerol, 1% Nonidet P-40, 5 mM dithiothreitol, 1 mM
EDTA, 1 mM EGTA, 50 mM leupeptin, and 30 mg/mL apro-
tinin). Lysates were subjected to sodium dodecyl sulfate
polyacrylamide gel electrophoresis and blotted on a Hybond
C super nitrocellulose membrane (GE Healthcare, Bucks,
UK), followed by incubation with the indicated primary and
secondary antibodies conjugated to horseradish peroxidase
(GE Healthcare). Signals were detected using the Amersham
ECL Western Blotting detection system (GE Healthcare) fol-
lowed by the quantiﬁcation of band intensity using Image J
software (National Institutes of Health), or chem-
iluminescence was detected and quantiﬁed by the Fusion
FX7 image acquisition system (Vilber Lourmat, Germany).
We used PDCD4 (ab51495; Abcam Plc., Cambridge, UK),
BTG2 (AV33561; Sigma-Aldrich Company Ltd., Dorset, UK)
monoclonal rabbit antibodies and NEDD4L (HPA024618;
Sigma-Aldrich), SORBS2 (SAB4200183; Sigma-Aldrich), and
glyceraldehyde-3-phosphate dehydrogenase (sc-137179;
Santa Cruz Biotechnology Inc., Santa-Cruz, CA) monoclonal
mouse antibodies.
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Cell Proliferation Assay
In order to assess the effects of miRNAs on cell growth,
PANC-1 and MIA PaCa-2 PDAC cells were seeded onto 24-
well plates (2.5  104 and 5  104 cells per well, respec-
tively) in triplicate. LPc006 and LPc167 PDAC cells were
seeded onto 24-well plates (both 2  104 cells per well) in
triplicate. The day after, cells were transfected with either
miRNA inhibitor (anti-miR) or a nontargeting negative
control inhibitor (antimiR-NC; Applied Biosystems).
The ﬁnal concentration was kept constant (90 nmol/L)
for single, double, or triple anti-miR transfection and the
antimiR-NC (eg, for 2 anti-miRs the ﬁnal concentration
was 45 nmol/L for each and 90 nmol/L was used for the
antimiR-NC). To measure the cell proliferation in culture,
the numbers of cells were counted manually after 1, 2, 3, 4,
and 5 days of incubation using a hemacytometer (Hawksley,
West Sussex, UK).20 This was done in combination with
trypan blue to stain dead cells in the culture sample.
In vivo Tumorigenicity Assay in Nude Mice
Bearing Orthotopic PDAC Xenografts
Four-week-old female BALB/c nude mice were pur-
chased (Charles River Laboratories, Margate, UK) and
maintained in speciﬁc pathogen-free conditions. To create
the subcutaneous human PDAC tumor xenograft model,
MIAPaca-2 or PANC-1 cells were subcutaneously inoculated
(5  106 cells suspended in a 1:1 mixture of 10% fetal
bovine serum-Dulbecco’s modiﬁed Eagle medium/Matrigel
(BD Biosciences per site); total volume 0.1 mL) bilaterally
into the ﬂanks of athymic mice. The animals were monitored
for activity, physical condition, determination of body
weight, and measurement of tumor volume (1/2  [the
major axis]  [the minor axis])2 twice a week. To measure
the tumors accurately, mice were given a quick inhalation
general anesthetic with isoﬂurane and oxygen to ensure that
the mice were still and digital calipers were used.
When the tumors reached a volume of 50 mm3 (day 0;
approximately 2 weeks after the initial inoculation with
PDAC cells), mice were randomized into 2 groups (n ¼ 6 in
each group) to receive intratumoral injections of anti-miRs
(group 1: antimiR-NC to the left ﬂank and antimiR-21
to the right ﬂank; group 2: antimiR-NC to the left ﬂank and
anti-miR-21/23a/27a to the right ﬂank).
Atelocollagen (Atelogene Local Use; Koken, Tokyo, Japan)
has been shown recently to be a useful system for the efﬁ-
cient delivery of small interfering RNA and miRNA molecules
into tumors in vivo.21–23 It has been pretreated with pepsin
to remove the telopeptides thereby reducing most of the
collagen’s antigenicity (http://www.kokenmpc.co.jp/english/
support/tecnical/collagen/index.html). Atelocollagen has not
been found to have any unspeciﬁc toxic effects on cell
growth.22 Complexes of the indicated anti-miR or antimiR-
NC with atelocollagen were prepared according to the man-
ufacturer’s instructions. The ﬁnal concentration of anti-miR
was 12 mM in a 50-mL injection volume for each tumor (for
the triple combination each anti-miR was 4 mM).
One intratumoral injection was administered every week
for 3 weeks, followed by a 3-week rest period, then another
treatment cycle and ﬁnally mice were sacriﬁced 3 weeks
after the last intratumoral injection. The whole experiment
lasted 12 weeks. Tumors were harvested, immediately snap
frozen in liquid nitrogen and stored at 80C until required.
To perform the intratumoral injection, mice were given a
quick inhalation general anesthetic with isoﬂurane and
oxygen. The site of injection was disinfected and forceps
were used to hold the tumor. The needle was then directly
inserted and the tumor was penetrated until the tip reached
the center. The solution was then slowly pushed into the
tumor. The needle was then slowly pulled back, but not out
of the tumor, and left in the tumor for about 20 seconds.
Finally, the needle was slowly pulled out of the tumor and
the puncture site in the skin pinched with ﬁne forceps to
avoid any leakage. No death, loss of body weight, or gross
adverse effects occurred in the mice as a result of treatment
with the antimiR-atelocollagen complexes. Animal exper-
imental procedures were conducted under the UK Home
Ofﬁce Project License number PPL 70/7256. Ethical con-
straints prevented xenografts growing past 400 mm3.
Oncomine and GEO2R Analysis
Oncomine’s gene search function (https://www.
oncomine.org/resource/login.html) was used to assess the
differential expression of a selected gene across all available
datasets (updated September 2012).24 We searched for
PDCD4, BTG2, and NEDD4L in human cancer using the
following threshold values: P value of <.05, fold change of
1.5, and gene rank in the top 10% among all differentially
expressed genes. Oncomine then listed all differential
expression analyses in which these genes were included. For
each listed analysis, the statistical results were provided and
linked to the original microarray dataset. We then examined
the 8 PDAC datasets for each transcript. Next, using
GEO2R,25 we examined a recently published dataset
(GSE2873526) that became publically available from July
2012 and is not yet included in the Oncomine database. This
dataset contains microarray gene-expression proﬁles for 45
pairs of tumor and adjacent nontumor tissues from 45 pa-
tients with PDAC. We searched for each gene (BTG2, tran-
script_cluster_id 7908917; PDCD4, transcript_cluster_id
7930454; and NEDD4L, transcript_cluster_id 8021376) and
extracted expression values for each pair of patient samples.
Ethical Approval
This study has received ethical approval from the
Camden & Islington REC, London (09/H0722/77) in the UK
and the ethics committee of Pisa University Hospital in Italy.
All animal experimental procedures were conducted under
the UK Home Ofﬁce Project License number PPL 70/7256.
Statistical Analysis
Experiments were performed at least 3 times. Values
represent the mean of triplicate samples and SD of the mean
unless indicated otherwise. The differential miRNA expres-
sion between tissues for all RT-qPCR and Western blotting
data was analyzed using the parametric t test (2-tailed for
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overexpression/loss-of-function experiments) with Graph-
Pad Prism 5.0 (GraphPad Software Inc., San Diego, CA).
Cell-proliferation experiments were analyzed by one-way
analysis of variance adjusted by Tukey test. All reported
P values were rated signiﬁcant if <.05.
Supplementary Discussion
We validated 3 genes as directs of at least 1 of the
miRNAs in the triple combination (miR-21/23a/27a).
PDCD4 inhibits neoplastic transformation and must be
down-regulated for malignant progression to occur.27
Although not novel, the interaction between miR-21 and
PDCD428–30 conﬁrmed the robustness of our seed-
enrichment analysis, serving as a positive control. Nagao
et al recently demonstrated a strong association between
high miR-21 expression levels and down-regulated nuclear
PDCD4 expression, and a signiﬁcant association between
poor OS and low PDCD4 expression in the same PDAC pa-
tients.28 We have conﬁrmed this in a larger PDAC patient
cohort (n ¼ 121).
BTG2 has considerable antiproliferative activity31 and
is a tumor suppressor that connects the p53 and Rb
pathways in human tumorigenesis.32 However, its role in
PDAC has never been investigated. BTG2 is a major
downstream effector of p53-dependent proliferation arrest
in mouse and human ﬁbroblasts transduced with onco-
genic Ras,32 which is relevant because the activating K-Ras
mutation is the signature event in PDAC carcinogenesis.33
For the ﬁrst time, we conﬁrmed the direct interaction of
miR-21 with the BTG2 30UTR in PDAC and validated miR-
27a as a new miRNA that also directly regulates this
gene. Synergistically, these 2 miRNAs reduced expression
of BTG2 at the protein level more effectively than over-
expression of miR-21 only (Figure 1C). This is consistent
with a previous demonstration that multiple miRNAs have
a larger effect on translation of a protein,34 and indicates
that a combination of miRNAs could be a new more effec-
tive approach in cancer therapeutics. We examined various
published datasets (Supplementary Figure 9A and B and
Supplementary Table 10) in addition to our microarray and
identiﬁed BTG2 transcripts as consistently down-regulated
in PDAC. Reduced BTG2 protein expression associated with
poor OS in our large cohort of surgically resected PDAC
patients. Clearly, further investigations about the role of
BTG2 in PDAC are warranted.
NEDD4L encodes the principal E3 ubiquitin ligase that
selectively targets activated, linker phosphorylated Smad2/
3 for destruction, thereby regulating signal termination of
the canonical transforming growth factorb pathway,35
which has an important role in PDAC development and
metastasis36 and loss of NEDD4L antagonism can enhance
this.37 NEDD4L is important in the progression of various
tumors.38–41 We have demonstrated that NEDD4L loss is a
feature of PDAC and this might be due in part to post-
transcriptional modiﬁcation by miR-23a.
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Supplementary Figure 1. An overview of our integrated molecular proﬁling based study for PDAC. The seed-match analysis
is shown in Figure 1 and Supplementary Table 7 and the seed-enrichment analysis can be seen in Supplementary Table 6.
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Supplementary Figure 2. miRNAs and mRNAs differentially expressed in PDAC vs normal pancreas. (A) Heatmap showing
miRNA expression across 18 samples for 22 differentially expressed miRNAs (selection: Benjamini-Hochberg adjusted t test,
P < .05). (B) Heatmap showing gene expression across 12 samples for 1328 top differentially expressed mRNAs (selection: t
test adjusted P < .05 and absolute log-ratio of cancer vs normal samples mean intensity signal 1). The heatmaps in (A) and
(B) report relative levels of miRNA or gene expression in a green (lower expression) to red (higher expression) scale. Although
the seed-enrichment analysis was used to investigate up-regulated miRNAs in PDAC, we also identiﬁed miRNAmRNA in-
teractions between down-regulated miRNAs and up-regulated genes. (C) Heatmap showing seed-match analysis for 4 PDAC
down-regulated miRNAs and 325 top up-regulated genes. Colored cells highlight the presence of an miRNA seed reverse-
complementary match in the 30UTR sequence of the crossing gene. Seeds: 6-mer seed ¼ nucleotides 27 in the miRNA
mature sequence; 7-mer seed ¼ nucleotides 28 in the miRNA mature sequence; predicted interaction ¼ predicted functional
interaction based on miRanda-mirSVR.14 For each colored cell at the intersection of a row (up-regulated miRNA) with a column
(down-regulated mRNA), the color identities are: dark red (miRanda-mirSVR predicted interaction); medium red (7-mer seed);
light red (6-mer seed); and yellow (no seed). Feature selection: miRNAs: down-regulated miRNAs (Benjamini-Hochberg
adjusted t test, P < .05). mRNAs: top up-regulated mRNAs (Benjamini-Hochberg adjusted t test, P < .05; log ratio of mean
signal intensity in cancer vs normal 1; mean signal intensity in cancer and/or normal samples log2(500)). Only mRNAs with
at least 1 seed-complementary match for any of the down-regulated miRNAs are shown in the heatmap.
277.e9 Frampton et al Gastroenterology Vol. 146, No. 1
Supplementary Figure 3. Validation of PDAC cDNA micro-
array by RT-qPCR. Relative mRNA expression of GATM,
ZEB2, NrCAM, S100P, and SNAI2 was measured in the same
normal and PDAC samples (n ¼ 9 for both) that were used for
the initial molecular proﬁling. The expression of all these
genes was conﬁrmed to be in the same direction as the initial
cDNA microarray. Gene expression was normalized to
RPLPO expression as an endogenous control (*P < .05; **P <
.01).
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Supplementary Figure 4. A selection of the top enriched (A) Gene Ontology (GO) biological processes and (B) Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathways for genes in PDAC with a Benjamini-Hochberg adjusted P value <.05.
We conﬁrmed a signiﬁcant enrichment of GO terms involved in cancer, including the apoptotic process (P ¼ 1.74  109), cell
proliferation (P ¼ 1.30  107), cell differentiation (P ¼ 5.95  1014), and angiogenesis (P ¼ 6.42  105). We also conﬁrmed a
signiﬁcant enrichment of KEGG terms, such as pathways in cancer (P ¼ 1.09  108) and pancreatic cancer (P ¼ 8.93  106),
as well as terms more relevant to PDAC, such as regulation of the actin cytoskeleton (P ¼ 3.85  109), axon guidance (P ¼
3.22  103), and transforming growth factorb signaling (P ¼ 4.16  103).
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Supplementary Figure 6. Expression of PDCD4 (a miR-21
target) in mice xenografts after antimiR-21 intratumoral in-
jections. At the end of 10 weeks, PDCD4 was signiﬁcantly de-
repressed, conﬁrming that the antimiR-21 treatment had an
effect. Representative Western blots of protein expression
from mice xenografts. Glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) was used as an endogenous loading
control. Bar diagram indicates density ratio (protein to
GAPDH; antimiR-21 [n ¼ 6] vs antimiR-NC [n ¼ 6]).
Data are shown as mean  SD (*P < .05). Negative control
(antimiR-NC) was set to 1.
Supplementary Figure 5. miRNA recognition elements (MREs) for miR-21, miR-23a, and miR-27a in the 30UTRs of the 5
genes chosen for further validation. MREs are based on miRanda-mirSVR target predictions (November 2012; http://www.
microrna.org/microrna/home.do).14 PDCD4 was chosen as a positive control.
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Supplementary Figure 7. Expression of miR-21, miR-23a, miR-27a or their combinations predicts survival in PDAC. Kaplan-
Meier (KM) curves for dichotomized groups of low (blue) vs high (red) miRNA expression on the full RT-qPCR validation cohort.
High tumoral expression of individual miRNAs was associated with poor OS in PDAC for (A) miR-23a and (B) miR-27a (KM
curve for miR-21 can be seen in Figure 6). However, high tumoral expression of double combinations of these 3 miRNAs: (C)
miR-21 and miR-23a, (D) miR-21 and miR-27a, and (E) miR-23 and miR-27a, was predictive of worse OS in PDAC. Statistical
differences were analyzed using the log-rank test.
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Supplementary Figure 8. Expression of 3 different up-regulated miRNAs in PDAC does not predict cancer-speciﬁc survival.
In order to conﬁrm that other signiﬁcantly enriched miRNAs in our PDAC signature did not associate with patient outcomes, 3
different up-regulated miRNAs (miR-142-3p, miR-199-3p, and miR-342-3p) were selected randomly by an independent person
not familiar with this subject for further validation in patient samples. Kaplan–Meier curves for dichotomized groups of low
(blue) vs high (red) miRNA expression for (A) miR-142-3p, (B) miR-199a-3p, (C) miR-342-3p, and (D) combined expression of all
3 miRNAs. High expression of these individual miRNAs or the combination was not associated with poor overall survival.
Statistical differences were analyzed using the log-rank test.
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Supplementary Figure 9. Data mining conﬁrms BTG2, PDCD4, and NEDD4L as clinically important in PDAC. (A) Summary of
BTG2, PDCD4, and NEDD4L mRNA expression in PDAC compared with normal pancreas (from Oncomine; datasets updated
as of September 2012). In total there were 8 cDNA microarray datasets available in Oncomine. Red color indicates up-
regulation and blue indicates down-regulation in cancer vs normal. The highlighted number (yellow) indicates the number of
datasets for which that ﬁnding was signiﬁcant (P < .05). Using GEO2R, the dataset GSE28735 was search for (B) BTG2, (C)
PDCD4, and (D) NEDD4L. All 3 transcripts were found to be signiﬁcantly down-regulated in PDAC vs matched normal
pancreas from the same patients. Data are shown as means  SD.
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Supplementary Figure 10. BTG2 and PDCD4 immunohistochemistry of PDAC tissue TMA. (A) Non-neoplastic pancreatic
ductal epithelium showed intense nuclear PDCD4 and cytoplasmic BTG2 expression compared with PDAC cores on the TMA.
(B) Reduced BTG2 expression (targeted by miR-21 and miR-27a) predicts poor OS in PDAC. Kaplan-Meier (KM) curves are
shown for groups dichotomized according to the H-score of low (red) vs high (blue) BTG2 expression on the TMA. (C) Reduced
PDCD4 expression (targeted by miR-21) also predicts poor OS in PDAC. Again, KM curves are shown for groups dichotomized
according to the H-score of low (purple) vs high (blue) PDCD4 expression on the TMA. Statistical differences were analyzed
using the log-rank test.
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Supplementary Figure 11. The 30UTRs
of other important tumor suppressors
contain miRNA recognition elements
(MREs) for miR-21, miR-23a, and miR-
27a. Using the miRanda-mirSVR target
predictions (November 2012; http://
www.microrna.org/microrna/home.do),14
we identiﬁed MREs for the 3 miRNAs in
important tumor suppressor genes,
including (A) PTEN, (B) Spry2, (C) LIFR,
and (D) NrCAM. Of note, mirSVR is a
machine learning method for ranking
miRanda-predicted miRNA target sites
by a down-regulation score, the sug-
gested mirSVR score cut-off for report-
ing target sites is 0.1 or lower. The
PhastCons score measures the conser-
vation of nucleotide positions across
multiple vertebrates.42
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Supplementary Figure 12. Interaction network for miR-21, miR-23a, and miR-27a in PDAC. Cytoscape visualization soft-
ware43 was used to display putative functional interaction network for miR-21/miR-23a/miR-27a. Nodes: red: PDAC up-
regulated miR-21, miR-23a, and miR-27a; green: PDAC top down-regulated genes. Edges between miRNA and gene
nodes are drawn whenever a seed match in the gene 30UTR is present according to our seed-match analysis and miRanda-
mirSVR target predictions (Supplementary Table 5). Gray circles indicate genes chosen for validation.
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